MXPA99004890A - Nucleic acid and amino acid sequences relating to helicobacter pylori - Google Patents

Nucleic acid and amino acid sequences relating to helicobacter pylori

Info

Publication number
MXPA99004890A
MXPA99004890A MXPA/A/1999/004890A MX9904890A MXPA99004890A MX PA99004890 A MXPA99004890 A MX PA99004890A MX 9904890 A MX9904890 A MX 9904890A MX PA99004890 A MXPA99004890 A MX PA99004890A
Authority
MX
Mexico
Prior art keywords
seq
polypeptide
nucleic acid
pyl ori
fragment
Prior art date
Application number
MXPA/A/1999/004890A
Other languages
Spanish (es)
Inventor
Smith Douglas
A Alm Richard
C Doig Peter
Kabok Zita
Marie Castriotta Lillian
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of MXPA99004890A publication Critical patent/MXPA99004890A/en

Links

Abstract

Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful for diagnostics and vaccine compositions, wherein the figure depicts an amino acid sequence alignment of five H. pylori proteins.

Description

SEQUENCES OF NUCLEIC ACID AND AMINO ACIDS REFERRING TO HELICOBACTER PYLORI AND COMPOSITIONS OF VACCINE OF THE SAME Background of the Invention Hel i coba c ter pyl ori is a gram-negative, S-shaped, microaerophilic bacterium that was discovered and cultured from a human gastric biopsy specimen. (Warren, J.R. and B. Marshall, (1983) Lan ce t 1_- 1273-1275, and Marshall et al., (1984) Mi crobi os Le tt. 25 .: 83-88). H. pyl ori has been strongly associated with chronic gastritis and duodenal ulcer disease. (Rathbone et al., (1986) Gut 27: 635-641). In addition, the evidence is cumulative for an etiological role of H. pyl ori in dyspepsia without ulcer, gastric ulcer disease, and gastric adenocarcinoma. (Blaser M. J., (1993) Trends My crobiol.1: 255-260). The transmission of the bacteria occurs through the oral route, and the risk of infection increases with age. (Taylor, D.N. and M. J. Blaser, (1991) Epi demi ol. Rev 13 ..- 42-50). H. pyl ori colonizes the gastric mucosa of humans, establishing an infection that usually persists for decades. H infection. pyl ori is prevalent throughout the world. Developed countries have REF: 30211 infection rates around 50% of the adult population, while developing countries have infection rates that reach 90% of adults above 20 years of age. (Hopkins R.J. and J.G. Morris (1994) Am. J. Med. 92: 265-277).
The bacterial factors necessary for the colonization of the gastric medium, and for the virulence of this pathogen, are poorly understood. Examples of putative virulence factors include the following: urease, an enzyme that could play a role in neutralizing the pH of gastric acid (Eaton et al., (1991) Infect. Immunol. 59: 2470-2475; Ferrero, RL and Lee (1991) Microb. Ecol. Hlth. Dis. 4 .-. 121-134; Labigne et al., (1991) J. Bacteriol. 173: 1920-1931); the bacterial flagellar proteins responsible for mobility through the mucosal layer. (Hazell et al., (1986) J. Inf. Dis. 153: 658-663; Leying et al., (1992) Mol.Microbiol.6 .: 2863-2874; and Haas et al., (1993) Mol. Microbiol 8: 153-160), Vac A, a bacterial toxin that induces the formation of intracellular vacuoles in epithelial cells (Schmitt, W. and R. Haas, (1994) Molecular Microbiol 12 (2): 307-319 ); and several adhesins specific for gastric tissues. (Boren et al., (1993) Science 262 .: 1892-1895, Evans et al., (1993) J. Baterian 175: 674-683, and Falk et al., (1993) Proc. Na tl Acad. Sci. USA j) 0_: 2035-203).
Numerous therapeutic agents that are currently available eradicate H. pylitis ori in vi tro infections. (Huesca et al., (1993) Zbl. Bakt. 280: 244-252; Hopkins, R.J. and J.G. Morris, supra). However, many of these treatments are suboptimally effective in vi ve due to the resistance of the bacteria, altered drug distribution, non-compliant patient, and poor drug availability. (Hopkins, R.J. and J.G. Morris, supra). Antibiotic treatment combined with bismuth are part of the standard regimen used to treat H. pylori infection. (Malfertheiner, P. and J.E. Dominguez-Munoz (1993) Cl i ni cal Therapeu ti cs ÍJ Supp. B: 37-48). Recently, combinations of proton pump inhibitors and a simple antibiotic have been shown to improve duodenal ulcer disease. (Malfertheiner, P. and J.E. Dominguez-Munoz supra). However, methods employing antibiotic agents may have the problem of the emergence of bacterial strains that are resistant to these agents.
(Hopkins, R.J. and J.G. Morris, supra). These limitations demonstrate that new, more effective methods are needed to combat H. pylori ori in vi vo infections. In particular, the design of new vaccines that could prevent infection by this bacterium is highly desirable.
Brief Description of the Invention This invention relates to new genes, p. ex. , genes encoding polypeptides such as bacterial surface proteins, from the organism Heli coba cter pyl ori (H. pyl ori), and other related genes, their products, and uses thereof. The nucleic acids and peptides of the present invention have diagnostic and therapeutic utility for H. pylori and other Hel i cobacter species. They can also be used to detect the presence of H. pylori and other species of jellyfish in a sample; and for use in screening compounds with the ability to interfere with the life cycle of H. pylori or to inhibit H. pylori infection. More specifically, this invention highlights nucleic acid compositions which correspond to complete coding sequences of H. pyl ori proteins, which include surface or secreted proteins or parts thereof, nucleic acids capable of binding protein H. pyl ori mRNA. to block the translation of the protein, and methods for producing H. pyl ori proteins or parts thereof using peptide synthesis and recombinant DNA techniques. This invention also highlights antibodies and nucleic acids useful as probes for detecting H. pylori infection. In addition, vaccine compositions and methods for the protection or treatment of H. pylori infection are within the scope of this invention.
Detailed Description of the Drawings Figure 1 shows an amino acid sequence alignment of five proteins of H. pyl ori (exposed in the lowercase amino acid code and designated by its Sequence ID Numbers of amino acids, shown N-terminal to C-terminal, from left to right).
Figure 2 shows the N-terminal portion of three proteins of H. pyl ori (exposed in the lowercase letter amino acid code and designated by its Sequence ID Amino acid numbers, shown N-terminal to C-terminal, from left to right ).
Detailed description of the invention In one aspect, the invention highlights a recombinant or substantially pure preparation of the H. pyl ori polypeptide of SEQ ID NO: 98. The invention also includes the substantially pure nucleic acid encoding an H. pyl ori polypeptide of SEQ ID NO: 98, such nucleic acid is contained in SEQ ID NO: 1. The H. pyl ori polypeptide sequences of the invention described herein are contained in the Sequence Listing, and the nucleic acids encoding the H. pyl ori polypeptides of the invention are contained in the Sequence Listing.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 99, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 2.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 100, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 3..
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 101, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: Four.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 102, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 5.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 103, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 6 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 104, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 7 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 105, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 8 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 106, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 9.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 107, such as a nucleic acid comprising a nucleotide sequence of SEQ ID. aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 108, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 11.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 109, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 12 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 110, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 13 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 111, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 14 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 112, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: fifteen.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 113, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 16 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 114, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 17 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 115, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 18 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 116, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 19 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 117, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: twenty.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 118, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: twenty-one.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 119, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 22 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 120, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 2. 3.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 121, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 24 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 122, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 25 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 123, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 26 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 124, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 27 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 125, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 28 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 126, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 29 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 127, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 30 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 128, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 31 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 129, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 32 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 130, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 33 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 131, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 3. 4.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 132, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 35 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 133, 'such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO. : 36 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 134, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 37 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 135, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 38 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 136, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 39 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 137, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: .
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 138, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 41 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 139, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 42 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 140, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 43 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 141, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 44 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 142, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: Four. Five.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 143, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 46 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 144, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 47 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 145, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 48 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 146, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 49 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 147, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: fifty.
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 148, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 51 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 149, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 52 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 150, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 53 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 151, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 54 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 152, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 55 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 153, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 56 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 154, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 57 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 155, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 58 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 156, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 59 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 157, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 60 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 158, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 61 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 159, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 62 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 160, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 63 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 161, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 64 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 162, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 65 .
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 163, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 66 In another aspect, the invention provides a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 164, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 67 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 165, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 68 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 166, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 69 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 167, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 70 In another aspect, the invention provides a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 168, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 71 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 169, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 72 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 170, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 73 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 171, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 74 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 172, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 75 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 173, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 76 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 174, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 77 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 175, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 78 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 176, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 79 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 177, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 80 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 178, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 81 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 179, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 82 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 180, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 83 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 181, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 84 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 182, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 85 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 183, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 86 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 184, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 87 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 185, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 88 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pylori polypeptide having an amino acid sequence of SEQ ID NO: 186, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 89 .
In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 187, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 90 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 188, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 91 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 189, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 92 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 190, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 93 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 191, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 94 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 192, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 95 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 193, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 96 In another aspect, the invention features a substantially pure nucleic acid encoding an H. pyl ori polypeptide having an amino acid sequence of SEQ ID NO: 194, such as a nucleic acid comprising a nucleotide sequence of SEQ ID NO: 97 In another aspect, the invention features an isolated nucleic acid having a nucleotide sequence encoding an H. pyl ori polypeptide of at least about 60% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 98- SEQ ID NO: 194. In a preferred embodiment, the isolated nucleic acid includes a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97, or a complement thereof.
In another aspect, the invention features an isolated nucleic acid having a nucleotide sequence encoding an H. pyl ori polypeptide selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194.
In another aspect, the invention features an isolated nucleic acid encoding an H. pyl ori polypeptide, having a nucleotide sequence of at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 -SEC ID NO: 97, or a complement to it.
In another aspect, the invention features an isolated nucleic acid molecule encoding a H. pyl ori polypeptide, having a nucleotide sequence that hybridizes under stringent hybridization conditions to a nucleic acid molecule having the selected nucleotide sequence. of the group consisting of SEQ ID NO: l-SEQ ID NO: 97, or a complement thereto.
In another aspect, the invention features an isolated nucleic acid having a nucleotide sequence of at least 8 nucleotides in length, wherein the sequence hybridizes under stringent hybridization conditions to a nucleic acid having a nucleotide sequence selected from the group consisting of of SEQ ID NO: 1-SEQ ID NO: 97, or a complement thereto.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a H. pyl ori cell envelope polypeptide or a fragment thereof, the nucleic acid being selected from the group consisting of SEQ ID NO: 63, SEC ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO : 28, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91 , SEQ ID NO: 94, SEQ ID NO: 5, SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEC ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO : 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 34 , SEQ ID NO: 35, SEQ ID NO: 60, SEQ ID NO: 69, and SEQ ID NO: 83, or a complement thereto.
In one embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is a H. pyl ori flagellum-associated polypeptide or a fragment thereof encoded by a nucleic acid having a nucleotide sequence of SEQ ID NO. NO: 63, or a complement to it.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is an internal polypeptide of that of H. pyl ori or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO. : 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, and SEQ ID NO: 39, or a complement of it.
In another embodiment, the inner polypeptide of the H. pyl ori membrane or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in transport encoded by a nucleic acid selected from the group consisting of SEQ ID NO. NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 44, or a complement thereto.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is an outer polypeptide of the H. pyl ori membrane or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO. NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 5, SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 65, and SEQ ID NO: 66, or a complement thereto.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a H. pyl ori polypeptide having a terminal phenylalanine residue or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: ll, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, and SEQ ID NO: 94, or a complement thereto.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is an H. pyl ori polypeptide having a phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof encoded by an acid nucleic acid selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, and SEQ ID NO: 52, or a complement thereto.
An isolated nucleic acid having a nucleotide sequence encoding a H. pylori cell envelope polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 160, SEQ ID NO: 104, SEQ ID NO. NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 103, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 157, SEQ ID NO: 166, and SEQ ID NO: 180.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is a flagellum-associated polypeptide of H. pyl ori or a fragment thereof having an amino acid sequence of SEQ ID NO: 160.
In another embodiment, the inner polypeptide of the H. pyl ori cell envelope or a fragment thereof is an internal polypeptide of the H. pyl ori membrane or a fragment thereof selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 135 and SEQ ID NO: 136.
In another embodiment, the internal polypeptide of the H. pyl ori membrane or a fragment thereof is a H. pyl ori polypeptide or a fragment thereof involved in transport is selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, and SEQ ID NO: 141.
In another embodiment, the cell envelope polypeptide of H. pyl ori o. a fragment thereof is an outer polypeptide of the membrane of. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO: 120, SEC ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO. : 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139 , SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, and SEQ ID NO: 163. In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a H. pyl ori polypeptide having a terminal phenylalanine residue or a fragment thereof selected from the group consisting of SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125 SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 158, SEQ ID NO. : 176, SEQ ID NO: 177, SEQ ID NO: 181 SEQ ID NO: 182, SEQ ID NO: 188, and SEQ ID NO: 191.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a H. pyl ori polypeptide having a terminal phenylalanine residue and a C-terminal tyrosine cluster or fragment thereof selected from the group which consists of SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, and SEQ ID NO: 149.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a cytoplasmic polypeptide of H. pyl ori or a fragment thereof, wherein the nucleic acid is selected from the group consisting of SEQ ID NO: 57, SEQ ID NO. : 58, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 92, and SEQ ID NO: 93, or a complement thereto.
In one embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the translation of the mRNA, wherein the nucleic acid is selected from the group consisting of SEC ID NO: 57, and SEQ ID NO: 58, or a complement thereof.
In another embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome, wherein the nucleic acid is selected from the group consisting of SEQ ID NO. : 86, SEQ ID NO: 87, or a complement thereof.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a H. pyl ori cytoplasmic polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO. .183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 189, and SEQ ID NO: 190.
In one embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in translation of mRNA selected from the group consisting of SEQ ID NO: 154, and SEC ID NO: 155 In another embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome selected from the group consisting of SEQ. NO: 183, and SEQ ID NO: 184.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a cytoplasmic polypeptide of H. pyl ori or a fragment thereof, the nucleic acid being selected from the group consisting of SEQ ID NO: 3, SEQ ID NO, SEC ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 20, SEQ ID NO: 25, SEC ID N0: 31, SEQ ID NO: 32, SEQ ID NO: 45, SEQ ID NO: 46, SEC ID NO: 53, SEQ ID NO: 64, SEQ ID NO: 67, SEQ ID NO: 70, SEC ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEC ID NO: 90, SEQ ID NO: 95, and SEQ ID NO: 97, or a complement thereto.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a secreted polypeptide of H. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 150, SEQ ID NO: 161, SEQ ID NO: 164, SEQ ID NO: 167, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 187, SEQ ID NO: 192, and SEQ ID NO: 194.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a H. pyl ori cellular polypeptide or a fragment thereof, the nucleic acid being selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16 , SEQ ID NO: 21, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 54, SEQ ID NO: 55, SEC ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO : 75, SEQ ID NO: 76, and SEQ ID NO: 96, or a complement thereto.
Particularly preferred is an isolated nucleic acid having a nucleotide sequence encoding a H. pyl ori cellular polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 118, SEQ ID NO: 130, SEQ ID NO: 134, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 156, SEQ ID NO: 159, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, and SEQ ID NO: 193.
In another aspect, the invention features a probe having a nucleotide sequence consisting of at least 8 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97, or a complement thereof. .
In another aspect, the invention features an H. pyl ori polypeptide having an amino acid sequence of an amino acid sequence of at least about 60% homologous to an H. pyl ori polypeptide selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194.
In another aspect, the invention features an isolated H. pyl ori polypeptide that is encoded by a nucleic acid having a nucleotide sequence of at least about 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97. In one embodiment, the polypeptide isolated from H. pyl ori is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97.
In another aspect, the invention features an isolated H. pyl ori polypeptide that is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to a nucleic acid selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97, or a complement thereof.
In another aspect, the invention features an isolated H. pyl ori polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 97-SEQ ID NO: 194.
Particularly preferred is an isolated H. pyl ori cell envelope polypeptide or a fragment thereof wherein the polypeptide is selected from the group consisting of SEQ ID NO: 160, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO.-120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEC ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO. : 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127 , SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEC ID NO: 141, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 103, SEQ ID NO: 131, SEQ ID NO.-132, SEQ ID NO: 157, SEQ ID NO: 166, and SEQ ID NO: 180.
In one embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is a flagellum-associated polypeptide of H. pyl ori or a fragment thereof having an amino acid sequence of SEQ ID NO: 160.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is an internal polypeptide of the H. pyl ori membrane or a fragment thereof selected from the group consisting of SEQ ID NO: 145, SEQ. ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 135, and SEQ ID NO: 136.
In another embodiment, the polypeptide of the inner membrane of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in transport selected from the group consisting of SEQ ID NO: 145, SEQ ID NO-.146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 135, and SEQ ID NO: 136.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is an outer polypeptide of the H. pyl ori membrane or a fragment thereof selected from the group consisting of SEQ ID NO: 104 SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: l39, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, and SEQ ID NO: 163.
In another embodiment, the outer membrane polypeptide of H. pyl ori or a fragment thereof is an H. pyl ori polypeptide having a terminal phenylalanine residue or a fragment thereof selected from the group consisting of SEQ ID NO: 104 , SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: III, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 123, SEC ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 158, SEQ ID NO. : 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, and SEQ ID NO: 191.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a H. pyl ori polypeptide having a terminal phenylalanine residue and a C-terminal tyrosine cluster or fragment thereof selected from the group which consists of SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, and SEQ ID NO: 149.
Particularly preferred is an isolated H. pyl ori cell envelope polypeptide or a fragment thereof, wherein the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 63, SEQ ID NO: 7, SEC ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO : 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94 , SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO: 29, SEC ID NO: 30, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO. : 43, SEQ ID NO: 44, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: l, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 34, SEQ ID NO: 35 , SEQ ID NO: 60, and SEQ ID NO: 69, SEQ ID NO: 83.
In one embodiment, the polypeptide of the cellular envelope H. pyl ori or of a fragment thereof is a polypeptide associated with H. pyl ori scourge or a fragment thereof encoded by a nucleic acid having a nucleotide sequence of SEQ ID NO: 63 In another embodiment, the polypeptide of the cellular envelope H. pyl ori or of a fragment thereof is an inner membrane polypeptide H. pyl ori or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, and SEQ ID NO : 39 In another embodiment, the inner polypeptide of the H. pyl ori membrane or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in transport encoded by a nucleic acid selected from the group consisting of SEQ ID NO. NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 44.
In another embodiment, the H. pyl ori cell envelope polypeptide or a fragment thereof is an outer polypeptide of the H. pyl ori membrane or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO. NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 5, SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 65, and SEQ ID NO: 66.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is an H. pyl ori polypeptide having a terminal phenylalanine residue or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO-11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEC ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO : 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, and SEQ ID NO: 94.
In another embodiment, the outer polypeptide of the H. pyl ori membrane or a fragment thereof is an H. pyl ori polypeptide having a terminal phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, and SEQ ID NO: 52.
Particularly preferred is an isolated H. pyl ori cytoplasmic polypeptide or a fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 183, SEQ ID NO. : 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 189, and SEQ ID NO: 190.
In another embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the translation of mRNA selected from the group consisting of SEQ ID NO: 154 and SEQ ID NO. NO: 155 In another embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome selected from the group consisting of SEQ ID NO. NO: 183, SEQ ID NO: 184.
Particularly preferred is an isolated H. pyl ori cytoplasmic polypeptide or a fragment thereof, wherein the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 92, and SEQ ID NO: 93.
In one embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the translation of mRNA, wherein the polypeptide is encoded by a nucleic acid selected from the group which consists of SEQ ID NO: 57, and SEQ ID NO: 58.
In another embodiment, the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome, wherein the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 86 and SEQ ID NO: 87.
Particularly preferred is an isolated H. pyl ori cell polypeptide or a fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 112 SEQ ID NO: 113, SEQ ID NO: 118, SEQ ID NO: 130, SEQ ID NO: 134, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 156, SEQ ID NO: 159, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, and SEC ID NO: 193 Particularly preferred is an isolated H. pyl ori cell polypeptide or a fragment thereof, wherein the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NOM, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 96.
Particularly preferred is an isolated H. pyl ori secreted polypeptide or fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO. : 109, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 150, SEQ ID NO: 161 , SEQ ID NO: 164, SEQ ID NO: 167, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 187, SEQ ID NO: 192, and SEQ ID NO: 194.
Particularly preferred is an isolated H. pyl ori secreted polypeptide or fragment thereof, wherein the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 3, SEQ ID NOM, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 53 SEQ ID NO: 64, SEC ID NO: 67, SEQ ID NO: 70, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 90, SEQ ID NO: 95, and SEQ ID NO: 97 In another aspect, the invention features a chimeric H. pyl ori polypeptide comprising at least two H. pyl ori polypeptides or fragments thereof wherein the polypeptides are selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97 In another aspect, the invention features an H. pyl ori polypeptide comprising at least two H. pyl ori polypeptides or fragments thereof wherein the polypeptides is selected from the group consisting of SEQ ID NO: 98-SEQ ID NO. : 194 In another aspect, the invention features a fusion protein comprising an H. pyl ori polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194 operably linked to a polypeptide that does not is from H. pyl ori.
In another aspect, the invention provides a vaccine formulation for prophylactic or therapeutic treatment of an H. pyl ori infection comprising an effective amount of at least one isolated nucleic acid of the invention.
In another aspect, the invention provides a vaccine formulation for prophylactic or therapeutic treatment of an H. pyl ori infection comprising an effective amount of at least one H. pyl ori polypeptide of the invention.
Preferably, the vaccine formulation of the invention includes a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutically acceptable carrier includes an adjuvant. In another embodiment, the pharmaceutically acceptable carrier includes a delivery system, e.g. ex. , a living vector, p. ex. a bacterium or a virus. In another embodiment, the pharmaceutically acceptable carrier includes an adjuvant and a delivery system.
In another aspect, the invention provides a method for treating or reducing a risk of H. pylori infection in a subject. The method includes administering to a subject a vaccine formulation of the invention, such that the treatment or reduction of risk of infection of H. pylori is presented.
In another aspect, the invention provides a method for producing a vaccine formulation of the invention. The method includes combining at least one isolated H. pyl ori polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194 with a pharmaceutically acceptable carrier to thereby form a vaccine formulation.
In another aspect, the invention provides a method for producing a vaccine formulation of the invention. The method includes culturing a cell under the condition that allows the expression of a H. pyl ori polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194; isolate the pellypeptide of H. pyl ori from the cell; and combining at least one polypeptide isolated from H. pyl ori or a fragment thereof with a pharmaceutically acceptable carrier to thereby form a vaccine formulation.
In another aspect, the invention relates to any individual H. pyl ori polypeptide or nucleic acid encoding such a member of the groups identified above of the H. pyl ori polypeptides.
In another aspect, the invention offers nucleic acids capable of binding H. pyl ori mRNA. Such a nucleic acid is capable of acting as an antisense nucleic acid to control the translation of H. pyl ori mRNA. An additional aspect offers a nucleic acid which is capable of binding specifically to a H. pyl ori nucleic acid. These nucleic acids are also referred to herein as complements and have utility as probes and as capture reagents.
In another aspect, the invention provides an expression system comprising an open reading frame corresponding to the H. pyl ori nucleic acid. The nucleic acid further comprises a control sequence compatible with a target host. The expression system is useful for making polypeptides corresponding to the H. pyl ori nucleic acid.
In another aspect, the invention features a cell transformed with the expression system to produce H. pyl ori polypeptides.
In another aspect, the invention provides a method for generating antibodies against H. pyl ori polypeptides that are capable of specifically binding to H. pyl ori polypeptides. Such antibodies have utility as immunoprotective reagents to evaluate the abundance and distribution of specific antigens of H. pyl ori.
In another aspect, the invention provides a method for generating vaccines for immunizing an individual against H. pylori. The method of vaccination includes: immunizing a subject with at least one pellypeptide of H. pylori according to the present invention, e.g. ex. , a surface or secreted polypeptide, or active portion thereof, and a pharmaceutically acceptable carrier. Such vaccines have therapeutic and / or prophylactic utilities.
In another aspect, the invention provides a method for generating a vaccine comprising a modified immunogenic H. pyl ori polypeptide, e.g. ex. , a surface or secreted polypeptide, or active portion thereof, and a pharmacologically acceptable carrier.
In another aspect, the invention provides a method for evaluating a compound, e.g. ex. a polypeptide, e.g. ex. , a fragment of a polypeptide of the host cell, by the ability to bind an H. pyl ori polypeptide. The method includes: contacting the candidate compound with an H. pyl ori polypeptide and determining whether the compound binds or otherwise interacts with an H. pyl ori polypeptide. The compounds that bind H. pyl ori are candidates as activators or inhibitors of the bacterial life cycle. These tests can be done in vi tro or in vivo.
In another aspect, the invention provides a method for evaluating a compound, e.g. ex. a polypeptide, e.g. ex. , a fragment of a polypeptide of the host cell, by the ability to bind a H. pyl ori nucleic acid, e.g. e. , DNA or RNA. The method includes: contacting the candidate compound with a H. pyl ori nucleic acid and determining whether the compound binds or otherwise interacts with an H. pyl ori polypeptide. The compounds that bind H. pyl ori are candidates as activators or inhibitors of the bacterial life cycle. These tests can be done in vi tro or in vi vo.
The invention provides polypeptides of H. pyl ori, preferably a substantially pure preparation of a H. pyl ori polypeptide, or a recombinant polypeptide of H. pyl ori. In preferred embodiments: the polypeptide has biological activity; the polypeptide has an amino acid sequence of at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% identical or homologous to an amino acid sequence of the invention contained in the Sequence Listing, preferably has about 65% sequence identity with an amino acid sequence of the invention contained in the Sequence Listing, and more preferably has about 92% to about 99% sequence identity with an amino acid sequence of the invention contained in The List of Sequences; the polypeptide has an amino acid sequence essentially the same as an amino acid sequence of the invention contained in the Sequence Listing; the polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acid residues in length; the polypeptide includes at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acid residues of the invention contained in the Sequence Listing. In yet another preferred embodiment, the amino acid sequence that differs in sequence identity from about 7% to about 8% of the amino acid sequences of H. pyl ori of the invention contained in the Sequence Listing is also encompassed by the invention . , In preferred embodiments: the H. pyl ori polypeptide is encoded by a nucleic acid of the invention contained in the Sequence Listing, or by a nucleic acid having at least 60%, 70%, 80%, 90%, 95% , 98%, or 99% homology with a nucleic acid of the invention contained in the Sequence Listing.
In a preferred embodiment, the subject H. pyl ori polypeptide differs in the amino acid sequence by 1, 2, 3, 5, 10 or more residues of a sequence of the invention contained in the Sequence Listing. The differences, however, are such that the H. pyl ori polypeptide exhibits a biological activity of H. pylori, p. ex. , the H. pyl ori polypeptide maintains a biological activity of the H. pyl ori polypeptide that occurs naturally.
In preferred embodiments, the polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence Listing; fused, in the reading frame, to additional amino acid residues, preferably to residues encoded by 5 'or 3' genomic DNA for the genomic DNA encoding a sequence of the invention contained in the Sequence Listing.
In still other preferred embodiments, the H. pyl ori polypeptide is a recombinant fusion protein having a first portion of the H. pyl ori polypeptide and a second portion of the polypeptide, e.g. ex. , a second portion of polypeptide having an amino acid sequence unrelated to H. pyl ori. The second polypeptide portion can be, e.g. ex. , either glutathione-S-transferase, a domain that binds DNA, or a domain that activates the polymerase. In the preferred embodiment, the fusion protein can be used in a two-hybrid test.
The polypeptides of the invention include those that arise as a result of alternative transcription events, alternative RNA overlap events, and alternative translational and post-translational events.
The invention also encompasses an immunogenic component that includes at least one H. pyl ori polypeptide in an immunogenic preparation; the immunogenic component that is capable of causing a specific immune response of the H. pyl ori polypeptide, p. ex. , a humoral response, an antibody response, or a cellular response. In preferred embodiments, the immunogenic component comprises at least one antigenic determinant of a polypeptide of the invention contained in the Sequence Listing.
In another aspect, the invention provides a substantially pure nucleic acid having a nucleotide sequence that encodes a H. pyl ori polypeptide. In preferred embodiments: the encoded polypeptide has biological activity; the encoded polypeptide has an amino acid sequence of at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homologous to an amino acid sequence of the invention contained in the Sequence Listing; the encoded polypeptide has an amino acid sequence essentially the same as an amino acid sequence of the invention contained in the Sequence Listing; the encoded polypeptide is at least 5, 10, 20, 50, 100, or 150 amino acid residues in length; the encoded polypeptide comprises at least 5, preferably at least 10, more preferably at least 20, more preferably at least 50, 100, or 150 contiguous amino acids of the invention contained in the Sequence Listing.
In preferred embodiments: the nucleic acid of the invention contained in the Sequence Listing; the nucleic acid is at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homologous with a nucleic acid sequence of the invention contained in the Sequence Listing.
In a preferred embodiment, the polypeptide encoded by H. pyl ori differs (eg, by substitution, addition or deletion of amino acid from at least one amino acid residue) in the amino acid sequence in 1, 2, 3, 5, 10 or more residues, of a sequence of the invention contained in the Sequence Listing. The differences, however, are such that: the polypeptide encoded by H. pylori exhibits a biological activity of H. pylori, p. ex. , the enzyme encoded by H. pyl ori maintains a biological activity of one of H. pyl ori that occurs naturally.
In preferred embodiments, the encoded polypeptide includes all or a fragment of an amino acid sequence of the invention contained in the Sequence Listing; fused, in the reading frame, to additional amino acid residues, preferably to residues encoded by 5 * or 3 'genomic DNA for the genomic DNA encoding a sequence of the invention contained in the Sequence Listing.
In preferred embodiments, the H. pyl or ri nucleic acid will include a transcriptional regulatory sequence, e.g. ex. at least one of a transcriptional promoter or a transcriptional enhancer sequence operably linked to the sequence of the H. pyl ori gene, p. ex. , to make the sequence of the H. pyl ori gene suitable for expression in a recombinant host cell.
Still in a further preferred embodiment, the nucleic acid encoding an H. pyl ori polypeptide of the invention, hybridizes under stringent conditions for a nucleic acid probe corresponding to at least 8 consecutive nucleotides of the invention contained in the Sequence Listing.; more preferably at least 12 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably at least 20 consecutive nucleotides of the invention contained in the Sequence Listing; more preferably at least 40 consecutive nucleotides of the invention contained in the Sequence Listing.
In a preferred embodiment, the nucleic acid encodes a peptide that differs at least one amino acid residue from the sequences of the invention contained in the Sequence Listing.
In a preferred embodiment, the nucleic acid differs by at least one nucleotide from a nucleotide sequence of the invention contained in the Sequence Listing which encodes amino acids of the invention contained in the Sequence Listing.
In another aspect, the invention encompasses: a vector that includes a nucleic acid encoding a H. pyl ori polypeptide or a variant of the H. pyl ori polypeptide as described herein; a host cell transfected with the vector; and a method for producing a recombinant H. pyl ori polypeptide or variant of H. pyl ori polypeptide; which includes growing the cell, p. ex. , in a cell culture medium, and isolating the H. pyl ori polypeptide or variant of the H. pyl ori polypeptide, p. ex. , from the cell or from the cell culture medium.
In another aspect, the invention provides, a recombinant nucleic acid having at least 60%, 70%, 80%, 90%, 95%, 98%, or 99% homology with a sequence of the invention contained in the Listing of Sequences The invention also provides a probe or primer that includes a substantially purified oligonucleotide. The oligonucleotide includes a region of the nucleotide sequence which hybridizes under stringent conditions at least 8 consecutive nucleotides of the sense or antisense sequence of the invention contained in the Sequence Listing, or which naturally presents mutants thereof. In preferred embodiments, the probe or primer further includes a label group attached thereto. The brand group can be, p. ex. , a radioisotope, a fluorescent compound, an enzyme, and / or an enzyme co-factor. Preferably the oligonucleotide is at least 8 and less than 10, 20, 30, 50, 100, or 150 nucleotides in length.
The invention also provides an asylated H. pyl ori polypeptide that is encoded by a nucleic acid that hybridizes under stringent hybridization conditions to a nucleic acid contained in the Sequence Listing.
The invention also provides nucleic acids, e.g. ex. , RNA or DNA, which encode a polypeptide of the invention. This includes double-stranded nucleic acids as well as single coding and antisense strands.
The H. pyl ori strain, from which the genomic sequences have been sequenced, has been deposited in the American Type Culture Collection (ATCC # 55679, deposited by Genome Therapeutics Corporation, 100 Beaver Street, Waltham, MA 02154) as an HP strain. -J99.
Included in the invention are: allelic variations; natural mutants; induced mutants; proteins encoded by DNA that hybridizes under conditions of high or low stringency with a nucleic acid encoding a polypeptide of the invention contained in the Sequence Listing (for definitions of high and low stringency see Current Protocols in Molecular Biology, John Wiley &Sons , New York, 1989, 6.3.1-6.3.6, and 6.4.1-6.4.10, incorporated herein by reference); and polypeptides specifically linked by antiserum to H. pyl ori polypeptides, especially by antiserum to an active site or binding domain of the H. pyl ori polypeptide. The invention also includes fragments, preferably biologically active fragments. These and other polypeptides are also referred to herein as analogues or variants of the H. pyl ori polypeptide.
Putative functions have been determined by several of the H. pyl ori polypeptides of the invention, as shown in Table 1.
Therefore, the uses of the claimed H. pyl ori polypeptides based on these identified functions, as well as other functions as described herein, are also within the scope of the invention.
In addition, the present invention encompasses H. pyl ori polypeptides characterized as shown in Table 1 below, which includes: H. pyl ori cell envelope proteins, H. pyl ori secreted proteins, H. cytoplasmic proteins. pyl ori and cellular proteins of H. pyl ori. The members of these groups are identified by searches of BLAST homology and by searches of the secretion signal or parts of the transmembrane protein. The polypeptides related by significant homology to the polypeptides of Table 1 are also considered to be classified in the manner of the homologs shown in Table 1.
TABLE 1 [In Table 1, w nt "represents nucleotide Sec. ID number and" aa "represents amino acid Sec. ID number] Definitions The terms "purified polypeptide" and "asylated polypeptide" and "a substantially pure preparation of a polypeptide" are used interchangeably herein and, as used herein, means a polypeptide that has been substantially, and preferably completely, separated from other proteins, lipids, and nucleic acids with which it occurs naturally. Preferably, the polypeptide is also separated from substances, e.g. ex. , antibodies on a gel matrix, p. ex. , polyacrylamide, which is used to purify it. Preferably, the polypeptide constitutes at least 10, 20, 50, 70, 80 or 95% dry weight of the purified preparation. Preferably, the preparation contains: sufficient polypeptide to allow sequencing of the protein; at least 1, 10, 0 100 μg of the polypeptide; at least 1, 10, or 100 mg of the polypeptide. In addition, the terms "purified polypeptide" and "isolated polypeptide" and "substantially pure preparation of a polypeptide", as used herein, refers to a polypeptide obtained naturally or produced by recombinant DNA techniques as described herein.
For example, an "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the H. pyl ori protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The term "substantially free of cellular material" includes preparations of the H. pyl ori protein in which the protein is separated from the cellular components of the cells from which they are isolated or recombinantly produced. In one embodiment, the term "substantially free of cellular material" includes preparations of the H. pyl ori protein having less than about 30% (dry weight) of non-H. pyl ori protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% protein that is not H. pyl ori, even more preferably less than about 10% protein which is not H. pyl ori, and more preferably less than about 5% protein which is not H. pyl ori. When the H. pyl ori protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, e.g. ex. , the culture medium represents less than about 20%, more preferably less than about 10%, and more preferably less than about 5% of the volume of the protein preparation.
The term "substantially free of chemical precursors or other chemicals" includes preparations of the H. pyl ori protein in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the term "substantially free of chemical precursors or other chemicals" includes preparations of the H. pyl ori protein having less than about 30% (dry weight) of non-H chemical or chemical precursors. pyl ori, more preferably less than about 20% chemical or chemical precursors that are not H. pyl ori, even more preferably less than about 10% chemical or chemical precursors that are not H. pyl ori, and more preferably less than about 5% chemical or chemical precursors that are not H. pyl ori.
A "purified cell preparation" refers to, in the case of plant or animal cells, an in vitro preparation of cells and not a whole intact plant or animal. In the case of cultured cells or microbial cells, it consists of a preparation of at least 10% and more preferably 50% of the cells of the subject.
A purified or isolated or substantially pure nucleic acid, e.g. ex. , a substantially pure DNA, (are interchangeably used terms herein) is a nucleic acid that is one of the following: not immediately contiguous with both of the coding sequences with which it is immediately contiguous (eg, one at the 5 terminus). 'and one at the 3' end) in the genome of the naturally occurring organism from which the nucleic acid is derived; or that is substantially free of a nucleic acid with which it occurs in the organism from which the nucleic acid is derived. The term includes, for example, a recombinant DNA that is incorporated into a vector, e. ex. , in a plasmid or virus that replicates autonomously, or in the genomic DNA of a prokaryote or eukaryote, or that exists as a separate molecule (eg, a cDNA or a DNA fragment produced by PCR or endonuclease treatment of restriction) independent of other DNA sequences. The substantially pure DNA also includes a recombinant DNA that is part of a hybrid gene that encodes the additional H. pyl ori sequence.
A "contiguous" as used herein is a nucleic acid representing a continuous extension of the genomic sequence of an organism.
An "open reading frame", also referred to herein as ORF, is a region of nucleic acid encoding a polypeptide. This region could represent a portion of a coding sequence or a total sequence and can be determined from a stop to stop codon or from a start to stop codon.
As used herein, a "coding sequence" is a nucleic acid that is transcribed into messenger RNA and / or translated into a polypeptide when placed under the control of the appropriate regulatory sequences. The limits of the coding sequence are determined by a translation start codon in the first five terms and a translation stop code in the first three terms. A coding sequence can include but is not limited to messenger RNA, synthetic DNA, and recombinant nucleic acid sequences.
A "complement" of an acid as used herein refers to an anti-parallel or antisense sequence that participates in the pairing of Watson-Crick bases with the original sequence.
A "gene product" is a protein or structural RNA that is specifically encoded by a gene.
As used herein, the term "probe" refers to a nucleic acid, peptide or other chemical entity that specifically binds to a molecule of interest. Probes are often associated with being able to associate with a mark. A brand is a chemical radical capable of detection. Typical labels include dyes, radioisotopes, luminescent and chemiluminescent radicals, fluorophores, enzymes, precipitation agents, amplification sequences, and similar. Similarly, a nucleic acid, peptide, or other chemical entity that specifically binds to a molecule of interest and immobilizes such a molecule is referred to as a "capture ligand". Capture ligands are typically associated with or capable of associating with a support such as nitro-cellulose, glass, nylon membranes, beads, particles and the like. Hybridization specificity is dependent on conditions such as the base pair composition of the nucleotides, and the temperature and salinity of the reaction. These conditions are easily discernible to one of ordinary skill in the art using routine experimentation.
Homolog refers to a sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When occupying a position in both of the two sequences compared by the same base or subunit of amino acid monomer, p. ex. If a position is occupied in each of the two DNA molecules by adenine, then the molecules are homologous in that position. The percent homology between the two sequences is a function of the number of equal or homologous positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 of the 10 positions in the two sequences are coupled or homologous then the two sequences are 60% homologous. By way of example, the DNA sequences ATTGCC and TATGGC share 50% homology. In general, a comparison is made when the two sequences are aligned to give maximum homology.
The nucleic acids are hybridizable with respect to each other when at least one strand of the nucleic acid can align the other nucleic acid under the defined stringency conditions. The hybridization stringency is determined by: (a) the temperature at which hybridization and / or washing is performed; (b) the ionic strength and the hybridization polarity of the washing solutions. Hybridization requires that the two nucleic acids contain complementary sequences; depending on the hybridization astringency, however, poor couplings could be tolerated. Typically, hybridization of two high stringency sequences (such as, for example, in a SSC solution, 0.5X to 65 ° C) requires that the sequences be essentially completely homologous. The conditions of intermediate astringency (such as, for example, 2X SSC at 65 ° C) and inferior astringency (such as, for example, 2X SSC at 55 ° C), require correspondingly less overall complementarity between the two hybridization sequences. (SSC IX is 0.15 M NaCl, 0.015 M Na citrate). A preferred, non-limiting example of the stringent hybridization conditions are hybridization in sodium chloride / 6X sodium citrate (SSC) at about 45 ° C, followed by one or more washes in SSC, 0.2X, 0.1% SDS a 50-65 ° C.
The terms peptides, proteins and polypeptides are used interchangeably herein.
As used herein, the term "surface protein" refers to all surface accessible proteins, e.g. ex. proteins of the internal and external membrane, proteins that adhere to the cell wall and secreted proteins.
A polypeptide has the biological activity H. pyl ori if it has one, two and preferably more of the following properties: (1) if, when expressed in the course of an H. pyl ori infection, it may promote, or mediate, the binding of H. pyl ori to a cell; (2) has an enzymatic activity, structural or regulatory function characteristic of a protein H. pyl ori; (3) the gene it encodes can rescue a lethal mutation in a H. pyl ori gene; (4) or is immunogenic in a subject. A polypeptide has biological activity if it is an antagonist, agonist or super-agonist of a polypeptide having one of the properties listed above.
A biologically active fragment or analog is one that has an in vi ve or in vi tro activity that is characteristic of the H. pyl ori polypeptides of the invention contained in the Sequence List, or of other naturally occurring H. pyori polypeptides. , p. ex. , one or more of the biological activities described here. Especially preferred are fragments that exist in vi, p. ex. , fragments that undergo post-transcriptional processing or that undergo translation of bound RNAs. The fragments include those expressed in native or endogenous cells in addition to those elaborated in the expression systems, e.g. ex. , in CHO cells. Because peptides such as H. pyl ori polypeptides frequently exhibit a range of physiological properties and because such properties could be attributable to different portions of the molecule, a fragment of H. pyl ori used or an analogue of H. pyl ori is one that exhibits a biological activity in any biological test for the activity of H. pyl ori. The most preferred fragment or analog possesses 10%, preferably 40%, more preferably 60%, 70%, 80% or 90% or greater of the activity of H. pylori, in any in vi ve or in vi tro test.
Analogs may differ from H. pyl ori polypeptides that occur naturally in the amino acid sequence or in forms that do not involve sequence, or both. Non-sequential modifications include changes in acetylation, methylation, phosphorylation, carboxylation or glycosylation. Preferred analogs include H. pyl ori polypeptides (or biologically active fragments thereof) whose sequences differ from the wild-type sequences by one or more conservative amino acid substitutions or by one or more non-conservative amino acid substitutions, substitutions, deletions or insertions that do not substantially decrease the biological activity of the H. pyl ori polypeptide. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, e.g. ex. , substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine and phenylalanine, tyrosine. Other conservative substitutions can be made in consideration of the following table.
TABLE 2 CONSERVATIVE AMINO ACID REPLACEMENTS Other analogs within the invention are those with the modifications that increase the stability of the peptide; such analogs could contain, for example, one or more non-peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: analogues that include residues other than naturally occurring L-amino acids p. ex. , D-amino acid or that do not occur naturally or synthetic amino acids, p. ex. , amino acids ß or?; and the cyclic analogues.
As used herein, the term "fragment," as applied to an H. pyl ori analog, will ordinarily be at least about 20 residues, more typically at least 40 residues, preferably at least 60 residues in length. Fragments of H. pyl ori polypeptides can be generated by methods known to those skilled in the art. The ability of a candidate fragment to exhibit a biological activity of the polypeptide of go. pyl ori can be ascertained by methods known to those skilled in the art as described above. Also included are H. pyl ori polypeptides that contain residues that do not require the biological activity of the peptide or that result from the alternative binding of mRNA or the cases of alternative processing of the protein.
An "immunogenic component" as used herein is a radical, such as an H. pyl ori polypeptide, analog or fragment thereof, that is capable of obtaining a humoral and / or cellular immune response in a host animal alone or in combination with an adjuvant.
An "antigenic component" as used herein is a radical, such as an H. pyl ori polypeptide, analog or fragment thereof, that is capable of binding to a specific antibody with sufficiently high affinity to form an antigen-antibody complex. detectable As used herein the term "transgene" means a nucleic acid (encoding, eg, one or more polypeptides), which is partially or completely heterogeneous, e.g. ex. , foreign, to the transgenic animal or the cell to which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell to which it is introduced, but which is designed to be inserted, or inserted, into the genome of the cell in such a way as to alter the genome of the cell into which it is inserted (eg, it is inserted in a location that differs from the natural gene or its insertion results in damage). A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, which might be necessary for optimal expression of the selected nucleic acid, all operably linked to the selected nucleic acid, and could include an enhancer sequence.
As used herein, the term "transgenic cell" refers to a cell that contains a transgene.
As used herein, a "transgenic animal" is any animal in which one or more, and preferably essentially all, of the cells of the animal includes a transgene. The transgene can be introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by a process of transformation of the component cells or by microinjection or by injection with a recombinant virus. This molecule could be integrated into a chromosome, or it could be extrachromosomally duplicated DNA.
The term "antibody" as used herein is intended to include fragments thereof which are specifically reactive with the H. pyl ori polypeptides.
As used herein, the term "cell-specific promoter" means a DNA sequence that serves as a promoter, e.g. ex. , regulates the expression of a selected DNA sequence operably linked to the promoter, and which effects the expression of the selected DNA sequence on the specific cells of a tissue. The term also covers so-called "weak" promoters, which regulate the expression of a DNA selected primarily in a tissue, but also cause expression in other tissues.
Mis-expression, as used herein, refers to a non-wild-type pattern of gene expression. Includes: expression at non-wild type levels, p. ex. , on or under expression; an expression pattern that differs from the wild type in terms of the time or stage at which the gene is expressed, p. ex. , increased or decreased expression (as compared to wild type) to a predetermined period or development stage; an expression pattern that differs from the wild type in terms of diminished expression (as compared to the wild type) in a predetermined cell type or tissue type; an expression pattern that differs from the wild type in terms of the binding size, the amino acid sequence, the post-transitional modification, or the biological activity of the expressed polypeptide; an expression pattern that differs from the wild type in terms of the effect of an environmental stimulus or extracellular stimulus on gene expression, p. ex. , an increased or decreased expression pattern (as compared to the wild type) in the presence of an increase or decrease in the strength of the stimulus.
As used herein, "host cells" and other terms denote microorganisms or cultured higher eukaryotic cell lines or unicellular entities refer to cells that may become or have been used as receptors for a recombinant vector or other transferred DNA, and include the progeny of the original cell that has been transfected. It is understood by individual experts in the art that the progeny of a single parental cell could not necessarily be completely identical in the compliance of genomic or total DNA with respect to the original cell, due to accident or deliberate mutation.
As used herein, the term "control sequence" refers to a nucleic acid having a base sequence which is recognized by the host organism to effect the expression of the encoded sequences to which they are linked. The nature of such control sequences differ depending on the host organism; in prokaryotes, such control sequences generally include a promoter, a ribosomal binding site, terminators, and in some cases operators; in eukaryotes, they generally include sequences that include promoters, terminators and, in some cases, enhancers. The term "control sequence" is intended to include to a minimum, all components whose presence is necessary for expression, and could also include additional components whose presence is advantageous, for example, leader sequences.
As used herein, the term "operably linked" refers to sequences linked or linked to function in the manner intended. For example, a control sequence is operably linked to encode the sequence by ligation such that expression of the coding sequence is achieved under conditions compatible with the control sequence in the host cell.
The metabolism of a substance, as used herein, means any aspect of the expression, function, action or regulation of the substance. The metabolism of a substance includes the modifications, p. ex. , covalent or non-covalent modifications of the substance. The metabolism of a substance includes the modifications, p. ex. , covalent or non-covalent modification, the substance is induced in other substances. The metabolism of a substance includes the changes that the substance induces in the distribution of the other substances.
A "sample" as used herein refers to a biological sample, such as, for example, tissue or fluid isolated from an individual (including without limitation plasma, serum, cerebrospinal fluid, lymph, tears, saliva and other sections of tissue) or the constituents of the cell culture in vi tro, in addition to the samples of the environment.
The practice of the invention will employ, unless otherwise indicated, the conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA and immunology, which are well within the skill of the art. Such techniques are fully explained in the literature. See p. ex. , Sambrook, Fritsch, and Maniatis, Mol ecular Cl oning; Labora tory Manual 2nd ed. (1989); DNA Cloning, Volumes I and II (D.?. Glover ed., 1985); Oli gonu cl eoti by Syn thesi s (M.J. Gait ed., 1984); Nucl ei c Aci d Hybri di za ti on (B. D. Hames &S.J. Higgins eds, 1984); the series, Methods in Enzymolgy (Academic Press, Inc.), particularly Vol. 154 and Vol. 155 (Wu and Grossman, eds.) and PCR -A Pra cti cal Approa ch (McPherson, Quirke, and Taylor, eds. , 1991) I. Isolation of Nucleic Acids from H. o? L ori and Uses of the Same Genomic sequence of H. p? L ori This invention provides the nucleotide sequence of the genome of H. pyl ori which thus comprises a library of the DNA sequence of the genomic DNA of H. pyl ori. The detailed description of continues provides the nucleotide sequences of H. pyl ori, and also describes how the sequences were obtained and how the ORF and coding sequences of the protein were identified. Methods for using the H. pyl ori sequences discussed in methods that include diagnostic and therapeutic applications are also described. In addition, the library can be used as a database for the identification and comparison of medically important sequences in this and other strands of H. pyl ori.
To determine the genomic sequence of H. pylori, the DNA was isolated from a strand of H. pylori (ATCC # 55679, deposited by Genome Therapeutics Corporation, 100 Beaver Street, Waltham, MA 02154) and mechanically cut by nebulization at an average size of 2 kb. Following size fractionation by gel electrophoresis, the fragments are cut, ligated to adapt the oligonucleotides, and cloned into each 20 different pMPX vectors (Rice et al., Abstracts of Meeting of Genome Mapping and Sequencing, Cold Spring Harbor, NY , 5 / 11-5 / 15, 1994, p.225) to construct a series of "shotgun" subclone libraries.
DNA sequencing was achieved using multiplex sequencing procedures essentially as set forth in Church et al., 1988, Sci ence 240: 185; U.S. Patent No. 4,942,124 and 5,149,625). The DNA was extracted from the poured cultures and subjected to chemical or enzymatic sequencing. The sequencing reactions were resolved by electrophoresis, and the products were transferred and covalently bound to the nylon membranes. Finally, the membranes were hybridized sequentially with a series of labeled oligonucleotides complementary to the tag sequences present in the different cloning vectors of the shooting gun. In this way, a large number of sequences could be obtained from a single group of sequencing reactions. The cloning and sequencing procedures are described in more detail in the Embodiment Example.
The readings of the individual sequences obtained in this way are assembled using the FALCON ™ program (Church et al., 1994, Automated DNA Sequencing and Analyzes, JC Venter, ed., Academic Press) and PHRAP (P. Green, Abstracts of DOE Human Genome Program Contractor-Grantee Workshop V. Jan. 1996, p.157). The contiguous length was approximately 3-4 kb.
A variety of methods are used to order the contiguous to obtain a continuous sequence representing the genome of H. pyl ori total. The synthetic oligonucleotides are designed to be complementary to the sequences at the end of each contiguous one. These oligonucleotides could be hybridized to the libraries of the genomic DNA of H. pyl ori in, for example, the phage lambda vectors or the plasmid vectors to identify the clones containing the sequences corresponding to the binding regions between the individual contiguous ones. Such clones are then used to isolate the template DNA and the same oligonucleotides are used as the primers in the polymerase chain reaction (PCR) to amplify the binding fragments, the nucleotide sequence of which is then determined.
The sequences of H. pyl ori are analyzed for the presence of open reading frames (ORF) comprising at least 1.80 oligonucleotides. As a result of the ORF analysis based on the stop-to-stop codon readings, it should be understood that these ORFs could not correspond to the ORF of the naturally occurring H. pyl ori polypeptide. These ORFs may contain the starter codons that indicate the initiation of protein synthesis of a naturally occurring H. pyl ori polypeptide. Such initiator codons within the ORFs provided herein can be identified by those of ordinary skill in the relevant art, and the resulting ORF and the encoded H. pyl ori polypeptide is within the scope of this invention. For example, within the ORFs as a codon such as AUG or GUG (which encodes methionine or valine) which is part of the initiation signal for protein synthesis can be identified and the ORF modified to a polypeptide of H. pyl ori that occurs naturally. The predicted coding regions were defined by evaluating the coding potential of such sequences with the GENEMARK ™ program (Borodovsky and Mclninch, 1993, Comp.Chem.Id: 123).
Other Nucleic Acids of H. p? L ori The nucleic acids of this invention could be obtained directly from the DNA of the H. pyl ori strain referred to above using the polymerase chain reaction (PCR). See "PCR A Pra cti cal Approa ch" (McPherson, Quirke, and Taylor, eds., IRL Press, Oxford, UK, 1991) for details about PCR. High fidelity PCR can be used to ensure a faithful copy of the DNA before expression. In addition, the authenticity of the amplified products can be verified by conventional sequencing methods. Clones carrying the desired sequences described in this invention could also be obtained by screening the libraries by means of PCR or by hybridization of the synthetic oligonucleotide probes to filter the removals of the colonies or plaques from the library as known in the art ( see, eg, Sambrook et al., Mol ecular Cloning, A Labora tory Manual 2nd edition, 1989, Cold Spring Harbor Press, NY).
It is also possible to obtain the nucleic acids encoding the H. pyl ori polypeptides from a cDNA library according to the protocols described herein. A cDNA encoding a H. pyl ori polypeptide can be obtained by isolating the total mRNA from an appropriate strain. The double-stranded ssDNA can then be prepared from the mRNA. Subsequently, the cDNAs can be inserted into an appropriate plasmid or virus vector (e.g., bacteriophage) using any number of known techniques. The genes encoding the H. pyl ori polypeptides can also be cloned using the polymerase chain reaction techniques established according to the nucleotide sequence information provided by the invention. The nucleic acids of the invention can be DNA or RNA. Preferred nucleic acids of the invention are contained in the Sequence List.The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing polydeoxynucleotides are known, including solid phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See, eg, Itakura et al., US Pat. No. 4,598,049, Caruthers et al, US Patent No. 4,458,066, and Itakura US Patent Nos. 4,401,796 and 4,373,071, incorporated herein by reference).
The nucleic acids isolated or synthesized according to the characteristics of the present invention are used, for example, without limitation, as probes, primers, capture ligands, antisense genes and for the development of expression systems for the synthesis of the proteins and peptides corresponding to such sequences. As the probes, primers, capture ligands and antisense agents, the nucleic acid normally consists of all or part (approximately twenty or more nucleotides for specificity in addition to the ability to form stable hybridization products) of the nucleic acids of the invention contained in the Sequence List. These uses are described in greater detail later Probes An isolated or synthesized nucleic acid according to the sequence of the invention contained in the Sequence List can be used as a probe to specifically detect H. pyl ori. With the sequence information set forth in the present application, sequences of twenty or more nucleotides are identified that provide the desired inclusiveness and exclusivity with respect to H. pyl ori, and foreign nucleic acids are likely to be found during the conditions of hybridization. More preferably, the sequence will comprise at least twenty to thirty nucleotides to bring stability to the hybridization product formed between the probe and target target molecules.
Sequences greater than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques. Individuals skilled in the art will readily recognize that nucleic acids, for use as probes, can be provided with a tag to facilitate the detection of a hybridization product.
The nucleic acid isolated and synthesized according to the sequence of the invention contained in the Sequence List as probes for detecting the homologous regions (especially homologous genes) of other Heli cobacter species using the appropriate astringent hybridization conditions as described here .
Capture Ligand For use as a capture ligand, the nucleic acid selected in the manner described above with respect to the probes may be readily associated with a support. The manner in which the nucleic acid is associated with the supports is well known. Nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence List is useful for separating the H. pyl ori nucleic acid from the nucleic acid of each of the other organisms. The nucleic acid having twenty or more nucleotides in a sequence of the invention contained in the Sequence List may also have utility in separating other Heli cobacter species from each of the other organisms. Preferably, the sequences will comprise at least twenty nucleotides to bring stability to the hybridization product formed between the probe and target target molecules. Sequences greater than 1000 nucleotides in length are difficult to synthesize but can be generated by recombinant DNA techniques.
Primers The nucleic acid isolated or synthesized according to the sequences described herein have utility as primers for the amplification of the H. pyl ori nucleic acid. These nucleic acids could also have utility as primers for the amplification of nucleic acids in other species of Heli cobater. With respect to polymerase chain reaction (PCR) techniques, the nucleic acid sequences of = 10-15 nucleotides of the invention contained in the Sequence List have utility in conjunction with appropriate enzymes and reagents to create copies of the H. pyl ori nucleic acid. More preferably, the sequence will comprise twenty or more nucleotides to bring the stability to the hybridization product formed between the primer and the targeted target molecules. The binding conditions of primers greater than 100 nucleotides are more difficult to control to obtain specificity. High fidelity PCR can be used to ensure a faithful copy of DNA before expression. In addition, the amplified products can be verified by conventional sequencing methods.
The copies can be used in diagnostic tests to detect specific sequences, which include the genes of H. pyl ori and / or other Heli cobacter species. The copies can also be incorporated into the cloning and expression vectors to generate the polypeptides corresponding to the nucleic acid synthesized by PCR, as described herein in greater detail.
Antisense The nucleic acid or nucleic acid hybridization derivatives isolated or synthesized according to the sequences described herein have utility as antisense agents to prevent the expression of the H. pyl ori genes. These sequences also have utility as antisense agents to prevent the expression of the genes of other Heli cobater species.
In one embodiment, the nucleic acid or derivatives corresponding to the H. pyl ori nucleic acids is loaded into an appropriate vehicle such as a liposome or bacteriophage for introduction into the bacterial cells. For example, a nucleic acid having twenty or more nucleotides is capable of binding bacterial nucleic acid and bacterial messenger RNA. Preferably, the antisense nucleic acid is comprised of 20 or more nucleotides to provide the necessary stability of a hybridization product of the non-naturally occurring nucleic acid and of the bacterial nucleic acid and / or the bacterial messenger RNA. Nucleic acid having a sequence greater than 1000 nucleotides in length is difficult to synthesize but can be generated by recombinant DNA techniques. Methods for loading the antisense nucleic acid into liposomes are known in the art as exemplified by U.S. Pat. 4,241,046 published on December 23, 1980 by Papahadj opoulos et al.
II. Expression of the Nucleic Acids of H. Oyl ori Nucleic acid isolated or synthesized according to the sequences described herein is useful for generating polypeptides. The nucleic acid of the invention exemplified in the Sequence Listing or fragments of the nucleic acid encoding the active portions of the H. pyl ori polypeptides can be cloned into the appropriate vectors or used to isolate the nucleic acid. The isolated nucleic acid is combined with the appropriate DNA linkers and cloned into an appropriate vector.
The function of a specific gene or operon can be ascertained by expression in a bacterial strain under conditions wherein the activity of the gene products specified by the gene or operon in question can be specifically measured. Alternatively, a gene product could be produced in large quantities in an expression strain for use as an antigen, an industrial reagent, for structural studies, etc. This expression can be performed in a mutant strain which lacks the activity of the gene to be tested, or in a strain that does not produce the same gene products. This includes, but is not limited to other strains of Heli cobacter, or other bacterial strains such as E species. coli, Norcardia, Corynebacterium, Campylobacter and Streptomyces. In some cases the expression host will use the natural promoter of Heli cobater while in others, it will be necessary to boost the gene with a promoter sequence derived from the expression organism (eg, a beta-galactosidase promoter from E. the expression in E. col i).
To express a product of the gene using the natural H. pyl ori promoter, a method such as the following may be used. A restriction fragment containing the gene of interest, together with its associated natural promoter element and regulatory sequences (identified using the DNA sequence data) is cloned into an appropriate recombinant plasmid containing an origin of replication that functions in the host organism and an appropriate selectable marker. This can be done by a number of procedures known to those skilled in the art. It is most preferably performed by cutting the plasmid and the fragment to be cloned with the same restriction enzyme to produce compatible ends that can be ligated to join the two pieces. The recombinant plasmid is introduced into the host organism by, for example, electroporation and the cells containing the recombinant plasmid are identified by selection for the marker on the plasmid. The expression of the desired gene product is detected using a specific test for such gene product.
In the case of a gene that requires a different promoter, the body of the gene (coding sequence) is cut and cloned into an appropriate expression plasmid. This subcloning can be carried out by several methods, but is carried out more easily by PCR amplification of a specific fragment and ligation in an expression plasmid after treating the PCR product with a restriction enzyme or exonuclease to create the appropriate ends for cloning A suitable host cell for the expression of a gene can be any prokaryotic or eukaryotic cell. For example, an H. pyl ori polypeptide can be expressed in bacterial cells such as E. coli, insect cells (baculovirus), yeast or mammalian cells such as Chinese hamster ovarian cells (CHO). Other appropriate host cells are known to those skilled in the art.
Expression in eukaryotic cells such as mammalian, yeast or insect cells can lead to partial or total glycosylation and / or formation of inter- or intra-chain disulfide bonds of a recombinant peptide product. Examples of the expression vectors in yeast S. ceri vi sa and include pYepSecl (Baldari, et al., (1987) Embo J. 6_ 229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30: 933-943),? JRY88 (Schultz et al., (1987) Gene 54l 113-123), and pYES2 (Invitrogen Corporation, San Diego, CA).
Baculovirus vectors available for the expression of proteins in cultured insect cells (SF 9 cells) include the pAc series (Smith et al., (1983) Mol. Cell Bi ol. _ 2156-2165) and the pVL series (Lucklow, V.A., and Summers, M.D., (1989) Virol osv 170: 31-39). In general, COS cells (Gluzman, Y., (1981) Cell 23: 175-182) are used in conjunction with such vectors as pCDM 8 (Aruffo, A. and Seed, B., (1987) Proc. Na tl. Acad. Sci. USA 84 .: 8573-8577) for transient amplification / expression in mammalian cells, while CHO cells (Chinese hamster ovaries dhfr ") are used with vectors such as pMT2PC (Kaufman et al. (1987), EMBO J. 6: 187-195) for stable amplification / expression in mammalian cells Vector DNA can be introduced into mammalian cells via conventional techniques such as co-precipitation of calcium phosphate or calcium chloride , DEAE-dextran-mediated transfection or electroporation Appropriate methods for the transformation of host cells can be found in Sambrook et al. (Molecular Clonins: A Laboratorv Manual, 2nd edition, Cold Spring Harbor Laboratory Press (1989)), and other manuals from laboratory .
Expression in prokaryotes is most frequently carried out in E. col i with either inducible fusion or non-fusion expression vectors. The fusion vectors usually add a number of terminal NH 2 amino acids with respect to the expressed target gene. These terminal NH2 amino acids are referred to as a reporter group. Such reporter groups usually serve two purposes: 1) increase the solubility of the target recombinant protein; and 2) aid in the purification of the target recombinant protein by acting as a ligand in the affinity purification. Frequently, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the reporter group and the target recombinant protein to allow separation of the target recombinant protein from the reporter group subsequent to the purification of the fusion. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England BioLabs, Beverly, Mass.) And pRIT5 (Pharmacia, Piscataway, NJ) that fuse glutathione S-transferase, a maltose binding protein. , or protein A, respectively, to the target recombinant protein. A preferred reporter group is poly (His), which could be fused to the amino or carboxy terminus of the protein and which makes the recombinant fusion protein easily purifiable by metal chelate chromatography.
The inducible non-fusion expression vectors include pTrc (Amann et al., (1988) Gene. 69: 301-315) and pETlld (Studier et al., Gene Expression Technology: Methods in Enzvmolo v 185, Academic Press, San Diego , California (1990) 60-89). While the expression of the target gene depends on the transcription of polymerase from the host RNA of the hybrid trp-lac fusion promoter in pTrc, the expression of the target genes inserted in pETlld depends on the transcription of the T7 gnlO-lac fusion promoter. 0 mediated by co-expressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by the BL21 (DE3) or HMS174 (DE3) host strains of a profago? resident that protects a T7 gnl under the transcriptional control of the lacUV 5 promoter.
For example, a host cell transfected with a nucleic acid vector that directs the expression of a nucleotide sequence encoding a H. pyl ori polypeptide can be cultured under the appropriate conditions to allow expression of the polypeptide to occur. The polypeptide could be secreted and isolated from a mixture of cells and the medium containing the peptide. Alternatively, the polypeptide could be retained cytoplasmically in the harvested, lysed and isolated proteins. A cell culture includes the host cells, the medium and other by-products. Suitable media for cell culture are well known in the art. The polypeptides of the invention can be isolated from the cell culture medium, the host cells or both using art-known techniques to purify proteins including ion exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and purification. immunoaffinity with antibodies specific for such polypeptides. Additionally, in many situations, the polypeptides can be produced by chemical cleavage of the native protein (eg, tryptic digestion) and the products of the cut can then be purified by standard techniques.
In the case of membrane-bound proteins, these can be isolated from a host cell by contacting a fraction of the protein associated by the membrane with a detergent that forms a solubilized complex, wherein the membrane-associated protein already it is not completely surrounded in the fraction of the membrane and it is solubilized at least to a degree that allows it to be isolated chromatographically from the fraction of the membrane. Many different criteria are used to choose an appropriate detergent to solubilize these complexes. For example, one property considered is the ability of the detergent to solubilize the H. pyl protein ori within the fraction of the membrane to minimal membrane-associated protein denaturation that allows the activity or functionality of the membrane-associated protein to return due to the reconstitution of the protein. Another property considered when detergent is selected is the critical micelle concentration (CMC) of the detergent wherein the detergent of choice has a high CMC value allowing ease of removal after reconstitution. A third property considered when selecting a detergent is the hydrophobicity of the detergent. Typically, membrane-associated proteins are very hydrophobic and therefore detergents that are also hydrophobic, e.g. ex. , the triton series, would be used to solubilize the hydrophobic proteins. Other important property for a detergent may be the detergent's ability to remove H. pyl ori protein with minimal protein-protein interaction facilitating further purification. A fifth property of the detergent that should be considered is the loading of the detergent. For example, if it is desired to use the ion exchange resins in the purification process then the detergent should preferably be an unfilled detergent. Chromatographic techniques that can be used in the final purification step are known in the art and include hydrophobic interaction, lectin affinity, ion exchange, affinity to dyes and immunoability.
Another strategy to maximize expression of recombinant H. pylori ori peptide in E. col i is expressing the protein in a host bacterium with a weakened ability to proteolytically cut the recombinant protein (Gottesman, S., Gene Exprssion Technology: Methods in Enzvmology 185, Academic Press, San Diego, California (1990) 119-128). Another strategy would be to alter the nucleic acid encoding an H. pyl ori peptide to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially used in the E proteins. col i highly expressed (Wada et al., (1992) Nuc. Aci ds Res. 20 .: 2111-2118). Such alteration of the nucleic acids of the invention can be carried out by standard DNA synthesis techniques.
The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods are known for chemically synthesizing polydeoxynucleotides, including solid phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See, eg, Itakura et al., US Patent No. 4,598,049; Caruthers et al, US Patent No. 4,458,066; and Itakura, US Patent Nos. 4,401,796 and 4,373,071, incorporated herein by reference).
III. Polypeptides of H. vyl ori This invention encompasses the isolated H. pyl ori polypeptides encoded by the exposed genomic sequences of H. pylori ori, which include the polypeptides of the invention contained in the Sequence Listing. The polypeptides of the invention are preferably at least 5 amino acid residues in length. Using the information of the DNA sequence provided herein, the amino acid sequences of the polypeptides encompassed by the invention can be deduced using methods well known in the art. It will be understood that the total sequence of the nucleic acid encoding a H. pyl ori polypeptide can be isolated and identified based on an ORF that encodes only a fragment of the cognate of the region encoding the protein. This can be achieved, for example, by using the isolated nucleic acid encoding the ORF, or fragments thereof, to prepare a polymerase chain reaction with H. pyl genomic DNA as a template; this is continued by sequencing the amplified product.
The polypeptides of the invention can be isolated from wild-type or mutant H. pyl ori cells or from heterogeneous organisms or cells (including, but not limited to, bacteria, yeast, insect, plant and mammalian cells) in the which an H. pyl ori nucleic acid has been introduced and expressed. In addition, the polypeptides can be part of the recombinant fusion proteins.
The H. pyl ori polypeptides of the invention can be chemically synthesized using commercially automated methods such as those referred to herein.
The H. pyl ori polypeptides of the invention are also intended to include chimeric proteins and truncated proteins as described herein.
Chimeric Proteins of H. P? L ori Chimeric H. pyl ori polypeptides comprise one or more fused H. pyl ori polypeptides. These combined sequences can be made by combining two or more genes, or two or more polypeptides encoding the sequences, or at least one gene and at least one polypeptide encoding the sequence in series, and the subsequent expression of the proteins encoded by the techniques of conventional molecular biology. The combined nucleotide sequences could be ordered from a combination of full length H. pyl ori nucleotide sequences or fragments of such sequences, e.g. ex. , the fragments containing the immunologically relevant portions of the encoded H. pyl ori protein. These chimeric H. pyl ori proteins then contain the potential combined or synergistic vaccine of each individual sequence of the H. pyl ori protein and can be used in the formulations of the vaccine of the invention.
Expression of truncated senna and protein production H. pyl ori proteins encoded by a given nucleotide sequence can also be used in a truncated biologically active form. Such truncation can be produced, for example, by removing the 5 'and / or 3' regions of the coding nucleotide sequence. These truncations can affect the recombinant expression of the encoded protein and / or the subsequent purification of the protein. For example, truncation of a nucleotide sequence that encodes a predicted exported sequence of a specific protein could alter the expression of the protein. Alternatively, the C-terminal truncation of an H. pyl ori polypeptide by removing the 3 'end of the nucleic acid encoding the region could also improve protein expression and subsequent purification and use, as depicted in FIG. Example VIII later. Removal of the nucleic acid regions encoding the internal H. pyl ori protein may also result in improved expression of the protein, purification and / or efficiency as a candidate vaccine.
IV. Identification of the Nucleic Acids that Codify the Components and the Targets of the Vaccine for Effective Agents Against H. vyl ori The exposed genome sequence of H. pyl ori includes the segments that direct the synthesis of ribonucleic acids and polypeptides, in addition to the origins of replication, promoters, other types of regulatory sequences and intergenic nucleic acids. The invention encompasses the nucleic acids encoding the immunogenic components of vaccines and targets for agents effective against H. pylori. The identification of said immunogenic components involved in the determination of the function of the exposed sequences can be achieved using a variety of methods. The non-limiting examples of these methods are briefly described below.
Homology for the known sequences: The computer-assisted comparison of the exposed H. pyl ori sequences with the previously reported sequences present in the publicly available databases is used for the identification of the functional nucleic acid of H. pyl ori and the sequences of polypeptides. It will be understood that the sequences encoding the protein, for example, could be compared as a whole, and that a high degree of sequence homology between two proteins (such as, for example,> 80-90%) and the level of amino acid indicates that the two proteins also possess some degree of functional homology, such as, for example between the enzymes involved in metabolism, DNA synthesis, or synthesis of the cell wall, and the proteins involved in transport, cell division, etc. In addition, many structural features of particular protein classes have been identified and correlated with specific consensus sequences, such as, for example, binding domains for nucleotides, DNA, metal ions and other small molecules; sites for covalent modifications such as phosphorylation, acylation, and the like; protein sites: protein interactions, etc. These consensus sequences could be very short and thus could represent only a fraction of the total sequence encoding the protein. The identification of such a characteristic in a sequence of H. pyl ori is therefore useful in the determination of the function of the encoded protein and the identification of the targets used of the antibacterial drugs.
Of particular relevance to the present invention are the structural features that are common for secretory, transmembrane and surface proteins, including secretory signal peptides and hydrophobic transmembrane domains. H. pyl ori proteins identified as containing putative signal sequences and / or transmembrane domains are used as immunogenic components of vaccines.
Identification of essential genes: Nucleic acids that encode proteins essential for the growth or viability of H. pylori are preferred target drugs. The genes of if. pyl ori can be tested for their biological relevance to the organism by examining the effect of the elimination and / or disruption of the genes, p. ex. , by means of the so-called "damage" of the gene, using the techniques known to those experts in the relevant art. In this way, the essential genes could be identified.
Specific sequences of the strain: Because the relationship would evolve between the different strains of H. pyl ori, it is believed that the H. pyl ori sequences currently exposed are used for the identification, and / or discrimination between, strains of . pyl ori previously known and new. It is believed that the other strains of if. pyl ori will exhibit at least 70% homology of the sequence with the sequence currently exposed. Systematic and routine analyzes of DNA sequences derived from samples containing strains of. pyl ori, and the comparison with the present sequence allows the identification of the sequences that can be used to discriminate between strains, in addition to those that are common to all if strains. pyl ori In one embodiment, the invention provides nucleic acids, including probes and sequences of peptides and polypeptides that discriminate between different different strains of. pyl ori The specific strain components can also be functionally identified by their ability to obtain or react with antibodies that selectively recognize one or more H. pyl ori strains.
In another embodiment, the invention provides nucleic acids, including probes and sequences of peptides and polypeptides that are common to all strains of H. pyl ori but that are not found in other species of bacteria.
Specific Example: Determination of the Antigens of the Candidate Protein for the Development of the Antibody and the Vaccine The selection of the antigens of the candidate protein for the development of the vaccine can be derived from the nucleic acids encoding the polypeptides of ß. pyl ori First, the ORF 's can be analyzed for homology with respect to other proteins exported or membrane known and analyzed using the discrimination analysis described by Klein, et al. (Klein, et al. (Klein, P., Kanehsia, M., and DeLisi, C. (1985) Bi ochimi a e t Bi ophysi ca Ac ta 815, 468-476) to predict the proteins exported and the membrane.
Homology searches can be performed using the BLAST algorithm contained in the Wisconsin Sequence Analysis Package (Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wl 53711) to compare each predicted ORF amino acid sequence with all sequences found in the current GenBank, SWISS-PROT and PIR databases. The BLAST searches for local alignments between the ORF and the database sequences and the reports of a probability marker that indicates the probability of finding this sequence through the change in the database. ORF 's with significant homology (eg probabilities lower than lxlO-6 of homology is only due to random change) for membrane or exported proteins represent protein antigens for vaccine development. Possible functions can be provided to the genes of. pyl ori based on sequence homology for genes cloned in other organisms.
The discrimination analysis (Klein, et al., Supra) can be used to examine the amino acid sequences of ORF. This algorithm uses the intrinsic information contained in the amino acid sequence of ORF and compares information derived from the properties of known membrane and export proteins. This comparison predicts that proteins will be exported, associated by membrane or cytoplasmic. The amino acid sequences of ORF identified as exported or membrane-bound by this algorithm are probably protein antigens for the development of the vaccine.
Exposed surface outer membrane proteins are probably the best antigens to provide a protective immune response against. pyl ori Among the algorithms that can be used to aid in the prediction of these outer membrane proteins include the presence of an amphipathic beta leaf region in its C terminus. This region has been detected in a large number of outer membrane proteins in negative bacteria Gram is frequently characterized by hydrophobic residues (Phe or Tyr) approximately at positions 1, 3, 5, 7 and 9 of the C term (eg, see Figure 1, block F). Importantly, these sequences have not been detected in the C term of the periplasmic proteins, thus allowing the preliminary distinction between these classes of proteins based on the primary sequence data. This phenomenon has been previously reported by Struyve et al. (J. Mol. Biol. 218: 141-148, 1991).
Also illustrated in Figure 1 are portions of the additional amino acid sequences in many outer membrane proteins of H. pyl ori. The alignment of the amino acid sequence in Figure 1 represents the portions of the sequence of five proteins of H. pyl ori (represented in the single-letter amino acid code) labeled with their Sequence Numbers ID of amino acid and showing the term N to term C, from left to right. There are six distinct blocks (labeled A through F) of sim amino acid residues that include the distinctive hydrophobic residues (Phe or Tyr; F or Y according to the single-letter code for amino acid residues) frequently found at nearby positions of the term C of the outer membrane proteins. The presence of several clearly shared portions clearly establishes the simity among the members of this group of proteins.
In addition, outer membrane proteins isolated from H. pyl ori frequently share a portion near the mature C-terminus (eg, after processing to remove the secretion signal) as illustrated by the amino acid residues blocked in the Figure 2. Figure 2 represents the N-terminal portion of the three if proteins. pyl ori (designated by their Sequence Numbers ID of amino acid and showing the term N to term C, from left to right).
An expert in the art would know that these portions of the shared sequence are highly significant and establish a simity between this group of proteins.
Infrequently it is not possible to distinguish between multiple possible nucleotides at a given position in the nucleic acid sequence. In these cases the ambiguities are denoted by an extended alphabet as follows: These are the official one-letter codes of the IUPAC-IUB Code Description of the Base Guanina A Adenine Ti ina Cytosine Code Description of the Base R Purine (A or G) and Pyrimidine (C or T or U) M Amino (A or C) K Ketone (G or T) S Interaction (C or G) Strong W (A or T) H Interaction (A or C) or T) Weak B (C or G or T) V No G (A or C or G) D No A (A or G or T) N No T (not U) (A or C or G or T) No C Anyone The amino acid translations of this invention take into account the ambiguity in the nucleic acid sequence by translating the ambiguous codon as the letter "X". In all cases, the permissible amino acid residues in a position are clear from an examination of the nucleic acid sequence based on the standard genetic code.
V. Production of Nucleic Acid Fragments and Analogs v. H. pyl ori Polypeptides Based on the discovery of the H. pyl ori gene products of the invention provided in the Sequence List, one skilled in the art can alter the exposed structure (of the genes of if. Pyl ori), p. ex. , producing the fragments or analogues, and testing the new structures produced for the activity. The examples of techniques known to those skilled in the relevant art which allow the production and testing of fragments and the like are discussed below. These, or the analogous methods can be used to make and screen the polypeptide libraries, e.g. ex. , random peptide libraries or libraries or fragments or analogs of cellular proteins for the ability to bind the polypeptides of. pyl ori Such screens are used for the identification of inhibitors of. pyl ori Generation of Fragments Fragments of a protein can be produced in several ways, e.g. ex. , recombinantly, by proteolytic digestion, or by chemical synthesis. The internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. The expression of the utagenized DNA produces the polypeptide fragments. Digestion with "bit-end" endonucleases can thus generate DNA encoding a fragment array. The DNAs encoding the fragments of a protein can also be generated by random cutting, restriction digestion or a combination of the methods discussed above.
The fragments can also be chemically synthesized using techniques known in the art such as conventional f-Moc chemistry or Merrifield solid phase t-Boc chemistry. For example, the peptides of the present invention could be arbitrarily divided into fragments of a desired length.
Alteration of Nucleic Acids and Polypeptides: Random Methods Variants of the amino acid sequence of a protein can be prepared by random mutagenesis of DNA encoding a protein or a particular domain or region of a protein. The methods used include PCR mutagenesis and saturation mutagenesis. A library of variants of the random amino acid sequence can also be generated by the synthesis of a group of oligonucleotide sequences. (Methods for screening proteins in a library of variants are also here).
(A) Mutagenesis by PCR In PCR mutagenesis, the fidelity of Taq polymerase is used to introduce random mutations into a cloned DNA fragment (Leung et al., 1989, Techni 1: 11-15). The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g. ex. , using a dGTP / dATP ratio of five and adding Mn + to the PCR reaction. The pool of the amplified DNA fragments is inserted into the appropriate cloning vectors to provide the random mutant libraries.
(B) Saturation Mutagenesis Saturation mutagenesis allows the rapid introduction of a large number of single-base substitutions in the cloned DNA fragments (Mayers et al., 1985, Sci in ce 229: 242). This technique includes the generation of mutations, p. ex. , by chemical treatment or irradiation of single-stranded DNA in vi tro, and the synthesis of a complementary DNA strand. The frequency of the mutation can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for the mutant fragments of both neutral substitutions, they are obtained in addition to those that alter the function. The distribution of point mutations does not lean with respect to the conserved sequence elements.
C) Degenerate Oligonucleotides A library of homologs can also be generated from a group of degenerate oligonucleotide sequences. The chemical synthesis of a degenerate sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes are then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (for example, Narang, SA (1983) Tetrahedron 39: 3, Itakura et al. (1981) Recombinant t DNA, Proc 3rd Cl eveland Sympos. Macromol ecul es, ed. AG Walton, Amsterdam: Elsevier pp 273-289, Itakura et al (1984) Annu Rev. Bi och em 53: 323, Itakura et al (1984) Sci en 198: 1056, Ike et al. (1983) ) Nu cli i c Aci d Res. 11: 477. Such techniques have been used in the directed evolution of other proteins (see, for example, Scott et al. (1990) Sci en ce 249: 386-390; Roberts et al. (1992) PNAS 89: 2429-2433; Devlin et al (1990) Sci en 249: 404-406; Cwirla et al. (1990) PNAS 87: 6378-6382; in addition to US Patent Nos. 5,223,409, 5 , 198, 346 and 5, 096, 815).
Alteration of Nucleic Acids and Polypeptides: Methods for Directed Mutagenesis The techniques of non-random or directed mutagenesis can be used to provide the specific sequences or mutations in specific regions. These techniques can be used to create variants that include, p. ex. , deletions, insertions or substitutions of residues of the known amino acid sequence of a protein. The sites for the mutation can be modified individually or in series, p. ex. , by (1) substituting first with the conserved amino acids and then with more radicals chosen depending on the results achieved, (2) eliminating the white residue, or (3) inserting the residues of the same or different class adjacent to the localized site, or combination of options 1-3.
(A) Mutagenesis by Alanine Search Alanine search mutagenesis is a method used for the identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis. Cunningham and Wells (Sci ence 244: 1081-1085, 1989). In the search for alanine, a residue or group of target residues (e.g., charged residues such as Arg. Asp, His, Lys and Glu) are identified and replaced by a neutral or negatively charged amino acid (more preferably, alanine or polyalanine). The replacement of an amino acid can affect the interaction of the amino acids with the aqueous environment that surrounds them on or outside the cell. Domains demonstrating sensitivity to functionality with respect to substitutions are then refined by introducing additional or other variants at or for substitution sites. Thus, while the site is predetermined to introduce a variation of the amino acid sequence, the nature of the previous mutation need not be predetermined. For example, to optimize the development of a mutation at a given site, the search for alanine or random mutagenesis could be carried out at the codon or target region and subunit variants of the desired protein expressed are screened for the combination optimum of the desired activity.
(B) Oligonucleotide-mediated Mutagenesis Oligonucleotide-mediated mutagenesis is a method used to prepare substitution, deletion and insertion variants of DNA, see p. ex. , Adelman et al. , (DNA 2: 183-, 1983). Briefly, the AD? desired is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, wherein the template is in the form of a single strand of a plasmid or bacteriophage containing the native or unaltered DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize a second complete complementary strand of the template which will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the DNA of the desired protein. In general, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on the side of the oligonucleotide encoding the mutation. This ensures that the oligonucleotide will properly hybridize to the single stranded DNA template molecule. Oligonucleotides are easily synthesized using techniques known in the art such as those described by Crea et al. (Proc. Na tl. Acad. Sci. USA, 75: 5765 [1978]).
(C) Mutagenesis of the Cásete Another method for the preparation of the variants, Cásete mutagenesis, is based on the technique described by Wells et al. (Gene, 34: 315 [1985]). The initiator material in a plasmid (or other vector) that includes the DNA of the subunit of the protein to be mutated. The codons are identified in the DNA of the subunit of the protein to be mutated. There must be a single endonuclease restriction site in each site of the identified mutation site. If there are no such restriction sites, could be generated using the oligonucleotide mediated mutagenesis method described above to introduce them at the appropriate locations in the DNA of the desired protein subunit. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide that encodes the DNA sequence between the restriction sites but that contains the desired mutation is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is designed to have the 3 'and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the DNA sequence of the subunit of the desired mutated protein.
(D) Combinatorial Mutagenesis Combinatorial mutagenesis can also be used to generate the mutants (Ladner et al., WO 88/06630). In this method, the amino acid sequences for a group of homologues or other related proteins are aligned, preferably to promote the highest possible homology. All the amino acids that appear in a given position of the aligned sequences can be selected to create a degenerate group of combinatorial sequences. The varied library of variants is generated by combinatorial mutagenesis at the level of the nucleic acid, and is encoded by a varied gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into the gene sequences such that the degenerate group of the potential sequences are expressed as individual peptides, or alternatively, as a group of higher fusion proteins containing the group of degenerate sequences.
Other Modifications of Nucleic Acids and Polypeptides of íf. It is possible to modify the structure of a H. pyl ori polypeptide for such purpose as increased solubility, stability of improvement (eg, shelf life ex vi ve and resistance to proteolytic degeneration in vi). A protein or peptide of if. pyl modified ori can be produced in which the amino acid sequence has been altered, such as by amino acid substitution, deletion or addition as described herein.
A peptide of H. pyl ori may also be modified by substitution of the cysteine residues preferably with alanine, serine, threonine, leucine or glutamic acid residues to minimize dimerization via the disulfide bonds. In addition, the amino acid side chains of the fragments of the protein of the invention can be chemically modified. Another modification is the cyclization of the peptide.
To improve stability and / or reactivity, an H. pyl ori polypeptide can be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein resulting from any natural allelic variation. Additionally, amino acids D, non-natural amino acids or analogs of non-amino acids can be substituted or added to produce a modified protein within the scope of this invention. In addition, an H. pyl ori polypeptide can be modified using polyethylene glycol (PEG) according to the method of A. Sehon et al. (Wie et al., Supra) to produce a protein conjugated with PEG. In addition, PEG can be added during the chemical synthesis of the protein. Other modifications of the proteins of íf. pyl ori include reduction / alkylation (Tarr, Methods of Pro tein Mi crochara cteri za ti on, J.E. Silver ed., Humana Press, Clifton NJ 155-194 (1986)); acylation (Tarr, supra); chemical coupling to an appropriate vehicle (Mishell and Shiigi, eds, Selected Me th ods in Cellular Immunolgy, WH Freeman, San Francisco, CA (1980), US Patent 4,939,239, or mild formalin treatment (Marsh, (1971 ) In t. Arch. Of Al lgy and Appl. Immunol., 4d: 199-215).
To facilitate purification and potentially increase the solubility of an H. pyl ori protein or peptide, it is possible to add an amino acid fusion residue to the structure of the peptide. For example, hexa-histidine can be added to the protein for purification by immobilized metal ion affinity chromatography (Hochuli, E. et al., (1988) Bi o / Technolgy, 6 .: 1321-1325). In addition, to facilitate the isolation of the free peptides from the irrelevant sequences, the specific endoprotease cleavage sites can be introduced between the sequences of the fusion moiety and the peptide.
To potentially add the appropriate antigen processing of the epitopes within a polypeptide of f. pyl ori, canonical protease susceptibility sites can be designed between regions, each comprising at least one epitope via recombinant or synthetic methods. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a protein or fragment during recombinant reconstruction thereof. The resulting peptide can be made sensitive to cleavage by cathepsin and / or other trypsin-like enzymes which would generate portions of the protein containing one or more epitopes. In addition, such charged amino acid residues may result in an increase in peptide solubility.
Primary Methods for the Screening of Polypeptides v Analogs Several techniques are known in the art for screening the products of the generated mutant gene. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming the appropriate cells with the resulting vector library, and expressing the genes under conditions in which the direction of a desired activity , p. ex. , in this case, bind to the if polypeptide. pyl ori or an interaction protein, facilitate relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is likely by high placement analysis for the screening of large numbers of created sequences, e.g. ex. , by means of random mutagenesis techniques.
(A) Two Hybrid Systems Two hybrid assays such as the system described above (as with the other screening methods described herein), can be used to identify polypeptides, e.g. ex. , fragments or analogues of an if polypeptide. pyl ori that occurs naturally, p. ex. , of cellular proteins, or of randomly generated polypeptides that bind to a protein of. pyl ori (The domain of P. pyl ori is used as the protein hook and the library of variants are expressed as fish fusion proteins). In an analogous embodiment, a two-hybrid test (as with the other screening methods described herein) can be used to find polypeptides that bind a polypeptide of f. pyl ori (B) Deployment Libraries In a method for screening tests, the candidate peptides are deployed on the cellular or viral particle surface, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the deployed product is detected in a "test". general". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein is detected by the general test (Ladner et al., WO 88/06630, Fuchs et al. (1991) Bi o / Technolgy 9: 1370-1371; and Goward et al. (1992) TIBS 18: 136-140). In a similar manner, a detectably labeled ligand can be used to label the homologues of the potentially functional peptide. The fluorescently labeled ligands, p. ex. , the receptors, can be used to detect homologs that maintain ligand binding activity. The use of fluorescently labeled ligand allows the cells to be visually inspected and separated under a fluorescent microscope, or, where the morphology of the cell allows, to be separated by a fluorescence activated cell sorter.
A library of the gene can be expressed as a fusion protein on the surface of a viral particle. For example, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of the infectious phage, thereby conferring two significant benefits. First, because these phages can be applied to affinity matrices at concentrations well above 1013 phage per milliliter, a large number of phages can be screened once. Second, because each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix at low yield, the phage can be amplified by another round of infection. The group of filamentous phages M13, fd, and fl. Of E. Nearly identical coli are used more frequently in phage display libraries. Either the gilí phage coat proteins or gVIII can be used to generate the fusion proteins without cutting the last packet of the viral particle. Foreign epitopes can be expressed at the terminal NH 2 terminus of pIII and the phage carrying such epitopes recovered from a large excess of phage lacking this epitope (Ladner et al., PCT publication WO 90/02909; Garrard et al., PCT publication). WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267: 16007-16010; Griffiths et al. (1993) EMBO J 12: 725-734; Clackson et al. (1991) Na ture 352 : 624-628; and Barbas et al. (1992) PNAS 89: 4457-4461).
A common method uses the maltose receptor of E. col i (the outer membrane protein, LamB) as a fusion partner of the peptide (Charbit et al. (1986) EMBO 5, 3029-3037). The oligonucleotides have been inserted into the plasmids encoding the LamB gene to produce the peptides fused to one or more of the extracellular bonds of the protein. These peptides are available to bind the ligands, e.g. ex. , to the antibodies, and they can get an immune response when the cells are administered to the animals. Other cell surface proteins, e.g. ex. , OmpA (Schorr et al. (1991) Vaccine 91, pp. 387-392), PhoE (Agterberg, et al., (1990) Gene 88, 37-45), and PAL (Fuchs et al. (1991) Bi o / Tech 9, 1369-1372), in addition to a large number of bacterial surface structures have served as vehicles for the deployment of the peptide. The peptides can be fused to pilin, a protein that is polymerized to form the pilo a conduit for the interbacterial exchange of the genetic information (Thiry et al (1989) Appl. Environ. Mi crobi., 55, 984-993). Due to its role in the interaction with other cells, the pilo provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for the deployment of the peptide is the organ of bacterial motif, the flagellum. The fusion of the peptides for the flagellin of the protein subunit offers a dense array of many copies of peptides on the host cells (Kuwajima et al (1988) Bi o / Tech. 6, 1080-1083). Surface proteins from other bacterial species have also served as peptide fusion partners. Examples include the Staphyl ococcus protein A and the outer membrane IgA protease from Nei sseri a (Hansson et al (1992) J. Ba cteri ol 174, 4239-4245 and Klauser et al (1990) EMBO J. 9, 1991-1999).
In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its coding DNA is presented by the content of DNA within a particle (cell or phage) carrying the peptide on its surface. The capture of the peptide captures the particle and the DNA inside. An alternative scheme uses the Lacl protein that binds DNA to form a link between the peptide and DNA (Culi et al (1992) PNAS USA 89: 1865-1869), This system uses a plasmid containing the Lacl gene with a oligonucleotide cloning the site at its 3 'end. Under the induction controlled by arabinose, a fusion protein of the Lacl peptide is produced. This fusion maintains Lacl's natural ability to bind to a short DNA sequence known as the LacO (LacO) operator. By installing two copies of LacO on the expression plasmid, the Lacl peptide fusion binds lightly to the plasmid encoding it. Because the plasmids in each cell contain only one oligonucleotide sequence and each cell expresses only one peptide sequence, the peptides become specifically and stably associated - with the DNA sequence directing their synthesis. The cells of the library are lysed gently and the peptide-DNA complexes are exposed to an immobilized receptor matrix to recover the complexes containing the active peptides. The DNA of the associated plasmid is then reintroduced into the cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As an administration of the practical utility of the method, a large random library of the dodecapeptides was made and selected on a monoclonal antibody raised against dynorphin B of the opioid peptide. A group of peptides was recovered, all related by a consensus sequence corresponding to a portion of six dynorphin B residues (Culi et al. (1972) Proc. Na tl. Acad. Sci. U. S. A. -1869).
This scheme, which is sometimes referred to as peptides on plasmids, differs in two important ways from phage display methods. First, the peptides bind to the C terminus of the fusion protein, resulting in the unfolding of the library members as the peptides have the term carboxy free. Both of the filamentous phage coat proteins, pIII and pVIII, are attached to the phage through their C terminus, and the host peptides are placed in the domain of the N terminus extending outward. In some designs, the peptides that display phages are shown to the right in the amino terminus of the fusion protein. (Cwirla, et al (1990) Proc. Na tl. Acad. Sci. U. S.A. 87, 6378-6382). A second difference in the group of biological differences that affect the population of the peptides actually present in the libraries. The Lacl fusion molecules are confined to the cytoplasm of the host cells. Flange-shell fusions are briefly exposed to the cytoplasm during translation but are rapidly secreted through the inner membrane in the periplasmic compartment, remaining attached to the membrane by their C-terminal hydrophobic domains, with the N term, which contains the peptides, which protrudes in the periplasm while assembly is awaited in the phage particles. The peptides in the Lacl and phage libraries could differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport through the inner membrane in the processing of the peptidase signal as a prelude to incorporation into phage. Certain peptides exert a detrimental effect on these processes and are poorly representative in libraries (Gallop et al (1994) J. Med. Chem. 37 (9): 1233-1251). These particular differences are not a factor in the Lacl deployment system.
The number of small peptides available in the recombinant random libraries is enormous. Libraries of independent clones 107-109 are routinely prepared. Libraries as large as 1011 recombinants have been created, but this size is close to the practical limit for clone libraries. This limitation on the size of the library occurs in the stage of transformation of the DNA containing the random segments in the host bacterial cells. To overcome this limitation, an in vi tro system based on the deployment of nascent peptides in polysome complexes has recently been developed. This method of the display library has the potential to produce libraries of 3-6 orders of magnitude greater than currently available phage / phagemid or plasmid libraries. In addition, the construction of the libraries, expression of the peptides and screening, is done in a completely cell-free format.
In one application of this method (Gallop et al. (1994) J. Med. Chem. 37 (9): 1233-1251), a molecular DNA library encoding the dodecapeptides 1012 was constructed and the library expressed in a system of transcription / coupled translation of E. coli S30 in vi tro. The conditions were chosen to evade ribosomes in the mRNA, causing the accumulation of a substantial proportion of the RNA in the polysomes and producing complexes containing the nascent peptides still bound to their coding RNA. The polysomes are large enough to be affinity purified on the immobilized receptors in most of the same way as most conventional recombinant peptide display libraries are screened. The RNA from the linked complexes is recovered, converted to the cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome deployment method can be coupled to the phage display system. Following several rounds of screening, the cDNA of the polysome-enriched pool was cloned into a phagemid vector. This vector serves as a peptide expression vector, which displays the peptides fused to the coated proteins, and as a DNA sequencing vector for the identification of the peptide. By expressing the peptides derived from the polysome in the phage, the affinity selection procedure in this format or test of the peptides on the individual clones can be continued for the binding activity in an ELISA phage, or for the specificity of binding in a complete ELISA phage (Barret, et al. (1992) Anal. Bi och em 204, 357-364). To identify the sequences of the active peptides a sequence is produced by the DNA by the phagemid host.
Secondary Screening of Polypeptides and Analogs The high selection tests described above can be continued by secondary screening to identify additional biological activities that, eg, ex. , will allow the skilled artisan to differentiate agonists from antagonists. The type of a secondary screening used will depend on the desired activity that needs to be tested. For example, a test in which the ability to inhibit an interaction between a protein of interest and a respective ligand can be used to identify antagonists of a group of isolated peptide fragments by means of one of the primary screens described above.
Therefore, the methods for generating the fragments and analogues and testing them for the activity are known in the art. Once the central sequence of interest is identified, it is routine for an expert in the art to obtain the analogs and fragments.
Mimetic peptides of polypeptides of íf. v? l ori The invention also provides for the reduction of the protein binding domains of the polypeptides of ß. pyl ori of interest to generate mimetic peptides, p. ex. peptidic or non-peptidic agents. The mimetic peptides are capable of breaking the binding of a polypeptide to its contra ligand, e.g. ex. , in the case of a H. pyl ori polypeptide that binds to a naturally occurring ligand. The critical residues of an if polypeptide. pyl ori of interest that are involved in a molecular recognition of a polypeptide can be determined and used to generate the similar peptides derived from H. pyl ori which competitively or non-competitively inhibit the binding of the polypeptide of i. pyl ori with an interaction polypeptide (see, for example, European Patent Publications EP-412,762A and EP-B13, 080A).
For example, search mutagenesis can be used to represent the amino acid residues of a polypeptide of a particular H. pyl ori polypeptide involved in the binding of an interaction polypeptide, the peptidomimetic compounds (eg, diazepine or isoquinoline derivatives). ) can be generated which resemble the residues in the binding of an interaction polypeptide, and which can therefore inhibit the binding of a polypeptide of. pyl ori to an interaction polypeptide and therefore interfere with the function of the polypeptide of f. pyl ori For example, hydrolysable peptide analogues of such residues can be generated using benzodiazepine (eg, see Freidinger et al., In Pep ti des: Chemi s try and Bi olgy, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands , 1988), azepine (eg, see Huffman et al., In Pepti des: Chemi s try and Bi olgy, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted rings lactam gamma (Garvey et al., In Pepti des: Chemi s try and Bi olgy, GR Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) J Med Chem 29: 295; and Ewenson et al., in Pep ti des: Stru cture and Fun cti on (Proceedings of the 9 th American Peptide Symposium) Pierce Chemical Co. Rockland , IL, 1985), ß-shift dipeptide centers (Nagai et al. (1985) Tetrahedron Let t 26: 647; and Sato et al. (1986) J Chem Soc Perkin Trans 1: 1231), and ß-aminoalcohols ( Gordon et al (1985) Bi och em Bi ophys Res Commun 126: 419, and Dann et al (1986) Bi ochem Bi ophys Res Commun 134: 71).
SAW. Vaccine Formulations for Nucleic Acids and Polypeptides of íf. p? l ori This invention also characterizes vaccine compositions or formulations (used interchangeably herein) for protection against yeast infection. pyl ori for the treatment of the infection by íf. pyl ori As used herein, the term "treatment of infection by P. pyl ori" refers to the therapeutic treatment of an existing or established infection by H. pyl ori. The terms "protection against infection by H. pyl ori" or "prophylactic treatment" refers to the use of the ff vaccine formulation. pyl ori to reduce the risk or prevention of an infection in a subject at risk for H. pylori infection. In one embodiment, the vaccine compositions contain one or more immunogenic components, such as a surface protein, of if. pyl ori, or portion thereof, and a pharmaceutically acceptable carrier. For example, in one embodiment, formulations of the vaccine of the invention contain at least one or combination of the H. pyl ori polypeptides or fragments thereof, of the same or different antigens of H. pyl ori. Nucleic acids and polypeptides of íf. pyl ori for use in the vaccine formulations of the invention include the nucleic acids and polypeptides set forth in the Sequence List, preferably the if nucleic acids. pyl ori that encode surface proteins or fragments thereof. For example, a preferred nucleic acid and the H. pyl ori polypeptide for use in the composition of the vaccine of the invention is selected from the group of nucleic acids encoding the cellular envelope proteins and the cellular envelope proteins of the invention. . pyl ori as set forth in Table 1. However, any nucleic acid encoding a protein of f. pyl ori immunogenic and polypeptide of íf. pyl ori, or portion thereof, may be used in the present invention. These vaccines have therapeutic and / or prophylactic utilities.
One aspect of the invention provides a vaccine composition for protection against if infection. pyl ori which contains at least one immunogenic fragment of an ßf protein. pyl ori and a pharmaceutically acceptable carrier. Preferred fragments include peptides of at least 10 amino acid residues in length, preferably about 10-20 amino acids in length, and more preferably about 12-16 amino acid residues in length.
The immunogenic components of the invention can be obtained, for example, by screening recombinantly produced polypeptides from the corresponding fragment of the nucleic acid encoding the protein. pyl ori of total length. In addition, the fragments can be chemically synthesized using techniques known in the art such as Merrifield's solid phase f-Moc or t-Boc chemistry.
In one embodiment, immunogenic components are identified by the ability of the peptide to stimulate T cells. Peptides that stimulate T cells, as determined by, for example, T cell proliferation or cytokine secretion are defined herein as comprising At least one T cell epitope. The T cell epitopes are believed to be involved in the initiation and perpetuation of the immune response to the protein that could induce an allergy that is responsible for the clinical symptoms of the allergy. These T cell epitopes are thought to trigger the cases at the helper T-cell level by binding an appropriate HLA molecule on the surface of an antigen presented by the cell, thereby stimulating the subpopulation of T cells with the receptor of T cells relevant to the epitope. These cases lead to the proliferation of T cells, the secretion of lymphokine, local inflammatory reactions, recruitment of *** (continued on page 61) These events lead to T cell proliferation, lymphokine secretion, local inflammation reactions, recruitment of additional immune cells to the antigen / T cell interaction site, and activation of the cell cascade T, leading to the production of antibodies. An epitope of the T cell is the basic element, or the smallest unit of recognition by a T cell receptor, where the epitope comprises essential amino acids for receptor recognition (eg, about 6 or 7 amino acid residues). Amino acid sequences that resemble those of the T cell epitopes are within the scope of this invention.
In another embodiment, the immunogenic components of the invention are identified through genomic vaccination. The basic protocol is based on the idea that expression libraries consist of all or part of a pathogenic genome, p. ex. , a genome of íf. pyl ori, can confer protection when used to genetically immunize a host. This immunization of the expression library (ELI) is analogous to clone expression and involve the reduction of a genomic expression library of a pathogen, e.g. ex. , H. pyl ori, in plasmids that can act as genetic vaccines. Plasmids can also be designed to encode genetic adjuvants that can dramatically stimulate the humoral response. These genetic adjuvants can be introduced into remote sites and act both extracellularly and intracellularly.
This is a new approach to the production of vaccines that has many of the advantages of live / attenuated pathogens but without the risk of infection. A pathogen DNA expression library is used to immunize a host thereby producing the effects of antigen presentation of a live vaccine without risk. For example, in the present invention, random fragments of the if-genome. pyl ori of the cosmid or clones of the plasmid, as well as PCR products of the genes identified by genomic sequencing, can be used to immunize a host. The feasibility of this approach has been demonstrated with Mycopl to sma pulmoni s (Barry et al., Na ture 377: 632-635, 1995), the libraries of uniform partial expression of Mycopl to sma pulmoni s, a natural pathogen in rodents, provides protection against pathogen testing.
ELI is a technique that allows the production of a non-infectious multipartite vaccine, even though little is known about the biology of the pathogen, because ELI uses the immune system to screen candidate genes. Once isolated, these genes can be used as genetic vaccines or for the development of recombinant protein vaccines. In this way, ELI allows the production of vaccines in a systematic, widely mechanized way.
The screening of immunogenic components can be performed using one or more of several different tests. For example, in vi tro, the stimulating activity of the T cell peptide is tested by contacting a known or suspected peptide that is immunogenic with an antigen presenting cells that exhibit appropriate MHC molecules in a culture of T cells. of an if immunogenic peptide. pyl ori in association with MHC molecules appropriate for T cells in conjunction with the necessary costimulation has the effect of transmitting a signal to the T cell that induces the production of increased levels of cytokines, particularly of interleukin-2 and interleukin-4. The culture supernatant can be obtained and tested for interleukin-2 or other known cytokines. For example, any of several conventional tests for interleukin-2 may be employed, such as the test described in Proc. Na tl. Aca d. Sci USA, JL6: 1333 (1989) the relevant portions of which are incorporated herein by reference. A test kit for the production of interferon is also available from Genzyme Corporation (Cambridge, MA).
Alternatively, a common test for T cell proliferation can be measured by determining the amount of 3 H-labeled thymidine incorporated into the DNA replication of the cultured cells. Therefore, the speed of DNA synthesis and, at the same time, the rate of cell division can be quantified.
The compositions or vaccine formulations of the invention that contain one or more immunogenic components (eg, polypeptide of p.pyl ori or fragment thereof or nucleic acid encoding a H. pyl ori polypeptide or fragment thereof) preferably includes a pharmaceutically acceptable vehicle. The term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and delaying absorption agents, and the like, compatible with pharmaceutical administration. Pharmaceutically acceptable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, and the like, as well as combinations thereof. The pharmaceutically acceptable carriers could comprise minor amounts of auxiliary substances such as wetting agents or emulsifiers, preservatives or buffers, which increase the shelf life or effectiveness of the nucleic acid or polypeptide of H. pyl ori. For vaccine formulations of the invention containing polypeptides of. pyl ori, the polypeptides are preferably coadministered with a suitable adjuvant and / or a delivery system described herein.
It will be apparent to those skilled in the art that the therapeutically effective amount of DNA or protein of this invention will depend, inter alia, on the timing of administration, the unit dose of a nucleic acid or polypeptide of. pyl ori administered, if the protein or nucleic acid is administered in combination with other therapeutic agents, the immune status and health of the patient, and the therapeutic activity of the particular protein or nucleic acid Vaccine formulations are conventionally administered parenterally, e.g. ex. , by injection, subcutaneously or intramuscularly. Methods for intramuscular immunization are described by Wolf et al. (1990) Sci in ce 247: 1465-1468 and by Sedegah et al. (1994) Immunol ogy 11: 9866-9870. Other forms of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Oral immunization is preferred over parenteral methods to induce protection against H. pylori infection. Czinn et al. (1993) Vaccine 11: 637-642. Oral formulations include excipients normally employed such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
In one embodiment, the vaccine formulation includes, as a pharmaceutically acceptable carrier, an adjuvant. Examples of adjuvants suitable for use in the vaccine formulations of the invention include, but are not limited to, aluminum hydroxide, N-acetyl-muramyl-L-threonine-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2- (1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy) -ethylamine (CGP 19835A, referred to an MTP-PE); RIBI, which contains three components of bacteria; lipid A monophosphoryl; Trehalose dimycholoate; structure of the cell wall (MPL + TDM + CWS) in a 2% squalene / Tween 80 emulsion; and cholera toxin. Others that could be used are non-toxic derivatives of cholera toxin, including its subunit B, and / or conjugates or genetically engineered fusions of the polypeptide of. pyl ori with cholera toxin or its B subunit, procolerangenoid, fungal polysaccharides, including schizophyllan, muramyl dipeptide, muramyl dipeptide derivatives, phorbol esters, labile toxin E. col i, bacterial lysates without íf. pyl ori, block polymers or saponins.
In another embodiment, vaccine formulations include, as a pharmaceutically acceptable carrier, a delivery system. Delivery systems suitable for use in the vaccine formulations of the invention include biodegradable microcapsules or immunostimulating complexes (ISCOM), cokelates, or liposomes, genetically engineered attenuated live vectors such as viruses or bacteria, and recombinant (chimeric) type particles virus, p. ex. , bluetongue. In another embodiment of the invention, the vaccine formulation includes a delivery system and an adjuvant.
Human release systems could include enteric-release capsules that protect the antigen from the acid medium of the stomach, and include the if-polypeptide. pyl ori in a soluble form as fusion proteins. Suitable carriers for the vaccines of the invention are enteric coating capsules and polylactide glycolide microspheres. Suitable diluents 0.2 N NaHCO3 and / or saline.
The vaccines of the invention can be administered as a primary prophylactic agent in adults or in children, as a secondary prevention, after the successful eradication of if. pyl ori in an infected host, or as a therapeutic agent in order to induce an immune response in a susceptible host to avoid H. pylori infection. Infection vaccines are administered in amounts determined readily by those skilled in the art. Thus, for adults a suitable dosage will be in the range of 10 μg to 10 g, preferably 10 μg to 100 mg, for example 50 μg to 50 mg. A suitable dosage for adults will also be in the range of 5 μg to 500 mg. Similar dosage ranges will be applicable for children.
The amount of adjuvant used will depend on the type of adjuvant used. For example, when the mucosal adjuvant is cholera toxin, it is suitably used in an amount of 5 μg to 50 μg, for example 10 μg to 35 μg. When used in the form of microcapsules, the amount used will depend on the amount used in the microcapsule matrix to achieve the desired dosage. The determination of this amount is within the practice of an expert in the air.
Those skilled in the art will recognize that the optimal dose could be more or less dependent on the patient's body weight, disease, route of administration, and other factors. Those skilled in the art will also recognize that appropriate dosage levels can be obtained based on the results with known oral vaccines such as, for example, a vaccine based on an E lysate. col i (dose of 6 mg daily up to a total of 540 mg) and with a purified E antigen. enterotoxigenic col i (4 doses of 1 mg) (Schulman et al., J. Urol. 150: 917-921 (1993)); Boedecker et al., Ameri can Gas troen terol ogi cal Assoc. 999: A-222 (1993)). The number of doses will depend on the disease, the formulation, and the efficiency results of clinical trials. Without attempting any limitation during the course of treatment, the treatment may be administered for 3 to 8 doses for a primary immunization schedule for 1 month (Boedecker, Ameri can Gas troen terol ogi cal Assoc. 888: A-222 (1993)).
In a preferred embodiment, a vaccine composition of the invention can be based on an E preparation. col i of complete death with an immunogenic fragment of an ßf protein. pyl ori of the invention expressed on its surface or can be based on a lysate of E. col i, where E. Col i murderer acts as a vehicle or an adjuvant.
It will be apparent to those skilled in the art that some of the vaccine compositions of the invention are useful only to avoid ff infection. pyl ori, some are useful only to treat the infection of íf. pyl ori, and some are useful to avoid and treat H. pyl ori infection. In a preferred embodiment, the vaccine composition of the invention provides protection against H. pyl ori infection by stimulating humoral and / or cell-mediated immunity against H. pyl ori. It should be understood that the improvement of any of the symptoms of the infection of if. pyl ori is a desirable clinical objective, including a decrease in the dosage of the medication used to treat the disease caused by H. pylori, or an increase in the production of antibodies in the serum or mucosa of patients.
VII. Reagent Antibodies With Polypeptides of íf. oyl ori The invention also includes antibodies specifically reactive with the subject H. pylori polypeptide. Anti-protein / anti-peptide or monoclonal antibodies can be made by standard protocols (See, for example, An tibodi is: A Labora tory Manual ed by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation of vehicles or other techniques well known in the art. An immunogenic portion of the subject H. pyl ori polypeptide can be administered in the presence of the adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA and other immunoprotes can be used with the immunogen as an antigen to evaluate antibody levels.
In a preferred embodiment, the subject's antibodies are immunospecific for antigenic determinants of the if polypeptides. pyl ori of the invention, p. ex. antigenic determinants of a polypeptide of the invention contained in the Sequence Listing, or a homolog of closely related human or non-human mammal (eg, 90% homologous, more preferably at least 95% homologous). Even in a preferred embodiment of the invention, anti-IF antibodies. pyl or ri do not react substantially cross-linked (eg, they react specifically) with a protein which is, for example, less than 80% percent homologous with a sequence of the invention contained in the Sequence Listing. By "does not substantially cross-react," it means that the antibody has a binding activity for a non-homologous protein that is less than 10 percent, more preferably less than 5 percent, and even more preferably less than 1 percent, of the binding affinity for a protein of the invention contained in the Sequence Listing. In a more preferred embodiment, there is no cross-reactivity between bacterial and mammalian antigens.
The term "antibody" as used herein is intended to include fragments thereof that are also specifically reactive with if polypeptides. pyl ori Antibodies can be fragmented using conventional techniques and fragments screened for utility in the same manner as described above for whole antibodies. For example, F (ab ') 2 fragments can be generated by treating the antibody with pepsin. The resulting F (ab ') 2 fragment can be treated to reduce the disulfide bridges to produce Fab' fragments. The antibody of the invention is further intended to include bispecific and chimeric molecules that have an anti-ßf moiety. pyl ori Monoclonal and polyclonal antibodies (Ab) directed against if polypeptides. pyl ori or variants of the polypeptide of íf. pyl ori, and fragments of the antibody such as Fab 'and F (ab') 2, can be used to block the action of the polypeptide of. pyl ori and allow the study of the role of a polypeptide of íf. pyl ori of the invention in aberrant or unwanted intracellular signaling, as well as the cellular function of .f. pyl ori and by microinjection of the anti-IFF polypeptide antibodies. pyl ori of the present invention.
Antibodies that specifically link if epitopes. pyl ori can also be used in immunohistochemical staining of tissue samples to evaluate the abundance and expression pattern of Î ± antigens. pyl ori Anti-IFF polypeptide antibodies. pyl ori can be used diagnostically in immuno-precipitation and immuno-staining to detect and evaluate if levels. pyl ori in the tissue or body fluid as part of a clinical trial procedure. In addition, the ability to monitor the levels of the H. pyl ori polypeptide in an individual allows the determination of the efficacy of a given treatment regimen for an individual afflicted with such a condition. The level of a H. pyl ori polypeptide can be measured in cells found in body fluid, such as urine samples or can be measured in tissue, such as that produced by gastric biopsy. Diagnostic tests that use anti-IF antibodies. pyl ori may include, for example, immunoprotes designed to aid in early diagnosis of viral infections. pyl ori The present invention can also be used as a method for detecting antibodies contained in samples of individuals infected by this bacterium using specific antigens of. pyl ori Another application of anti-IFF polypeptide antibodies. pyl ori of the invention is the immunological screening of cDNA libraries constructed in expression vectors such as? gtll,? gtl8-23,? ZAP, XORF8. Message libraries of this type, which have coding sequences inserted in the correct reading and orientation frame, can produce fusion proteins. For example,? Gtll will produce fusion proteins whose amino terminus consists of the amino acid sequences of β-galactosidase and whose carboxy terminus consists of a foreign polypeptide. The antigenic epitopes of a polypeptide of. pyl ori of the subject can then be detected with antibodies, such as, for example, nitrocellulose filters that react placed on infected plates with anti-IFF polypeptide antibodies. pyl ori The phage, measured by this test, can be isolated after the infected plaques. Thus, the presence of the H. pyl ori homologous gene can be detected and cloned from other species, and alternative isoforms (including splice variants) can be detected and cloned.
VIII. Cases Containing Nucleic Acids, Polypeptides or Antibodies of the Invention The nucleic acid, polypeptides and antibodies of the invention can be combined with other reagents and articles to form kits. The kits for diagnostic purposes typically comprise the nucleic acid, polypeptides or antibodies in vials or other suitable containers. The kits typically comprise other reagents for developing the hybridization reactions, polymerase chain reactions (PCR), or for the reconstitution of lyophilized components, such as aqueous medium, salts, buffers, and the like. The kits could also comprise reagents for sample processing such as detergents, chaotropic salts and the like. The cases could also comprise immobilization means such as particles, supports, wells, slashes and the like. The kits could also comprise labeling means such as dyes, growth reagents, radioisotopes, fluorescent agents, luminescent or chemiluminescent agents, enzymes, interleaving agents and the like. With the information of the nucleic acid and amino acid sequence provided herein, those skilled in the art can easily assemble kits to fulfill their particular purpose. The kits may also include instructions for use.
IX. Screening tests for Drug sue Usan Polypeptides of íf. oyl ori By making the purified and recombinant H. pyl ori polypeptides available, the present invention provides tests that can be used to screen drugs that are agonists or antagonists of normal cell function, in this case, of the polypeptides of. pyl ori of the subject, or of its role in intracellular signaling. Such inhibitors or enhancers could be useful as new therapeutic agents to combat if infections. pyl ori in humans. A variety of test formats will be sufficient and, in light of the present inventions, will be understood by those skilled in the art.
In many drug screening programs in which the test libraries of natural compounds and extracts, high throughput tests are desired to maximize the number of compounds examined in a given period of time. Tests that are performed on cell-free systems, such as could be derived with purified or semi-purified, are often preferred as "primary" screens in that they can be generated to allow rapid development and relatively easy detection of an alteration in a white molecule that is mediated by a test compound. In addition, the effects of cellular toxicity and / or bioavailability of the test compound can be generally ignored in the in vi tro system, the test rather than focusing mainly on the effect of the drug on the molecular target that could be manifested in an alteration. of binding affinity with other proteins or change in enzymatic properties of the molecular target. Therefore, in an example of a screening test of the present invention, the compound of interest is contacted with an isolated and purified H. pyl ori polypeptide.
Screening tests can be constructed in vi tro with a purified H. pyl ori polypeptide or fragment thereof, such as an H. pyl ori polypeptide having enzymatic activity, such that the activity of the polypeptide yields a reaction product. detectable The efficacy of the compound can be evaluated by generating dose response curves from the results obtained using various concentrations of the test compound. In addition, a control test can also be performed to provide a baseline for comparison. Suitable products include those with distinctive absorption, fluorescence, or chemo-luminescence properties, for example, because the detection could easily be automated. A variety of synthetic or naturally occurring compounds can be tested in the assay to identify those that inhibit or potentiate the activity of the αf polypeptide. pyl ori Some of these active compounds could directly, or with chemical alterations promote the permeability or solubility of the membrane, also inhibit or potentiate the same activity (eg, enzymatic activity) in β cells. pyl ori complete and alive.
This invention is further illustrated by the following examples that should not be construed as limiting.
The contents of all published references and patent applications cited throughout this application are incorporated herein by reference.
EXEMPLIFICATION I. Cloning and DNA Sequencing of íf. vyl ori Chromosomal DNA of H. pyl orx was isolated according to a basic DNA protocol highlighted in Schleif R.F. and Wensink PC, Pra cti cal Methods in Molecular Bi olgy, the cells formed packs, resuspended in TE (10 mM Tris, 1 mM EDTA, pH 7.6) and added GES lysis buffer (5.1 M guanidium thiocyanate, 0.1 M EDTA, pH 8.0, 0.5% N-lauryl sarcosine). The suspension was frozen and ammonium acetate (NH4Ac) was added for final concentration of 2.0 M. The DNA was extracted, first with chloroform, then with phenol-chloroform, and reextracted with chloroform. The DNA was precipitated with isopropanol, washed twice with 70% EtOH, dried and resuspended in TE.
After isolation the genomic DNA of H. pyl ori complete was nebulized (Bodenteich et al., Au takes DNA Sequen ci ng and Analyzes (JC Venter, ed.), Academic Press, 1994) at a median size of 2000 bp . After nebulization, the DNA was concentrated and separated on a standard 1% agarose gel. Several fractions, corresponding to approximate sizes of 900-1300 bp, 1300-1700 bp, 1700-2200 bp, 2200-2700 bp, were cut from the gel and purified by the GeneClean procedure (BiolOl, Inc.).
The purified DNA fragments were blunted at the ends after using T4 DNA polymerase. The purified DNA was then ligated to unique BstXI-linker adapters in 100-1000 fold molar excess. These linkers are complementary to the pMPX vectors cut with BstXI, while the overhang is not self-complementary. Therefore, the linkers will not easily concatenate or re-tune the cut vector. The inserts adopted to the linker were separated from the linkers not incorporated in a 1% agarose gel and purified using GeneClean. The insertions adopted to the linker were then linked to each of the 20 pMPX vectors to construct a series of "shotgun" subclone libraries. The vectors contain a lacZ outer frame gene in the cloning site that becomes an internal frame in the event that an adapter dimer is cloned, allowing these to be avoided by their blue color.
All subsequent steps were based on the multiple DNA sequencing protocols highlighted in Church G.M. and Kiegger-Higgins S., Sci en 240: 185-188, 1988. Only the main modifications to the protocols are the most outstanding. Briefly, each of the 20 vectors was then transformed into DH5 competent cells (Gibco / BRL, DH5o1 transformation protocol). Libraries were evaluated by plating on antibiotic plates containing ampicillin, methicillin and IPTG / Xgal. The plates were incubated overnight at 37 ° C. Successful transformants were then used to plate the clones and store them in multiple containers. The clones were collected and combined in 40 ml of growth medium cultures. The cultures were grown overnight at 37 ° C. The DNA was purified using the Qiagen Midi-prep and Tip-100 columns (Qiagen, Inc.). In this way, 100 μg of DNA were obtained by combination. Fifteen 96-well DNA plates were generated to obtain sequence redundancy of 5-10 times assuming average reading lengths of 250-300 bases.
These samples of purified DNA were then sequenced using the multiple DNA sequence based on chemical degradation methods (Church GM and Kieffer-Higgins S., Sci in ce 240: 185-188, 1988) or by means of dideoxy sequencing protocols. Sequithrem (Epicenter Technologies). The sequencing reactions were subjected to electrophoresis and transferred to nylon membranes by direct transfer electrophoresis of 40 cm gels (Richterich P. and Church GM, Me thods in Enzymology 218: 187-222, 1993) or by electrospinning ( Church, supra). 24 samples were run in gel. 45 successful membranes were produced by chemical sequencing and 8 were produced by dideoxy sequencing. The DNA was covalently bound to the membranes by exposure to ultraviolet light, and hybridized with the oligonucleotides labeled in addition to the tag sequences in the vectors (Church, supra). The membranes were washed to rinse the unbound probes specifically, and exposed to X-ray film to visualize the scales of the individual sequence. After autoradiography, the hybridized probe was removed by incubation at 65 ° C, and the hybridization cycle was repeated with another tag sequence until the membrane had been tested 38 times by chemical sequencing membranes and 10 times by sequencing membranes. dideoxy. Thus, each gel produced a large number of films, each containing new sequencing information. Each time a new spot was processed, it was initially tested by an internal standard sequence added to each of the combinations.
Digital images of the films were generated using a laser search densitometer (Molecular Dynamics, Sunnyvale, CA). The digitized images were processed on computer workstations (VaxStation 4000 's) using the REPLICA ™ program (Church et al., Automated DNA Sequencing and Analyzes (J.C. Venter, ed.), Academic Press, 1994). Image processing includes adjusting the path and contrast rectification to smooth the intensity differences, and increase the resolution by iterative Gaussian display. The sequences were then captured in REPLICA ™ and deployed for interactive test reading before they were stored in a project database. The test reading was performed by a quick visual search of the image of the film followed by hits with the mouse on the bands of the displayed image to modify the base calls. Many of the errors in the sequence could be detected and corrected because multiple sequence readings covering the same portion of the genomic DNA provide redundancy of the sequence suitable for editing. Each sequence automatically received an identification number (corresponding to the microtiter plate, probe information, and route group number). This number serves as a permanent identifier of the sequence so it is always possible to identify the original of any particular sequence without resorting to a specialized database.
The routine arrangement of the sequences of íf. pyl ori was made using the FALCON program (Church, Church et al., Automated DNA Sequencing and Analyzes (J.C. Venter, ed.), Academic Press, 1994). This program has proven to be fast and reliable for most sequences. The contiguous assemblies were deployed using a modified version of GelAssemble, developed by the Genetics Computer Group (GCG) (Devereux et al., Nucl ei c Aci d Res. 12: 387-95, 1984) which interacts with REPLICA ™. This is provided by an integrated editor that allows multiple images of the gel sequence that are instantaneously called from the REPLICA ™ database and deployed to allow quick search of contiguous and gel trace test readings where discrepancies occur between the different readings of the sequence in the assembly.
II. Identification, cloning and expression of DNA sequences of íf. oyl ori To facilitate the cloning, expression and purification of membrane proteins and secreted from. pyl ori was selected a powerful gene expression system, the pET System (Novagen), for cloning and expression of recombinant proteins in E. coli Also, a DNA sequence encoding a tag peptide, His-Mark, was fused to the 3 'end of the DNA sequences of interest to facilitate purification of the products of the recombinant protein. The 3 'end was selected by fusion to avoid alteration of any 5' terminal signal sequence. The exception to the above was ppiB, a cloned gene to be used as a control in expression studies. In this study, the sequence of íf. pyl ori ppiB contains a DNA sequence encoding a His-Label fused to the 5 'end of the full-length gene, because the protein product of this gene does not contain a signal sequence and is expressed as a cytosolic protein.
Ampli fi cation by PCR and cloning of DNA sequences with membrane ORF and proteins secreted from the J99 strain of Heli coba cter pyl ori.
The sequences selected (from the list of DNA sequences of the invention) by cloning the J99 strain of H. pyl ori were prepared by amplification of the cloning by polymerase chain reaction (PCR). The synthetic oligonucleotide primers (Table 3) specific for the 5 'and 3' ends of the open reading frames (ORF) were designed and obtained in (GibcoBRL Life Technologies, Gaisburg, MD, USA). All forward primers (specific for 5 'end of sequence) were designed to include a Ncol cloning site at 5' terminus of terminus, except for HpSeq .4821082 where Ndel was used. e primers were designed to allow initiation of translation of protein into a methionine residue followed by a valine residue and sequence encoding remainder of DNA sequence of if. pyl native ori. An exception is sequence of 4821082 of íf. pyl ori where initiator methionine is followed immediately by rest of DNA sequence of H. pyl ori. All inverse primers (specific 3 'end of any ORF of f pyl ori) included an EcoRI site at 5' terminus of end to allow cloning of each H. pyl ori sequence in pET reading frame. 28b. pET-28b vector provides sequence encoding 20 additional carboxy-terminal amino acids (only 19 amino acids in HpSeq, 26380318 and HpSeq, 14640637) that include six histidine residues (at end of C term), which comprises His-Label. An exception to above, as noted before, is construction of vector for ppiB gene. A synic oligonucleotide primer specific for 5 'end of ppiB gene encoded a BamH1 site at its 5' end terminus and primer for 3 'end of ppiB gene encoded an Xhol site at its 5' end terminus.
TABLE 3 Oligonucleotide primers used for the PCR amplification of the DNA sequences of. p? l ori The genomic DNA prepared from strain J99 of íf. pyl ori (ATCC # 55679; deposited by Genome Therapeutics Corporation, 100 Beaver Street, Waltham, MA 02154) was used as the template DNA source for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc. ., F. Ausubel et al., Eds., 1994). To amplify a DNA sequence containing an ORF of íf. pyl ori, the genomic DNA (50 nanograms) was introduced into a reaction vial containing 2 mM MgCl 2, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers) complementary to and surrounding a defined ORF of αf. pyl ori, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP. DCTP, dTTP and 2.5 units of heat-stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 100 microliters. The following thermal cyclization conditions were used to obtain the amplified DNA products for each ORF using a Perkin Elmer Cetus / GeneAmp PCR System 9600 thermal cycler: Protein 26054702, protein 7116626, protein 29479681, protein 30100332, and protein 4821082; Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 sec, 30 ° C for 15 sec and 72 ° C for 1.5 min 23 cycles at 94 ° C for 15 sec, 55 ° C for 15 sec and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Protein 16225006 Denaturation at 94 ° C for 2 min, 25 cycles at 95 ° C for 15 sec, 55 ° C for 15 sec and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Protein 4721061 Denaturation at 92 ° C for 2 min, 2 cycles at 94 ° C for 15 sec, 36 ° C for 15 sec and 72 ° C for 1.5 min 23 cycles at 94 ° C for 15 sec, 60 ° C for 15 sec and 72 ° C for 1.5 min Reactions were concluded at 72 ° C for 6 minutes.
Protein 26380318 Denature at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 sec, 38 ° C for 15 sec and 72 ° C for 1.5 min 23 cycles at 94 ° C for 15 sec, 62 ° C for 15 sec and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Protein 14640637 Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 sec, 33 ° C for 15 sec and 72 ° C for 1.5 min 30 cycles at 94 ° C for 15 sec, 55 ° C for 15 sec and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Conditions for the amplification of H. pylori ppiB; Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 sec, 30 ° C for 15 sec and 72 ° C for 1.5 min 25 cycles at 94 ° C for 15 sec, 56 ° C for 15 sec and 72 ° C for 1.5 min The reactions were concluded at 72 ° C for 6 minutes.
Upon completion of the thermal cycle reactions, each amplified DNA sample was washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA). All amplified DNA samples were digested with restriction endonucleases, Ncol and EcoRI (New England BioLabs, Beverly, MA, USA), or in the case of HpSeq. 4821082 (SEQ ID NO: 1309), with Ndel and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). The DNA samples were then subjected to electrophoresis on 1% NuSeive agarose gels (FMC BioProducts, Rockland, ME USA). The DNA was visualized by exposure to ethidium bromide and long-wave UV irradiation. The DNA contained in the isolated sections of the agarose gel was purified using the protocol of the Bio 101 GeneClean Kit (Bio 101 Vista, CA, USA).
Sequence cloning of DNA sequences. pyl ori in prokaryotic expression vector pET-28b The vector? ET-28b was prepared by cloning by »digestion with Ncol and EcoRI, or in the case of the protein 4821082 of H. pyl ori with Ndel and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). In the case of cloning ppiB, the vector pET-28a was used, which encodes a His-Mark that can be fused to the 5 'end of an inserted gene, and the cloning site was prepared by cloning the ppiB gene by digestion with the restriction endonucleases BamHI and XhoI.
After digestion, the DNA inserts were cloned (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994) into the previously digested pET-28b expression vector, except by the amplified insertion of ppiB, which was cloned into the expression vector pET-28a. The products of the ligation reaction were then used to transform strain BL21 of E. col i (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994) as described below.
Transformation of the competent bacteria with recombinant plasmids The competent bacterium, E col i strain BL21 or E col i strain BL21 (DE3), was transformed with recombinant pET expression plasmids carrying the sequences of ß. pyl ori cloned according to standard methods (Current Protocols in Molecular, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). Briefly, 1 microliter of the ligation reaction was mixed with 50 microliters of electrocompetent cells and subjected to a high voltage pulse, after which the samples were incubated in 0.45 milliliters of SOC medium (0.5% yeast extract, 2.0% tryptone, NaCl mM, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) at 37 ° C with shaking for 1 hour. The samples were then imaged on LB agar plates containing 25 micrograms / l of kanamycin sulfate to grow overnight. The transformed colonies of BL21 were then collected and analyzed to evaluate the cloned insertions as described below.
Iden tifi ca tion of pET expression plasmids recombining testers that carry sequences of H. pyl ori Individual BL21 clones transformed with recombinant pET-28b-ORF from H. pylori were analyzed by PCR amplification of the cloned inserts using the same forward and reverse primers, specific for each sequence of ß. pyl ori, which were used in the original cloning reactions by PCR amplification. Successful amplification verified the integration of the íf sequences. pyl ori in the expression vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994).
Isolate and prepare the DNA of the plasmid of the transformers BL21 The individual clones of the recombinant pET-28b vectors carrying the ORFs of íf. pyl ori clones were collected and incubated in 5 ml of LB broth plus 25 micrograms / ml of kanamycin sulfate overnight. The next day the plasmid DNA was isolated and purified using the Qiagen plasmid purification protocol (Qiagen Inc., Chatsworth, CA, USA).
Sequence expression of H. pyl ori recombine tes in E. coli The pET vector can be propagated in any strain of E. col i K-12 p. ex. HMS174, HB101, JM109, DH5, etc. for the purpose of cloning or preparation of the plasmid. The guests for the expression include E strains. coli that contain a chromosomal copy of the T7 RNA polymerase gene. These hosts are lysogens of bacteriophage DE3, a lambda derivative carrying the lacl gene, the lacUV5 promoter and the T7 RNA polymerase gene. T7 RNA polymerase is induced by the addition of isopropyl-B-D-thiogalactoside (IPTG), and the T7 RNA polymerase transcribes any white plasmid, such as pET-28b, which carries a T7 promoter and a gene of interest. The strains used include: BL21 (DE3) (Studier, F.W., Rosenberg, A.H., Dunn, J.J., and Dubendorff, J.W. (1990) Meth. Enzymol., 185, 60-89).
To express the sequences of íf. pyl ori recombinants, 50 nanograms of isolated plasmid DNA as described above was used to transform the competent BL21 (DE3) bacterium as described above (provided by Novagen as part of the pET expression kit). The lacZ (beta-galactosidase) gene was expressed in the p-ET System as described for the recombinant constructs of .f. pyl ori The transformed cells were cultured in SOC medium for 1 hour, and then the culture was placed on LB plates containing 25 micrograms / ml kanamycin sulfate. The next day, the bacterial colonies were combined and grown in LB medium containing kanamycin sulfate (25 micrograms / ml) for an optical density in 600 nM of 0.5 to 1.0 OD units, at this point, 1 millimolar IPTG was added. to the culture for 3 hours to induce the expression of the gene of the recombinant DNA constructs of. pyl ori After induction of expression of the gene with IPTG, a pack was formed with the bacteria by centrifugation in a Sorvall RC-3B centrifuge at 3500 x g for 15 minutes at 4 ° C. The packs were resuspended in 50 milliliters of cold 10 mM Tris-HCl, pH 8.0, 0.1 M NaCl and 0.1 mM EDTA (STE buffer). The cells were then centrifuged at 2000 x g for 20 min at 4 ° C. The wet packages were weighed and frozen at -80 ° C until ready for purification of the protein.
III. Purification of recombinant E proteins. col i All of them The concentrations of purified protein preparations were quantified spectrophotometrically using absorbance coefficients calculated from the amino acid content (Perkins, S.J. 1986 Eur. J. Biochem. 157, 169-180). Protein concentrations were also measured by the method of Bradford, M.M. (1976) Anal. Biochem. 72, 248-254, and Lowry, O.H., Rosebrough, N., Farr, A.L. & Randall, R.J. (1951) J. Biol. Chem. 193, pages 265-275, using bovine serum albumin as a standard.
The SDS-polyacrylamide gels (12% acrylamide gels or 4.0 to 25% gradient) were purchased from BioRad (Hercules, CA, USA), and stained with Coomassie blue. Molecular weight markers included rabbit skeletal muscle myosin (200 kDa), E. col i (-galactosidase (116 kDa), rabbit muscle phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (45 kDa), bovine carbonic anhydrase (31 kDa), trypsin inhibitor soybean (21.5 kDa), egg white lysozyme (14.4 kDa) and bovine aprotinin (6.5 kDa). 1 . Protein purifi cation of sun s ubl protein All steps were carried out at 4 ° C. The frozen cells were thawed, resuspended in 5 volumes of lysis buffer (20 mM Tris, pH 7. 9, 0.5 M NaCl, 5 mM imidazole with 10% glycerol, 0.1% 2-mercaptoethanol, 200 μg / ml lysozyme, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 10 μg / ml each of leupeptin, aprotinin , L-chloro-3- [4-tosylamido] -7-amino-2-heptanone (TLCK), L-chloro-3- [4-tosylamido] -4-phenyl-2-butanone (TCPK), and inhibitor of soybean trypsin, and broke through several steps through a small volume microfluidizer (Model M-110S, Microfluidics International Corporation, Newton, MA). The resulting homogenates were made with 0.1% Brij 35, and centrifuged at 100,000 x g for 1 hour to produce a clear supernatant (crude extract).
After filtration through a 0.8 μm Supor filter (Gelman Sciences, FRG) the crude extract was directly loaded onto a Ni2 + -nitrilotriacetate-agarose (NTA) with a pad volume of 5 milliliters (Hochuli, E., Debeli). , H., and Schacheer, A. (1987) J. Chromatography 411, 177-184) pre-equilibrated in lysis buffer containing 10% glycerol, 0.1% Brij 35 and 1 mM PMSF.
The column was washed with 250 ml (50 volumes) of lysis buffer containing 10% glycerol, 0.1% Brij 35, and eluted with sequential steps of lysis buffer containing 10% glycerol, 0.05% Brij. , 1 mM PMSF, and imidazole 20, 100, 200, and 500 mM in succession. Fractions were monitored by absorbance at OD 280 nm, and peak fractions were analyzed by SDS-PAGE. The fractions containing the recombinant protein were eluted in 100 mM imidazole.
Pro tein recombine 14640637 te and s protein, beta gala ctosi da sa (the c Z) and pepti dil -prolil ci s -trans i perfruct (ppiB) Fractions containing recombinant proteins from the Ni2 + -NTA-agarose columns were collected and then concentrated to approximately 5 ml by centrifugal filtration (Centriprep-10, Amicon, MA), and loaded directly onto a 180 ml column (1.6 X 91 cm) of Sephacryl S-100 HR gel filtration medium equilibrated in Shock Absorber A (10 mM Hepes, pH 7.5, 150 ml NaCl, 0.1 mM EGTA) and run in buffer A at 18 ml / h. The fractions containing the recombinant protein were identified by absorbance at 280 nm and analyzed by SDS-PAGE. The fractions were collected and concentrated by centrifugal filtration.
Recombinant protein 711 6626 Fractions containing the recombinant protein from the Ni2-NTA-agarose column were collected and dialyzed overnight against 1 liter of dialysis buffer (10 mM MOPS, pH 6.5, 50 mM NaCl, 0.1 mM EGTA, 0.02% of Brij 35 and 1 mM PMSF). In the morning, a fine white precipitate was removed by centrifugation and the resulting supernatant was loaded on a high liquid chromatography column.
'MonoS resolution of 8 ml (8 x 75 mm) (Pharmacia Biotechnology, Inc., Piscataway, NJ, USA) was equilibrated in buffer B (10 mM MOPS, pH 6.5, 0.1 mM EGTA) containing 50 mM NaCl. The column was washed with 10 volumes of buffer B containing 50 mM NaCl, and developed with a linear gradient of 50 ml of increasing NaCl (50 to 500 mM). The recombinant protein 7116626 was eluted as an acute peak in 300 mM NaCl. 2. Purifi cation of insolubl proteins of inclination bodies The following steps were carried out at 4 ° C. Cell packets were resuspended in lysis buffer with 10% glycerol 200 g / ml lysozyme, 5 mM EDTA, 1 mM PMSF and 0.1% mercaptoethanol. After passing through the apparatus to break cells, the resulting homogenate was made with 0.2% deoxycholate, stirred 10 minutes, then centrifuged at 20,000 x g, for 30 min. The packs were washed with lysis buffer containing 10% glycerol, 10 mM EDTA, 1% Triton X-100, 1 mM PMSF and 0.1% mercaptoethanol, followed by several washes with lysis buffer containing 1 M urea, 1 mM PMSF and 0.1% 2-mercaptoethanol. The resulting white package was composed primarily of inclusion bodies, free of unbroken cells and membrane materials.
Pro teins recombine tes 26054 702, 1 6225006, 301 00332, 4 721 061 The following steps were carried out at room temperature. The purified inclusion bodies were dissolved in 20 ml of 8.0 M urea in lysis buffer with 1 mM PMSF and 0.1% 2-mercaptoethanol, and incubated at room temperature for 1 hour. The materials that did not dissolve were removed by centrifugation. The supernatant was filtered, then loaded onto a Ni2 + -NTA agarose column pre-equilibrated in 8.0 M urea in Lysis Buffer. The column was washed with 250 ml (50 pad volumes) of lysis buffer containing 8 M urea, 1.0 mM PMSF and 0.1% 2-mercaptoet anol, and developed with sequential steps of lysis buffer containing urea. M, 1 mM PMSF, 0.1% 2-mercaptoethanol and imidazole 20, 100, 200, and 500 mM in succession. Fractions were monitored by absorbance at OD 280 nm, and peak fractions were analyzed by SDS-PAGE. The fractions containing the recombinant protein were eluted with 100 M imidazole.
Recombinant proteins tes 294 79681, 26380318 The package containing the inclusion bodies was solubilized in buffer B urea 8 M, 1 mM PMSF and 0.1% 2-mercaptoethanol, and incubated for 1 hour at room temperature. The insoluble materials were removed by centrifugation at 20,000 xg for 30 min, and the clarified supernatant was loaded onto a 15 ml SP-Sepharose column (1.6 x 7.5 cm) pre-equilibrated in buffer B, 6 M urea, 1 mM PMSF, 0.1% of 2-mercaptoethanol. After washing the column with 10 pad volumes, the column was developed with a linear gradient of NaCl from 0 to 500 mM.
Dialysis and concentration of protein samples Urea was slowly removed from the protein samples by dialysis against Tris saline buffer (TBS, 10 mM Tris pH 8.0, 150 mM NaCl) containing 0.5% deoxycholate (DOC) with sequential reduction in the urea concentration as follows; 6 M, 4 M, 3 M, 2 M, 1 M, 0.5 M and finally TBS without any urea. Each dialysis step was conducted for a minimum of 4 hours at room temperature.
After dialysis, the samples were concentrated by pressurized filtration using cells stirred with Amicon. Protein concentrations were measured using the methods of Perkins (1986 Eur. J. Biochem. 157, 169-180), Bradford ((1976) Anal. Biochem. 72, 248-254) and Lowry ((1951) J. Biol. Chem. 193, pages 265-275).
The recombinant proteins purified by the methods described above are summarized in Table 4 below.
TABLE 4 External Membrane Proteins Periplasmic / secreted protein Other Surface Proteins Internal proteins of the Membrane Proteins Control with His-Brand IV. Analysis of the proteins of íf. oyl ori as vaccine candidates To analyze the H. pylori proteins for use in the vaccine formulations of the invention, several proteins were expressed. pylori, characterized immunogenically and tested in studies of animal efficacy as highlighted below. Specifically, the immunomodulatory effects of the proteins of. pylori were investigated in a mouse / íf model. pylori resembling human H. pylori infection in humans. In these studies, the effect of oral immunization of the selected H. pylori polypeptides on mice infected with ff was determined. pylori.
Identification, cloning and expression of recombinant Helicobacter pylori sequences To facilitate the cloning, expression and purification of membrane proteins and / or secreted of íf. pylori, the pET gene expression system (Novagen) was selected for cloning and expression of recombinant proteins in Escherichia coli. In addition, of the proteins having a signal sequence at their amino-terminal end, a DNA sequence encoding a tag peptide (His-tag) was fused to the 5 'end of the DNA sequences of if. pylori of interest to facilitate the purification of the products of the recombinant protein.
PCR amplification and cloning of the DNA sequences that have membrane ORF and proteins secreted from the J99 strain of Heli cobacter pyl ori.
Selected sequences (from the list of DNA sequences of the invention) for cloning of strain J99 of H. pyl ori were prepared by cloning the amplification of the polymerase chain reaction (PCR). All selected sequences encode for H. pyl ori outer membrane proteins with the vac9 (SEQ ID NO: 125), vac1o (SEQ ID NO: 147), vac22 (SEQ ID NO: 121) and vac41 (SEQ ID NOs: 147) sequences. N0: 176) that all share a terminal phenylalanine residue. In addition, all vac32 (SEQ ID NO: 108), vac36 (SEQ ID NO: 149) and vac37 (SEQ ID NO: 139) sequences share a terminal phenylalanine residue and a tyrosine cluster in the C terminus. Oligonucleotide primers Synthetic for each ORF of interest (Table 5) specific for the predicted mature 5 'end of the ORF and downstream (3') of the predicted translational stop codon were designed and purchased (Gibco BRL Life Technologies, Gaithersburg, MD, USES) . All forward primers (specific for the 5 'terminus of the ORF region of interest) were designed to include a BamlII restriction site followed by an Ndel restriction site. These primers were designed to allow initiation of translation of the protein into a methionine residue encoding within the Ndel restriction site sequence (in the case of producing a recombinant protein without His-tagged) or to fuse in frame with the sequence of AD? which encodes the His-tag (to produce the His-tagged recombinant protein), followed by the coding sequence for the rest of the AD? if native pyl ori All reverse oligonucleotide primers (specific downstream (3 ') of the predicted translational stop codon of the ORF) were designed to include an .EcoRI restriction site. This combination of primers would allow each ORF to be cloned into pET28b (to produce a His-tagged recombinant protein) or pET30a (to produce a protein without His-tagged or native recombinant). The pET28b vector provides the sequence encoding 20 additional amino-terminal amino acids (plus methionine at the Ndel restriction site) including an extension of six histidine residues that make the His-tag.
The genomic DNA prepared from strain J99 of ff. pyl ori (ATCC 55679) was used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify a DNA sequence containing an H. pyl ori specific ORF, the genomic DNA (50 nanograms) was introduced into a reaction tube containing 200 nanograms of the forward and reverse synthetic oligonucleotide primer specific for the ORF of interest , and 45 microliters of PCR SuperMix purchased from (GibcoBRL Life Technologies, Gaithersburg, MD, USA) in a total of 50 microliters. SuperMix PCR is supplied in 1. IX concentrations and contains 22 mM Tris-HCl (pH 8.4), 55 mM KCl, 1.65 mM MgCl2, 220 micromolar each of dATP, dCTP, dGTP and dTTP, 22 units of Ta q polymerase recombinant / ml of stabilizer. The following thermal cycling conditions were used to obtain the amplified DNA products for each ORF using the Perkin Elmer Cetus thermal cycler / Gene Amp PCR System.
Table 5: Oligonucleotide primers Sequences for Vac32, Vac9 and Vac22 Denaturation at 94 ° C for 30 sec 35 cycles at 94 ° C for 15 sec, 55 ° C for 15 ° C, and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 8 minutes Sequences for VaclO and Vac41 Denaturation at 94 ° C for 30 sec 35 cycles at 94 ° C for 15 sec, 55 ° C for 15 ° C, and 72 ° C for 2.5 min Reactions were concluded at 72 ° C for 8 minutes Sequences for Vac36 and Vac37 Denaturation at 2 cycles at 94 ° C for 15 sec, 55 ° C for 15 ° C, and 72 ° C for 1.5 min The reactions were concluded at 72 ° C for 6 minutes At the end of the thermal cyclization reactions, each sample of amplified DNA was subjected to electrophoresis in 1.0% agarose gels. The DNA was visualized by exposure to ethidium bromide and long-wave UV irradiation, and the gel was cut into strips. The DNA was purified using the Wizard PCR Preps Kit (Promega Corp., Madison, WI, USA), and then digested with BamRI and JScoRI (Current Protocols in Molecular 'Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). The digested PCR amplification was then electrophoresed again and purified as before.
Li ga tion of ff DNA sequences. pylori in cloning vectors The pOK12 vector (J. Vieira and Messing, Gene 100: 189-194, 1991) was prepared by cloning by digestion with BamK? and f? coRI in the case of Vac9, 10, 22, 31 and 32, while vector pSU21 (B. Bartolomé et al., Gene 102: 75-78, 1991) was prepared by cloning by digestion with BamHl and EcoRI in the case of Vac41 (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The vectors were electrophoresed in 1.0% agarose gels and purified using the Wizard PCR Preps kit (Promega Corp., Madison, WI, USA). After ligation of the purified, digested vector and the ORF of if. pyl ori amplified purified, digested, the products of the ligation reaction were transformed into competent E cells. col i JM109 according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). • Individual bacterial colonies were screened for those containing the correct recombinant plasmids. incubated in LB broth overnight (plus 25 ug / ml kanamycin sulfate for plasmids based on pOKl2 or 25 ug / ml chloramphenicol for plasmids based on pSU21) followed by preparation of plasmid DNA using the Magic system Minipreps (Promega Corp., Madison, WI, USA), and then analyzed by restriction digestion (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds, 1994).
Sequence cloning of H. pyl ori DNA in the expression vectors pET28b and pET30a prokaryotic The expression vectors pET28b and pET30a were prepared by cloning by digestion with Ndel and EcoR1 (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds, 1994). The DNA sequences of íf. pyl ori were removed from the structures of the plasmids pOK12 (Vac9, 10, 23, 31 and 32) or pSU21 (Vac41) by digestion with Ndel and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). The sequences of AD? of pET28b, pET30a and ff. pyl ori were all electrophoresed on a 1% agarose gel using the Wizard PCR Preps kit (Promega Corp., Madison, WI, USA). After ligation of the purified, digested vector and AD? of íf. pyl ori purified, digested, the products of the ligation reaction were transformed into competent E cells. coli JM109 (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The individual bacterial colonies were screened for those containing the correct recombinant plasmids by preparing the AD? of the plasmid as described above followed by the profiles of restriction digestion and sequencing of AD? (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). These recombinant plasmids were then used to transform the E expression strains. col i specific Transformation of the competent bacterium with recombinant expression plasmids Strains of the competent bacterium (BL21 (DE3), BL21 (DE3) pLyS, HMS174 (DE3) and HMS174 (DE3) pLysS were prepared and transformed with the recombinant pET28b expression plasmids carrying the cloned H. pyl ori sequences according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994.) These expression host strains contain a copy of the chromosome of the T7 RNA polymerase gene. hosts are lysogens of the bacteriophage DE3, a lambda derivative carrying the cl gene, the cUVd promoter and the T7 RNA polymerase gene.The expression of T7 RNA polymerase is induced by the addition of isopropyl-β-D thiogalactosidase (1PTG ), and the T7 RNA polymerase then transcribes any white plasmid, such as pET28b, which carries a T7 promoter sequence and a gene of interest.
Expression sequences of H. pyl ori recombine tes in E. The transformants were collected from LB agar plates containing 25 ug / ml kanamycin sulfate (ensures maintenance of the recombinant plasmids based on pET28b) and used to inoculate the LB broth containing 25 ug / ml kanamycin sulfate and were grown to an optical density at 600 nm of 0.5 to 1.0 OD units, at this point 1 mM 1PTM was added to the culture for one to three hours to induce the expression of the recombinant DNA constructs of H. pyl ori. . After induction of the expression gene with 1PTG, bacterial packets were made by centrifugation and resuspended in SDS-PAGE solubilization buffer and subjected to SDS-PAGE (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Proteins were visualized by Coomassie Brilliant Blue staining or were detected by western immunoblot using the anti-His-tag specific monoclonal antibody (Clontech, Palo Alto, CA, USA) using standard methods. { Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds. 1994). The host strain that provides the highest level of recombinant protein production was then chosen for use in a large-scale induction to purify the recombinant protein. All of the following listed proteins were expressed recombinantly and the strain that gives the highest expression level is listed: BL21 (DE3) (vac31, vac26, vac37); BL21 (DE3) pLysS (vac9, 32); HMS174 (DE3) (vac1, 11).
Protein purifi cation of proteins recombines and generates a specific serum Large-scale cultures were inoculated and grown as before, and induced with 1 mM 1PTM for 3 hours. After induction, bacterial packs were made by centrifugation in a Sorvall centrifuge at 3500 x g for 15 min at 4 ° C. All expressed recombinant proteins were present in the insoluble inclusion body fraction. The inclusion bodies were purified according to standard protocols (Antibodies, Cold Spring Harbor Laboratory Press, E. Harlow and D. Lane, eds., 1988). The recombinant protein produced by vac32 was solubilized in 8M urea and partially purified by nickel chromatography (REF here). Denatured recombinant proteins were purified by electrophoresis on SDS-PAGE gels, and after visualization with Coomassie Brilliant Blue, the protein was cut from the gel and gel sections were homogenized. This material was used to increase specific polyclonal antibodies in mice or rabbits according to standard protocols (Antibodies, Cold Spring Harbor Laboratory Press, E. Harlow and D. Lane, eds., 1988).
Immunological characterization of recombinant proteins In all cases where an attempt was made to increase the antibody, high titre of antiserum was generated, confirming the immunogenicity of the recombinant proteins. In addition, these specific antisera were used to analyze whether the protein encoded by the cloned gene was expressed in if. pyl ori Western blot analysis using standard protocols (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds, 1994) confirmed that the J99 strain of. pyl ori expressed proteins of the expected molecular weight that reacted with the vaclO antiserum, vac32, vac31, vac36. The specific antiserum was also used to determine the level of antigenic conservation among a large number of ff isolates. pyl ori that have been obtained from different geographical sites around the world, and from all kinds of clinical manifestations, including gastritis, duodenal ulcer, gastric ulcer and gastric cancer. It was found that each strain produces a protein that reacts specifically with each antiserum.
In addition, the cells of ff. pyl ori of strains J99, 17874, AH244 and SS1 were distributed in different cell compartments (Doig and Trust 1994 Infect, Immun, 62: 4526-4533: O'Toole et al, 1995 J. Bacteriol, 177: 6049-6057). The specific antiserum was used to test these fractions by western immunoblot to identify in which fraction the protein was located. In all cases, the immunoreactive protein was present in the outer membrane as predicted by the characteristics of the sequence and searched parts described here.
Demonstration of effi ciency of protein as a cradle Vacuum purification for efficiency studies All the following steps were carried out at 4 ° C. The cell packets were resuspended in 5 volumes per gram of lysis buffer cells (50 mM Sodium Phosphate pH 8.0, 0.5 M NaCl, 5 mM Imidazole) with 10 mM EDTA, 1 mM phenylmet ylsulfonyl fluoride (PMSF) and 0.1% β-mercaptoethanol, and broke through several steps through a microfluidizer of small volume (Model M-110S, Microfluidics International Corporation, Newton, MA). The resulting homogenate was made with 0.2% sodium deoxycholate (DOC), stirred 20 minutes, then centrifuged (10,000 g x 30 min). The packs were washed twice with Lysis Buffer containing 10 mM EDTA, 1% Triton X-100, 1 mM PMSF and 0.1% β-mercaptoethanol, then with lysis buffer containing 1M urea, 1 mM PMSF and 0.1 % of β-mercaptoethanol. The resulting white pack consists mainly of inclusion bodies, free of unbroken cells and membrane materials.
The inclusion bodies were dissolved in 20 ml of 6 M guanidine-HCl in lysis buffer with 1 mM PMSF and 0.1% β-mercaptoethanol, and incubated on ice for 1 hour. Materials that did not dissolve were removed by centrifugation (100, 000 g x 30 min.) The clear supernatant was filtered through a 0.8 μm Supor filter (Gelman Sciences, FRG) and loaded directly onto a 10 ml Ni2 + -NTA agarose column (Hochuli et al. equilibrated in / Guanidine lysis buffer 6 M HCl containing 1 mM PMSF and 0.1% β-Mercaptoethanol. The column was washed with 20 ml (2 pad volumes) of Lysis Buffer containing 6 M guanidine-HCl, 1 mM PMSF and 0.1% β-mercaptoethanol, then the guanidine-HCl was removed slowly with a linear gradient 100 ml (from 6M to 0 M Guanidine-HCl) of lysis buffer containing 0.5% Brij 35, 1 mM PMSF, 0.1% β-mercaptoethanol. The column was then worked with a linear gradient of 25 ml of increasing imidazole (5 to 500 mM) in Lysis buffer containing 0.5% Brij 35, lmM PMSF and 0.1% β-mercaptoethanol. The recombinant proteins elute as a peak centered on 100 mM imidazole.
The fractions containing the recombinant proteins were collected and then concentrated to approximately 8 ml by centrifugal filtration (Centriprep-10, Amicon, MA), and loaded directly onto a 350 ml (2.2x91 cm) column of filtration medium. Sephacryl S-100 HR balanced gel in Shock Absorber A (50 mM Sodium Phosphate, pH 8.0, 500 mM NaCl, 0.1 mM EGTA, 1 mM PMSF, 0.1% β-mercaptoethanol, 0.5% Brij 35) and was run in Shock absorber A at 30 ml / h. The fractions containing the recombinant protein were identified by absorbance at 280 nm and analyzed by SDS-PAGE. The fractions were collected, concentrated to 1.5 to 2 mg / ml and dialyzed overnight against 10 mM Potassium Phosphate pH 7.5, 150 mM NaCl, 0.1 mM EGTA and 0.5% Brij 35. The concentration of the protein was quantified in the dialysate, aliquots were then taken to cool to -20 ° C.
Mouse model of Heli infection coba cter oyl ori A murine model of ff infection. pyl ori was produced by infection of C57BL / 6 mice with the Sidi SSI strain of ff. pyl ori and was used to evaluate the efficacy of vac36 of if. pyl recombinant ori. This strain of if. pyl ori adapted to mouse is ca gA + va cA +, shows colonization levels in C57BL / 6 mice equivalent to those observed in humans, forms adhesion pedestals, colonizes for at least 8 months, and produces atrophy of chronic active gastritis and of the mucosa (Lee et al., Gastroenterology, 112: 1386-1397, 1997). Dose-response studies have shown degrees of infection of 100% of C57BL / 6 and Balb / C mice in situ at 8 weeks post-dosing with a simple inoculation of 106 organisms.
Evaluation of gastric infection of íf. oyl ori The presence of organisms of íf. pyl ori in gastric tissue was determined by gastric tissue culture and by a quantitative urease test. In the latter method, a longitudinal segment of antrum, representing approximately 1/4 of the total antral region was placed in 1 ml of urea broth. After 4 hr, the degree of change resulting from urea hydrolysis and pH increase was quantified by spectrophotometric measurement of A550 (Fox et al., Immunol. 88: 400-406, 1996). The sensitivity of the test is ~ 103 of if organisms. pyl ori A positive gastric tissue (infected with H. pyl ori) was defined as the sample presenting 2 standard deviations above the average value of A550 derived from a group of control mice of the same age uninfected undosed.
Evaluation of the local immune response for immunization in gastric tissue The longitudinal sections of gastric tissue from the junction of the esophagus to the duodenum were immersed in a compound that includes OCT, frozen in liquid nitrogen, and the cryosections were immunostained with monoclonal antibodies that recognize CD4 + or CD8 + T cells or with antiserum against IgA. mouse for the identification of IgA containing the plasma cells (IgACC) (Pappo et al., Infect.Immun 63: 1246-1252, 1995). The degree of local gastric immune response was expressed quantitatively as the number of CD4 +, CD8 + or IgACC cells per mm2 of the gastric region examined.
Protective activity of the vac36 antigen of íf. Purified recombinant ori The capacity of the purified recombinant vac36 antigen derived from αf. pyl ori to interfere with the establishment of an ßf infection. pyl ori was examined in mice. Groups of 6-7 week old female C57BL / 6 mice (n = 10) were orally immunized 4 times at weekly intervals as follows: 1) 100 μg of recombinant vac36 antigen and 10 μg of cholera toxin adjuvant (CT) ), 2) 1 mg of lysate antigens. pyl ori and 10 μg of CT, and 3) 0.2 M bicarbonate buffer and 10 μg of CT adjuvant. The mice were dosed 2 weeks later on 3 consecutive days by oral administration of 108 ß-organisms. pyl ori The experiment was completed 2 weeks post-dosing, and the infection level of H. pyl ori was evaluated by bacterial colony counts and by quantitative urease tests.
Oral immunization with vac36 antigen interfered with the establishment of the infection of. pyl ori in the dosage with íf organisms. pyl ori live. Mice immunized with purified recombinant vac36 antigen exhibited a significantly lower level of colonization by ff. pyl ori, as assessed by the gastric urease and bacterial count activity tests (Table 6). Oral immunization with vac36 antigen also resulted in the generation of a local protective gastric immune response. Larger numbers of CD4 + T and IgACC cells were enlisted in the gastric tissues of mice immunized with vac36 when compared to mice infected with. pyl ori not immunized (Table 7).
Table 6 Mice protected with vac36 recombinant antigen to test with. pyl ori The urease activity is expressed as the average of A550 ± SEM of duplicate antral samples from the group of mice n = 10. Wilcoxon Rank Sum test compared to mice immunized with adjuvant CT alone The level of ff. pyl ori in gastric tissue was evaluated by bacterial counts, and is shown as the average of colony-forming units ± SEM Table 7 Mice immunized with vac36 generate a local gastric immune response to treat with íf. pylori Average number of cells / mm2 of gastric region ± SEM p < 0.05 by Wilcoxon Rank Sum Test when compared to mice infected with H. pyl ori not immunized V. Analysis of variance of gene sequence of strains of Heli coba cter pyl ori Four genes were cloned and sequenced from several strains of H. pyl ori to compare the DNA and deduce the amino acid sequences. This information was used to determine the variation of the sequence between the strain of H. pyl ori, J99 and other strains of. pyl ori isolated from human patients.
Preparation of chromosomal DNA The cultures of the strains of if. pyl ori (as listed in Table 10) were grown in BLBB (1% Tryptone, 1% Peptamine 0.1% Glucose, 0.2% Yeast Extract 0.5% Sodium Chloride, 5% Fetal Serum Bovine) at an OD600 of 0.2. The cells were centrifuged in a Sorvall RC-3B at 3500 x g at 4 ° C for 15 minutes and the package was resuspended in 0.95 ml of 10 mM Tris-HCl, 0.1 mM EDTA (TE). Lysozyme was added to a final concentration of 1 mg / ml along with 1% SDS and RNAse A + TI for 0.5 mg / ml and 5 units / ml respectively, and incubated at 37 ° C for one hour. Proteinase K was added to a final concentration of 0.4 mg / ml and the sample was incubated at 55 C for more than one hour. NaCl was added to the sample for a concentration of 0.65 M, carefully mixed, and 0.15 ml of 10% BCTA in 0.7 M NaCl (final is 1% CATB / 70 mM NaCl) was added followed by incubation at 65 ° C during 20 minutes. At this point, the samples were extracted with chloroform: isoamyl alcohol, extracted with phenol, and extracted again with chloroform: isoamyl alcohol. The DNA was precipitated with ether EtOH (1.5 x volumes) or isopropanol 0.6 x volumes) at -70 ° C for 10 minutes, washed in 70% EtOH and resuspended in TE.
Amplifi cation by PCR and cloning Genomic DNA prepared from twelve strains of Heli coba cter pyl ori was used as the source of template DNA for PCR amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. , editors, 1994). To amplify a DNA sequence containing an ORF of H. pyl ori, genomic DNA (10 nanograms) was introduced into a reaction vial containing 2 mM MgCl2, 1 micromolar synthetic oligonucleotide primers (forward and reverse primers, see Table 8) complementary to and surrounding an ORF of íf. pyl defined ori, 0.2 mM of each deoxynucleotide triphosphate; dATP, dGTP, dCTP, dTTP and 0.5 units of thermo stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA) in a final volume of 20 microliters in duplicate reactions.
TABLE 8 Oligonucleotide primers used for PCR amplification of DNA sequences of IF. p? l ori The following thermal cycling conditions were used to obtain the amplified DNA products for each ORF using a Perkin Elmer Cetus / GeneAmp PCR System 9600 thermal cycler: Protein 7116626 and Protein 346; Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 ° C sec, 30 ° C for 15 sec and 72 ° C for 1.5 min 23 cycles at 94 ° C for 15 sec, 55 ° C for 15 sec Y 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Protein 26054702 from sepals AH5, 5155, 7958, AH24, and J99; Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 ° C sec, 30 ° C for 15 sec and 72 ° C for 1.5 min 25 cycles at 94 ° C for 15 sec, 55 ° C for 15 sec Y 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 6 minutes.
Protein 26054702 and Protein 294796813 of the sepals AH4, AH15, AH61, 5294, 5640, AH18 and Hp244; Denaturation at 94 ° C for 2 min, 2 cycles at 94 ° C for 15 ° C sec, 30 ° C for 20 sec and 72 ° C for 2 min 25 cycles at 94 ° C for 15 sec, 55 ° C for 20 sec and 72 ° C for 2 min. The reactions were concluded at 72 ° C for 8 minutes.
At the end of the thermal cyclization reactions, each pair of samples were combined and used directly to clone into the pCR cloning vector as described above.
Cloning of the sequences of íf. pyl ori in the cloning vector pCR TA.
All amplified inserts were cloned into the pCR 2.1 vector by the method described in the Original TA cloning kit (Invitrogen, San Diego, CA). The products of the ligation reaction were then used to transform the strain TOP10F '(INVaF' in the case of sequence 350 of if.pyl ori) of E. coli as described later.
Transformation of the competent bacteria with recombinant plasmids Competent bacteria, E coli strain TOP10F 'or E. coli strain INVaF ', were transformed with recombinant pCR expression plasmids carrying the sequences of. pyl ori cloned according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). Briefly, 2 microliters of micromolar BME was added to each vial of 50 microliters of competent cells. Subsequently, 2 microliters of the ligation reaction was mixed with the competent cells and incubated on ice for 30 minutes. The cells and the ligation mixture were then subjected to a "heat shock" at 42 ° C for 30 seconds, and subsequently placed on ice for an additional 2 minutes, after which the samples were incubated in 0.45 milliliters of SOC medium. (0.5% yeast extract, 2.0% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgC12, 10 mM MgSO4 and 20 mM glucose) at 37 ° C with shaking for 1 hour. The samples were then imaged on LB agar plates containing 25 microgram / ml kanamycin sulfate or 100 microgram / ml ampicillin to grow overnight. The transformed colonies of TOP10F 'or INVaF' were then collected and analyzed to evaluate the cloned insertions as described below.
Identification of recombinant PCR plasmids carrying sequences of H. pyl ori The individual transformed clones of TOP10F 'or INVaF' with recombinant ORF of. pyl ori by pCR were analyzed by PCR amplification of the cloned insertions using the same forward and reverse primers, specific for each sequence of f. pyl ori, which were used in the original PCR amplification cloning reactions. Successful amplification verified the integration of the íf sequences. pyl ori in the cloning vector (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994).
The individual clones of the vectors carrying the ORF of íf. pyl ori clones were appropriately collected for sequence analysis. Sequence analysis was performed on ABI Sequencers using standard protocols (Perkin Elmer) using vector-specific primers (as found in PCRII or pCR2.1, Invitrogen, San Diego, CA) and ORF-specific sequencing primers as listed in Table 9 below.
Table 9 Oligonucleotide primers used for the sequencing of the DNA sequences of If. pyl ori Resulted To establish the degree of error in these experiments, five individual clones of Protein 26054702, prepared from five separate PCR reaction mixtures of the J99 strain of ff. pyl ori, were sequenced in a total length of 897 nucleotides for a total accumulation of 4485 bases of the DNA sequence. The DNA sequence for the five clones was compared to a DNA sequence previously obtained by a different method, e.g. ex. , cloning by random shot and sequencing. The degree of error of PCR for the experiments described here was determined that 2 bases change from 4485 bases, which is equivalent to an estimated degree of error of less than or equal to 0.04%.
The DNA sequence analysis was performed in four different open reading frames identified as genes and amplified by PCR methods from a dozen different strains of the bacterium Heli coba cter pyl ori. The amino acid sequences deduced from three of the four open reading frames that were selected for this study show statistically significant BLAST homology to define the proteins present in other bacterial species. ORFs include: Protein 26054702, homologous to the A & amp; B that encode an ABC transporter in G. novicida; Protein 7116626, homologous to lipoprotein e (P4) present in the outer membrane of H. influenza; Protein 29479681, homologous to fecA, an external receptor of the membrane in the transport of iron (III) dicyrate in E. col i. The 346 protein was identified as an unknown open reading frame, because it shows low homology with the sequences in the public databases.
To evaluate the degree of conservation or variance in the ORF through several strains of íf. pyl ori, the changes in the DNA sequence and the deduced sequence of the protein were compared to the DNA and the deduced sequences of the protein found in strain J99 of íf. pyl ori (see Table 10 below). The results are presented as percent identity to strain J99 of íf. pyl ori sequenced by random cloning. To control for any variation in J99 sequence, each of the four open reading frames were cloned and sequenced against bacterial strain J99 and the sequence information was compared to the sequence information that had been collected from cloned insertions by sequencing of random shooting of strain J99. The results show that there is variation in the DNA sequence that is in the range of the difference so low of 0.12% (Protein 346, strain J99) to about 7% change (Protein 26054702, strain AH5). The deduced protein sequences show no variation (Protein 346, strains AH18 and AH24) or as much as 7.66% of changed amino acids (Protein 26054702, Strain AH5).
Table 10 Analysis of Multiple Strain DNA Sequence of H. pylori Vaccine Candidates Pro2605 260 7116 7116 2947 2947 346 346 Theina 4702 547 626 626 9681 9681 J99 # 02 Longi248 746 232 96 182 548 273 819 tud of a. to . nt. to . to . nt a. to . nt. to . to . nt. The Sequence region Proven strain IdenIdenIdenIdenIdenIdenIdenIdentity Identity of Identity AA of AA of AA of AA of NUC. Nuc. Nuc. Nuc.
J99 100.0 100. 100.0 100.0 100.0 100.0 99.63 99.88 0% 00% 0% 0% 0% 0%%% AH244 95.16 95.0 n.d. n.d. 99.09 96.71 98.90 96.45% 4%%%%% AH4 95.97 95.9 97.84 95.83 n.d. n.d. 97. 95.73% 8%% 80%% AH5 92.34 93.0 98.28 96.12 98.91 96.90 98.53 95.73 % 3% % % % % % % AH15 95.16 94.9 97.41 95.98 99.82 97.99 99.63 96.09 % 1% % % % % % % AH61 n.d. n.d. 97.84 95.98 99.27 97.44 n.d. n.d. 5155 n.d. n.d. n.d. n.d. 99.45 97.08 98.53 95.60 5294 94.35 94.3 98.28 95.40 99.64 97.26 97.07 95.48 % 7%%%%%%% 7958 94.35 94.1 97.84 95.40 n.d. n.d. 99.63 96.46 % 0%%%%% 5640 95.16 94.3 97.41 95.69 99.09 97.63 98.53 95.48 % 7%%%%%%% AH18 n.d. n.d. 98.71 95.69 99.64 97.44 100.0 95.97%%%% 0%% AH24 94.75 95.0 97.84 95.40 99.27 96.71 100.0 96.46% 4%%%%% 0%% n. d. = was not done VI. Experimental Expulsion Protocol for the determination of Essential Genes of fr. oyl ori as Potential Therapeutic Targets Therapeutic targets are chosen from genes whose protein products appear to play key roles in essential cellular pathways such as cell envelope synthesis, DNA synthesis, transcription, translation, regulation and colonization / virulence.
The protocol for the deletion of gene / ORF portions of ff. pyl ori and the insertional mutagenesis of a kanamycin resistance cassette to identify genes that are essential to the cell is modified from previously published methods (Labigne-Roussel et al., 1988, J. Bacteriology 170, pp. 1704-1708; Cover et al., 1994, J. Biological Chemistry 269, pp. 10566-10573; Reyrat et al., 1995, Proc. Natl. Acad. Sci. 92, pp 8768-8772). The result is an "expelled" gene.
Iden tifi cation and Cloning of the Sequences of the Gene of íf. pyl ori The sequences of the genes or ORF (open reading frames) selected as ejected targets are identified from the genomic sequence of íf. pyl ori and are used to design primers to specifically amplify the genes / ORF. All synthetic oligonucleotide primers are designed with the help of the OLIGO program (National Biosciences, Inc., Plymouth, MN 55447, USA), and can be obtained from Gibco / BRL Life Technologies (Gaithersburg, MD, USA). If the ORF is smaller than 800 to 1000 base pairs, the primers that surround it are chosen external to the open reading frame.
The genomic DNA prepared from the HpJ99 strain of Heli coba cter pyl ori (ATCC 55679, deposited by Genome Therapeutics Corporation, 100 Beaver Street, Waltham, MA 02154) is used as the source of the DNA template for amplification of the ORF by PCR ( polymerase chain reaction) (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., editors, 1994). For the preparation of genomic DNA of íf. pyl ori, see Example I. PCR amplification is carried out by introducing 10 nanograms of HpJ99 genomic DNA into a reaction vial containing 10 mM Tris pH 8.3, 50 mM KCl, 2 mM MgCl 2, 2 microMolar synthetic oligonucleotide primers (forward = Fl and inverse = Rl), 0.2 mM each of deoxynucleotide triphosphate (dATP, dGTP, dCTP, dTTP), and 1.25 units of thermo stable DNA polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ , USA) in a final volume of 40 microliters. The PCR is carried out with Perkin Elmer Cetus / GeneAmp PCR System 9600 thermal cycler.
At the end of the thermal cyclization reactions, each amplified DNA sample is visualized on a 2% TAE agarose gel stained with Etidium Bromide (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. ., editors, 1994) to determine that a simple product of the expected size has resulted from the reaction. The amplified DNA is then washed and purified using the Qiaquick Spin PCR purification kit (Qiagen, Gaithersburg, MD, USA).
The PCR products are cloned into the Vector pT7Blue T (catalog # 69820-l, Novagen, Inc., Madison, WI, USA) using the cloning strategy TA (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Editors, 1994). Ligation of the PCR product into the vector is done by mixing a 6-fold molar excess of the PCR product, 10 ng of the vector pT7Blue-T (Novagen), 1 microliter of the T4 DNA Ligase Buffer (New England BioLabs, Beverly, MA , USA), and 200 units of T4 DNA Ligase (New England BioLabs) in a final reaction volume of 10 microliters. The ligation is allowed to proceed for 16 hours at 16 ° C.
The ligation products are subjected to electrophoresis (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Editors, 1994) in competent cells to electroporation of E. coli XL-1 Blue or DH5-a (Clontech Lab, Inc. Palo Alto, CA, USA). Briefly, 1 microliter of the ligation reaction is mixed with 40 microliters of electrocompetent cells and subjected to a high voltage pulse (25 microFarads, 2.5 kV, 200 or more) after which the samples are incubated in 0.45 ml of SOC medium (0.5% yeast extract, 2% tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) at 37 ° C with shaking for 1 hour. The samples are then aspected on LB plates (10 g / 1 bacto tryptone, 5 g / 1 bacto yeast extract, 10 g / 1 sodium chloride) containing 100 micrograms / ml Ampicillin, 0.3% X -gal, and 100 micrograms / ml of IPTG. These plates are incubated overnight at 37 ° C. The white-colored ampicillin-resistant colonies are selected, grown in 5 ml of liquid LB containing 100 micrograms / ml of Ampicillin, and the plasmid DNA is isolated using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).
To verify that the correct H. pyl ori DNA insertions have been cloned, these pT7Blue plasmid DNAs are used as templates for PCR amplification of the cloned insertions, using the same forward and reverse primers used for the initial amplification of the if sequence. pyl ori J99. The recognition of the primers and a PCR product of the correct size as visualized in a 2% TAE agarose gel, stained with ethidium bromide are confirmation that the correct inserts have been cloned. Two to six such verified clones are obtained for each ejection target, and frozen at -70 ° C for storage. To minimize errors due to PCR, the plasmid DNA of these verified clones is collected, and used in subsequent cloning steps.
The sequences of the genes / ORF are used again to design a second pair of primers that surround the DNA region of f. pyl ori to be interrupted or eliminated (up to 250 base pairs) within the ORF but oriented away from each other. The circular plasmid DNA pool of the previously isolated clones are used as templates for this round of PCR. Since the orientation of the amplification of this pair of elimination primers is far from each other, the portion of the ORF between the primers is not included in the resulting PCR product. The PCR product is a linear piece of DNA with DNA. pyl ori at each end and the structure of the pT7Blue vector between them that, in essence, results in the removal of a portion of the ORF. PCR is visualized on a 1% TAE agarose gel, stained with ethidium bromide to confirm that only a single product of the correct size has been amplified.
A cassette of Canamycin resistance (Labigne-Roussel et al., 1988 J. Bacteriology 170, 1704-1708) is linked to this PCR product by the previously used TA cloning method (Cúrrente Protocols in Molecular Biology, John Wiley and Sons , Inc., F. Ausubel et al., Editors 1994). The Canamycin cassette containing a kanamycin resistance gene from Campyl obater is obtained by digesting with EcoRI the recombinant plasmid pCTB8: Jran (Cover et al., 1994, J. Biological Chemistry 269, ppl0566-10573). The appropriate fragment (1.4 kb) is isolated on a 1% TAE gel, and isolated using the QIAquick gel extraction kit (Qiagen, Gaithersburg, MD, USA). The fragment is repaired at the end using the Klenow filler protocol, which involves mixing 4 ug of the DNA fragment, 1 microliter of dATP, dGTP, dCTP, dTTP at 0.5 mM, 2 microliters of Klenow Shock Absorber (New England BioLabs) and 5 units of the Large Fragment of DNA Polymerase I from Klenow (Klenow) (New England BioLabs) in 20 microliters of reactions, incubating at 30 ° C for 15 min, and activating the enzyme by heating at 75 ° C for 10 minutes. This cassette of blunt-ended Canamycin is then purified by a Qiaquick column (Qiagen, Gaithersburg, MD, USA) to remove nucleotides. The "T" projection is then generated by mixing 5 micrograms of the blunt-ended kanamycin cassette, 10 mM Tris pH 8.3, 50 mM KCl, 2 mM MgCl2, 5 units of DNA Polymerase (Amplitaq, Roche Molecular Systems, Inc., Branchburg, NJ, USA), 20 microliters of 5 mM dTTP, in 100 microliters of reaction and incubating the reaction during 2 hours at 37 ° C. The "Kan-T" cassette is purified using a QIAquick column (Qiagen, Gaithersburg, MD, USA). The PCR product of the elimination primers (F2 and R2) is ligated to the Kan-T cassette by mixing 10 to 25 ng of the PCR product of the elimination primer, 50-75 ng of Kan-T cassette DNA, 1 microliter. of reaction mixture lOx T4 DNA Ligase, 0.5 microliters T4 DNA Ligase (New England BioLabs, Beverly, MA, USA) in 10 microliters of reaction and incubating for 16 hours at 16 ° C.
The ligation products are transformed into E cells. col i XL-1 Blue or DH5-a by electroporation as previously described. After the recovery in SOC, the cells are placed in LB plates containing 100 micrograms / ml of Ampicillin and grown overnight at 37 ° C. These plates are then placed on a replica plate containing 25 micrograms / ml of Canamycin and allowed to grow overnight. The resulting colonies have the Ampicillin resistance gene present in the pT7Blue vector, and the Canamycin resistance gene introduced again. The colonies are collected in LB containing 25 micrograms / ml of Canamycin and the plasmid DNA is isolated from the cultured cells using the Qiagen miniprep protocol (Qiagen, Gaithersburg, MD, USA).
Several tests by PCR amplification were conducted on these plasmids to verify that Canamycin is inserted into the gene / ORF of íf. pyl ori, and to determine the orientation of the insertion of the Canamycin resistance gene relative to the gene / ORF of íf. pyl ori To verify that the kanamycin cassette is inserted in the sequence of. pyl ori, the plasmid DNAs are used for PCR amplification with the group of primers originally used to clone the ff gene. pyl ori / ORF. The correct PCR product is the size of the deleted / ORF gene but it increases in size by the addition of a kamycin cassette of 1.4 kilobases. To avoid the potential polar effects of the kanamycin resistance cassette on the if expression gene. pyl ori with respect to the ejected gene / ORF is determined and both orientations are eventually used in the transformations of H. pyl ori (see below). To determine the insertion orientation of the kanamycin resistance gene, the primers are designed from the ends of the kanamycin resistance gene ("Kan-1" 5'-ATCTTACCTATCACCTCAAAT-3 '(SEQ ID NO: 255)), and "Kan-2" 5 '-AGACAGCAACA CTTTGTGAA-3' (SEQ ID NO: 256)). Using each of the cloning primers in conjunction with each of the Kan primers (4 primer combinations), the orientation of the kanamycin cassette is determined relative to the H. pyl ori sequence. Positive clones are classified either as in the "A" orientation (the same direction or transcript is present for the gene of P. pyl ori and the kanamycin resistance gene), or in the "B" orientation (the direction or transcription for the H. pyl ori gene is opposite to that of the kanamycin resistance gene). The clones that share the same orientation (A or B) are collected for the subsequent experiments and are transformed independently into íf. pyl ori Transformation of the plasmid DNA in H. pyl ori cells Two strains of H. pyl ori are used for the transformation: ATCC 55679, the clinical isolate that provides the DNA from which the database of the sequence of If is obtained. pyl ori, and AH244, an isolate that had been passed on, and has the ability to colonize the mouse stomach. Cells for transformation are grown at 37 ° C, 10% C02, 10% humidity, either in sheep blood agar plates or in Brucella Broth liquid. The cells were grown to the exponential phase, and examined microscopically to determine that the cells are "healthy" (cells that are actively moving) and not contaminated. If they were grown in plates, the cells were harvested by scraping the cells from the plate with a sterile loop, suspended in 1 ml of Brucella broth, rotating (1 minute, high speed in microcentrifuge for eppendorf) and resuspended in Brucella Broth. 200 microliters If grown in Brucella Broth liquid, the cells were centrifuged (15 minutes at 3000 rpm in a Beckman TJ6 centrifuge) and the cell pack was resuspended in 200 microliter Brucella broth. An aliquot of cells is taken to determine the optical density at 600 nm, to calculate the cell concentration. An aliquot (1 to 5 OD600 / 25 microliter units) of the resuspended cells is placed on a preheated sheep blood agar plate, and the plate is further incubated at 37 ° C, 6% C02, 100% humidity during 4 hours. After this incubation, 10 microliters of the plasmid DNA (100 micrograms per microliter) is stained on these cells. A positive control (plasmid DNA with the ribonuclease gene H broken by the kanamycin resistance gene) and a negative control (non-plasmid DNA) is made in parallel. These plates are returned at 37 ° C, 6% C02 for an additional 4 hours of incubation. The cells are then aspected on such a plate using a humidified sponge in Brucella broth, and grown for 20 hours at 37 ° C, 6% C02. The cells were then transferred to a sheep blood agar plate containing 25 micrograms / ml kanamycin, and allowed to grow for 3 to 5 days at 37 ° C, 6% C02, 100% humidity. If the colonies appeared, they are harvested and regrown as patches on a sheep blood agar plate containing 25 micrograms / ml kanamycin.
Three sets of PCR tests are done to verify that the colonies of the transformants have arisen from the homologous recombination at the appropriate chromosomal location. The PCR (colony DNA) template is obtained by a rapid boiling DNA preparation method as follows. An aliquot of the colony is introduced (puncturing the colony with a toothpick) is introduced in 100 microliters of 1% Triton X-100, Tris 20 nM, pH 8.5, and boiled for 6 minutes. An equal volume of phenol: chloroform (1: 1) is added and vortexed. The mixture is centrifuged in a microcentrifuge for 5 minutes and the supernatant is used as the DNA template for PCR with combinations of the following primers to verify homologous recombination at the appropriate chromosomal location.
TEST 1. PCR with the cloning primers originally used to amplify the gene / ORF. A positive result of the homologous recbination at the correct chromosomal location should show a single PCR product whose size is expected to be the size of the deleted / ORF gene but increases in size by the addition of a kamycin cassette of 1.4 kilobases. A PCR product of only the size of the gene / ORF is proved that the gene had not been expelled and that the transformant is not the result of homologous recombination at the location of the correct chromosome.
TEST 2. PCR with F3 (designed primer of the sequence upstream of the gene / ORF and not present in the plasmid), and the Kan-1 or Kan-2 primer (designed primers from the ends of the kanamycin resistance gene ), depending on whether the plasmid DNA used was of the "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size (eg, from the location of F3 to the insertion site of the kanamycin resistance gene). The PCR product or PCR products of the wrong sizes will not prove that the plasmid had not integrated into the correct site and that the gene had not been expelled.
TEST 3. PCR with R3 (designed primer of the sequence downstream of the gene / ORF and not present in the plasmid) and either the Kan-1 or Kan-2 primer, depending on whether the plasmid DNA used was the "A" or "B" orientation. Homologous recombination at the correct chromosomal location will result in a single PCR product of the expected size (eg, from the insertion of the kanamycin resistance gene to the downstream location of R3). Again, the PCR product or PCR products of the wrong sizes will not prove that the plasmid had not integrated into the correct site and that the gene had not been expelled.
The transformants that showed positive results for the three previous tests indicate that the gene is not essential for in vi tro survival.
A negative result in any of the three previous tests for each transformant indicates that the gene had not been broken, and that the gene is essential for survival in vi tro.
In the case of the colonies result from two independent transformations while the positive control with the DNA of the plasmid broken by the ribonuclease H produces the transformants, the plasmid DNA is further analyzed by PCR in DNA of the transformant populations before the formation of The plaque for the formation of the colony This will verify that the plasmid can enter the cells and undergo homologous recombination at the correct site Briefly, the plasmid DNA is incubated according to the transformation protocol described above. It is extracted from H. pyl ori cells immediately after incubation with the plasmid DNA and the DNA is used as the template for TEST 2 and TEST 3. The positive results in TEST 2 and TEST 3 would verify that the plasmid DNA could enter the cells and undergo homologous recombination at the correct chromosomal location, if the TEST 2 and the TEST 3 are positive, then the failure to obtain viable transformations indicates that the gene is essential, and the cells that undergo a break in such a gene are incapable of forming the colony.
VII. Screening test for high-performance drug Cloning, expression and purifi cation of the protein The cloning, transformation, expression and purification of the H. pyl ori white gene and its protein product, p. ex. , an enzyme of if. pyl ori, to be used in a screening test for high performance drug, is carried out essentially as described in Examples II and III above. The development and application of a screening test for a particular H. pyl ori gene product, peptidyl-propyl cy-trans isomerase, is described below as a specific example.
Enzyme test The test is essentially as described by Fisher (Fisher, G. et al. (1984) Bi omed, Ci ochim, Acta 43: 1101-1111). The measurements of the cis-trans isomerization test of the Ala-Pro bond in the N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide test peptide (Sigma # S-7388, lot # 84H5805) . The test is coupled with α-chymotrypsin, where the ability of the protease to break the test peptide occurs only when the Ala-Pro link is in trans. The conversion of the test peptide to the trans isomer in the test is continued at 390 nm in a Beckman Model DU-650 spectrophotometer. The data is collected every second with an average search time of 0.5 seconds. The tests are carried out in 35 mM Hepes, pH 8.0, in a final volume of 400 ul, with 10 μM a-chymotrypsin (type 1-5 of bovine pancreas, Sigma # C-7762, lot # 23H7020) and PPIase 10 nM.
To initiate the reaction, 10 μl of the substrate (2 mM N-Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide in DMSO) is added to 390 μl of the reaction mixture at room temperature.
Enzyme test in crude bacterial extract.
A 50 ml culture of the Heli coba cter pyl ori culture (strain J99) in Brucella broth is harvested at medium logarithmic phase (OD600 nm ~ 1) and resuspended in lysis buffer with the following protease inhibitors: 1 mM PMSF , and 10 μg / ml of each inhibitor of aprotinin, leupeptin, pepstatin, TLCK, TPCK and soybean trypsin. The suspension was subjected to 3 cycles of freeze-thaw (15 minutes at -70 ° C, then 30 minutes at room temperature) followed by sonication (three irruptions of 20 seconds). The lysate was centrifuged (12,000 g x 30 minutes) and the supernatant was tested for enzyme activity as described above.
Many of the enzymes of íí. pyl ori can be expressed at high levels and in the active form in E. col i Such high yields of the purified protein provide the design of several high-throughput screening tests for the drug.
VIII. Expression of the truncated gene and production of the protein Tifi cation, cloning and expression of the recombinant sequences of Heli coba cter pyl ori To facilitate the cloning, expression and purification of if membrane proteins. pyl ori, the pET gene expression system (Novagen) was selected for the cloning and expression of the recombinant proteins in Escheri chia coli. In addition, for proteins having a signal sequence at their amino-terminal end, a DNA sequence encoding a peptide tag (His-tag) was fused to the 5 'end of the DNA sequences of i. pyl ori of interest to facilitate the purification of the products of the recombinant protein. In some cases, the DNA sequence was cloned in frame with the glutathione-S-transferase protein to produce a GST fusion protein. The vectors used in this case were the pGEX series from Pharmacia LKB (Uppsala, Sweden).
Amplifi cation by PCR and cloning of the DNA sequences that have ORFs for the membrane and secreted proteins of the J99 strain of Heli coba cter pyl ori.
The sequences chosen (from the list of the DNA sequences of the invention) for the cloning of strain J99 of íf. pyl ori were prepared for cloning by amplification by the polymerase chain reaction (PCR). Synthetic oligonucleotide primers for the ORF of interest (Table 11) specific for the predicted mature 5 'end of the ORF and either downstream (3') of the predicted translational stop codon or at specific points within the codon region were designed and acquired (GibcoBRL Life Technologies, Gaithersburg, MD, USA). All forward primers (specific for the 5 'terminus of the ORF region of interest) were designed to include either a BamHI or an Ndel restriction site. These primers within the Ndel restriction site sequence were designed to allow the initiation of translation of the protein into a methionine residue (encoded within the Ndel restriction site sequence, in the case of the production of a recombinant protein marked in His) or to merge in the frame with the sequence of AD? coding for the His-tag (to produce the recombinant protein tagged in His), followed by the coding sequence for the rest of the AD? of íf. pyl native ori. The primer with the restriction site BamHl was produced to fuse the specific sequence of αf. pyl ori in the frame with the C-terminus of the glutathione-S-transferase gene in the pGEX vectors (Pharmacia LKB, Uppsala, Sweden). All reverse oligonucleotide primers are designed to include an .EcoRI restriction site at the 5 'terminus. Several inverse oligonucleotide primers were selected that would cause truncation of the polypeptide to remove certain portions of the C terminus, and in these cases the restriction site. EcoRI at the 5 'end was followed by a translational stop codon. This combination of primers would allow the ORF of interest (or portions of the ORF of interest) to be cloned into pET28b (to produce a His-labeled recombinant protein), pET30a (to produce a recombinant protein without labeled or native His) or the pGEX series -4T or pGEX-5X (to produce a GST fusion protein). The pET28b vector provides the sequence encoding 20 additional amino-terminal amino acids (plus the methionine at the Ndel restriction site) including an extension of six histidine residues that produce the His-tag, while the pGEX vectors fuse the tag protein. . pyl ori to a glutathione-S-transferase protein of 26,000 Da.
The AD? genomic prepared from strain J99 of íf. pyl ori (ATCC 55679) was used as the source of AD? of the template for amplification reactions (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). To amplify a sequence of AD? that contains an ORF of ff. pyl ori specific, the AD? genomic (50 nanograms) was introduced into a reaction tube containing 200 nanograms of the forward and reverse oligonucleotide primer specific for the ORF of interest, and 45 microliters of SuperMix PCR purchased from (GibcoBRL Life Technologies, Gaithersburg, MD, USA) in a total of 50 microliters. SuperMix PCR is supplied in 1. IX concentrations and contains 22mM Tris-HCl (pH 8.4), 55mM KCl, 1.65mM MgCl2, 220 micromolar each of dATP, dCTP, dGTP, dTTP, 22 units of recombinant Taq polymerase / ml and stabilizers. The following thermal cycling conditions were used to obtain the amplified DNA products for each ORF using a Perkin Elmer Cetus thermal cycler / GeneAmp PCR System.
Table 11: Oligonucleotide primers Sequences for Vac38 (full length or truncated) Denaturation at 94 ° C for 30 sec, 35 cycles at 94 ° C for 15 sec, 55 ° C for 15 sec, and 72 ° C for 1.5 min. The reactions were concluded at 72 ° C for 8 minutes At the end of the thermal cyclization reactions, each sample of amplified DNA was subjected to electrophoresis in 1.0% agarose gels. The DNA was visualized by exposure to ethidium bromide and long-wave UV irradiation, and the gel was cut into strips. The DNA was purified using the Wizard PCR Preps kit (Promega Corp., Madison Wl, USA), and then digested with BamHI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. al., eds., 1994). The digested PCR amplicon was then subjected to electrophoresis and purified as before.
Li ga tion of ff DNA sequences. pyl ori in cloning vectors The vector pOK12 (J, Vieira and J. Messing, Gene 100: 189-194, 1991) was prepared by cloning by digestion with BamHI and EcoRl or Ndel and EcoRI in the case of Vac 41 (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The vectors were electrophoresed on 1% agarose gels and purified using the Wizard PCR Preps kit (Promega Corp., Madison Wl, USA). After ligation of the purified, digested vector and the digested purified H. pyl ori ORF, the products of the ligation reaction were transformed into f7 competent cells. col i JM109 according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). Individual bacterial colonies were screened for those containing the correct recombination plasmids by incubating in LB broth overnight (plus 25 ug / ml kanamycin sulfate) followed by preparation of the plasmid DNA using the Magic Minipreps system (Promega Corp ., Madison Wl, USA), and then analyzed by restriction digestion (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994).
Cloning of the DNA sequences of íf. pyl ori in the prokaryotic expression vectors pET28b, pET30a and pGEX4 T-3 The expression vectors pET28b and pET30a were prepared by cloning by digestion with Ndel and EcoR1, and vector pGEX4T-3 was prepared by cloning by digestion with BamHI and EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The sequences of AD? of íf. pyl ori were removed from the plasmid pOK12 structures by digestion with Ndel and f7coRI or BamHl and .EcoRI (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). The sequences of pET28b, pET30a, pGEX4T-3 and AD? of íf. pyl ori were all electrophoresed on a 1% agarose gel and purified using the Wizard PCR Preps kit (Promega Corp., Madison Wl, USA). After ligation of the purified expression vector, digested and AD? of íf. pyl ori purified, digested, the products of the ligation reaction were transformed into competent E cells. coli JM109 according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). Individual bacterial colonies were screened for those containing the correct recombination plasmids by preparing the plasmid DNA as described above followed by restriction digestion analysis (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. al., eds., 1994). These recombinant plasmids were then used to transform E-specific expression strains. col i.
Transformation of competent bacteria with recombinant expression plasmids Competent bacterial strains BL21 (DE3), BL21 (DE3) pLysS, HMS174 (DE3) and HMS 174 (DE3) pLysS were prepared and transformed with the recombinant expression plasmids pET28b carrying the sequences of i. pyl ori cloned according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., eds., 1994). These expression host strains contain a chromosomal copy of the T7 RNA polymerase gene. These hosts are lysogens of the bacteriophage DE3, a lambda derivative carrying the l a cl gene, the cUV5 promoter and the T7 RNA polymerase gene. The expression of T7 RNA polymerase is induced by the addition of isopropyl-β-D-thiogalactoside (IPTG), and the T7 RNA polymerase then transcribes any white plasmid, such as pET28b, which carries a T7 promoter sequence and a interest.
Competent bacterial strains JM109 and DH5a were prepared and transformed with the recombinant expression plasmid pGEX4T-3 carrying the cloned H. pyl ori sequences according to standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc. , F. Ausubel et al., Eds., 1994).
Expression of recombinant sequences of íf. pyl ori in E coli Transformants were collected from LB agar plates containing 25 ug / ml kanamycin sulfate (ensures the maintenance of recombinant plasmids based on pET28b) or 100 ug / ml ampicillin (ensures maintenance of recombinant plasmids based on pGEX4T- 3) and were used to inoculate the LB broth containing 25 ug / ml kanamycin sulfate or 100 ug / ml ampicillin and grown to an optical density in 600 nm of 0.5 to 1.0 OD units, at this point it was added 1 mM IPTG to the culture for one to three hours to induce the expression of the recombinant DNA constructs gene. pyl ori After induction of the expression gene with IPTG, the bacteria were packaged by centrifugation and resuspended in SDS-PAGE solubilization buffer and subjected to SDS-PAGE (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al., Eds., 1994). Proteins were visualized by staining with Coomassie blue or detected by western immunoblot using the anti-His-specific monoclonal antibody label (Clontech, Palo Alto, CA, USA) or the anti-GST brand (Pharmacia LKB) using standard methods (Current Protocols in Molecular Biology, John Wiley and Sons, Inc., F. Ausubel et al. , eds., 1994). The host strain that provided the highest level of recombinant protein production was then chosen for use in a large-scale induction to purify the recombinant protein. The strains used were HMS174 (DE3) (constructions based on pET28b) and DH5 (constructions based on pGEX4T-3).
The removal of the C-terminal regions appeared in both systems to improve the level of expression, although this increase was much more prominent in the GST fusion system. All the recombinant proteins produced were of the predicted molecular weight based on the DNA sequence plus, if necessary, the size of the fusion tag. The truncated portion of the protein. pyl ori contains some extremely hydrophobic regions, and the removal of these could be the reason for the increased expression.
EQUIVALENTS Those skilled in the art will recognize, or be able to guess using no more than routine experimentation, many equivalents to the specific modalities and methods described herein. Such equivalents are intended to encompass the scope of the following claims.
It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is the conventional one for the manufacture of the objects to which it relates.
Having described the invention as above, the content of the following is claimed as property.
LIST OF SEQUENCES (1. GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Astra Aktiebolag (B) STREET: S-151 85 (C) CITY: Sodertalje (D) STATE: (E) COUNTRY: Sweden (F) ZIP CODE: (ZIP) (ii) TITLE OF THE INVENTION: SEQUENCES OF NUCLEIC ACID AND AMINO ACID THAT THEY REPEATED TO HELICOBACTER PYLORI AND VACCINE COMPOSITIONS FROM THE SAME (iii) NUMBER OF SEQUENCES: 275 (iv) COMPUTER READING FORM: (A) TYPE OF MEDIA: CD / ROM ISO9660 * (B) COMPUTER: (C) OPERATING SYSTEM: (D) PACKAGE: (v) DATA OF THE CURRENT APPLICATION: (A) NUMBER OF THE APPLICATION: (B) DATE OF SUBMISSION: (vi) DATA FROM THE PREVIOUS APPLICATION: (A) NUMBER OF THE APPLICATION: US 08 / 759,625 (B) DATE OF SUBMISSION: 05-DEC-1996 (vii) DATA FROM THE PREVIOUS APPLICATION: (A) NUMBER OF THE APPLICATION: US 08 / 823,745 (B) DATE OF SUBMISSION: MAR 25, 1997 (viii) DATA FROM THE PREVIOUS APPLICATION: (A) NUMBER OF THE APPLICATION: US 08 / 891,928 (B) DATE OF SUBMISSION: JULY 14, 1997 (ix) ADDRESS FOR CORRESPONDENCE: (A) ADDRESS: LAHIVE & COCKFIELD (B) STREET: 28 State Street (C) CITY: Boston (D) STATE: Massachusetts (E) COUNTRY: USA (F) ZIP CODE: 02109-1875 (x) INFORMATION ATTORNEY / MANDATORY: (A) NAME: Mandragouras, Amy E. (B) REGISTRY NO .: 36,207 (C) REFERENCE NUMBER / LIST: GTN-011CP2PC (xi) TELECOMMUNICATION INFORMATION (A) TELEPHONE: (617) 227-7400 (B) TELEFAX: (617) 227-5941 (2) INFORMATION FOR SEC ID NO: 1: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 687 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 687 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 1: ATGAGATTTA AGGGTTCAAG AGTGGAAGCG TTTTTAGGAG CGTTAGAATT TCAAGAGAAT 60 GAATATGAAG AGTTTAAAGA GCTTTATGAG AGCTTAAAAA CCAAGCAAAA GCCCCACACT 120 TTGTTCATTT CTTGCGTGGA TTCACGAGTC GTGCCTAATT TAATCACAGG CACCCAACCG 180 GGCGAATTGT ATGTGATCCG CAACATGGGC AATGTGATCC CCCCTAAAAC AAGCTATAAA 240 GAATCCCTTT CTACCATTGC GAGCGTTGAA TACGCTATCG CGCATGTGGG CGTTCAAAAC 300 TTAATCATTT GCGGGCATAG CGATTGTGGG GCTTGCGGGA GCATTCATTT AATCCATGAT 360 GAAACCACCA AAGCTAAAAC CCCTTACATT GCAAACTGGA TACAATTTTT AGAGCCTATT 420 AAAGAAGAAT TAAAAAACCA CCCGCAATTC AGCAACCATT TCGCCAAGCG TTCATGGCTT 480 ACAGAGCGTT TGAATGCGCG CTTGCAACTC AACAACCTCT TAAGCTATGA TTTCATTCAA 540 GAAAGAGTAA TAAATAACGA ATTAAAAATT TTTGGTTGGC ACTATATCAT AGAAACAGGC 600 AGGATTTATA ATTATAATTT TGAAAGCCAT TTTTTTGAGC CGATTGAAGA AACCATTAAA 660 CAAAGGATA GTCATGAAAA CTTCTAA 687 (2) INFORMATION FOR SEQ ID NO: 2: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 666 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 666 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 2: GTGGAAGCGT TTTTAGGAGC GTTAGAATTT CAAGAGAATG AATATGAAGA GTTTAAAGAG 60 CTTTATGAGA GCTTAAAAAC CAAGCAAAAG CCCCACA.CTT TGTTCATTTC TTGCGTGGAT 120 TCACGAGTCG TGCCTAATTT AATCACAGGC ACCCAACCGG GCGAATTGTA TGTGATCCGC 180 AACATGGGCA ATGTGATCCC CCCTAAAACA AGCTATAAAG AATCCCTTTC TACCATTGCG 240 AGCGTTGAAT ACGCTATCGC GCATGTGGGC GTTCAAAACT TAATCATTTG CGGGCATAGC 300 GATTGTGGGG CTTGCGGGAG CATTCATTTA ATCCATGATG AAACCACCAA AGCTAAAACC 360 CCTTACATTG CAAACTGGAT ACAATTTTTA GAGCCTATTA AAGAAGAATT AAAAAACCAC 420 CCGCAATTCA GCAACCATTT CGCCAAGCGT TCATGGCTTA CAGAGCGTTT GAATGCGCGC 480 TTGCAACTCA ACAACCTCTT AAGCTATGAT TTCATTCAAG AAAGAGTAAT AAATAACGAA 440 TTAAAAATTT TTGGTTGGCA CTATATCATA GAAACAGGCA GGATTTATAA TTATAATTTT 600 GAAAGCCATT TTTTTGAGCC GATTGAA «3AA ACCATTAAAC AAAGGATAAG TCATGAAAAC 660 TTCTAA 666 (2) INFORMATION FOR SEC ID NO: 3: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1008 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 1008 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 3: ATGTTAGTTA CTCGTTTTAA AAAAGCCTTC ATTTCTTATT CTTTAGGCGT GCTTGTTGTT 60 TCATTATTAT TGAATGTGTG CAACGCTTCA GCACAAGAAG TCAAAGTCAA GGATTATTTT 120 GGGGAGGAAA CCATAAAGCT TCCTGTTTCC AAAATAGCCT ATATAGGGAG TTATGTAGAA 180 GTGCCTGCCA TGCTTAATGT TTGGGATAGG GTTGTAGGCG TTTCTGATTA TGCCTTTAAG 240 GATGACATTG TCAAAGCCAC TCTCAAAGGC GAGGATCTTA AACGAGTCAA ACACATGAGC 300 ACCGATCATA CAGCCGCGTT GAATGTGGAA TTATTAAAAA AGCTTAGCCC TGATCTTGTG 360 GTAACCTTTG TGGGTAACCC TAAAGCGGTA GAGCATGCGA AAAAATTTGG GATTTCATTC 420 CTTTCTTTCC AAGAGACAAC GATTGCAGAG GCCATGCAAG CTATGCAAGC TCAAGCCACG 480 GTCTTAGAAA TTGACGCTTC CAAAAAATTC GCCAAAATGC AAGAAACTTT GGACTTTATT 540 GCTGAGCGTT TGAAGGGCGT TAAAAAGAAA AAGGGGGTGG AGCTTTTCCA TAAAGCCAAT 600 AAAATCAGCG GCCATCAAGC CATTAGCTCA GACATTTTAG AAAAAGGGGG TATAGATAAT 660 TTTGGCTTGA AATACGTTAA GTTTGGACGC GCTGACATTA GTGTGGAAAA AATCGTTAAA 720 GAAAACCCTG AAATCATTTT CATTTGGTGG GTAAGCCCAC TCACTCCTGA AGACGTGTTG 780 AACAACCCTA AATTTTCCAC TATCAAAGCC ATTAAAAATA AGCAAGTCTA TAAGCTCCCC 840 ACGATGGATA TTGGCGGTCC TAGAGCCCCA CTCATTAGTC TTTTTATCGC TTTAAAAGCC 900 CACCCTGAAG CCTTTAAAGG CGTGGATATT AATGCGATAG TCAAAGATTA TTATAAAGTG 960 GTCTTTGATT TGAATGATGC GGAAATTGAG CCATTCTTAT GGCACTGA 1008 (2) INFORMATION FOR SEC ID NO: 4: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 825 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 825 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 4: ATGTTAGTTA CTCGTTTTAA AAAAGCCTTC ATTTCTTATT ATTTAGGCGT GCTTGTTGTT 60 TCATTATTAT TGAATGTGTG CAACGCTTCA GCACAAGAAG TCAAAGTCAA GGATTATTTT 120 GGGGAGCAAA CCATAAAGCT TCCTGTTTCC AAAATAGCCT ATATAGGGAG TTATGTAGAA 180 GTGCCTGCCA TGCTTAATGT TTGGGATAGG GTTGTAGGCG TTTCTGATTA TGCCTTTAAG 240 GATGACATTG TCAAAGCCAC TCTCAAAGGC GAGGATCTTA AACGAGTCAA ACACATGAGC 300 ACCGATCATA CAGCCGCGTT GAATGTGGAA TTATTAAAAA AGCTTAGCCC TGATCTTGTG 360 GTAACCTTTG TGGGTAACCC TAAAGCGGTA GAGCATGCGA AAAAATTTGG GATTTCATTC 420 CTTTCTTTCC AAGAGACAAC GATTGCAGAG GCCATGCAAG CTATGCAACG TCAAGCCACG 480 GTCTTAGAAA TTGACGCTTC CAAAAAATTC GCCAAAATGC AAGAAACTTT GGACTTTATT 540 GCTGATCGTT TGAAGGGCGT TAAAAAGAAA AAGGGGGTGG AGCTTTTCCA TAAAGCCAAT 600 AAAATCAGCG GCCATCAAGC CATTAACTCA GACATTTTAC AACAAGGGGG TATTGATAAT 660 TTTGGCTTGA AATACGTCAA GTTTGGACGC GCTGACATTA GTGTGGAAAA AATCGTTAAA 720 GAAAACCCTG AAATCATTTT CATTAGGTGG GTAACCCCAC TCACTCCTGA TTACGTGTTG 780 AACAACCCAA AATTTTCTAC TATCAATGCC ATTAAAAACA TATAA 825 (2) INFORMATION FOR SEQ ID NO: 5: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1287 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1287 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 5: ATGAAGAAAA AATTTCTGTC ATTAACCTTA GGTTCGCTTT TAGTTTCCGC TTTAAGCGCT 60 GAAGACAACG GCTTTTTTGT GAGCGCCGGC TATCAAATCG GTGAATCCGC TCAAATGGTG 120 AAAAACACCA AAGGCATTCA AGATCTTTCA GACAGCTATG AAAGATTGAA CAACCTTTTA 180 ACGAATTATA GCGTCCTAAA CGCTCTCATC AGGCAGTCCG CCGACCCCAA CGCCATCAAT 240 AACGCAAGGG GCAATTTGAA CGCGAGCGCG AAGAATTTGA TCAATGATAA AAAGAATTCC 300AAGCCGTGCT TTTAGCCTTG AATGCGGCAG CGGGGTTGTG GCAAGTCATG 360 AGCTATGCGA TCAGCCCTTG TGGTCCCGGT AAAGACACAA GCAAAAATGG GGGCGTTCAA 420 ACTTTCCACA ACACGCCTTC AAATCAATGG GGAGGCACTA CCATTACTTG TGGCACTACT 480 GGTTATGAAC CAGGACCATA CAGCATTTTA TCCACTGAAA ATTACGCGAA AATCAATAAA 540 GCTTATCAAA TCATCCAAAA GGCTTTTGGG AGCAGCGGAA AAGATATTCC TGCCTTAAGC 600 GACACCAACA CAGAACTCAA ATTCACAATC AATAAAAATA ATGGAAACAC GAATACGAAT 660 AATAATGGAG AAGAAATTGT TACAAAAAAT AACGCTCAAG TTCTTTTAGA ACAGGCTAGC 720 ACCATTATAA CTACCCTTAA TAGCGCATGC CCATGGATCA ACAATGGTGG TGCAGGTGGT 780 GCGAGTAGTG GTAGTTTATG GGAAGGAATA TAT? TGAAAG GCGATGGGAG CGCTTGCGGG 840 ATTTTTAAAA ATGAAATCAG CGCGATTCAA GACATGATCA AAAACGCTGC AATAGCCGTA 900 GAGCAATCCA AGATCGTTGC TGCAAACGCG CAAAACCAGC GCAACCTAGA CACCGGGAAG 960 ACATTCAACC CCTATAAAGA CGCCAACTTC GCCCAAAGCA TGTTCGCTAA CGCCAAAGCG 1020 CAACCGGAGA TTTTAAACCG CGCCCAAGCA GTGGTGAAAG ACTTTGAAAG AATCCCTGCA 1080 GAGTTCGTAA AAGACTCTTT AGGGGTGTGC CATGAAGTGC AAAACGGCCA TCTCCGTGGC 1140 ACGCCATCCG GCACGGTAAC TGATAACACT TGGGGAGCCG GTTGCGCGTA TGTGGGAGAG 1200 ACCGTAACGA ATCTAAAAGA CAGCATCGCT CATTTTGGCG ACCAAGCCGA GCGAATCCAT 1260 AACGCGCGCA ACCTCGCTAC ACTTTAG_1287_(2) INFORMATION FOR SEQ ID NO: 6: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 537 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO. (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 537 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 6: ATGAACCCCT TATTGCAAGA TTATGCGCGC ATCCTTTTAG AATGGAATCA AACGCACAAC 60 TTGAGCGGCG CGAGAAATTT AAGCGAATTA GAACCCCAGA TCACAGACGC TCTAAAGCCC 120 TTAGAATTTG TCAAAGATTT TAAAAGCTGC TTGGATATTG GGAGCGGGGC GGGACTTCCT 180 GCTATCCCTT TAGCCCTTGA AAAACCTGAA GCGCAATTCA TTCTTTTAGA GCCAAGGGTA 240 AAAAGAGCGG CTTTTTTAAA CTACCTTAAA AGCGTTTTGC CTTTAAACAA CATTGAAATC 300 ATTAAAAAGC GTTTAGAAGA TTATCAAAAT CTTTTACAAG TGGATTTAAT CACTTCTAGA 360 GCGGTCGCTA GCTCTTCTTT TTTGATAGAA AAAAGCCAAC GCTTCCTAAA AGATAAGGGG 420 TATTTTTTAT TCTATAAAGG CGAGCAGTTA AAGAATGAAA TCGCTTATAA AACCACTGAA 480 TGCTTTATGC ATCAAAAGCG CGTTTATTTT TACAAATCAA AGGTTTGTTT ATGTTAA 537 (2) INFORMATION FOR SEQ ID NO: 7: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 723 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 723 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 7: TTGGGTCTTA AAAAACGAGC TATTTTATGG TCTTTAATGG GATTTTGTGC AGGATTGAGC 60 GCGCTTGATT ATGACACCCT AGACCCAAAA TATTACAAAT ATATCAAGTA TTATAAGGCT 120 TATGAAGATA AAGAAGTTGA AGAATTGATC AGAGACTTGA AAAGGGCGAA CGCTAAAAGC 180 GGGCTTATTT TAGGGATCAA TACCGGTTTT TTTTATAACC ATGAAATCAT GGTCAAAACC 240 AATAGCTCCA GTATCACCGG GAATATTTTA AATTATTTGT TCGCCTATGG CTTGCGTTTT 300 GGCTATCAAA CTTTCAGACC GTCGTTTTTT GCGCGCTTGG TTAAGCCCAA TATCATTGGC 360 AGGCGCATCT ATATTCAATA TTATGGAGGA GCTCCTAAGA AAGCGGGCTT TGGGAGCGTG 420 GGGTTTCAAT CGGTCATGTT GAATGGGGAT TTTTTATTAG ACTTTCCTTT GCCCTTTGTG 480 GGGAAATACC TTTATATGGG GGGGTATATG GGTTTAGGCT TGGGGGTTGT GGCGCATGGG 540 GTGAATTATA CGGCGGAATG GGGGATGTCT TTTAACGCAG GATTGGCTCT AACGGTATTA 600 GAAAAAAACC GCATTGAATT TGAATTTAAA ATTTTGAATA ATTTCCCTTT TTTGCAATCT 660 AATTCTTCAA AAGAGACTTG GTGGGGAGCT ATAGCAAGCA TTGGGTATCA ATATGTGTTC 720 TAA 723 (2) INFORMATION FOR SEC ID NO: 8: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 942 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_caracteríatica (B) LOCATION: 1 ... 942 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: TTGAAACTCA AATACTGGTT AGTTTATCTG GCGTTCATTA TAGGACTTCA AGCGACAGAT 60 TATGACAATT TAGAAGAAGA AAACCAACAA TTAGACGAAA AAATAAACAA TTTAAAGCGA 120 CAGCTCACCG AAAAAGGGGT TTCACCCAAA GAGATGGATA AGGATAAGTT TGAAGAAGAA 180 TATTTAGAGC GAACTTACCC AAAGATTTCT TCAAAGAAAA GAAAAAAATT GCTCAAATCT 240 TTTTCCATAG CCGATGATAA GAGTGGGGTG TTTTTAGGGG GCGGGTATGC TTATGGGGAA 300 CTTAACTTGT CTTATCAAGG GGAGATGTTA GACAGGTATG GCGCAAATGC CCCTAGCGCG 360 TTTAAAAACA ATATCAATAT TAACGCTCCT GTTTCTATGA TTAGCGTTAA ATTTGGGTAT 420 CAAAAATACT TCGTGCCTTA TTTTGGGACA CGATTTTATG GGGATTTGTT GCTTGGGGGA 480 GGGGCGTTAA AAGAGAACGC GCTCAAGCAG CCTGTAGGCT CGTTTTTTTTA TGTTTTAGGG 540 GCTATGAATA CCGATTTATT GTTTGACATG CCTTTAGATT TTAAGACTAA AAAGCATTTT 600 TTAGGCGTTT ATGCGGGTTT TGGGATAGGG CTTATGCTTT ATCAAGACAA GCCTAATCAA 660 AACGGGAGGA ATTTGATAGT AGGGGGTTAT TCAAGCCCTA ATTTTTTTATG GAAATCTTTG 720 ATTGAAGTGG ATTACACTTT TAATGTGGGC GTGAGTTTAA CGCTTTATAG GAAACACCGC 780 TTAGAGATTG GCACAAAATT ACCGATTAGC TATTTGAGGA TGGGAGTAGA AGAGGGAGCG 840 ATTTATCACA ATAAAGAAAA TGATGAACGA TTGTTGATTT CGGCTAACAA CCAGTTCAAA 900 CGATCCAGTT TTTTATTAGT GAATTATGCG TTCATTTTTT GA 942 (2) INFORMATION FOR SEQ ID NO: 9: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1182 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1182 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 9: ATGACTTCAG CTTCAAGCCA TTCTTTTTAAA GAACAAGATT TTCATTTCC TATCGCTTTC 60 GCTTTTGATA AGAATTATCT CATTCCTGCG GGCGCATGCA TTTATTCCTT GCTAGAAAGC 120 ATCGCTAAAG CCAATAAAAA AATCCGTTAC ACCTTACACG CTTTAGTGGT AGGCTTGAAT 180 GAAGAAGATA AAACAAAACT TAACCAAATC ACAGAGCCTT TTAAAGAATT TGCTGTTTTA 240 GAAGTAAAAG ATATTGAACC TTTTTTTAGAC ACTATCCCTA ACCCTTTTGA TGAGGATTTC 300 ACCAAGCGTT TTTCTAAAAT GGTGTTAGTG AAGTATTTTC TAGCGGATTT ATTCCCCAAA 360 TATTCTAAAA TGGTGTGGAG CGATGTGGAT GTTATCTTTT GTAATGAATT TAGCGCTGAT 420 TTCTTAAACA TTAAAGAAGA TGATGAGAAT TATTTTTATG GGGTTTATGA CAAAATATAC 480 CCGTATGAAG GCTTTTTTTA TTGCAACTTA ACTTACCAGC GAAAAAATCA ATTTTGTAAA 540 AAAATATTAG AAATCATACG CGCACAAAAA ATAGATAAAG AACCGCAATT GACAGAATTT 600 TGTCGTTCAA AGATCGCGCC ATTAAAAATA GAGTATTGTA TTTTCCCACA CTATTATAGC 660 CTTTCTGAAG AGCATTTAAA GGGCGTGGCC AATGCAATTT ATCATAACAC CATTAAACAA 720 GCCCTAAGAG AACCTATCGT TATACAATAT GACTCTCATC CTTATTTTCA AATCAAGCCT 780 TGGACATATC CTTTTGGTTT GAAAGCGGAT TTATGGCTGA ACGCTTTGGC TAAAACCCCA 840 TTTATGAGCG ATTGGTCTTA TTTGATCACA GGGGGTGGGG GGATAGGTGG AGAAAAATGG 900 CATTACTACC ATGGCATTGC CGCTTATCAT TACTACTTTC CTTTATGGAA AGCAGAAGAA 960 CAGATTGCCC ATGACGCTCT TAAGACATTT TTAAAACATT ATTTTTTTGCA CATTCATGAG 1020 ATTCCCCAAA ACGCAAGGCG AAGACTATTC AAATACTGCA TTTCAATACC GCTTAAGAGC 1080 TTTATTAGTA AAACCCTTAA ATTTCTAAAA CTCCATGCAT TGGTGAAAAA AATCCTAATC 1140 CAACTCAAGC TCTTAAAAAA GAACCAGAGC CAAAACTTTT AA 1182 (2) INFORMATION FOR SEQ ID NO: 10: I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1308 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1308 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 10: TTGATTTTCT TAAAAAAATC TCTTTGCGCG TTGTTAATTT CAGGTTTTTT CATACCACCC 60 TTAATGAAAG CGGCTAGTTT TGTCTATGAC TTGAAGTTTA TGAGCTTTAA TTTCAATCTG 120 GCTTCCCCTC CAAATAACCC CTATTGGAAG AGCCTAACCA AAATGCAAGG TCGTCTCATG 180 CCTCAAATTG GCGTCCAATT AGACAAAAGA CAGGCCTTGA TGTTTGGGGC GTGGTTCATT 240 CAAAATTTGC ACACGCATTA TAGGTATTTC CCTTATTCGT GGGGGGTTAC CATGTATTAC 300 CAATACATAG GGAAAAATTT GAGATTTTTT TTAGGCATTG TGCCACGAAG CTATCAAATA 360 GGGCATTACC CTTTAAGCGC TTTTAAAAAA CTTTTCTGGT TTATAGACCC TACTTTTAGG 420TCCAATTCAA ACCGGCTTAT GATCCCAATC GTTGGTGGAA TGGGTGGTTT 480 GAGGGCGTTG TGGATTGGTA TGGGGGGCGT AATTGGAACA ACCAGCCCAA AAAGAAAAAT 540 TACGATTTTG ATCAATTCTT GTATTTTGTT TCTTCAGAAT TTCAGTTTCT TAAAGGGTAT 600 TTAGGTTTGG GGGGACAGCT TGTCATTTTT CATAACGCCA ACTCTCATAG TATGGGGGAT 660 AACTACCCTT ATGGCGGGAA TTCCTACTTA AAACCAGGCG ATGCAACCCC ACAATGGCCT 720 AATGGCTACC CTTATTTCAG CCAAAAAGAT AACCCACAAG GCGGAGAAAT AGGGAAATAC 780 TCTAACCCTA CCATTTTAGA CAGGGTTTAT TACCATGCTT ATTTAAAAGC AGATTTTAAA 840 AATCTCATGC CTTATATGGA CAATATTTTC ATGACCTTTG GCACGCAGTC GTCTCAAACC 900 CATTATTGCG TGCGTTATGC TAGCGAGTGT AAAAACGCCC GATTTTATAA CAGCTTTGGG 942 GGGGAATTTT ACGCTCAAGC GCAATACAAA GGCTTTGGGA TCTTTAACAG ATACTATTTT 1020 TCCAACAAAC CCCAAATGCA TTTTTATGCC ACTTATGGCC AATCCCTTTA TACCGGATTG 1080 CCATGGTATA GAGCCCCTAA TTTTGACATG ATAGGGCTTT ATTATCTTTA TAAAAACAAA 1140 TGGTTAAGCG TGCGAGCGGA TGCGTTTTTT AGCTTTGTGG GTGGGGGCGA TGGGTACCAT 1200 TTGTATGGCA AGGGGGGTAA GTGGTTTGTG ATGTATCAGC AATTTTTAAC CCTAACCATA 1260 GACACAAGAG AGTTGATTGA TTTTGTCAAA TCTAAAATCC CTAAATAA 1308 (2) INFORMATION FOR SEQ ID NO: 11: i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 663 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 663 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 11; ATGAATAAAA CAACAATTAA AATATTAATG GGCATGGCGT TATTATCATC GCTTCAAGCC 60 GCAGAGGCAG AGCTTGATGA AAAATCAAAA AAACCTAAAT TTGCGGATAG GAATACGTTT 120 TATTTAGGGG TTGGGTATCA GCTTAGCGCG ATCAACACGT CTTTTAGCAC CAGTTCTATA 180 GATAAATCGT ATTTCATGAC CGGCAATGGT TTTGGCGTGG TGTTGGGGGG GAAATTTGTG 240 GCTAAAACGC AAGCTGTAGA GCATGTGGGT TTTCGTTACG GGTTGTTTTA TGATCAGACC 300 TTTTCTTCTC ACAAATCCTA TATTTCTACC TATGGTTTAG AATTTAGCGG TTTGTGGGAC 360 GCTTTCAATT CGCCAAAGAT GTTTTTGGGG TTGGAGTTTG GCTTAGGCAT CGCTGGGGCG 420 ACTTACATGC CAGGAGGGGC CATGCATGGG ATTATCGCTC AATATTTAGG CAAAGAAAAT 480 TCGCTTTTCC AATTGCTTGT GAAAGTGGGT TTTCGTTTTG GCTTTTTCCA CAATGAAATC 540 ACCTTTGGGT TGAAATTCCC TGTCATTCCT AACAAAAAAA CGGAAATCGT TGATGGCTTG 600 AGCGCGACCA CTTTATGGCA ACGCTTGCCG AGTGCCTATT TCAATTATAT CTATAATTTT 660 TAG_663_(2) INFORMATION FOR SEQ ID NO: 12: [i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 351 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic! (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 351 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 12: TTGAATCTCC ATTTTATGAA AGGATTTGTT ATGAGTGGAT TAAGAACATT TAGTTGTGTA 60 GTGGTTTTAT GCGGTGCAAT GGTTAATGTA GCTGTAGCTG GTCCTAAAAT AGAGGCAAGG 120 GGTGAATTAG GCAAATTTGT AGGGGGAGCT GTTGGAAATT TTGTTGGTGA TAAAATGGGC 180 GGATTTGTTG GTGGTGCAAT AGGAGGATAT ATTGGGTCTG AAGTAGGCAG TAGGGTAGAA 240 GATTATATCC GTGGCGTTGA TAGAGAGCCA CAAAACAAAG AACCACAAAC CCCAAGAGAA 300 CCTATCCGTG ATTTTTATGA TTACGGCTAT AGTTTTGGGC ATGCTTGGTG A 351 (2) INFORMATION FOR SEQ ID NO: 13: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1311 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1311 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 13: ATGTCAAGGG ATTTTAAATT TGATTCTAAC TATTTAAATG TCAATACCAA TCCTAAATTA 60 GGCCCCGTTT ATACCAATCA AAATTATCCA GGATTTTTTA TCTTTGATCA TTTAAGGCGT 120 TATGTGATGA ACGCTTTTGA GCCTAATTTG AACTTAGTTG TCAATACCAA TAAAGTTAAG 180 CAAACTTTTA ATGTGGGCAT GCGTTTTATG ACAATGGATA TGTTCATTAG ATCCGATCAA 240 AGCACATGCG AAAAAACAGA TATTATCAAT GGGGTGTGCC ACATGCCTCC TTATGTCCTT 300 TCTAAAACGC CTAACAATAA TCAAGAAATG TTTAATAACT ATACAGCGGT ATGGTTGAGC 360 GATAAAATAG AGTTTTTTGA TTCTAAATTG GTGATAACTC CAGGGCTTAG ATACACTTTT 420 TTGAACTATA ACAACAAAGA GCCAGAAAAG CATGATTTTT CCGTATGGAC CAGTAAAAAA 480 CAGCGTCAAA ACGAATGGAG TCCTGCCCTT AATATTGGCT ATAAACCTAT GGAAAATTGG 540 ATATGGTATG CGAACTACCG CCGCAGTTTT ATCCCCCCAC AACACACAAT GGTAGGCATT 600 ACTAGGACTA ATTACAACCA AATTTTTAAT GAAATTGAAG TGGGGCAGCG CTATAGTTAT 660 AAAAATCTAT TGAGTTTTAA CACCAATTAT TTTGTGATTT TTGCCAAGCG TTACTATGCG 720 GGAGGCTATA GCCCACAGCC TGTGGATGCC AGAAGTCAAG GGGTGGAATT GGAATTGTAT 780 TACGCGCCGA TTAGGGGTTT GCAATTCCAT GTGGCTTACA CTTATATTGA TGCGCGCATC 840 ACTTCTAACG CTGATGATAT TGCTTATTAT TTTACAGGCA TTGTCAATAA ACCCTTTGAC 900 ATTAAAGGGA AGCGCTTGCC CTATGTGAGT CCTAACCAAT TCATATTTGA CATGATGTAT 942 ACTTACAAGC ACACGACTTT TGGTATCAGC AGCTATTTTT ATAGCCGCGC TTATAGTTCC 1020 ATGCTCAATC AAGCCAAAGA TCAAACCGTA TGCCTGCCCT TAAACCCAGA ATACACAGGG 1080 GGGTTAAAGT ATGGTTGTAA TTCAGTGGGG TTATTGCCCT TGTATTTTGT GTTGAATGTC 1140 CAAGTAAGCT CAATCTTATG GCAAAGCGGT AGGCATAAAA TCACAGGGAG TTTGCAAATC 1200 AATAACCTTT TTAACATGAA GTATTATTTT AGGGGGATTG GCACAAGCCC TACAGGGAGA 1260 GAACCCGCGC CAGGGAGATC CATTACAGCG TATTTGAATT ATGAGTTTTA A 1311 (2) INFORMATION FOR SEQ ID NO: 14: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2304 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 2304 (xi) SEQUENCE DESCRITION: SEQ ID NO: 14 ATGAAAAGAA TTTTAGTTTC TTTGGCTGTT TTGAGTCATA GCGCGCATGC TGTCAAAACT 60 CATAATTTGG AAAGGGTGGA AGCTTCAGGG GTGGCTAACG ATAAAGAAGC GCCTTTAAGC 120 TGGAGGAGCA AGGAAGTTAG AAATTATATG GGTTCTCGCA CGGTGATTTC TAACAAGCAA 180 CTCACTAAAA GCGCCAATCA AAGCATTGAA GAAGCTTTGC AAAATGTGCC AGGCGTGCAT 240 ATTAGAAACT CTACCGGTAT TGGAGCTGTG CCTAGCATTT CCATTAGGGG GTTTGGTGCT 300 GGAGGCCCAG GGCATTCTAA TACGGGAATG ATTCTAGTCA ATGGGATTCC CATTTATGTC 360 GCGCCCTATG TTGAAATTGG CACGGTTATT TTTCCTGTAA CCTTTCAGTC TGTGGATAGA 420 ATCAGCGTAA CTAAGGGTGG GGAGAGCGTG CGTTATGGCC CTAACGCTTT TGGCGGTGTG 480 ATCAACATCA TCACCAAAGG CATTCCTACC AATTGGGAAA GTCAGGTGAG CGAGAGGACC 540 ACTTTTTGGG GCAAGTCTGA AAACGGGGGC TTTTTCAATC AAAATTCTAA AAACATTGAT 600 AAAAGCTTAG TTAATAACAT GCTTTTTAAC ACCTATTTAA GAACGGGGGG TATGATGAAT 660 AAGCATTTTG GAATCCAAGC TCAAGTCAAT TGGCTCAAAG GGCAAGGGTT TAGATACAAC 720 AGCCCTACGG ATATTCAAAA TTACATGTTA GATTCATTGT ATCAAATCAA TGATAGCAAT 780 AAAATCACCG CTTTTTTTCA ATATTATAGT TATTTCTTGA CAGACCCTGG ATCTTTAGGC 840 ATAGCCGCTT ACAATCAAAA TCGTTTTCAA AACAACCGCC CCAATAACGA TAAAAGCGGG 900 AGAGCGAAGC GATGGGGAGC TGTGTATCAA AACTTTTTTG GGGACACGGA TAGGGTAGGG 960 GGGGATTTCA CTTTTAGCTA CTATGGGCAT GACATGTCAA GGGATTTTAA ATTTGATTCT 1020 AATTATTTAA ATGTCAATAC CAATCCTAAA TTAGGCCCCG TTTATACCAA TCAAAATTAT 1080 CCAGGATTTT TTATCTTTGA TCATTTAAGG CGTTATGTGA TGAACGCTTT TGAGCCTAAT 1140 TTGAACTTAG TTGTCAATAC CAATAAAGTT AAGCAAACTT TTAATGTGGG CATGCGTTTT 1200 ATGACAATGG ATATGTTCAT TAGATCCCAT CAAAGCACAT GCGAAAAAAC AGATATTATC 1260 AATGGGGTGT GCCACATGCC TCCTTATGTC CTTTCTAAAA CGCCTAACAA TAATCAAGAA 1320 ATGTTTAATA ACTATACAGC GGTATGGTTG AGCGATAAAA TAGAGTTTTT TGATTCTAAA 1380 TTGGTGATAA CTCCAGGGCT TAGATACACT TTTTTGAACT ATAACAACAA AGAGCCAGAA 1440 AAGCATGATT TTTCCGTATG GACCAGTAAA AAACAGCGTC AAAACGAATG GAGTCCTGCC 1500 CTTAATATTG GCTATAAACC TATGGAAAAT TGGATATGGT ATGCGAACTA CCGCCGCAGT 1560 TTTATCCCCC CACAACACAC AATGGTAGGC ATTACTAGGA CTAATTACAA CCAAATTTTT 1620 AATGAAATTG AAGTGGGGCA GCGCTATAGT TATAAAAATC TATTGAGTTT TAACACCAAT 1680 TATTTTGTGA TTTTTGCCAA GCGTTACTAT GCGGGAGGCT ATAGCCCACA GCCTGTGGAT 1740 GCCAGAAGTC AAGGGGTGGA ATTGGAATTG TATTACGCGC CGATTAGGGG TTTGCAATTC 1800 CATGTGGCTT ACACTTATAT TGATGCGCGC ATCACTTCTA ACGCTGATGA TATTGCTTAT 1860 TATTTTACAG GCATTGTCAA TAAACCCTTT GACATTAAAG GGAAGCGCTT GCCCTATGTG 1920 AGTCCTAACC AATTCATATT TGACATGATG TATACTTACA AGCACACGAC TTTTGGTATC 1980 AGCAGCTATT TTTATAGCCG CGCTTATAGT TCCATGCTCA ATCAAGCCAA AGATCAAACC 2040 GTATGCCTGC CCTTAAACCC AGAATACACA GGGGGGTTAA AGTATGGTTG TAATTCAGTC 2100 GGGTTATTGC CCTTGTATTT TGTGTTGAAT GTCCAAGTAA GCTCAATCTT ATGGCAAAGC 2160 GGTAGGCATA AAATCACAGG GAGTTTGCAA ATCAATAACC TTTTTAACAT GAAGTATTAT 2220 TTTAGGGGGA TTGGCACAAG CCCTACAGGG AGAGAACCCG CGCCAGGGAG ATCCATTACA 2280 GCGTATTTFA ATTATGAGTT TTAA 2304 (2) INFORMATION FOR SEQ ID NO: 15: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 348 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 15: TTGCACCCTC TATGCGCACA CGGCCAATGT GGAAGCGAAG GGATTGCGTG TTTAGAAGCC 60 ATTAGCGTGG GGATTGTGCC TGTTATCGCT AATAGCCCTT TAAGCGCGAC CAGGCAATTC 120 GCGCTAGATG AACGATCGTT ATTTGAGCCT AATAACGCTA AAGATTTGAG CGCTAAAATA 180 GACTGGTGGT TAGAAAACAA ACTTGAAAGA GAAAGAATGC AAAACGAATA CGCTAAAAGC 240 GCTTTAAACT ACACTTTAGA AAATTCAGTC ATTCAAATTG AAAAAGTTTA TGAAGAAGCG 300 ATCAAAGATT TTAAAAACAA CCCCAACCTC TTTAAAACCT TATCGTAA 348 (2) INFORMATION FOR SEQ ID NO: 16: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1170 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTIC: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 1170 (xi) SEQUENCE DESCRITION: SEQ ID NO: 16: ATGGTTATTG TTTTAGTCGT GGATAGCTTT AAAGACACCA GTAATGGCAC TTCTATGACA 60 GCGTTTCGTT TTTTTGAAGC GCTGAAAAAA AGAGGGCATG CGATGAGAGT GGTCGCCCCT 120 CATGTGGATA ATTTAGGGAG TGAAGAAGAG GGGTATTACA ACCTTAAAGA GCGCTATATC 180 CCCCTAGTTA CAGAAATTTC ACACAAGCAA CACATTCTTT TTGCCAAACC GGATGAAAAA 240 ATTCTACGAA AGGCTTTTAA GGGAGCGGAT ATGATCCATA CTTACTTGCC TTTTTTGCTA 300 GAAAAAACAG CCGTAAAAAT CGCGCGAGAA ATGCGAGTGC CTTATATTGG CTCTTTCCAT 360 TTACAGCCAG AGCATATTTC TTATAACATG AAATTGGGGC AATTTTCTTG GCTAAATACC 420 ATGCTTTTTT CATGGTTTAA ATCTTCGCAT TACCGCTATA TCCACCATAT CCATTGCCCA 480 TCAAAATTCA TTGTAGAAGA ATTGGAAAAA TACAACTATG GAGGAAAAAA ATACGCTATC 540 TCTAACGGCT TTGATCCCAT GTTTAAGTTT GAGCACCCGC AAAAAAGCCT TTTTGACACC 600 ACGCCCTTTA AAATCGCTAT GGTAGGGCGC TATTCTAATG AAAAAAATCA AAGCGTTCTC 660 ATTAAAGCGG TTGCTTTAAG CCGATACAAA CAAGACATTG TATTATTACT CAAAGGCAAG 720 GGGCCTGATG AGAAAAAAAT CAAACTTCTA GCCCAAAAAC TAGGCGTAAA AACGGAGTTT 780 GGGTTTGTCA ATTCCCATGA ATTGTTAGAG ATTTTAAAAA CTTGCACCCT CTATGCGCAC 840 ACGGCCAATG TGGAAAGCGA AGCGATTGCG TGTTTAGAAG CCATTAGCGT GGGGATTGTG 900 CCTGTTATCG CTAATAGCCC TTTAAGCGCG ACCAGGCAAT TCGCGCTAGA TGAACGATCG 960 TTATTTGAGC CTAATAACGC TAAAGATTTG AGCGCTAAAA TAGACTGGTG GTTAGAAAAC 1020 AAACTTGAAA GAGAAAGAAT GCAAAACGAA TACGCTAAAA GCGCTTTAAA CTACACTTTA 1080 GAAAATTCAG TCATTCAAAT TGAAAAAGTT TATGAAGAAG CGATCAAAGA TTTTAAAAAC 1140 AACCCCAACC TCTTTAAAAC CTTATCGTAA 1170 (2) INFORMATION FOR SEQ ID NO: 17 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 939 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) iiii) HYPOTHETICAL: NO [iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 939 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 17: TTGGCTTCTT ACGGGTTTTT TTTAGGAGCG TTGTTTATTT TAGCGAGCGG GATCGTGTGC 60 TTACAGACTG CCGGTAATCC CTTTGTAACC TTGCTTTCTA AAGGTAAAGA AGCCAGAAAC 120 TTGGTTTTAG TCCAGGCGTT CAATTCGCTT GGCACGACTT TAGGGCCTAT TTTTGGGAGC 180 TTGTTGATTT TTAGCGCGAC CAAAACGAGC GATAATTTAA GCCTGATAGA CAAGTTAGCG 240 GACGCTAAAA GCGTTCAAAT GCCTTATTTG GGTTTAGCGG TGTTTTCGCT TCTTTTAGCG 300 CTTGTGATGT ATCTTTTAAA ATTGCCTGAT GTGGAAAAAG AAATGCCCAA AGAAACGACG 360 CAAAAAAGCC TGTTTTCGCA CAAACACTTT GTTTTTGGGG CTTTAGGGAT CTTTTTCTAT 420 GTGGGGGGAG AAGTGGCGAT TGGATCATTC TTGGTGCTAA GCTTTGAAAA GCTTTTGAAT 480 TTAGACGCTC AATCAAGCGC GCATTACTTG GTGTATTATT GGGGCGGCGC GATGGTAGGG 540 CGTTTCTTAG GCAGCGCTTT GATGAATAAA ATCGCTCCTA ATAAATACCT GGCTTTCAAC 600 GCCTTAAGCT CTATCATTCT TATCGCTTTG GCTATTCTTA TTGGAGGCAA GATCGCTTTA 660 TTCGCTCTGA CTTTTTTGTGGG CTTTTTTCAAC TCTATCATGT TCCCTACAAT CTTTTCTTTG 720 GCTACGCTCA ATTTAGGGCA TCTCACTTCT AAGGCTTCTG GAGTGATTAG CATGGCGATT 780 GTGGGAGGGG CGTTAATCCC CCCCATTCAA GGCGTGGTTA CAGACATGCT CACAGCAACC 840 GAATCGAATC TGCTCTACGC TTATAGCGTG CCGTTGTTGT GCTATTTTTA TATCCTCTTC 900 TTGCACTTA AGGGGTATAA ACAAGAAGAA AACTCCTAA 939 (2) INFORMATION FOR SEQ ID NO: 18: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1224 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iü) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1224 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 18 ATGCAAAAA CTTCTAACAC TTTAGCGCTG GGGAGTTTGA CGGCGCTATT CTTTCTAATG 60 GGTTTTATCA CGGTTTTAAA CGACATTTTG ATCCCGCATT TAAAGCCCAT TTTTGACTTG 120 ACCTATTTTG AAGCTTCGCT CATTCAATTT TGCTTTTTTG GGGCGTATTT CATCATGGGG 180 GGAGTCTTTG GGAACGTGAT CAGTAAAATC GGCTACCCTT TTGGCGTGGT GCTTGGTTTT 240 GTGATCACAG CGAGCGGGTG CGCGTTGTTT TATCCGGCGG CGCATTTTGG CTCTTACGGG 300 TTTTTTTTTAG GAGCGTTGTT TATTTTAGCG AGCGGGATCG TGTGCTTACA GACTGCCGGT 360 AATCCCTTTG TAACCTTGCT TTCTAAAGGT AAAGAAGCCA GAAACTTGGT TTTAGTCCAG 420 GCGTTCAATT CGCTTGGCAC GACTTTAGGG CCTATTTTTG GGAGCTTGTT GATTTTTAGC 480 GCGACCAAAA CGAGCGATAA TTTAAGCCTG ATAGACAAGT TAGCGGACGC TAAAAGCGTT 540 CAAATGCCTT ATTTGGGTTT AGCGGTGTTT TCGCTTCTTT TAGCGCTTGT GATGTATCTT 600 TTAAAATTGC CTGATGTGGA AAAAGAAATG CCCAAAGAAA CGACGCAAAA AAGCCTGTTT 660 TCGCACAAAC ACTTTGTTTT TGGGGCTTTA GGGATCTTTT TCTATGTGGG GGGAGAAGTG 720 GCGATTGGAT CATTCTTGGT GCTAAGCTTT GAAAAGCTTT TGAATTTAGA CGCTCAATCA 780 AGCGCGCATT ACTTGGTGTA TTATTGGGGC GGCGCGATGG TAGGGCGTTT CTTAGGCAGC 840 GCTTTGATGA ATAAAATCGC TCCTAATAAA TACCTGGCTT TCAACGCCTT AAGCTCTATC 900 ATTCTTATCG CTTTGGCTAT TCTTATTGGA GGCAAGATCG CTTTATTCGC TCTGACTTTT 960 GTGGGCTTTT TCAACTCTAT CATGTTCCCT ACAATCTTTT CTTTGGCTAC GCTCAATTTA 1020 GGGCATCTCA CTTCTAAGGC TTCTGGAGTG ATTAGCATGG CGATTGTGGG AGGGGCGTTA 1080 ATCCCCCCCA TTCAAGGCGT GGTTACAGAC ATGCTCACAG CAACCGAATC GAATCTGCTC 1140 TACGCTTATA GCGTGCCGTT GTTGTGCTAT TTTTATATCC TCTTCTTTGC ACTTAAGGGG 1200 TATAAACAAG AAGAAAACTC CTAA 1224 (2) INFORMATION FOR SEQ ID NO: 19; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 378 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 378 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 19: ATGAATAAAA TCGCTCCTAA TAAATACCTG GCTTTCGGCG CCTTAAGCTC TATCATTCTT 60 ATCGCTTTGG CTATTCTTAT TGGAGGCAAG ATCGCTTTAT TCGCTCTGAC TTTTGTGGGC 120 TTTTTCAACT CTATCATGTT CCCTACAATC TTTTCTTTGG CTACGCTCAA TTTAGGCATC 180 TCACTTCTAA TGGCTTCTGG AGTGATTAGC ATGGCGATTG TGGGAGGGGC GTTAATCCCC 240 CCCATTCAAG GCGTGGTTAC AGACATGCTC ACAGCAACCG AATCGAATCT GCTCTACGCT 300 TATAGCGTGC CGTTGTTGTG CTATTTTTAT ATCCTCTTCT TTGCACTTAA GGGGTATAAA 360 CAAGAAGAAA ACTCCTAA 378 (2) INFORMATION FOR SEQ ID NO: 20: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 993 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 993 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 20: TTGAAAAAAA TATTACCGGC TTTGTTAATG GGGTTTGTGG GATTGAATGC TAGTGATCGT 60 TTGTTAGAAA TCATGCGCCT TTATCAAAAA CAAGGCTTGG AAGTGGTGGG TCAAAAATTG 120 GATTCTTATT TAGCGGATAA GTCTTTTTGG GCAGAAGAGC TTCAAAACAA GGACACGGAT 180 TTTGGCTATT ATCAAAACAA GCAGTTTTTA TTTGTGGCGG ATAAATCCAA GCCCAGTTTG 240 GAGTTTTATG AAATAGAAAA TAACATGCTT AAAAAAATCA ACAGCTCTAA AGCCCTTGTA 300 GGCTCTAAAA AGGGCGATAA AACTTTAGAG GGCGATTTGG CCACGCCTAT TGGAGTGTAT 360 CGTATCACGC AGAAATTAGA GCGTTTGGAT CAATATTATG GCGTTTTGGC TTTTGTAACG 420 AATTACCCTA ATTTGTATGA CACTTTGAAA AAACGCACCG GGCATGGCAT TTGGGTGCAT 480 GGAATGCCTT TAAATGGCGA TAGGAATGAA TTGAACACTA AGGGTTGCAT TGCGATTGAA 540 AACCCTATTC TAAGCTCTTA TGACAAAGTG TTAAAAGGCG AAAAAGCGTT CCTTATCACT 600 TATGAAGACA AGTTTTCCCC TAGCACTAAA GAAGAATTGA GCATGATTTT AAGCTCCCTT 660 TTCCAATGGA AAGAAGCTTG GGCTAGGGGC GATTTTGAAC GCTACATGCG TTTTTATAAC 720 CCCAATTTCA CTCGCTATGA CGGCATGAGT TTTAACGCTT TTAAAGAGTA TAAAAAAAGG 780 GTGTTTGCAA AAAATGAAAA AAAGAATATC GCTTTTTCCT CAATCAATGT GATCCCTTAC 840 CCCAACTCTC AAAACAAACG CTTGTTTTAT GTGGTATTTG ACCAAGATTA CAAAGCCTAC 900 CAGCAAAACA AGCTCTCTTA TAGCGCCAAT TCTCAAAAAG AACTCTATGT AGAGATTGAA 960 AACAAATCAAG CGTCTATTAT AATGGAAAAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 510 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 510 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 21: TTGTTTGAGA AATGGATTGG TCTGACCTTA CTCCTTAGTT CCTTAGGCTA TCCATGCCAA 60 AAGGTAAGTA TTAGTTTCAA GCAATACGAA AATCTTATCC ATATCCATCA AAAAGGTTGC 120 AACAATGAAG TGGTGTGCAG AACGCTCATC TCTATCGCTT TACTATGAAG CTCTCTAGGG 180 TTGAACAACA AGCGAGAAAA ATCCCTTAAA GACACTTCTT ACTCCATGTT CCATATCACC 240 TTAAACACCG CTAAAAAGTT CTACCCTACC TATTCTAAAA CGCTCCTCAA AACCAAATTG 300 TTAAATGATG TGGGTTTTGC GATCCAATTA GCCAAACAAA TTTTAAAAGA AAATTTTGAT 360 TATTACCACC AAAAACACCC CAACAAAAGC GTGTATCAAT TAGTACAAAT GGCCATAGGC 420 GCTTACAATG GGGGAATGAA ACACAACCCT AATGGCGCTT ACATGAAGAA GTTTCGTTGC 480 ATTTATTCTC AAGTGCGATA CAACGAATAA 510 (2) INFORMATION FOR SEC ID NO: 22: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 648 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 648 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 22: ATGAAAAAAC CCTACAGAAA GATTTCTGAT TATGCGATCG TGGGTGGTTT GAGCGCGTTA 60 GTGATGGTAA GCATTGTGGG GTGTAAGAGC AATGCCGATG ACAAACCAAA AGAGCAAGC 120 TCTTTAAGTC AAAGCGTTCA AAAAGGCGCG TTTGTGATTT TAGAAGAGCA AAAGGATAAA 180 TCTTACAAGG TTGTTGAAGA ATACCCCAGC TCAAGAACCC ACATTGTAGT GCGCGATTTG 240 CAAGGCAATG AACGCGTGTT GAGCAATGAA GAGATTCAAA AGCTCATCAA AGAAGAAGAA 300 GCCAAAATTG ATAACGGCAC GAGCAAGCTT GTCCAGCCTA ATAATGGAGG GAGTAATGAA 360 GGATCAGGCT TTGGCTTGGG AAGCGCGATT TTAGGGAGCG CGGCGGGGGC GATTTTAGGG 420 AGTTATATTG GCAATAAGCT TTTTAATAAC CCTAATTATC AGCAAAACGC CCAACGGACC 480 TACAAATCCC CACAAGCTTA CCAACGCTCT CAAAATTCTT TTTCTAAAAG CGCACCCAGC 540 GCTTCAAGCA TGGGCACAGC GAGTAAGGGA CAGAGCGGGT TTTTTGGCTC TAGTAGGCCT 600 ACTAGTTCGC CTGCAATAAG CTCTGGGACA AGGGGCTTA ACGCATAA 648 (2) INFORMATION FOR SEQ ID NO: 23: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 762 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 762 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 23: TTGAAAACTC TATTTAGTGT TTATCTCTTT TTGTCGTTGA ATCCACTCTT TTTAGAAGCT 60 AAAGAAATCA CTTGGTCTCA ATTCTTGGAA AATTTTAAAA ACAAGAATGA AGACGACAAA 120 CCTAAACCCC TAACCATTGA CAAAAACAAT GAAAAACAGC AAATCCTAGA CAAAAACCAG 180 CAAATCTTAA AAAGGGCTTT AGAAAAAAGC CTTAAATTTT TCTTTATTTT TGGATACAAC 240 TATTCGCAAG CCGCTTATTC AACCACTAAT CAAAACTTGA CTCTTACGGC GAATAGCATA 300 GGGTTTAACA CCGCTACAGG CTTGGAGCAT TTTTTAAGAA ACCACCCTAA AGTCGGTTTT 360 AGAATCTTTA GCGTCTATAA CTATTTCCAT TCCGTTTCGC TCTCCCAGCC TCAAATAATA 420 ATGGTGCAAA ATTACGGAGG CGCGTTAGAT TTTTCTTGGA TTTTTGTGGA TAAAAAAACC 480 TATCGCTTTA GGAGTTATTT AGGAATCGCT TTAGAGCAAG GGGTGTTGTT AGTGGATACG 540 ATTAAAACCG GCTCTTTCAC AACCATCATC CCAAGAACCA AGAAAACCTT TTTTCAAGCC 600 CCTTTGCGTT TTGGTTTTAT CGTGGATTTT ATCGGCTATT TGTCTTTGCA ATTAGGGATT 660 GAAATGCCCT TAGTGAGGAA TGTTTTTTAC ACCTACAATA ACCATCAAGA AAGATTCAAA 720 CCACGATTTA ACGCTAATGT TTCTTTAATC GTTTCGTTTT AG 762 (2) INFORMATION FOR SEC ID NO: 24: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1011 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY:? rtisc_characteristic (B) LOCATION: 1 ... 1011 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 24: TTGTTTTTCA AATTTATTTT ATGTTTATCA TTAGGAATAT TTGCATGGGC AAAAGAGGTC 60 ATTCCCACCC CTTCAACCCC ATTAACGCCC TCTAAACGCT ATTCTATCAA TTTGATGACT 120 GAAAATGATG GTTATATCAA TCCTTACATT GATGAGTATT ACACGGCAGG CAATCAAATA 180 GGCTTTTCTA CTAAAGAGTT TGATTTTTCT AAAAATAAAG CGATGAAATG GTCTTCGTAT 240 TTAGGGTTTT TCAATAAAAG CCCTAGGGTT ACTCGTTTTG GCATTTCTCT CGCCCAAGAC 300 ATGTATACCC CCTCACTTGC AAACAGAAAA CTGGTGCATT TGCATGACAA CCACCCTTAT 360 GGGGGGTATT TGAGGGTGAA TTTGAACGTG TATAACCGCC ATCAAACTTT CATGGAGTTA 420 TTCACGATTT CTTTAGGCAC GACAGGGCAA GATTCTTTGG CCGCTCAAAC GCAGCGTCTC 480 ATTCATAAAT GGGGTCATGA TCCCCAATTT TATGGCTGGA ACACGCAGCT CAAAAACGAA 540 TTTATCTTTG AACTGCACTA CCAATTGCTT AAAAAAGTCC CCCTTTTAAA GACTCGTTTT 600 TTTTCTATGG AGTTGATGCC TGGGTTTAAT GTGGAACTGG GTAATGCGAG GGATTATTTC 660 CAACTCGGCT CGCTCTTTAG GGCTGGGTAT AACTTGGACG CTGATTATGG GGTCAATAAG 720 GTCAATACCG CTTTTGATGG GGGCATGCCT TATAGCGATA AGTTTTCCAT CTATTTTTTT 780 GCAGGGGCTT TTGGGCGCTT CCAACCCCTT AACATCTTCA TTCAAGGCAA TAGCCCTGAA 840 ACTAGGGGCA TTGCCAATTT GGAATACTTT GTTTATGCCA GTGAAATAGG AGCGGCTATG 900 ATGTGGCGTA GCCTCAGGGT GGCTTTTACA ATCACTGATA TTAGTAAAAC CTTTCAGTCC 960 CAGCCTAAGC ACCATCAGAT CGGCACCTTA GAATTGAATT TCGCCTTTTG A 1011 (2) INFORMATION FOR SEQ ID NO: 25; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 327 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 327 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 25: ATGAAACCAA TCTTTAGCCT CTTTTTTCCTC CTTATTGTTT TAAAAGCGCA CCCCATAAAC 60 CCCTTATTAG AGCCGTTATA TTTCCCCAGT TACACGCAAT TTTTAGATTT AGAACCTCAT 120 TTTGTCATTA AAAAAAAGCG CGCTTACAGG CCTTTTCAAT GGGGGAACAC TATTATTATC 180 AAACGCCATG ATTTAGAAGA GCGCCAGAGC AACCAACCAA GCGATATTTT CCGCCAGAAC 240 GCTGAAATCA ATGTGTCTTC TCAAACTTTT TTAAGAGGAA TCAGCAGCGC TTCTTCACGC 300 ATAGTGATCG ATTCGGTCGC TCAGTAA 327 (2) INFORMATION FOR SEQ ID NO: 26; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 588 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 588 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 26: ATGAGCAATA ACCCCTTTAA AAAAGTGGGC ATGATCAGCT CTCAAAACAA TAACGGCGCT 60 TTGAACGGGC TTGGCGTGCA AGTGGGTTAT AAACAATTCT TTGGCGAAAG CAAAAGATGG 120 GGGTTAAGGT ATTATGGTTT CTTTGATTAC AACCACGGCT ATATCAAATC CAGCTTTTTT 180 AATTCTTCTT CTGATATATG GACTTATGGC GGTGGGAGCG ATTTGTTAGT GAATTTTATC 240 AACGATAGCA TCACAAGAAA GAACAACAAG CTTTCTGTGG GTCTTTTTTGG TGGTATCCAA 300CTACATGGCT TAATTCTCAA TACATGAATT TAACAGCGTT CAATAACCCT 360 TACAGCGCGA AAGTCAATGC TTCCAATTTC CAATTTTTGT TCAATCTCGG CTTGAGGACG 420 AATCTCGCTA CAGCTAAGAA AAAAGACAGC GAACGTTCCG CGCAACATGG CGTTGAACTG 480 GGCATTAAAA TCCCTACCAT TAACACCAAT TATTATTCTT TTCTAGGCAC TAAGCTAGAA 540 TACAGAAGGC TTTATAGCGT GTATCTCAAT TATGTGTTTG CTTATTAA 588 (2) INFORMATION FOR SEQ ID NO: 27: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 684 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 684 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 27: GTGCGTTTTG GTAAAATTGA TTATTTGAAC ATGCTCCCTT TTGATGTGTT TATCAAATCC 60 TACCCCACCC CTTGTTATTT CAAACAATTC TTACGGCTTA AAAAAACCTA CCCCTCCAAA 120 CTCAATGAGA GTTTTTTATT CAGGCGCATT GATGCGGGGT TTATTTCTTC TATCGCTGGC 180 TATCCATTCG CTCTTTGTTC TTATTCTCTA GGCATTGTCG CTTATAAGGA AGTTTTAAGC 240 GTGTTGGTTG TAAATAGAGA AAACGCTTTT GACAAAGAAA GCGCTTCTTC AAACGCCCTC 300 TCTAAAGTGT TAGGGTTAAA AGGCGAGGTC TTAATCGGCA ATAAAGCGCT GCAATTTTAT 360 TATTCCAACC CTAAAAAAGA TTTTATAGAT TTAGCCGCTC TGTGGTATGA AAAAAAACGC 420 TTGCCGTTTG TTTTTGGGCG TCTGTGCTAT TATCAAAACA AGGATTTTTA CAAACGCTTG 480 TCTTTAGCCT TCAAACATCA AAAAACAAAA ATCCCTCACT ACATCCTTAA AGAAGCCGCT 540 s > TTGAAAACCA ACTTGAAACG CCAAGATATT CTAAACTACT TGCAAAAAAT TTACTACACT 600 TTAGGCAAAA AGGAACAATC AGGCCTTAAA GCGTTCTATC GTGAATTGTT GTTCAAACGC 660 ATCCAAAAAC CCAAGCGGTT TTAG_684_(2) INFORMATION FOR SEQ ID NO: 28: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 918 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 918 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 28: ATGGGTAGAA TTGAATCAAA AAAGCGTTTG AAAGCACTCA TTTTTTTAGC GAGTTTGGGG 60 GTGTTGTGGG GCAATGCGGC TGAAAAAACG CCTTTTTTTA AAACTAAAAA CCACATTTAT 120 TTGGGTTTTA GGCTAGGCAC AGGGGCTACT ACGCGCACAA GCATGTGGCA ACAAGCCTAT 180 AAAGACAACC CCACTTGCCC TAGCAGCGTG TGTTATGGCG AGAAATTAGA AGCCCATTAT 240 AAGGGGGGTA AAAACTTATC TTATACCGGG CAAATAGGCG ATGAAATAGC TTTTGATAAA 300 TACCATATTT TAGGCTTAAG GGTATGGGGG GATGTAGAAT ACGCTAAGGC TCAATTAGGT 360 CAAAAAGTGG GGGGTAACAC CCTTTTATCC CAAGCGAATT ATAACCCAAG CGCGATTAAA 420 ACCTACGATC CTACTTCAAA CGCTCAAGGC TCTTTAGTTT TGCAAAAAAC CCCAAGCCCC 480 CAAGATTTCC TTTTCAATAA CGGGCATTTC ATGGCGTTTG GTTTGAACGT GAACATGTTT 540 GTCAATCTCC CTATAGACAC CCTTTTAAAA CTCGCTTTAA AAACGGAAAA AATGCTGTTT 600 TTTAAAATAG GCGTGTTTGG TGGGGGTGGG GTGGAATACG CAATCTTGTG GAGTCCTCAA 660 TATAAAAATC AAAATACCCA TCAAGACGAT AAATTTTTTG CCGCAGGTGG GGGGTTTTTT 720 GTGAATTTTG GAGGCTCTTT GTATATAGGC AAGCGCAACC GCTTCAATGT GGGGCTAAAA 780 ATCCCTTATT ATAGCTTGAG CGCGCAAAGT TGGAAAAATT TTGGCTCTAG CAATGTGTGG 840 CAGCAACAAA CGATCCGACA AAACTTCAGC GTTTTTAGGA ATAAAGAAGT TTTTGTCAGC 900 TACGCGTTCT TGTTTTAG_918_(2) INFORMATION FOR SEQ ID NO: 29: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 777 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 777 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 229: ATGTTTTTAA GATiATACCC AAAGCTTAGA TACGCTTTAT GTTACCCCCT ACTCACTGAG 60 ACTTGCTATA GCGAGGAGCG CACTTTAAAT AAGGTTACCA CCCAAGCTAA AAGGATTTTC 120 ACTTACAATA ATGAGTTTAA GGTTACTTCT AAAGAATTGG ATCAACGCCA AAGCATTGAA 180 GTCAAAGACC TGTTTAGGAC TAACCCTGAT GTGAATGTGG GCGGAGGGAG CGTGATGGGG 240 CAGAAAATCT ACGTGAGAGG CATTGAAGAC AGGCTTTTAA GGGTTACGGT GGATGGGGCT 300GCAACATCTA CCACCACCAA GGCAACACCG TGATTGACCC TGGCATGCTC 360 AAAAGCGTGG AAGTTACTAA AGGCGCGGCG AATGCGAGCG CGGGGCCCCGG AGCGATCGCG 420 GGAGTGATTA AAATGGAGAC TAAAGGAGCG GCTGATTTTA TCCCTAGGGG GAAAAATTAT 480 GCAGCGAGTG GGGCGGTGAG TTTTTATACC AATTTTGGGG ACAGAGAGAC TTTTAGATCG 540 GCCTATCAAA GCGCGCATTT TGATATTATC GCTTACTACA CGCACCAAAA TATTTTCTAT 600 TATAGGAGCG GCGCCACAGT GATGAAAAAC CTTTTCAAAC CCACACAAGC CGATAAAGAG 660 CCAGGAACTC CCAGCGAGCA AAACAACGCT TTGATTAAAA TGAATGGCTA TTTGAGCGAC 720 AGAGACACGC TCACTTTCAG CTGGAACATG ACACGAGATA ACGCCACACG CCTTTAA 777 (2) INFORMATION FOR SEQ ID NO: 30; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 579 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 579 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 30: ATGTTTTTAA GATCATACCC AAAGCTTAGA TACGCTTTAT GTTTACCCCT ACTCACTGAG 60 ACTTGCTATA GCGAGGAGCG CACTTTAAAT AAGGTTACCA CCCAAGCTAA AAGGATTTTC 120 ACTTACAATA ATGAGTTTAA GGTTACTTCT AAAGAATTGG ATCAACGCCA AAGCAATGAA 180 GTCAAAGACC TGTTTAGGAC TAACCCTGAT GTGAATGTGG GCGGAGGGAG CGTGATGGGG 240 CAGAAAATCT ACGTGAGAGG CATTGAAGAC AGGCTTTTAA GGGTTACGGT GGATGGGGCT 300 GCGCAAAATG GCAACATTTA CCACCACCAA GGCAACACCG TGATTGACCC TGGCATGCTC 360 AAAAGCGTGG AAGTTACTAA AGGCGCGGCG AATGCGAGCG CGGGGCCCCGG AGCGATCGCG 420 GGAGTGATTA AAATGGAGAC TAAAGGAGCG GCTGATTTTA TCCCTAGGGG GAAAAATTAT 480 GCAGCGAGTG GTGCGGTGAG TTTTTATACC AATTTTGGGG ACAGAGAGAC TTTTAGATCG 540 GCCTATCAAA GCGCGCATTT TGATATTATC GCTTACTAG_579_(2) INFORMATION FOR SEQ ID NO: 31: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 381 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 31: GTGCCCTTGA GTTTGGGAGG CAACCTCTTA AACCCTAACA ACAGTAGCGT GCTGAATTTA 60 AAAAACAGCC AGCTTGTTTT TAGCGATCAA GGGAGCTTGA ATATCGCTAA CATTGATTTA 120 CTAAGCGATC TGAATGGTAA TAAAAATCGT GTGTATAACA TCATTCAAGC GGACATGAAT 180 GGTAATTGGT ATGAGCGTAT CAACTTCTTT GGCATGCGCA TTAATGATGG GATTTATGAC 240 GCTAAAAACC AAACTTATAG TTTCACTAAC CCTCTCAATA ACGCCGTAAA ATTCACCGAG 300 AGCTTTTTCA TACACCGCCT GTGCGGTTCG CTCTCTCAAA TACAAAAAAA AAAAAACACA 360 ATAGTCTCAC CTCGGCTCTG A 381 (2) INFORMATION FOR SEC ID NO: 32: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1698 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: myc_characteristic (B) LOCATION: 1 ... 1698 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 32: GTGTATTCTT ATAGCGATGA CGCACAAGGC GTGTTTTATC TCACGAGCAG CGTGAAAGGC 60 TATTACAACC CCAACCAATC CTATCAAGCC AGCGGCAGCA ATAACACCAC GAAAAATAAC 120 AATCTAACCT CTGAATCTTC TGTCATTCG CAAAACCTATA ACGCGCAAGG CAACCCTATC 180 AGCGCGTTAC ACGTCTATAA CAAGGGCTAT AATTTCAGTA ATATCAAAGC GTTAGGGCAA 240 ATGGCGCTCA AACTCTACCC TGAAATCAAA AAGATATTAG GGAATGATTT TTCGCTTTCA 300 AGTTTGAGCA ATTTAAAAGG CGATGCGCTA AACCAGCTTA CCAAGCTCAT CACGCCTAGC 360 GATTGGAAAA ACATTAACGA GTTGATTGAT AACGCTTTCA ATTCGGTCGT GCAAAATTTC 420 AATAACGGCA CTTTGATTAT AGGAGCGACT AAAATAGGGC AAACAGACAC CAATAGTGCG 480 GTGGTTTTTGGGGGCTTGGG CTATCAAAAG CCTTGCGATT ACACTGATAT TGTGTGCCAA 540 AAATTTAGAG GCACTTATTT GGGGCAGCTT TTGGAGTCCA ACTCCGCTGA TTTGGGCTAT 600 ATTGACACGA CTTTTAACGC TAAAGAAA? T TATCTTACCG GCACTTTAGG GAGCGGGAAC 660 GCATGGGGGA CTGGGGGGAG TGCGAGCGTA ACTTTTAACA GCCAAACTTC GCTCATTCTC 720 AACCAAGCGA ATATCGTAAG CTCGCAAACC GATGGGATTT TTAGCATGCT GGGTCAAGAG 780 GGCATCAATA AGGTTTTCAA TCAAGCCGGG CTCGCTAATA TTTGGGCGA AGTGGCAATG 840 CAATCCATTA ACAAAGCCGG GGGATTAGGG AAATTTGATG TAAATACGCT AGGAGTGAT 900 AGCGTGATTG GGGGGTATTT AACGCCTGAG CAAAAAAATC AAACCCTAAG CCAGCTTTTG 960 GGGCAGAATA ATTTTGATAA CCTCATGAAC GATAGCGGTT TGAACACGCG GATTAAGGAT 1020 TTGATCAGAC AAAAATTAGG CTTTTGGACC GGGCTAGTGG GGGGATTAGC CGGACTGGGG 1080 GGCATTGATT TGCAAAACCC TGAAAAGCTT ATAGGCAGCA TGTCCATCAA TGATTTATTG 1140 AGTAAAAAGG GGTTGTTCAA TCAGATCACC GGCTTTATTT CCGCTAACGA TATAGGGCAA 1200 GTCATAAGCG TGATGCTGCA AGATATTGTC AAGCCGAGCG ACGCTTTAAA AAACGATGTA 1260 GCCGCTTTGG GCAAGCAAAT GATTGGCGAA TTTTTAGGCC AAGACACGCT CAATTCTTTA 1320 GAAAGCTTGC TGCAAAACCA GCAGATTAAA AGCGTTTTAG ACAAAGTCTT AGCGGCTAAA 1380 GGATTAGGGT CTATTTATGA ACAAGGTTTG GGGGATTTGA TCCCTAATCT TGGTAAAAAG 1440 GGGATTTTCG CTCCCTATGG CTTGAGTCAA GTGTGGCAAA AAGGGGATTT TAGTTTCAAC 1500 GCGCAAGGCA ATGTTTTTGT GCAAAATTCC ACTTTCTCTA ACGCTAATGG AGGCACGCTC 1560 AGTTTTAACG CAGGAAATTC GCTCATTTTT GCCGGAAACA ACCACATCGC TTTCACTAAC 1620 CATTCTGGAA CGCTCAATTT GTTGTCTAAT CAAGTTTCTA ACATTAACGT CACCATGCTT 1680 AACGCAGCAA CGGCCTAA 1698 (2) INFORMATION FOR SEQ ID NO: 33: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 519 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iü) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 519 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 33: GTGTTTGGAT TGAGTTTGGC GGATATGATT TTAGAGCGTT TTAAAGATTT TATGAGAGAA 60 TACCCTGAGC CTTACAAGTT TTTACAGGTT TTTTACGCGC AAGAAAAAGA ACGCTTCTTA 120 AATCATAAAA TGAACGATTA TATCAAGCAA AATAAGAGCA AGGAAGAGGC TAGTATTTTG 180 GCCAGACAAG GCTTTGTCAG CGTAATTGGA AGAGCGTTAG AAAAAATCAT AGAACTTTTA 240 TTAAAAGATT TTTGTATTAA AAACAATGTA AAAATGACGA ACGATAAAAC CTTAAGGGCT 300 AAGCGCATTA ATGGCGAATT AGATAAGGTC AAACGGGCTT TATTGGTGCA TTTTGGAGGA 360 TATAGCGTTT TACCCGATAT TATTCTTTAT CAAACCAACA AAGATAATAT CAAAATCCTA 420 GCGATTTTAT CGGTAAAAAA TTCGTTTAGA GAGCGTTTCA CAAAAGACGC CTTATTGGAA 480 ATTAAAACTT TTGCAATCGC CTGTAACTTC TCACATTAA 519 (2) INFORMATION FOR SEQ ID NO: 34; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 996 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular di) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 996 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 34: ATGAAAAGAT TTGTTTTATT CTTGTTATTC ATATGTGTTT GCGTTTGCGT TCAAGCTTAC 60 GCTGAGCAAG ATTACTTTTT TAGGGATTTT AAATCTATAG ATTTGCCCCA AAAACTCCAC 120 CTTGATAAAA AGCTCTCCCA AACAATACAG CCATGCGCGC AACTTAACGC ATCAAAACAC 180 TACACTGCTA CTGGGGTTAG AGAGCCTGAT GCCTGCACCA AGAGTTTTAA AAAATCCGCT 240 ATGGTTTCCT ATGATTTAGC GCTAGGCTAT TTAGTGAGCC AAAACAAACC ATACGGCTTA 300 AAAGCTATAG AGATTTTAAA CGCTTGGGCT AATGAGCTTC AAAGCGTGGA TACTTATCAA 360 AGCGAGGACA ATATCAATTT TTACATGCCT TATATGAACA TGGCTTATTG GTTTGTCAAA 420 AAAGAATTTC CTAGCCCAGA ATATGAAGAT TTCATTAGGC GGATGCGTCA GTATTCTCAA 480 TCAGCTCTTA ACACTAACCA TGGGGCGTGG GGGATTCTCT TTGATGTGAG CTCTGCACTA 540 GCGCTAGATG ATCATGCCCT TTTGCAAAGT AGCGCTAATC GGTGGCAGGA GTGGGTGTTT 600 AAAGCCATAG ATGAGAACGG GGTTATTGCT AGCGCGATCA CTAGGAGCGA TACGAGCGAT 660 TATCATGGCG GCCCTACAAA GGGCATTAAG GGGATAGCTT ATACCAATTT TGCGCTTCTT 720 GCGATAACTA TATCAGGCGA ATTGCTTTTT GAGAACGGGT ATGATTTGTG GGGTAGTGGA 780 GCCGGGCAAA GGCTCTCTGT GGCGTATAAC AAAGCCGCAA CATGGATTCT AAACCCTGAA 840 ACTTTCCCCT ATTTTCAGCC TAACCTCATT GGGGTGCATA ACAACGCCTA TTTCATTATT 900 TTAGCCAAAC ATTATTCTAG CCCTAGCGCG GATGAGCTTT TAGAGCAAGG CGATTTGCAT 960 GAAGATGGCT TCAGGCTGAA ACTCCGATCG CCATGA 996 (2) INFORMATION FOR SEQ ID NO: 35: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 384 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 384 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 35: ATGCGTCAGT ATTCTCAATC AGCTCTTAAC ACTAACCATG GGGCGTGGGG GATTCTCTTT 60 GATGTGAGCT CTGCACTAGC GCTAGATGAT CATGCCCTTT TGCAAAGTAG CGCTAATCGG 120 TGGCAGGAGT GGGTGTTTAA AGCCATAGAT GAGAACGGGG TTATTGCTAG CGCGATCACT 180 AGGAGCGATA CGAGCGATTA TCATGGCGGC CCTACAAAGG GCATTAAGGG GATAGCTTAT 240 ACCAATTTTG CGCTTCTTGC GATAACTATA TCAGGCGAAT TGCTTTTTGA GAACGGGTAT 300 GATTTGTGGG GTAGTGGAGC CGGGCAAAGG CTCTCTGTGG CGTATAACAA AGCCGCAACA 360 TGGATTCTAA ACCCTGAAAC TTC 384 (2) INFORMATION FOR SEQ ID NO: 36: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 738 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 738 [xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 36: TTGAGAACCT TGTTAAAAAT GTTGGTTGGT GTGAGCTTAC TAACACACGC TTTAATGGCT 60 ACAGAAGAAA GCGCTGCCCC TTCTTGGACA AAAAATTTGT ATATGGGATT CAATTACCAA 120 ACAGGTTCTA TCAATTTAAT GACTAATATT CATGAAGTTA GAGAAGTTAC TAGCTATCAA 180 ACCGGTTACA CCAATGTAAT GACTAGCATT AATAGCGTTA AAAAACTCAC TAACATGGGT 240 TCTAATGGGA TTGGCTTAGT CATGGGCTAT AACCACTTTT TCCATCCGGA TAAAGTCTTG 300 GGTTTGCGCT ATTTTGCTTT TTTAGATTGG CAAGGCTATG GCATGAGATA CCCTAAAGGC 360 TATTATGGGG GCAATAACAT GATCACTTAT GGCGTGGGCG TGGATGCGAT ATGGAATTTC 420 TTCCAAGGGA GTTTTTATCA AGATGATATT GGCGTGGATA TTGGCGTTTT TGGGGGGATT 480 GCGATTGCTG GGAATAGCTG GTATATTGGC AATAAAGGGC AGGAATTATT AGGCATCACC 540 AATAGTAGTG CGGTTGATAA CACCTCTTTT CAATTCCTCT TTAACTTTGG TTTCAAAGCT 600 TTATTTGTAG ATGAACATGA ATTTGAAATT GGGTTTAAAT TCCCCACTCT TAACAACAAA 660 TACTACACCA CCGACGCGCT CAAGGTTCAA ATGCGTAGGG TCTTTGCCTT TTATGTGGGG 720 TATAATTACC ACTTCTAA 738 (2) INFORMATION FOR SEQ ID NO: 37: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 873 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 873 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 37: ATGTTTGAAG AAATTACCCT AGCGCATAAG GACTTGTTTT CAAGGTTTTT ACAAACTCAA 60 AAAATCGTTT TATCGGATGT GAGTTTTACC AATTGCTTTT TATGGCAGCA CGCAAGGCTC 120 ATTCAAGTGG CTGTGATTAG GGATTGTTTG GTGATTCAAA CCACTTATGA AAACCAAAAA 180 CCCTTTTATT TCTATCCTAT CGGTAAGAGG CCGCATGAAT GCGTGAAAGA GCTTTTGGAA 240 TTAGAAAAAA ATTTAAGATT CCACTCCCTG ACTTTAGAGC AAAAAGACGA TTTGAAAGAC 300 AATTTTGTAG GGGTGTTTGA TTTCACTTAC AACCGAGACA GGAGCGATTA TGTTTATTCT 360 ATTGAAGAAC CAGTTTTTAA CCAATCATGC GAATTTTGTT TATGAAAAAA TTTCTCCTCA 420 CAGTTTTTAA CCAATCATGC GAATTTTGTT TATGAAAAAA TTTCTCCTCA AAACAGAAAG 480 GAAGTTTTAG AAGCCTCTAA AGCGTGGTTT TTAGAAAGCC AGACCGATGA TATAGGGTTA 540 ATCAACGAAA ATAAGGGCAT TCAAAGCGTT TTAGAAAATT ATGAAAGCTT GGATTTAAAG 600 GGGGGGGTATA TTAGGGTTAA TGGGGAAATA GTCTCGTTTA GTTTTGGGGA AGTTTTAAAC 660 GAAGAGAGCG CGCTCATCCA CATTGAAAAA GCCCGCACAG ATATTGCAGG CGCGTATCAA 720 ATCATCAACC AACAATTGCT TTTGAATGAA TTTAGCCATT TAACTTACGC TAACAGAGAA 780 GAAGATCTAG GATTAGAGGG CTTAAGAAGG TCTAAAATGA GCTATAACCC GGTGTTTTTG 840 ATAGACAAAT ACGAAGCGGT TGCTAGAAAT TAA 873 (2) INFORMATION FOR SEQ ID NO: 38: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) ; iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 333PTION OF THE SEQUENCE: SEQ ID NO: 38: ATGATGTTCA TTGTAGCGGT TTTGATGCTG GCGTTTTTGA TCTTTGTCCA TGAGTTAGGG 60 CATTTCATTA TCGCTAGGAT TTGTGGGGTG AAAGTGGAAG TGTTTAGCAT TGGTTTTGGT 120 AAAAAACTCT GGTTTTTCAA GCTTTTTGGC ACGCAATTCG CTCTGTCTTT GATCCCGCTT 180 GGGGGCTATG TGAAATTAAA GGGCATGGAT AAAGAAGAAA ATGAAGAAAA TAAAATTAAT 240 CAAGCGAATG ATAGCTACGC CAAAAAAGCC CTTTCCAAAA GCTATGGATA TTGTTTGGTG 300 GGGCGTTTTT TAATTTTCTT TTTGCGGTTT TAG_333_(2) INFORMATION FOR SEQ ID NO: 39 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1056 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1056 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 39: ATGATGTTCA TTGTAGCGGT TTTGATGCTG GCGTTTTTGA TCTTTGTCCA TGAGTTAGGG 60 CATTTCATTA TCGCTAGGAT TTGTGGGGTG AAAGTGGAAG TGTTTAGCAT TGGTTTTGGT 120 AAAAAACTCT GGTTTTTCAA GCTTTTTGGC ACGCAATTCG CTCTGTCTTT GATCCCGCTT 180 GGGGGCTATG TGAAATTAAA GGGCATGGAT AAAGAAGAAA ATGAAGAAAA TAAAATTAAT 300 CAAGCGAATG ATAGCTACCG GCAAAAAAGC CCTTTCCAAA AGCTATGGAT ATTGTTTGGT 360 GAAAAAGTCT TACTGCCCGT CATTGGCGGT TTAGAAAAAA ACGCGCTAGA AGCCGGGCTG 420 TTAAAGGGGG ATAGAATCCT TTCTATCAAC CATCAAAAAA TAGCGAGTTT TAGAGAGATT 480 AGAGAGATAG TGGCGCGTTC TCAAGGCGAC TTAATTTTAG AAATAGAGCG AAACAATCAG 540 ATTTTAGAAA AACGACTGAC CCCCAAAATC GTGGCGGTGA TAAGCGAGTC TAATGATCCT 600 AATGAAATCA TCAAGTATAA AATAATAGGC ATTAAACCGG ACAGGCAAAA AATGGGCGTT 660 GTCTCTTATT CCGTGTTTCA AGCGTTTGAA AAGGCTTTGA GTCGGTTTAA AGAGGGCGTT 720 GTTTTTGATTG TGGATTCTTT AAGGCGTTTG ATTATGGGGA GCGCTTCAGT TAAAGAATTG 780 AGTGGGGTAA TAGGCATTGT GGGGGCGTTA AGCCATGCCA ATAGCGTGAG CATGCTTTTG 840 TTGTTTGGGG CGTTTTTATC TATCAATCTA GGGATTTTAA ATTTATTACC CATTCCAGCC 900 TTAGATGGGG CGCTTTTGCT AGGGGTCGTT TTTAAAAATA TTTTTCATAT CGCTTTGCCA 960 ACGCCCATAC AAAATGCGTT GTGGCTAGTG GGGGTGGGGT TTTTGGTTTT TGTCATGTTT 1020 TTAGGGCGGG TTAATGACAT TACTCGTTTG CTATAA 1056 [2) INFORMATION FOR SEC ID NO: 40: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 303 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 303 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 40: ATGCAAAAGA ATTTGGATAG TCTTTTAGAA AATTTAAGGG CTGAAATTGA TGCGTTGGAT 60 AATGAATTGA GCGATCTTTT AGACAAACGC TTAGGAATCG CTTTAAAAAT CGCTCTCATC 120 AAACAAGAAA GCCCCCAAGA AAACCCCATT TATTGCCCTA AAAGAGAGCA AGAGATTTTA 180 AAACGACTCA GCCAAAGGGG TTTCAAGCAT TTGAATGGAG AAATCCTTGC AAGTTTTTAT 240 GCAGAGGTTT TTAAGATTTC TAGAAATTTT CAAGAAAACG CCCTAAAAGA GTTAAAAAAA 300 TAA 303 (2) INFORMATION FOR SEQ ID NO: 41; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 525 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 525 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 41; GTGAAAATGC GTTTTTTTTAG TGGTTTTGGG TTTGTTAATG AAATCGTTTT GTTTGAAGAG 60 TGGCTTTTAA AAGGGGCTTA TGATGTGTCA GGCTTTTCTA TGGGGGCGAT TAAGGCGATA 120 GAATACGCCT ATAATGAAGT CTTGCAACAA CGGCGCATCC ATTCCTTATT GTTGTTTTCG 180 CCTTGCATGC TAGCGCATAA GAGTTTGGCG TTCAAACGCT TGCAACTTTT CTTGTTTCAA 240 AAAGATCCGC AAAGCTACAT GGATAACTTT TATAAGGAAG TGGGATTGGA CGCTCAATTG 300 GAGCGTTTTA AAAAAGAGGG TTCTTTAGAA GAATTGGAAT TTTTATTGGA TTACAAGTAT 360 AGTGATTCTA TAATTAGATT TTTATTGGAA AAGGGCGTGA AGATTGAAGT GTTTATCGGT 420 TTAAAAGATA GAATCACTGA CATTCAAGCC CTTTTAGAAT TTTTTATGCC CTTAGTTCAA 480 GTGTGGCAGT TTAAGGATTG TAACCATTTG TTGCAAAAAT CTTAA 525 (2) INFORMATION FOR SEQ ID NO: 42: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1416 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1416 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 42: ATGAAAAATA CCAATACAAA AGAGATAAAG AATACAAGGA TGAAAAAAGG TTATAGTCAA 60 TACCACACGC TCAAAAAAGG GCTTTTAAAA ACCGCTCTGC TTTTTAGCCT TCCTTTAAGC 120 GTGGCGTTAG CTGAAGACGA TGGCTTTTAT ATGGGAGTGG GCTATCAAAT CGGCGGCGCG 180 CAACAAAACA TCAACAACAA AGGCAGCACC CTAAGGAATA ATGTCATTGA TGATTTCCGC 240 CAAGTGGGCG TGGGTATGGC AGGGGGTAAT GGGCTTTTAG CTTTAGCGAC AAACACGACC 300 ATGGACGCTC TTTTAGGGAT AGGCAACCAA ATTGTCAATA CTAATACAAC TGTTGGCAAC 360 AACAACGCAG AGTTAACCCA GTTTAAAAAA ATACTCCCCC AAATTGAACA ACGCTTTGAG 420 ACGAATAAAA ACGCTTATAG CGTTCAAGCC TTGCAAGTGT ATTTGAGTAA TGTGCTTTAT 480 AACTTGGTTA ATAATAGTAA TAATGGTAGC AATAATGGAG TCGTTCCTGA ATATGTAGGG 540 ATTATAAAAG TTCTCTATGG TTCTCAAAAT GAATTCAGTC TCTTAGCCAC GGAGAGTGTG 600 GCGCTTTTAA ACGCGCTCAC GAGAGTGAAT CTGGATAGTA ATTCGGTGTT TTTAAAAGGG 660 CTATTAGCCC AAATGCAGCT TTTTAATGAC ACTTCTTCAG CAAAGCTAGG TCAGATCGCA 720 TAAAACTTGA AGAACGGTGG TGCAGGGGCC ATGCTTCAAA AGGATGTGAA AACCATCTCG 780 GATCGAATCG CTACTTACCA AGAGAATCTA AAACAGCTAG GAGGGATGTT AAAGAATTAC 840 GATGAGCCAT ACCTACCCCA ATTTGGGCCA GGCACAAGCT CTCAGCATGG GGTTATTAAT 900 GGCTTTGGCA TTCAAGTGGG CTATAAGCAA TTTTTTGGGA GCAAGAAGAA TATAGGCTTA 960 CGATATTACG CTTTCTTTGA TTATGGCTTT ACGCAATTGG GCAGTCTTAA CAGTGCTGTT 1020 AAAGCGAACA TCTTTACTTA TGGTGCTGGC ACGGACTTTT TATGGAATAT CTTTAGAAGG 1080 GTTTTTAGCG ATCAGTCCTT GAATGTGGGG GTGTTTGGGG GCATTCAAAT AGCGGGTAAC 1140 ACTTGGGATA GCTCTTTAAG AGGTCAAATT GAAAACTCGT TTAAAGAATA AAAAACTCCC 1200 ACGAATTTCC AATTTTTGTT TAATTGGGCG TTAAGGGCTC ATTTTGCCAG CACCATGCAC 1260 CGCCGGTTTT TGAGCGCGTC TCAAAGCATT CAGCATGGTA TGGAATTTGG CGTGAAAATC 1320 CCAGCTATCA ATCAAAGGTA TTTGAAAGCG AATGGGGCTG ATGTGGATTA CAGGCGTTTG 1380 TATGCGTTCT ATATCAATTA CACGATAGGT TTTTAA 1416 (2) INFORMATION FOR SEC ID NO: 43: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 390 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 390 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 43: ATGAAAAGCA TCAGAAGAGG CGATGGGCTG AATGTTGTCC CTTTCATTGA TATTATGCTC 60 GTCTTACTAG CGATTGTGTT GAGTATTTCT ACTTTTATCG CGCAAGGTAA GATTAAAGTC 120 AGTCTCCCTA ACGCTAAAAA TGCGGAAAAA TCCCAGCCAA ACGATCAAAA AGTGGTGGTC 180 ATCTCTGTGG ATGAGCATGA CAATATTTTC GTAGATGACA AACCGACGAA TTTAGAAGCT 240 TTGAGCGCTG TAGTCAAGCA AACAGACCCT AAAACCCTTA TAGATTTAAA AAGCGACAAG 300 AGCTCTCGTT TTGAAACTTT TATCAGCATT ATGGATATTT TAAAAGAGCA TAATCATGAA 360 AATTTCTCCA TCTCCACGCA AGCTCAGTAA 390 \ 2) INFORMATION FOR SEC ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 225 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 225 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 44: ATGCTCGTCT TACTAGCGAT TGTGTTGAGT ATTTGTACTT TTATCGCGCA AGGTAAGATT 60 AAAGTCAGTC TCCCTAACGC TAAAAATGCG GAAAAATCCC GACCAAACGA TCAAAAAGTG 120 GTGGTCATCT CTGTGGATGA GCATGACAT ATTTTCGTAG ATGACAAACC GACGAATTTA 180 GAAGCTTTGA GCGCTGTAGT CAAGCAAACA GACCCTAAAA CCCTT 225 (2) INFORMATION FOR SEQ ID NO: 45: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 672 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circularF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 672 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 45; ATGTTTTCAC TTTCTTATGT TTCCAAGAAA TTTTTAAGCG TGTTGCTATT GATTTCGCTG 60 TTTTTAAGCG CTTGCAAATC CAACAATAAA GACAAATTGG ATGAAAATCT TTTAAGCTCC 120 GGCACTCAAA GCTCCAAAGA ATTAAACGAC AAGCGAGACA ATATAGACAA AAAGAGCTAC 180 GCTGGTTTAG AAGATGTTTT TTTAGACAAC AAGTCCATTA GCCCTAATGA TAAATACATG 240 CTTTTAGTTT TTGGCCGTAA TGGTTGCTCC TATTGTGAAA GGCTTAAAAA AGATCTCAAA 300 AATGTCAAAG AATTGCGCAA CTATATTAAA GAGCATTTTA GTGCTTACTA TGTCAATATC 360 AGCTATTCTA AAGAGCATAA TTTTAAAGTC GGCGATAAGG ATAAAAATGA TGAAAAAGAA 420 ATCAAAATGT CCACAGAAGA ATTAGCGCAA ATTTATGCCG TCCAATCCAC CCCTACGATT 480 GTTTTATCCG ATAAAACCGG CAAAACCATC TATGAATTGC CGGGCTATAT GCCTTCTGTG 540 CAATTTTTAG CCGTGTTAGA ATTTATCGGC GATGGGAAGT ATCAAGACAC GAAAAACGAT 600 GAGGATCTCA CTAAAAAATT AAAGGCTTAC ATCAAGTATA AAACCAACCT TTCTAAGAGC 660 AAGTCCAGCT AG 672 (2) INFORMATION FOR SEQ ID NO: 46: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 351 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 351 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 46: TTGATGAAAT CTAAAATCAC TCATTTTATC GTTATCTCTT TTGTTTTAAG CGTGTTGAGC 60 GCCTGCAAAT ATGAGCCTAA AAAATCGTCC CAATCGCACC AAAACAACAC TAAAACCACT 120 CAAAACAATC AAATCAATCA ACCTAATAAG GATATAAAAA AGATTGAGCA TGAAGAAGAA 180 GATGAAAAAG TCACCAAAGA AGTGAATGAT CTGATCAATA ACGAAAATAA AATTGATGAA 240 ATCAATAATG AAGAAAACGC TGATCCTTCG CAAAAAAGAA CGAACAATGT TTTGCAACGA 300 GCCACTAACC ACCAAGACAA TCTCAGTTCC CCACTCAACA GGAAGTATTA A 351 (2) INFORMATION FOR SEQ ID NO: 47: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori dx) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 240 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 47 ATGTTTGAAA AAATACGCAA GATTTTAGCG GATATTGAAG ATTCGCAAAA TGAAATTGAA 60 ATGCTTTTAA AATTAGCGAA TTTGAGTTTG GGGGATTTTA TTGAGATTAA AAGAGGGAGC 120 ATGGACATGC CAAAGGGCGT GAATGAAGCG TTTTTTACGC AATTAAGCGA AGAAGTGGAG 180 CGCCTAAAGG AGCTTATCAA CGCTTTGAAT AAAATCAAAA AAGGGTTATT GGTGTTTTAA 240 (2) INFORMATION FOR SEQ ID NO: 48 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 156 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 156 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 48: ATGTCTATGT TCATTTCTAA TCTGGCTTTC ACGAGCGAAC ATAAGGACGC TATGGAAGTG 60 GCAAAAATTG CGATTTTACT CGGATCTTTG ATTTCTGGGA TCATAGGGGC TTTATATTTA 120 TTCGCACTAG ATAAAAGAGC GGCTTTAAAG AAATAG_156_(2) INFORMATION FOR SEQ ID NO: 49 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1350 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1350 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 49: ATGGGTTTGA AAATAAAAAT TTTAAGGTTG TCTATGAATC TCAAAAAAAC AGAAAACGCG 60 CTCAGTTTGA CGCTTAAAAA CTTCATTAAA AGCGAGTCTT TTGGAGGGAT TTTCCTCTTT 120 TTGAACGCCG TTTTAGCGAT GGTGGTGGCT AATTCGTTTT TAAAAGAAAG TTATTTTGCG 180CCCCTTTTGG GTTTCAAGTA GGGGATTTTT TTATCGGCTT TAGTTTGCAC 240 AACTGGATTG ATGATGTCTT AATGGCGTTA TTCTTTTTAA TGATAGGCTT AGAGATCAAG 300 CGAGAATTGT TGTTTGGGGA ATTATCCAGT TTTAAAAAAG CTTCTTTCCC TGTCATCGCA 360 GCCATAGGGG GCATGATAGC TCCAGGATTG ATTTATTTTT TTCTTAACGC CAACACGCCC 420 TCTCAGCATG GTTTTGGGAT CCCTATGGCA ACGGATATTG CGTTCGCTTT AGGCCTGATC 480 ATGCTTTTAG GCAAGAGGGT GCCAACCGCC TTAAAGGTTT TTTTAATCAC TCTAGCGGTG 540 GCTGATGACT TAGGGGCTAT TGTGGTGATC GCGCTCTTTT ATACCACGAA TTTAAAATTC 600 CCATGGCTTT TAGGGGCTTT AGGGGTGGTT CTTGTTTTAG CCATATTGAA CCGCCTGAAT 660 ATCCGATCGC TCATCCCTTA CTTGCTTTTA GGGG? GTTGC TTTGGTTTTG CGTGCATCAA 720 AGCGGTATCC ATGCGACGAT CGCTGCGGTG GTTCTAGCTT TTATGATACC GGTGAAAATC 780 CCTAAAGATT CTAAAAATGT AGAGCTTTTG GAATTAGGCA AACGATACGC ACAGACGAGT 840 TCAGGAGTGC TTTTAACCAA AGAGCAGCAA GAAATCTTGC ATTCTATTGA AGAAAAAGCG 900 AGTGCTTTAC AAAGCCCCTT AGAAAGATTG GAGCATTTTC TAGCCCCCAT CAGCGGGTAT 960 TTCATCATGC CCTTATTCGC GTTTGCAAAC GCTGGGGTGA GCGTTGATTC TAGCATCAAT 1020 TTAGAAGTGG ATAAGGTGCT TTTAGGGGTT ATTTTAGGGC TTTGTTTGGG CAAGCCTTTA 1080 GGGATTTTCT TAATCACTTT CATAAGCGAA AAGCTTAAAA TCACTGCGCG CCCTAAAGGC 1140 ATCGGCTGGT GGCATATTTT AGGGGCTGGG CTTTTAGCAG GGATTGGCTT TACCATGTCT 1200 ATGTTCATTT CTAATCTGGC TTTCACGAGC GAACATAAGG ACGCTATGGA AGTGGCAAAA 1260 ATTGCGATTT TACTCGGATC TTTGATTTCT GGGAGCATAG GGGCTTTATA TTTATTCGCA 1320 GTAGATAAAA GAGCGGCTTT AAAGAAATAG_1350_(2) INFORMATION FOR SEQ ID NO: 50 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2448 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc__characteristic (B) LOCATION: 1 ... 2448 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 50 ATGAATGACA AGCGTTTTAG AAAATATTGT AGTTTTTCTA TTTTTTTGTC CTTATTAGGA 60 ACGTTTGAAT TAGAGGCTAA AGAAGAAGAA AAAGAAGAAA AAAAGACAGA AAGGAACAAA 120 GATAAAGAAA AGAACGCCCA ACACACTTTG GGTAAAGTTA CCACTCAAGC GGCTAAAATC 180 TTTAATTACA ACAACCAGAC AACCATTTCA AGTAAAGAAT TAGAAAGAAG GCAAGCCAAC 240 CAAATCAGCG ACATGTTTAG AAGAAACCCC AATATCAATG TGGGCGGTGG TGCGGTGATA 300 GCGCAAAAAA TTTACGTGCG CGGTATTGAA GACAGATTGG CTAGGGTTAC GGTGGATGGC 360 GTGGCGCAAA TGGGCGCAAG CTATGGGCAT CAAGGCAATA CAATCATTGA CCCTGGAATG 420 CTCAAAAGCG TGGTGGTTAC CAAGGGGGCG GCTCAAGCGA GCGCGGGGCC TATGGCTTTA 480 ATTGGCGCGA 'TCAAAATGGA GACTAGGAGC GCGAGCGATT TTATCCCTAA AGGCAAAGAC 540 TACGCCATAA GTGGGGCTGC CACTTTTTTA ACCAACTTTG GGGATAGGGA AACCATTATG 600 GGCGCTTATC GTAACCATCA TTTTGATGCG CTTTTGTATT ACACGCACCA AAATATTTTT 660 TATTATCGTG ATGGGGATAA CGCGATGAAA AATCTTTTTG ACCCTAAAGC GGATAATAAA 720 GTTACAGCAA GCCCTAGCGA ACAAAACAAT GTGATGGCTA AGATCAATGG TTATTTGAGC 780 GAAAGGGATA CCTTAACGCT CAGTTATAAC ATGACTAGAG ATAACGCCAA TCGCCCTTTA 840 AGAGCGAATT TTACCGGCAC TTTTTTTACCC TATTCTTGTG GTGATTTCAA CGCTTTCCCT 900 AACGAGAAAA ACCCTAGCGA TTGTTTGTTT GAAAATGACG CCAGTTTGTT TAAAACTTAT 960 AGCGTCAATT TAGTGCATAA CGTGAGCTTG AATTATGAAA GGGAAGGGGG GAGTCGCTTT 1020 GGCGATCCTA AATTAAAAAT CAATGGCTAC ACGAGCATTA GGAATGTCCA AATTGATCCG 1080 CTTTTCAGAC CTAGCGATAT AGCGACTACC ATTCCTTTCA CCCCAAACCC GCAGCTCTCT 1140 CAAGGCGAAG AAAATCAATG CGTGGCGCAA GGGGGCATTT ATGACGCTCT TAAACAAACT 1200 TGCTCCATCA CTTTTAAAAG CCTTGGAGGC GGTTCTGTTG TCGCTAATAA AAATTTATTC 1260 ATCATCAATT CTGGGTTTAA TGCGAACGTG ATCCACACCA TAGACCACAA GAATGACAAT 1320 CTTTTGGAAT ACGGGTTGAA TTACCAGAAT TTAACCACTT TTGATAAAGC GATCCCTGAT 1380 AGCGAATTAG TCAAGCCCGG CGATGCCCCT GATGCGTGCT TAAGAGTTAC AGGACCTGAT 1440 GATCCTAACA TGAACGGGCG CTGCCAACGG AATGGCGCTA CGGCGAATGT GGTTGGGGTG 1500 TATGCGCAAG CGAATTACAC CTTGCACCCT ATGGTAACTT TAGGGGCAGG GACTCGTTAT 1560 GACGTTTATA CTTTAGTGGA TAAAGACTGG CAATTGCACG TAACTCAAGG GTTTAGCCCT 1620 AGCGCGGCTT TAAACGTCTC GCCTTTAGAA AATTTGAATT TCAGGCTTTC TTACGCGTAT 1680 GTAACTAGAG GCCCTATGCC TGGAGGTTTG GTGTGGATGC GTCAAGACAA TTTGCGCTAT 1740 AACCGCAATT TAAAGCCAGA AATTGGGCAA AATGCGGAAT TTAACAGGGA ATACAGCAGT 1800 CAGTATTTTG ATTTCAGAGC CGCCGGTTTT GTCCAATTGA TTTCTAATTA CATCAATCAA 1860 TTTTCTTCAA CGCTTTTTGT CACCAACTTG CCCGCACAAG ATATTATTTA TGTGCCTGGC 1920 TATGAAGTTT CAGGGACGGC TAAATACAAG GGTTTTTCTT TAGGCTTGAG CGTGGCGCGA 1980 TCATGGCCTT CTTTAAAAGG GCGTTTGATC GCTGACGTGT ATGAATTGGC GGCTACGACA 2040 GGCAATGTGT TTATTTTAAC GGCAAGCTAT ACAATCCCAC GCACCGGCCT TAGCATCACT 2100 TGGCTTTCAC GCTTTGTTAC TAATTTGAGT TATTGCTCTT ATAGCCCTTA TCGTAACGGC 2160 CCTACGGATA TTGACAGAAG GCCTAGTAAT TGCCCTAAAA CGCCCGGGAT TTTTCATGTG 2220 CATAAACCCG GCTATGGGGT GAGCAGTTTC TTTATCACTT ACAAGCCTAC TTATAAGAAA 2280 CTCAAAGGGT TGAGCCTGAA CGCGGTGTTT AATAATGTTT TTAACCAACA ATATATTGAT 2340 CAAGCAAGCC CGGTGATGAG CCCTGATGAA CCCAATCAAG ACAAATACGC AAGGGGCATG 2400 GCAGAGCCTG GCTTTAACGC TAGGTTTGAA ATTTCTTATA AGTTTTAA 2448 (2) INFORMATION FOR SEQ ID NO: 51: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2445 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 2445 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 51: ATGACAAGCG TTTTAGAAAA ATATTGTAGT TTTTCTATTT TTTTGTCCTT ATTAGGAACG 60 TTTGAATTAG AGGCTAAAGA AGAAGAAAAA GAAGAAAAAA AGACAGAAAG GAACAAAGAT 120 AAAGAAAAGA ACGCCCAACA CACTTTGGGT AAAGTTACCA CTCAAGCGGC TAAAATCTTT 180 AATTACAACA ACCAGACAAC CATTTCAAGT AAAGAATTAG AAAGAAGGCA AGCCAACCAA 240 ATCAGCGACA TGTTTAGAAG AAACCCCAAT ATCAATGTGG GCGGTGGTGC GGTGATAGCG 300 CAAAAAATTT ACGTGCGCGG TATTGAAGAC AGATTGGCTA GGGTTACGGT GGATGGCGTG 360 GCGCAAATGG GCGCAAGCTA TGGGCATCAA GGCAATACAA TCATTGACCC TGGAATGCTC 420 AAAAGCGTGG TGGTTACCAA GGGGGCGGCT CAAGCGAGCG CGGGGCCTAT GGCTTTAATT 480 GGCGCGATGA AAATGGAGAC TAGGAGCGCG AGCGATTTTA TCCCTAAAGG CAAAGACTAC 540 GCCATAACTG GGGCTGCCAC TTTTTTAACC AACTTTGGGG ATAGGGAAAC CATTATGGGC 600 GCTTATCGTA ACCATCATTT TGATGCGCTT TTGTATTACA CGCACCAAAA TATTTTTTAT 660 TATCGTGATG GGGATAACGC GATGAAAAAT CTTTTTGACC CTAAAGCGGA TAATAAAGTT 720 ACAGCAAGCC CTAGCGAACA AAACAATGTG ATGGCTAAGA TCAATGGTTA TTTGAGCGAA 780 AGGGATACCT TAACGCTCAG TTATAACATG ACTAGAGATA ACGCCAATCG CCCTTTAAGA 840 GCGAATTTTA CCGGCACTTT TTTACCCTAT TCTTGTGGTG ATTTCAACGC TTTCCCTAAC 900 GAGAAAAACC CTAGCGATTG TTTGTTTGAA AATGACGCCA GTTTGTTTAA AACTTATAGC 960 GTCAATTTAG TGCATAACGT GAGCTTGAAT TATGAAAGGG AAGGGGGGAG TCGCTTTGGC 1020 GATCCTAAAT TAAAAATCAA TGGCTACACG AGCATTAGGA ATGTCCAAAT TGATCCGCTT 1080 TTCAGACCTA GCGATATAGC GACTACCATT CCTTTCACCC CAAACCCGCA GCTCTCTCAA 1140 GGCGAAGAAA ATCAATGCGT GGCGCAAGGG GGCATTTATG ACGCTCTTAA ACAAACTTGC 1200 TCCATCACTT TTAAAAGCCT TGGAGGGGGT TCTGTTGTCG CTAATAAAAA TTTATTCATC 1260 ATCAATTCTG GGTTTAATGC GAACGTGATC CACACCATAG ACCACAAGAA TGACAATCTT 1320 TTGGAATACG GGTTGAATTA CCAGAATTTA ACCACTTTTG ATAAAGCGAT CCCTGATAGC 1380 GAATTAGTCA AGCCCGGCGA TGCCCCTGAT GCGTGCTTAA GAGTTACAGG ACCTGATGAT 1440 CCTAACATGA ACGGGCGCTG CCAACGGAAT GGCGCTACGG CGAATGTGGT TGGGGTGTAT 1500 GCGCAAGCGA ATTACACCTT GCACCCTATG GTAACTTTAG GGGCAGGGAC TCGTTATGAC 1560 GTTTATACTT TAGTGGATAA AGACTGGCAA TTGCACGTAA CTCAAGGGTT TAGCCCTAGC 1620 GCGGCTTTAA ACGTCTCGCC TTTAGAAAAT TTGAATTTCA GGCTTTCTTA CGCGTATGTA 1680 ACTAGAGGCC CTATGCCTGG AGGTTTGGTG TGGATGCGTC AAGACAATTT GCGCTATAAC 1740 CGCAATTTAA AGCCAGAAAT TGGGCAAAAT GCGGAATTTA ACACCGAATA CAGCAGTCAG 1800 TATTTTGATT TCAGAGCCGC CGGTTTTGTC CAATTGATTT CTAATTACAT CAATCAATTT 1860 TCTTCAACGC TTTTTGTCAC CAACTTGCCC GCACAAGATA TTATTTATGT GCCTGGCTAT 1920 GAAGTTTCAG GGACGGCTAA ATACAAGGGT TTTTCTTTAG GCTTGAGCGT GGCGCGATCA 1980 TGGCCTTCTT TAAAAGGGCG TTTGATCGCT GACGTGTATG AATTGGCGGC TACGACAGGC 2040 AATGTGTTTA TTTTAACGGC AAGCTATACA ATCCCACGCA CCGGCCTTAG CATCACTTGG 2100 CTTTCACGCT TTGTTACTAA TTTGAGTTAT TGCTCTTATA GCCCTTATCG TAACGGCCCT 2160 ACGGATATTG ACAGAAGGCC TAGTAATTGC CCTAAAACGC CCGGGATTTT TCATGTGCAT 2220 AAACCCGGCT ATGGGGTGAG CAGTTTCTTT ATCACTTACA AGCCTACTTA TAAGAAACTC 2280 AAAGGGTTGA GCCTGAACGC GGTGTTTAAT AATGTTTTTA ACCAACAATA TATTGATCAA 2340 GCAAGCCCGG TGATGAGCCC TGATGAACCC AATCAAGACA AATACGCAAG GGGCATGGCA 2400 GAGCCTGGCT TTAACGCTAG GTTTGAAATT TCTTATAAGT TTTAA 2445 (2) INFORMATION FOR SEC ID NO: 52: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1584 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) dii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 1584 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 52: ATGAAACAAA ATTTAAAGCC ATTCAAAATG ATTAAGGAAA ATTTAATGAC ACAATCTCAA 60 TTTGTAAGAT TCTTAGCCCC TTTGAGCCTA GCGTTAAGCT TGAGCTTCAA TCCAGTGGGC 120 GCTGAAGAAG ATGGGGGCTT TATGACCTTT GGGTATGAAT TAGGTCAGGT GGTCCAGCAA 180 GTGAAAAACC CGGGTAAAAT CAAAGCCGAA GAATTAGCGG GCCTGTTAAA CTCTACCACG 240 ACAAACAACA CCAATATCAA TATTGCAGGC ACAGGAGGGA ATGTCGCCGG GACTTTGGGC 300 AACCTTTTTA TGAACCAATT GGGCAATTTG ATTGATTTGT ATCCTACTTT GAAAACTAAT 360 AATCTTCACC AATGCGGTAG CACTAATAGC GGTAATGGCG CTACTGCTGC CGCTGCTACT 420 AACAATAGCC CTTGTTTCCA AGGTAACCTG GCTCTTTATA ACGAAATGGT TGACTCTATC 480 AAAACTTTGA GTCAAAACAT CAGCAAGAAC ATCTTTCAAG GCGACAACAA CACCACGAGC 540 GCTAATCTCT CCAACCAGCT CAGTGAGTTG AACACCGCTA GCGTTTATTT GACTTACATG 600 AACTCGTTCT TAAACGCCAA CAACCAAGCG GGTGGGATTT TTCAAAACAA CACCAATCAA 660 GCTTACGAGA ATGGTGTTAC CGCTCAACAA ATCGCTTATG TCCTAAAGCA AGCTTCAATC 720 ACTATGGGGC CAAGCGGTGA TAGTGGGGCT GCGGGAGCGT TTTTAGACGC CGCTTTAGCC 780 CAACATGTTT TCAACTCGGC TAACGCTGGG AACGATTTGA GCGCTAAGGA ATTCACTAGC 840 TTGGTGCAAA ACATCGTCAA TAATTCTCAA AACGCTTTAA CGCTAGCCAA CAACGCTAAC 900 ATCAGCAATT CAACAGGCTA TCAAGTGAGC TATGGTGGGA ATATTGATCA AGCGCGCTCT 960 ACCCAACTGT TAAACAACAC CACAAACACT TTGGCTAAAG TTACCGCTCT AAACAACGAG 1020 CTTAAAGCTA ACCCATGGCT TGGGAATTTC GCTGCTGGTA ACAGCTCTCA AGTGAATGCG 1080 TTTAACGGGT TTATCACTAA AATCGGTTAT AAGCAATTCT TCGGGGAAAA CAAGAATGTG 1140 GGCTTACGCT ACTACGGGTT CTTCAGCTAT AACGGCGCGG GCGTGGGTAA TGGCCCCACT 1200 TACAATCAAG TCAATCTGCT CACTTATGGG GTGGGGACTG ATGTGCTTTA CAATGTGTTT 1260 AGCCGCTCTT TTGGCAGTAG GAGTCTTAAT GCGGGCTTCT TTGGGGGTAT CCAACTCGCA 1320 GGGGACACTT ACATCAGCAC GCTAAGAAAC AGCCCTCAGC TTGCGAGCAG ACCTACAGCG 1380 ACAAAATTCC AATTCTTGTT TGATGTGGGC TTACGCATGA ACTTTGGTAT CTTGAAAAAA 1440 GACCTAAAAA GCCATAACCA GCATTCTATA GAAATCGGTG TGCAAATCCC TACGATTTAC 1500 AACACTTACT ATAAAGCTGG TGGCGCTGAA GTGAAATACT TCCGCCCTTA TAGCGTGTAT 1560 TGGGTCTATG GCTACGCCTT CTAA 1584 (2) INFORMATION FOR SEQ ID NO: 53; I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1380 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 1380 * (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 53: GTGGTGTTAT TAACAATGAC AAAACGACTT TTTAAAGGGT TGTTAGGGAT TTCTCTTGCG 60 GTGAGTTTGC ATGGTGGTGA AGTTAAGGAA AAAAAGCCGG TCAAGCCGGT CAAAGAAGAT 120 CCGCAAGAAT TAGCGGCTAA AAGGGTGGAA GCGTTCAGTC GTTTCTCTAA TGTGGTTACA 180 GAAATTGAAA AAAAGTATGT GGATAAGATC AGTATTTCTG AGATCATGAC TAAAGCGATT 240 GAAGGCTTAC TCTCTAATTT GGACGCGCAT TCAGCGTATT TGAATGAAAA GAAGTTTAAG 300 GAATTTCAGG CCCAAACCGA GGGCGAATTT GGGGGGCTTG GGATCACGGT GGGCATGCGC 360 GATGGCGTTT TGACCGTTAT TGCACCTTTA GAGGGCACTC CAGCTTACAA GGCTGGGGTT 420 AAATCAGGCG ATAGCATTTT AAAAATCCAT AACGAAAGCA CGCTGAGCAT GAGCATTGAT 480 GATGCGGTTA ATCTCATGCG CGGCAAGCCA AAAACCTCTA TTCAGATCAC TGTTGTTAGG 540 AAAAATGAGC CAAAACCCTT GGTATTTAAT ATCCTTAGGG ATATTATCAA GATCCCCTCT 600 GTCTATGTGA AAAAGATTAA AGACACACCT TATTTGTACG TGAGAGTCAA TTCTTTTGAT 660 AAAAATGTTA CCAAATCGGT TTTAGACGGC TTGAAGGCTA ACCCTAACAT TAAGGGCGTT 720 GTGTTGGATT TGAGGGGGAA TCCTGGAGGG CTATTAAACC AGGCGGTAGG CTTGTCTAAC 780 CTTTTCATTA AAGAGGGGGT TTTAGTCTCT CAAAGAGGCA AAAATAAGGA GGAAAACTTA 840 GAATACAAGG CTAATGGCAG AGCCCCTTAT ACCAATTTAC CTGTTGTGGT GTTAGTCAAT 900CGAGCGCGAG CGAGATCGTC GCAGGGGCAC TGCAAGATCA CAAGCGAGCC 960 ATCATTATCG GTGAAAAAAC CTTTGGTAAG GGAAGCGTGC AAGTGTTGCT CCCTGTCAAT 1020 AAAGACGAAG CCATTAAAAT CACGACCGCG CGCTATTATT TGCCGAGCGG GCGCACCATT 1080 CAAGCTAAGG GGATCACGCC TGATATTGTG ATTTATCCGG GTAAAGTGCC AGAAAATGAA 1140 AATAAATTCA GTTTGAAAGA AGCGGATTTA AAACACCATT TAGAGCAAGA GCTTAAAAAA 1200 CTTGATGATA AAACCCCTAT TTCCAAAGAG GCGGATAAAG ACAAGAAAAG CGAAGAGGAA 1260 AAAGAGGTTA CTCCTAAAAT GATCAATGAT GATATTCAGC TAAAAACCGC TATTGACAGC 1320 TTGAAAACCT GGTCTATCGT AGATGAGAAA ATGGATGAAA AAGTGCCTAA GAAGAAATAA 1380 (2) INFORMATION FOR SEQ ID NO: 54: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 315 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 315 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 54: TTGCTTTTGC ACCCCTTGCA TGCTCATGCA CAAGTGCTTG GCTTCACAAA CCACGATCAC 60 GCCCCTTGGC TCTATGATTT CATCAAAAGT TTCTGCAATT TGAGTGGTCA GCCTTTCTTG 120 GATTTGCAGG CGTTTGCTAT AAATTTCAAT GAGTTTAGCG ATCGCGCTAA TGCCTACAAT 180 CTTTTCCTTA GGGATATATC CCACGCTAAT ATTCCCAAAA AAAGGGAGCA AATGGTGCTC 240 GCAAGTGGAG TAAAATTCAA TGTTTTGAGC CACTATCATT TCATCGCAAA CGCCTTGAAA 300 ATACGCGCTT TTTAA 315 (2) INFORMATION FOR SEC ID NO: 55: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 498 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: mise characteristic (B) LOCATION: 1 ... 498 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 55: ATGATTGAAC TAATCTTACA CAATAAGTCC ATACAAATTG ATGAAACATT GCTGAATGTA 60 AAAGAGCATT TAGAAAAGTT TTATTCAAAC AAAGAACAAG AGACAATCGC AAAAACCTTA 120 GAGAGCCAAA CAGAGCTTAC TTGCAGTTAT TTATTGGATA AAGATTTTTC ATTGCTAGAA 180 AAGCATTTAG AAAATAGCTT AGGGCATTTT ACTTTTGAGA GTGAGTTTGC CCTACTAAAA 240 GACAAAGAGC CTTTGAATTT AGCTCAAATC AAACAAATCG GTGTTTTAAA GGTTATTACC 300 TATGAAATGA CACAAGCCTT AAAAAATCAA ATCATTCATT TAACGCAAAT TGTCAATGAA 360 GAAAAATTAG AGTTTGATGA AGAACTTGTT ATTTATCACT TAAATTTTAA GCTCAATCAA 420 AATACTTACA AAGTGTTAGC GAAATTTTGC GTATTAAAAA AGAAAGGAAC ATTGCATGAA 480 AAATTTAAGG CATTTTAG_498_2) INFORMATION FOR SEC ID NO: 56: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 642 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: mise_característica (B) LOCATION: 1 ... 642 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 56: ATGGATACCG AAACACAAGA AAAGTTTTTA GCGTATTTGT TTGAAAAAGC TTTACAAAAA 60 AATCTACAAG CTTATTGGAT AACAACAACT GAAACTAAGA ATGAATTAAC AAGAGAAGAG 120 TTTTCAAATT TAATAAGAAA AACAATGATT GAACTAATCT TACACAATAA GTCCATACAA 180 ATTGATGAAA CATTGCTGAA TGTAAAAGAG CATTTAGAAA AGTTTTATTC AAACAAAGAA 240 CAAGAGACAA TCGCAAAAAC CTTAGAGAGC CAAACAGAGC TTACTTGCAG TTATTTATTG 300 GATAAAGATT TTTCATTGCT AGAAAAGCAT TTAGAAAATA GCTTAGGGCA TTTTACTTTT 360 GAGAGTGAGT TTGCCCTACT AAAAGACAAA GAGCCTTTGA ATTTAGCTCA AATCAAACAA 420 ATCGGTGTTT TAAAGGTTAT TACCTATGAA ATGACACAAG CCTTAAAAAA TCAAATCATT 480 CATTTAACGC AAATTGTCAA TGAAGAAAAT TTAGAGTTTG ATGAAGAACT TGTTATTTAT 540 CACTTAAATT TTAAGCTCAA TCAAAATACT TACAAAGTGT TAGCGAAATT TTGCGTATTA 600 AAAAAGAAAG GAACATTGCA TGAAAAATTT AAGGCATTTT AG 642 (2) INFORMATION FOR SEQ ID NO: 57: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 762 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 762 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 57: ATGGCGATCT CTATTAAAAG CCCAAAAGAA ATCAAAGCCC TAAGAAAAGC CGGGGAATTA 60 ACCGCTCAAG CGTTAGCCCT TTTAGAGCGA GAAGTAAGGC CTGGGGTTTC ACTTTTAGAG 120 CTGGATAAAA TGGCTGAAGA TTTTATCAAA TCCTCGCATG CTAGGCCTGC TTTTAAGGGG 180 CTCTATGGTT TCCCTAACTC TGTGTGCATG TCCTTAAATG AGGTGGTTAT TCATGGTATT 240 CCTACGGATT ATGTTTTACA AGAAGGGGAT ATTATAGGCT TGGATTTGGG GGTGGAGGTG 300 GATGGCTATT ATGGCGATTC AGCCCTCACG CTTCCCATAG GCGCGATAAG CCCGCAAGAT 360 GAAAAATTGC TCGCTTGCTC TAAAGAGAGC TTGATGCATG CCATTAGCTC AATTAGAGTG 420 GGCATGCATT TTAAAGAGTT GAGTCAGATT TTAGAGGGCG CTATTACAGA AAGGGGCTTT 480 GTGCCTTTGA AGGGATTTTG CGGGCATGGC ATTGGTAAAA AGCCCCATGA AGAGCCAGAA 540 ATCCCCAACT ACCTAGAAAA AGGCGTCAAA GCTAATAGCG GCCCTAAAAT CAAAGAGGGC 600 ATGGTGTTTT GTTTAGAGCC TATGGTGTGT CAAAAACAAG GCGAGCCTAA AATACTAGCG 660 GATAAGTGGA GCGTGGTTTC AGTGGATGGA CTTAACACAA GCCACCATGA GCATACTATC 720 GCCATAGTTG GCAATAAAGC AGTGATTCTT ACGGAGCGTT AA 762 (2) INFORMATION FOR SEQ ID NO: 58: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 744 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 744 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 58: AAGCCCAAAA GAAATCAAAG CCCTAAGAAA AGCCGGGAAT TAACCGCTCA AGCGTTAGCC 60 CTTTTAGAGC GAGAAGTAAG GCCTGGGGTT TCACTTTTAG AGCTGGATAA AATGGCTGAA 120 GATTTTATCA AATCCTCGCA TGCTAGGCCT GCTTTTAAGG GGCTCTATGG TTTCCCTAAC 180 TCTGTGTGCA TGTCCTTAAA TGAGGTGGTT ATTCATGGTA TTCCTACGGA TTATGTTTTA 240 CAAGAAGGGG ATATTATAGG CTTGGATTTG GGGGTGGAGG TGGATGGCTA TTATGGCGAT 300 TCAGCCCTCA CGCTTCCCAT AGGCGCGATA AGCCCGCAAG ATGAAAAATT GCTCGCTTGC 360 TCTAAAGAGA GCTTGATGCA TGCCATTAGC TCAATTAGAG TGGGCATGCA TTTTAAAGAG 420 TTGAGTCAGA TTTTAGAGGG CGCTATTACA GAAAGGGGCT TTGTGCCTTT GAAGGGATTT 480 TGCGGGCATG GCATTGGTAA AAAGCCCCAT GAAGAGCCAG AAATCCCCAA CTACCTAGAA 540 AAAGGCGTCA AAGCTAATAG CGGCCCTAAA ATCAAAGAGG GCATGGTGTT TTGTTTAGAG 600 CCTATGGTGT GTCAAAAACA AGGCGAGCCT AAAATACTAG CGGATAAGTG GAGCGTGGTT 660 TCAGTGGATG GACTTAACAC AAGCCACCAT GAGCATACTA TCGCCATAGT TGGCAATAAA 720 GCAGTGATTC TTACGGAGCG TTAA 744 (2) INFORMATION FOR SEQ ID NO: 59: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1023 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 1023 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 59: ATGTATCGTA AAGATTTGGA TAATTACTTA AAACAGCGCC TCCCTAAAGC GGTGTTTTTG 60 TATGGGGAGT TTGATTTTT CATCCATTAT TATATTCAAA CGATTAGCGC GCTTTTTAAAA 120 GGCAATAACC CTGACACAGA AACTTCGCTT TTTTATGCGA GCGATTATGA AAAAAGCCAG 180 ATTGCGACCC TTTTAGAGCA GGATTCTTTA TTTGGAGGGA GCAGTTTAGT TATTTTAAAA 240 CTGGATTTTG CATTGCATAA GAAATTTAAG GAAAATGATA TCAATCCTTT TTTAAAAGCT 300 TTAGAGCGGC CTAGCCATAA TAGGCTTATC ATAGGGCTTT ATAATGCTAA AAGCGACACC 360 ACAAAATACA AATACACTAG CGAAATTATC GTTAAATTTT TCCAAAAAAG CCCCTTGAAA 420 GATGAAGCCA TTTGCGTGCG CTTTTTTACC CCTAAAGCGT GGGAGAGTTT GAAATTCTTG 480 CAAGAAAGGG CTAATTTTTT GCATTTAGAC ATCAGCGGCC ATCTTTTAAA CGCTCTTTTT 540 GAAATTAATA ACGAAGATTT AAGCGTTTCG TTTAACGATT TAGACAAGCT AGCGGTTTTA 600 AACGCGCCCA TCACTTTAGA AGACATTCAA GAATTAAGCT CCAATGCGGG GGATATGGAT 660 TTGCAAAAGC TCATTTTAGG GCTTTTTTTG AAAAAAAGCG TCCTTGATAT TTATGATTAT 720 TTGTTAAAAG AGGGCAAAAA GGATGCGGAT ATTTTAAGGG GGTTAGAGCG CTATTTTTAC 780 CAGCTTTTTT TATTTTTCGC CCACATTAAA ACGACCGGTT TAATGGACGC TAAAGAGGTC 840 TTAGGCTACG CTCCTCCTAA AGAGATTGTA GAAAATTACG CTAAAAACGC CCTGCGTTTG 900 AAAGAAGCCG GCTATAAGAG GGTTTTTGAA ATTTTTAGGT TATGGCACCT TCAAAGCATG 960 CAAGGGCAAA AGGAATTGGG CTTTTTGTAT TTGACCCCCA TTCAAAAAAT CATTAACCCT 1020 TGA 1023 (2) INFORMATION FOR SEC ID NO: 60: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 603 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 603 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 60: GTGTTTATGA CAAGCGCTCT GTTAGGCTTA CAAATTGTTT TAGCGGTATT GATTGTGGTG 60 GTGGTTTTGT TGCAAAAAAG TTCTAGCATC GGCTTAGGGG CTTATAGCGG AAGCAACGAT 120 TCTTTATTTG GCGCTAAAGG GCCCGCAAGC TTTATGGCGA AATTGACCAT GTTTTTAGGT 180 TTATTGTTTG TCATCAACAC CATCGCTTTG GGCTATTTTT ACAACAAAGA ATACGGCAAG 240 AGCGTTTTAG ATGAAACTAA AACCAATAAA GAGCTTTCGC CCTTAGTCCC TGCCACCGGC 300 ACGCTCAACC CTACGCTTAA TCCCACATTA AACCCAACGC TCAACCCTTT AGAGCAAGCC 360 CCCACTAATC CTTTAATGCC TACACAAACG CCTAAAGAGC TTCCTAAAGA GCCAGCCAAA 420 ACGCCTTTTG TTGAAAGCCC CAAACAGAAT GAAAAGAATG AAAAGAATGA TGCCAAAGAA 480 AATGGTATAA AGGGTGTTGA AAAAAACAAA GAGAACGCCA AAACGCCCCC AACCACCCAC 540 CAAAAGCCTA AAACGCATGC GACAACCAAC GCCCATACCA ACCAAAAAAA GGATGAAAAA 600 TAA 603 (2) INFORMATION FOR SEQ ID NO: 61: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 480 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: mise characteristic (B) LOCATION: 1 ... 480 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 61: ATGCGTTCTC CAAATTTAGA AAAAGAAGAA ACTGAAATCA TAGAAACGCT TCTTGTGCGT 60 GAAAAAATGC GTTTATGCCC CTTGTATTGG CGCATCTTAG CGTTTTTTAAT CGATAGTTTA 120 TTGGTGGCGT TTTTATTGAG CGATCTTTTA AGGGCATGCG CTTTTTTTACA TTCTTTATAT 180 TGGCTGACTA ACCCCATTTA TTACAGCGCG TTTGTTGTGA TGGGTTTTAT CATCTTGTAT 240 GGCGTTTATG AAATCTTTTT TGTGTGTTTG TGCAAGATGA GTTTGGCTAA ACTGGTTTTT 300 AGGATTAAGA TCATTGATAT TTATTTAGCG GATTGCCCCA GTAGGGCTAT TTTATTGAAG 360 CGTTTAGGGT TAAAAATCGT GGTTTTTTCTA TGCCCCTTTT TATGGTTTGT GGTGTTTAAA 420 AACCCCTATC ATAGGGCATG GCATGAAGAA AAAAGCAAAA GTCTTTTGGT GTTGTTTTAA 480 (2) INFORMATION FOR SEQ ID NO: 62: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 705 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 705 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 62: TTGAATACGG ACTTTAGCCA TATCACCGAT ATTGAGGGCA TGCGTTTTGT TAATGAAGAA 60 GACGCTTTAA ACAAATTGAT TAATGAAATC CACACGCGCC ACATTGATTT AAAAGATTCC 120 ATCATGCTCG CTTTGAGTTT TAACGCCTTG TATTTAGCTA ACGCTTTAGC GCAAAAATTT 180 GGGGCGACTT ATGATATACT TTTTTTAGAA CCTATCTTAG CCCCTTTAAA CTCAAAGTGT 240 GAAATCGCTT TAGTGAGTGA AAGCATGGAT ATAGTGATGA ATGAAAGTTT AATCAATTCC 300 TTTGACATCG CTTTAGACTA TGTTTATGGG GAAGCCAAGC GGGCTTATGA AGAAGACATT 360 CTGTCTCACA TCTATCAGTA TCGCAAAGGC AATGCGATCA AAAGCCTAAA AGATAAAAAT 420 ATTTTTTATCG TAGATAGGGG GATTGAGACC GGGTTTAGAG CAGGGTTAGG CGTGCAAACT 480 TGTTTGAAAA AAGAATGCCA AGACATÍTAT ATTTTAACCC CCATTCTCGC GCAAAATGTC 540 GCTCAAGGCT TAGAAAGCTT GTGCGATGGG GTGATTAGCG TGTATCGCCC TGAATGTTTT 600 GTCTCTGTGG AACACCATTA TAAAGAACTC AAGCGATTAA GCAATGAAGA AATTGAAAAA 660 TACTTGGGCG CTAACAACGC GCCCAATCTC AAAAAGGAAC ATTAA 705 (2) INFORMATION FOR SEQ ID NO: 63: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 864 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 864 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 63: TTGAAACAAA GCGAAATGGC CATGGAATTT AATGATCCTA GGATGCGTTT TTTTATTGGC 60 GATGTCAGGG ATTTAGAACG CTTGAATTAC GCTTTAGAGG GCGTGGATAT TTGTATCCAT 120 GCGGCCGCGC TCAAGCATGT GCCTATCGCT GAATACAACC CCCTAGAATG CATTAAAACT 180 AACATCATGG GAGCGAGCAA TGTGATTAAC GCATGCTTAA AAAATGAAAT CAGCCAGGTT 240 ATTGCCCTAA GCACCGATAA AGCCGCTAAC CCCATTAACC TCTACGGCGC AACCAAATTG 300 TGCAGCGACA AGCTCTTTGT GAGCGCGAAC AACTTTAAAG GCCCTTCTCA AACGCAATTT 360 GGCGTGGTGC GTTATGGTAA TGTGGTGGGG AGTCGTGGGA GCGTGGTGCC GTTTTTTAAA 420 AAATTAGTCC AAAACAAAGC GAGTGAAATC CCCATTACCG ATATTCGCAT GACACGATTT 480 TGGATCACCT TAGATGAGGG GGTTTCTTTT GTGCTTAAAA GCTTGAAAAG AATGCATGGG 540 GGGGAAATTT TTGTGCCTAA AATCCCCAGC ATGAAAATGA TTGATCTCGC CAAAGCCCTA 600 GCCCCCAATA TCCCTACTAA AATCATAGGG ATTCGCCCGG GCGAAAAACT CCATGAAGTG 660 ATGATCCCTA AAGATGAAAG CCATTTAGCC CTAGAATTTG AAGACTTTTT TATTATTCAG 720 CCCACTATAA GCTTCCAAAC GCCTAAAGAT TACACGCTCA CCAAACTCCA TGAAAAAGGC 780 CAAAAAGTCG CCCCTGATTT TGAATACAGC AGCCATACTA ATAACCAATG GCTAGAGCCT 840 GATGATTTGT TAAAATTATT ATGA 864 (2) INFORMATION FOR SEQ ID NO: 64: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 606 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 606 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 6 ATGCGTTTGC ACACTGCCTT TTTTGGTATT AATTCGTTGC TTGTCGCCAC TCTTTTGATA 60 AGCGGTTGCA GTCTCTTTAA AAAGCGTAAC ACTAACGCTC AGCTAATCCC CCCTTCAGCT 120 AACGGGTTGC AAGCCCCCAT TTATCCCCCA ACCAATTTCA CCCCCAGAAA GAGCATTCAG 180 CCTCTCCCAA GCCCTCGCCT TGAGAATAAC GATCAGCCCA TCATTAGCTC TAATCCCACT 240 AACGCTATCC CTAACACCCC CATTCTCACG CCCAATAATG TCATTCAGTT GAATGCGGTG 300 GGCATGGGTG TGGCTCCAGA ATCCACCATT TCGCCCTCTC AAGCTCTAGC TTTAGCTAAG 360 CGAGCGGCTA TTGTTGATGG CTACCGCCAG TTGGGTGAAA AAATGTATGG CATCAGAGTG 420 AACGCTCAAG ACACCGTCAA AGACATGGTT TTACAAAATT CCGTGATTAA AACGAGAGTG 480 AATGCCCTCA TTCGTAACGC TGAAATCACT GAGACTATCT ATAAAGACGG CTTGTGCCAG 540 GTAAGCATGG AGCTTAAATT AGACGGCAGG ATTTGGTATC GTATTTTGAG CGGATCGAGA 600 GGATAA 606 (2) INFORMATION FOR SEQ ID NO: 65: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1068 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1068 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 65: ATGAGTTATA CTATTAATAA ACGCTTTTCT GTGGGTGTGG GTTTAAGGGG GCTTTATGCG 60 ACCGGGAGCT TTAATAACAC CGTTTATGTG CCTTTAGAGG GCGCTTCAGT TTTGAGCGCG 120 GAGCAAATCT TAAACTTACC CAACAATGTT TTTGCCGATC AAGTGCCAAG TAACATGATG 180 ACTTTATTAG GCAATATTGG CTACCAACCA GCGCTTAATT GCCAAAAAGC CGGTGGGGAC 240 ATGAGTGATC AGAGCTGTCA AGAGTTTTAC AACGGCTTGA AAAAAATCAT GGGTTATAGC 300 GGTTTAATCA AAGCGAGCGC GAATCTTTAT GGCACGACTC AAGTCGTGCA AAAATCTAAC 360 GGACAAGGCG TATCGGGGGG GTATAGAGTG GGTTCGAGTT TGCGTGTGTT TGATCATGGC 420 ATGTTTTCTG TGGTGTATAA TTCTTCAGTT ACCTTTAACA TGAAAGGCGG TTTGGTGGCT 480 ATCACAGAGC TTGGCCCTTC TTTAGGGAGC GTTTTGACTA AAGGCAGCTT GAATATCAAT 540 GTTTCACTCC CCCAAACTTT AAGCTTAGCC TACGCCCACC AATTTTTTAA AGATCGCCTA 600 AGGGTTGAAG GGGTGTTTGA GCGCACTTTT TGGAGTCAAG GGAATAAATT TTTAGTCACC 660 CCTGATTTTG CGAACGCCAC TTACAAGGGC TTGAGCGGGA CGGTGGCTTC CTTGGACTCT 720 GAAACGCTTA AAAAAATGGT AGGCCTAGCG AATTTTAAAA GCGTGATGAA CATGGGGGCT 780 GGCTGGAGGG ACACCAACAC CTTTAGATTA GGGGTAACTT ACATGGGTAA AAGCTTGCGT 840 TTAATGGGCG CTATTGATTA TGATCAAGCC CCAAGCCCCC AAGACGCGAT AGGCATTCCG 900 GACTCTAATG GCTATACCGT GGCTTTTGGG ACTAAATACA ATTTTAGGGG CTTTGATTTG 960 GGCGTAGCGG GGAGTTTCAC TTTTAAGAGC AACCGCTCCA GTTTGTATCA ATCCCCAACT 1020 ATTGGGCAAT TGAGAATCTT TAGCGCCTCT TTAGGCTATC GCTGGTAA 1068 (2) INFORMATION FOR SEQ ID NO: 66: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1764 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1764 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 66: ATGAAAAACT TTTCCCCACT CTATTGTCTT AAAAAGCTCA AAAAACGCCA TTTAATCGCT 60 CTGAGTCTGC CCTTGCTTTC TTATGCGAAT GGCTTTAAAA TCCAAGAGCA AAGCTTGAAT 120 GGCACGGCTT TAGGCTCGGC GTATGTCGCT GGGGCTAGGG GTGCTGACGC TTCTTTTTAC 180 AACCCGGCTA ACATGGGCTT TACTAACGAT TGGGGCGAAA ACAGAAGCGA ATTTGAAATG 240 ACCACCACCG TGATCAATAT CCCGGCCTTT AGCTTTAAAG TCCCTACGAC CAATCAAGGC 300 TTATATTCGG TAACAAGTTT AGAAATTGAT AAAAGCCAAC AAAATATTTT AGGCATCATC 360 AACACTATAG GGTTAGGCAA TATCCTTAAA GCGCTTGGCA ATACGGCCGC TACCAATGGC 420 TTAACACAAG CTATCAATCG TGTTCAAGGG CTTATGAACT TAACCAATCA AAAAGTCGTA 480 ACCCTCGCTT CAAAACCTGA CACTCAAATC GTGAATGGCT GGACAGGCAC GACTAATTTT 540 GTTTTACCTA AATTCTTTTA TAAAACGCGC ACGCATAACG GCTTCACTTT TGGGGGGAGT 600 TTTACCGCTC CTAGTGGGTT GGGTATGAAA TGGAATGGTA AGGGGGGGGA ATTTTTGCAT 660 GACGTGTTTA TCATGATGGT AGAGCTTGCC CCTAGCATGA GTTATACTAT TAATAAACGC 720 TTTTCTGTGG GTGTGGGTTT AAGGGGGCTT TATGCGACCG GGAGCTTTAA TAACACCGTT 780 TATGTGCCTT TAGAGGGCGC TTCAGTTTTG AGCGCGGAGC AAATCTTAAA CTTACCCAAC 840 AATGTTTTTG CCGATCAAGT GCCAAGTAAC ATGATGACTT TATTAGGCAA TATTGGCTAC 900 CAACCAGCGC TTAATTGCCA AAAAGCCGGT GGGGACATGA GTGATCAGAG CTGTCAAGAG 960 TTTTACAACG GCTTGAAAAA AATCATGGGT TATAGCGGTT TAATCAAAGC GAGCGCGAAT 1020 CTTTATGGCA CGACTCAAGT CGTGCAAAAA TCTAACGGAC AAGGCGTATC GGGGGGGTAT 1080 AGAGTGGGTT CGAGTTTGCG TGTGTTTGAT CATGGCATGT TTTCTGTGGT GTATAATTCT 1140 TCAGTTACCT TTAACATGAA AGGCGGTTTG GTGGCTATCA CAGAGCTTGG CCCTTCTTTA 1200 GGGAGCGTTT TGACTAAAGG CAGCTTGAAT ATCAATGTTT CACTCCCCCA AACTTTAAGC 1260 TTAGCCTACG CCCACCAATT TTTTAAAGAT CGCCTAAGGG TTGAAGGGGT GTTTGAGCGC 1320 ACTTTTTGGA GTCAAGGGAA TAAATTTTTA GTCACCCCTG ATTTTGCGAA CGCCACTTAC 1380 AAGGGCTTGA GCGGGACGGT GGCTTCCTTG GACTCTGAAA CGCTTAAAAA AATGGTAGGC 1440 CTAGCGAATT TTAAAAGCGT GATGAACATG GGGGCTGGCT GGAGGGACAC CAACACCTTT 1500 AGATTAGGGG TAACTTACAT GGGTAAAAGC TTGCGTTTAA TGGGCGCTAT TGATTATGAT 1560 CAAGCCCCAA GCCCCCAAGA CGCGATAGGC ATTCCGGACT CTAATGGCTA TACCGTGGCT 1620 TTTGGGACTA AATACAATTT TAGGGGCTTT GATTTGGGCG TAGCGGGGAG TTTCACTTTT 1680 AAGAGCAACC GCTCCAGTTT GTATCAATCC CCAACTATTG GGCAATTGAG AATCTTTAGC 1740 GCCTCTTTAG GCTATCGCTG GTAA 1764 (2) INFORMATION FOR SEQ ID NO: 67: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 618 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 618 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 67: TTGATTTTTA GATTTTTCTT AATCTTAAGC CTTTTAAAAG GGGTTTTACT GGCCAAAAAG 60 GATTGGAATT TTTTCAAACC TTTAGAGCCT ACTAAAAAAT ATTTTGGCTC TTTTAAAATC 120 GGCTATCTTT ACCAACATGC AGAAACGACT AAAAGATTCC CCATCCGCCC TAAAAACCGC 180 CCGCCTATTT TAATGGATAA AATTTACCAT GACGCTTCTT TGGGTTTTGA CGCAGGGTAT 240 GTTTTGAAAA AGAAAGCTTT ATTGGGGGGG TATTTGGATG CAGGAATGGG CGATTCGTAT 300 TTCATGAGCG CTGGGCTAGT CGCTGGGGTG AGGCTTTTTA AGGGGTGGGT TATCCCTAAA 360 ATCGCCTTAG GCTATCAGCT TCAAATTTTA GGGGCTAAGA TTGATAAGTA TCAATTCAAT 420 ATCCAATCAG CGGTGGGGAG TGTGGGCTTG TTTTTCAATG CGGCTAAAAA TTTTGGCTTG 480 AGTATAGAAG CAAGGGGCGG TATCCCTTTT TATTTCATTC AGAGCAGGTT TTCTAAGGCT 540 TTCGGCACGC CACGATTGAA TATCTATTCT GTTGGTATCA CATTCACTTT TTATGACTTT 600 ACGAGATTTT TAGGGTAA 618 (2) INFORMATION FOR SEC ID NO: 68: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 762 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NOENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 762 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 68: TTGTGGCATG CTGCCTTTAG CGTTGGCGAG TGGGGATGGA ACGGCGATGA AATCCCCTAT 60 AGGGATTGCG ATGAGTGGGG GCTTGATGAT TTCTATGGTG TTAAGCCTAC TGATTGTGCC 120 GGTGTTTTAT CGTTTGCTCG CTCCCATAGA CGACAAAATC AAGCGGTTTT ATCAAAACCA 180 AAAAGCTTTA GAATGAAAAA AATTGCTTTC ATTTTGGCTT TATGGGTGGG CTTGTTAGGG 240 GCGTTTGAGC CTAAAAAAAG TCATATTTAT TTTGGGGCTA TGGTGGGTTT AGCCCCTGTT 300 AAAATAACCC CAAAACCGGC TAGTGATTCT TCTTATACGG CTTTTTTATG GGGGGCTAAA 360 GGGGGGGTATC AATTCGCTTT TTTTAAAGCT CTAGCGTTAA GGGGTGAATT TTCCTACCTT 420 ATGGCGATCA AACCCACCCG ACTGCACACG ATTAACACTT CTTTATTGAG TTTAAATATG 480 GATGTGTTGA GCGATTTTTA CACTTATAAA AAATACAGCT TTGGGGTGTA TGGGGGGCTT 540 TTTATATTTG ATTTTTATCA AAGCAACCAT TTAGGCATGA AAAATAGTTC GTTTATGGGT 600 TATAACGGCT TGTTTAATGT GGGGCTTGGC AGCACGATCG ATCGCCACCA CCGCGTAGAG 660 CTTGGGGCTA AGATCCCTTT TTCAAAGACT AGAAATTCTT TTAAAAATTC TTATTTTTTA 720 GAGAGCGTTT TTATCCATGC GGCTTATAGT TATATGTTTT AA 762 (2) INFORMATION FOR SEQ ID NO: 69: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1239 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1239 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 69: ATGGAATCAG TAAAAACAGT AAAAACAAAT AAAGTTGGCA AAAACACAGA GACAGCTAAC 60 ACAGAGGCAA GTAAAGAGAC TCATTTTAAA CAAGCGAGTG CCATTACAAA TACGCTCCGA 120 TCAATTGGTG GGATTTTTAC AAAAATTGCA AAGAAAGTTA GAGAACTTGT GAAAAAACAT 180 CCCAAGAAAA GCAGTGTCCT ATTAGTAGTA TTGACCCATA TTGCGTGCAA GAGGGCAAAA 240 GAATTGGACG ATAAAGTCCA AGATAAATCC AAACAAGCTG AAAAAGAAAA TCAAATCAAT 300 TGGTGGAAAT ATTCAGGATT AACAATAGCG GCAAGTTTAT TATTAGCCGC TTGTAGCACT 360 GGTGATATTG ATAAACAAAT AGAACTAGAA CAAGAAAAAA AGGAAGCAAA TAAGAGTGGG 420 ATAAAGTTAG AACAAGAAAG ACAGAAAACA GAACAAGAAA GACAGAAGAC AAATAAGAGT 480 GAGATAGAGT TAGAACAAGA AAGACAAAAA ACAAACAAGA GTGGGATAGA ACTCGCTAAT 540 AGTCAAATAA AAGCAGAACA AGAAAGACAA AAGACAGAAC AAGAAAAACA AAAAGCAAAT 600 AAGAGTGAGA TAGAGTTAGA ACAGCAAAAA CAAAAGACAA TTAATACACA AAGAGATTTG 660 ATTAAAGAAC AGAAA «GATTT CATTAAAGAA ACAGAACAAA ATTGCCAAGA AAAACATGGC 720 CAATTGTTTA TTAAAAAAGC AAGAATTAAG ACCGGTATTA CTACTGGTAT TGCCATAGAA 780 ATAGAAGCTG AATGCAAAAC CCCTAAACCT GCAAAAACCA ATCAAACCCC TATCCAGCCA 840 AAACACCTCC CAAACTCTAA ACAACCCCGC TCTCAAAGAG GATCAAAAGC GCAAGAGCTT 900 ATCGCTTATT TGCAAAAAGA GCTAGAATCT CTGCCCTATT CGCAAAAAGC TATCGCTAAA 960 CAAGTGGATT TTTATAAACC AAGTTCTATC GCTTATTTAG AACTAGACCC TAGAGATTTT 1020 AAGGTTACAG AAGAATGGCA AAAAGAAAAT TTAAAAATAC GCTCTAAAGC TCAAGCTAAA 1080 ATGCTTGAAA TGAGAAACCC ACAAGCCCAC CTTCCAACCT CTCAAAGCCT TTTGTTCGTT 1140 CAAAAAATAT TTGCTGATAT TAATAAAGAA ATAGAAGCAG TTGCTAATAC TGAAAAGAAA 1200 ACAGAAAAAG CGGGTTATGG TTATAGTAAA AGGATGTAG_1239_(2) INFORMATION FOR SEC ID NO: 70: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 450 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 70: TTGAATTGGG AGCATTTGAT GAAAAAATTA GCGTTTTCTT TATTATTTAC AGGGACTTTT 60 TTGGGGCTTT TTTTGAATGC GAGTGATTTT AAGAGCATGG ATAACAAGCA ACTATTAGAG 120 CAAGCAGGGA AAGTCGCTCC TAGCGAAGTT CCAGAGTTTC GCACAGAAGT CAATAAACGA 180 TTAGAAGCGA TGAAAGAAGA AGAGCGTCAA AAATATAAAG CGGATTTTAA GAAAGCGATG 240 GATAAGAATT TGGCTTCTTT AAGCCAAGAA GATCGCAACA AGCGTAAAAA AGAAATCCTT 300 GAAGTCATTG CTAACAAAAA GAAAACAATG ACCATGAAAG AGTATCGTGA AGAGGGGTTG 360 GATTTGCATG ATTGCGCATG CGAAGGCCCT TTTCATGATC ATGAAAAAAA GGGGCAAAAA 420CAAGCCATCA TAAGCATTAG_450_(2) INFORMATION FOR SEQ ID NO: 71: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 615 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 71: ATGCAAGCAG TGATTTTAGC GAATGGGGAG TTTCCJAAAT CTAAAAAATG CTTAGACATT 60 TTACAAAACG CTCCCTTTTT AATCGCATGC GATGGGGCTG TTATATCATT CCATGCGCTT 120 CAATTCAAAC CCAGCGTTGT TATAGGCGAT TTGGATAGCA TTGATTCGCA TTTGAAAGCC 180 TTGTATAACC CTATACGCGT GAGCGAACAA GACAGCAACG ATTTGTCCAA AGCCTTTTTT 240 TATGCTTTGA ATAGGGGTTG TGATGATTTT ATTTTTTTTAG GGTTGAATGG CAAGCGAGAA 300 GACCACGCTT TAGCGAACAC TTTTTTATTG TTGGAGTATT TTAAATTTTG CAAAAAAATC 360 CAATCCGTAA GCGATTATGG CCTTTTTTAGG GTGTTAGAAA CCCCTTTTAC TTTGCCCAGT 420 TTTAAGGGGG AGCAAATCTC GCTTTTTAGC TTGGATCTTA AAGCCCGATT CACTTCTAAA 480 AACCTCAAAT ACCCCTTAAA AGACTTGCGT CTAAAAACGC TCTTTTCCGG CTCGCTCAAT 540 GAAGCCACTA ATCATTGTTT TAGCCTTAGC TCTGAACCTA AATCGGTGGT GCTAGTGTAT 600 CAAAAATTCT CATGA 615 (2) INFORMATION FOR SEQ ID NO: 72: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 843 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 843 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 72: GTGTTTGACT CATTGGGCGG ATTTTTGGGG TATAAAACTT TTAAGCCGAT AGTGGATAAG 60 GTTAAAAATA TAAACGCTTG GATAAAAAAT TACGATAATA AAAAAGCTCA AGAGATTATG 120 GGTTTTTATAG AAAATCCTAC GCCTGATTTC CAAAATAATA AGTTTTTTGTG TGTTTTAAAC 180 CGACAAGGAA CAAGGCACAA CAATTATCTT GGTTTAACCT CTACAAACCT TCTAATCGGC 240 GCGATCTATT TCTCCATCCG CCATTGCATC AAAGCCACAT GGCAAAACGA TAGGGATCAA 300 TTCTACGCCC CTTATGATGA CGCTTTCCAA GACGACAGCG AGTTTAAAAA CAATTGTTTG 360 GCGTTCATGC TTTTTCACAC CCAAAACCGC ATCACTGCCA CTCAAGGGAC TAACCATTTT 420 ATCCCCTTTA GCGAAGATGA AGTTGATTCT AAAGAAAGGT ATTTGAGCCA TGCTTTATTA 480 GACTTTTTAA AAGGCGAAAT CAAAGAACCT AAAAAGAGCG ATAGCCTCTT TTTAAACGCC 540 AAAAAAGAAA ACAAGCCCCT AAAATTCAGC TCGAGCGCTT CAAAGGTGTT TGACGCTGGC 600 AGAGAGATTT ATCGCTATTA CCACACACAA GATTTCATCC ACACCCCCTA TAACGCTAAC 660 GCAAGCCTTT ATGACATCAA AGAATTTTTT CAAGGCCGTA ACAAGCAAGG CAGATTAAAC 720 TCACCCACCA AAGCCAAAGA TGAATATTAC AAACAGCTTT ACGCTAACTT GCAATACGCC 780 CTAAAAGATC TCGCCAAAGA AATACAGCCT AAAGTCTATG AATACGGATT TTTAAGGGAG 840 TAG_843_(2) INFORMATION FOR SEQ ID NO: 73: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 930 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 930 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 73: TGTGACAGGG CAATTCCCCA TTGGCTTTTT AGTCTGGGAT ACCGCTACCC CCCCCCCTAA 60 AAACCAACCA ACGCGTTCAA TTTAGAAGTG TTTGACTCAT TGGGCGGATT TTTGGGGTAG_120_AAAACTTTTA AGCCGATAGT GGATAAGGTT AAAAATATAA ACGCTTGGAT AAAAAATTAC 180 GATAATAAAA AAGCTCAAGA GATTATGGGT TTTATAGAAA ATCCTACGCC TGATTTCCAA 240 AATAATAAGT TTTTGTGTGT TTTAAACCGA CAAGGAACAA GGCACAACAA TTATCTTGGT 300 TTAACCTCTA CAAACCTTCT AATCGGCGCG ATCTATTTCT CCATCCGCCA TTGCATCAAA 360 GCCACATGGC AAAACGATAG GGATCAATTC TACGCCCCTT ATGATGACGC TTTCCAAGAC 420 GACAGCGAGT TTAAAAACAA TTGTTTGGCG TTCATGCTTT TTCACACCCA AAACCGCACT 480 ACTGCCACTC AAGGGACTAA CCATTTTATC CCCTTTAGCG AAGATGAAGT TGATTCTAAA 540 GAAAGGTATT TGAGCCATGC TTTATTAGAC TTTTTAAAAG GCGAAATCAA AGAACCTAAA 600 AAGAGCGATA GCCTCTTTTT AAACGCCAAA AAAGAAAACA AGCCCCTAAA ATTCAGCTCG 660 AGCGCTTCAA AGGTGTTTGA CGCTGGCAGA GAGATTTATC GCTATTACCA CACACAAGAT 720CCCCCTATAA CGCTAACGCA AGCCTTTATG ACATCAAAGA ATTTTTTCAA 780 GGCCGTAACA AGCAAGGCAG ATTAAACTCA CCCACCAAAG CCAAAGATGA ATATTACAAA 840 CAGCTTTACG CTAACTTGCA ATACGCCCTA AAAGATCTCG CCAAAGAAAT ACAGCCTAAA 900 GTCTATGAAT ACGGATTTTT AAGGGAGTAG_930_(2) INFORMATION FOR SEQ ID NO: 74: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 564 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 564 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 74 TTGGAAACTT ATATCATTGA TGCAGATAAT ATAGATGGGG ATTTATTTTT CTATAATCTT 60 ACTAGAAACA GCAATGATTT TTCCATGTTG CCCGTTTTTG AACTCGATCG CATTGCCCAA 120 AAAATTAGAA ATATTCTTAA AAAACATGGC AGTAGAAAAG ACATTATTTT AAAACACAAT 180 GAAATTAAAG AAGCCTTTTT TAGCCCGTTC AAACCGCAGC TAAAAACCGT TCAAGTGTTC 240 CTCTCGCACT CGCATGCGGA TAAAAATAAG GCTTTAGGGG TTAAGGACTA TTTGGAAAGC 300 AAAACAAAAC GCAAAGTGTT TATCGATTCG CTTTTTTGGG ATTATAAAGA CGATGTTTTA 360 AACAAATTGG CAAAACACGA TGATATAAGC AAGATTGAAG ACGCTTTCAC GCTCATTCTC 420 AGAAAATCTT TACAAGATAT GATTGAAAAA TGCCCTTATT TTGTGTTTTT ACAAAGCAAG 480 AACAGCGTTT CTAATCAAGG GCTATCACGC ATCACTTATT CCGCATGGAT TTATGAAGAA 540 TTAAAAATCG CTTCATTCTA TTAG_564_(2) INFORMATION FOR SEC ID NO: 75: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 597 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 597 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 75: TTGGAAACTT ATATCATTGA TGCAGATAAT ATAGATGGGG ATTTATTTTT CTATAATCTT 60 ACTAGAAACA GCAATGATTT TTCCATGTTG CCCGTTTTTG AACTCGATCG CATTGCCCAA 120 AAAATTAGAA ATATTCTTAA AAAACATGGC AGTAGAAAAG ACATTATTTT AAAACACAAT 180 GAAATTAAAG AAGCCTTTTT TAGCCCGTTC AAACCGCAGC TAAAAACCGT TCAAGTGTTC 240 CTCTCGCACT CGCATGCGGA TAAAAATAAG GCTTTAGGGG TTAAGGACTA TTTGGAAAGC 300 AAAACAAAAC GCAAAGTGTT TATCGATTCG CTTTTTTGGG ATTATAAAGA CGATGTTTTA 360 AACAAATTGG CAAAACACGA TGATATAAGC AAGATTGAAG ACGCTTTCAC GCTCATTCTC 420 AGAAAATCTT TACAAGATAT GATTGAAAAA TGCCCTTATT TTGTGTTTTT ACAAAGCAAG 480 AACAGCGTTT CTAATCAAGG GCTATCACGC ATCACTTATT CCGCATGGAT TTATGAAGAA 540 TTAAAAATCG CTTCATTTCT ATTAGCGCTA TTAACGAGAG TCGCCCAATT CCAATGA 597 (2) INFORMATION FOR SEQ ID NO: 76: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 570 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 570 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 76: ATGATGACTA AGAACGCTTA TGCGTTTGTC GTGATTGAAA AAAGTATTAT GGTGTTTAAA 60 TGCGCCAAAG ACAAGGGGCT AATCCCTATC ACTGAAGGCT TTGTGCCGTT AAAAGAGGGC 120 TTTTTTGAGAA GTTTTAAAGA GCGTTGCAAT CTGGATTTTT TAGAAAATTT AGACCTTTTG 180 TTTTTGTATG ACTACCAATT TCCAAGCGAG GTTTTTTTCAT TGTGTAAGGA TTTGAAAAAT 240 TCCATTTGGG ACAGAAAGCT TGTGGTAGTG CTAGTGGAGG CTTTGGAGGG TTTTAAGGGT 300 TTGAATTTGT CTCTTAAGAT AGAAGATAGG CATTCTAATA GCTTGGGTAA TGGCGTTCAA 360 AAATTGCTCA CCAACGCTGA TTTGGGGAGC AACCACAAAC CAATCGTAAT AGACAGCATG 420 AAAACATACC ACCAAAGCCA GCAAGAAAAA TACAAAAGAG AAAGAGGCGA AACGCTAGAC 480 GTTCGCCCCA CAACACCCCC TAGCTATGGG GGTGGGAGCA TTAGAATCAG CGGCGATAAA 540 AAGCCTGATT CCAATGAAGA AAATTTTTAA 570 (2) INFORMATION FOR SEQ ID NO: 77 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1773 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1773 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 77: ATGAAAGCGA TAAAAATACT TCTTATAATG ACACTCAGTT TAAACGCTAT CAGCGTGAAT 60 AGGGCGTTGT TTGATTTAAA AGATTCGCAA TTAAAAGGGG AATTAACGCC AAAAATAGTG 120 GATTTTGGGG GTTATAAAAG CAACACCACA GAGTGGGGAG CTACGGCTTT AAACTATATC 180 AATGCGGCTA ATGGCGATGC GAAAAAATTC AGCGCGTTAG TGGAAAAAAT GCGTTTTAAC 240 TCTGGTATCT TGGGGAATTT TAGAGCGCAT GCACATTTGA GGCAAGCCCT AAAATTGCAA 300 AAGAATTTGA AATATTGCCT TAAAATCATC GCTAGGGATT CTTTTTATAG TTACCGCACC 360 GGTATTTATA TCCCCTTAGG CATTTCTTTA AAAGATCAAA AAACGGCTCA AAAAATGCTC 420 GCTGATTTGA GCGTGGTAGG GGCGTATCTT AAAAAGCAAC AGGAGAATGA AAAGGCTCAA 480 AGCCCTTATT ACAGGAGCAA CAACTATTAC AACTCCTACT ATAGCCCTTA TTATGGCATG 540 TATGGCATGT ATGGAATGGG CATGTATGGA ATGTATGGCA TGGGCATGTA TGATTTTTAT 600 GACTTTTATG ATGGCATGTA TGGGTTCTAC CCTAACATGT TTTTCATGAT GCAAGTTCAA 660 GACTACTTGA TGTTAGAAAA TTACATGTAT GCACTCGATC AAGAAGAGAT TTTAGACCAT 720 GACGCTTCCA TCAACCAACT TGATACGCCT ACTGATGATG ACAGAGACGA TAAAGACGAT 780 AAATCTTCGC AACCAGCGAA TCTCATGACG TTTTATCGTG ATCCCAAATT CAGCAAAGAC 840 ATTCAAACCA ACCGCTTGAA TAGCGCCTTA GTCAATTTAG ACAACAGCCA CATGCTCAAA 900 GACAATTCGC TCTTCCACAC TAAAGCCATG CCCACTAAAA GCGTGGATGC GATCACTTCT 960 CAAGCTAAAG AGCTTAACCA TTTGGTGGGG CAAATCAAAG AGATGAAGCA AGACGGGGCG 1020 AGTCCTAATA AGATTGATTC AGTGGTCAAT AAAGCTATGG AGGTTAGGGA CAAATTAGAC 1080 AACAACCTCA ACCAACTAGA CAATGACTTA AAAGATCAAA AAGGGCTTTC AAGCGAGCAG 1140 CAAGCCCAAG TGGATAAAGC CTTAGACAGC GTGCAACAAT TAAGCCATAG CAGCGATGTG 1200 GTAGGGAATT ATTTAGACGG GAGTTTGAAA ATTGATGGCG ATGACAGAGA CGATTTGAAT 1260 GATGCGATCA ATAACCCTAT GCAACAACCT GCGCAACAAA CGCCTATTAA CAACATGGAC 1320 AACACCCATG CAAATGACAG CAAAGATCAA GGGGGTAGG CGCTCATAAA CCCTAACAAC 1380 GCCACCAACG ATGATCACAA CGATGATCAC ATGGACACTA ACACCACTGA CACTAGCAAC 1440 GCAAACGACA CCCCCACTGA TGATAAAGAT GCTAGCGGCA ACAATACCGG CGATATGAAT 1500 AACACCGACA CCGGCAATAC GGACACTGGC AACACCGACA CCGGTAACAC TGATGATATG 1560 AGCAACATGA ACAACGGCAA CGATGATACG GGTAACACTA ACGACGACAT GGGTAATAGC 1620 AACGACATGG GCGATGACAT GAATAACGCG AACGACATGA ACGACGACAT GGGTAACAGC 1680 AACGATGACA TGGGCGATAT GGGGGACATG AACGATGACA TGGGTGGCGA TATGGGAGAC 1740 ATGGGGGATA TGGGTGGCGA TATGGGGTTA TGA 1773 (2) INFORMATION FOR SEQ ID NO: 78: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 588 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: mise characteristic (B) LOCATION: 1 ... 588 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 7 TTGAATTTAC GATTGGCTGG AGCAAGCGTT TTAACGGCTT GTGTCTTTTC GGGGTGTTTT 60 TTTTTAAAAA TGTTTGACAA AAAACTTTCT AGCAACGATT GGCATATCCA AAAAGTAGAA 120 ATGAACCATC AAGTGTATGA CATTGAAACC ATGCTCGCTG ATAGCGCTTT TAGAGAGCAT 180 GAAGAAGAGC AAGACTCCTC TTTAAATACC GCTTTGCCTG AAGATAAAAC AGCGATTGAA 240 GCCAAAGAGC AAGAGCAAAA AGAAAAAAAGG AAACACTGGT ATGAGCTTTT TAAAAAGAAG 300 CCAAAGCCCA AAAGCTCTAT GGGAGAGTTT TGTTTTGATC AAAAAGAAAA TCGTATTTAT 360 TTTAAAGGCT ATTGCAACCG GTATTTTGCT AGCTACACAT GGCAGGGCGA TAGGCACATC 420 GCAATTGAAG ATAGCGGGAT TTCAAGAAAA GTGTGTAGAG ATGAGCATTT GATGGCGTTT 480 GAATTGGAAT TTATGGAGAA TTTTAAGGGT AATTTTGCGG TAACTAAGGG CAAGGACACG 540 CTCATTTTAG ACAACCAAAA AATGAAAATT TATTTGAAAA CGCCATGA 588 (2) INFORMATION FOR SEQ ID NO: 79: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 2235 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_carateristics (B) LOCATION: 1 ... 2235 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 79: ATGTTAAAAC TGCGCAGTAA AACGATTTGT TTGTCCCTAA TCAGCTCATT CACGGCTGTA 60 GAAGCCTTTC AAAAACACCA AAAAGACGGC TTTTTCATAG AAGCCGGCTT TGAAACCGGG 120 CTATTACAAG GCACACAAAC CCAAGAACAA ACCATAGCCA CCACTCAAGA AAAACCCAAA 180 CCCAAACCCA AACCAAAACC CATTACCCCT CAAAGCACCT ATGGGAAATA CTACATCTCC 240 CAAAGCACCA TTTTAAAGAA TGCGACTGAG TTGTTTGCAG AGGATAATAT CACCAACTTA 300 ACCTTTTACT CTCAAAACCC TGTGTATGTA ACCGCTTATA ACCAAGAAAG CGCTGAAGAA 360 GCTGGCTATG CTAATAACAG CTTGATTATG ATACAAAACT TCTTGCCTTA TAACTTGAAC 420 AACAGGGAGC TGAGTTACAC GGACGATCAA GGCAATGTGG TCAGTTTGGG CGTGATAGAG 480 ACTATCCCTA AACAATCTCA AATCATTCTG CCCGCAAGCT TGTTTAACGA CCCACAGCTT 540 AACGCCGATG GCTTCCAACA ACTCCAAACC AACACCACAC GATTTTCTGA TGCCAGCACG 600 CAGAATCTGT TTAACAAGCT CAGCAAGGTT ACAACCAATC TTCAAATGAC TTATATCAAT 660 TACAACCAAT TTTCTAGCGG TAACGGCAGT GGCTCTAAAC CCCCATGCCC CCCATACGAA 720 AACCAAGCAA ATTGTGTGGC TAAAGTGCCG CCTTTCACCT CTCAAGACGC TAAAAATTTG 780 ACCAATTTAA TGCTGAACAT GATGGCGGTG TTTGATTCTA AATCTTGGGA AGACGCCGTC 840 TTAAACGCTC CTTTCCAATT CAGCGACAAC AACCTGTCAG CGCCATGTTA TTCTGATTAC 900 CTTACATGCG TGAATCCTTA CAACGATGGG CTTGTTGATC CTAAATTGAT CGCCAAAAAT 960 AAAGGAGATG AATACAATAT AGAAAACGGG CAAACAGGCT CAGTGATATT AACGCCGCAA 1020 GATGTTATCT ATAGCTATAG AGTCGCTAAT AATATTTATG TGAATCTCTT GCCCACAAGA 1080 GGAGGGGATT TAGGGTTAGG GTCTCAATAT GGTGGCCCGA ATGGCCCAGG CGATGATGGC 1140 ACCAATTTTG GCGCTTTAGG GATATTGTCC CCTTTCTTAG ACCCTGAAAT ATTGTTTGGC 1200 AAAGAATTGA ATAAAGTCGC CATCATGCAA TTAAGAGACA TCATCCATGA ATACGGCCAT 1260 ACTTTAGGCT ATACGCATAA CGGGAACATG ACTTATCAAA GAGTGCGCAT GTGCGAAGAA 1320 AACAATGGGC CAGAAGAGCG CTGTCAGGGC GGAAGGATAG AGCAAGTGGA TGGGAAAGAA 1380 GTGCAAGTGT TTGACAACGG GCATGAAGTG CGAGACACCG ATGGCTCTAC CTATGATGTG 1440 TGTTCTCGTT TTAAAGATAA GCCCTATACA GCGGGCAGCT ATCCTAATTC CATCTATACC 1500 GATTGCTCTC AAGTCCCCGC TGGGCTTATA GGCGTTACCA GCGCTGTTTG GCAACAACTC 1560 ATTGATCAAA ACGCCCTACC GGTGGATTTT ACTAATTTGA GCAGCCAAAC CAACTATTTG 1620 AACGCCAGCT TGAACACGCA AGACTTTGCG ACCACCATGC TTAGCGCGAT CAGTCAAAGC 1680 CTTTCATCTT CTAAATCTAG CGCCACTACT TATCGCACTT CAAAAACCTC ACGGCCCTTT 1740 GGAGCCCCCC TATTAGGCGT TAATCTTAAA ATGGGCTATC AAAAATATTT TAATGATTAT 1800 CTAGGGTTGT CTTCTTATGG CATTATCAAA TACAACTACG CTCAAGCCAA CAACGAAAAA 1860 ATCCAGCAAT TAAGCTATGG CGTGGGAATG GATGTGCTGT TTGATTTCAT CACCAATTAC 1920 ACTAACGAAA AGAACCCCAA AAGCAATCTA ACCAAGAAAG TTTTCACTTC CTCTCTTGGG 1980 GTGTTTGGGG GGTTAAGGGG CTTATACAAC AGCTATTATT TGTTGAACCA ATACAAAGGG 2040 AGCGGTAATT TAAATGTGAC CGGTGGGTTG AATTACCGCT ACAAGCATTC CAAATATTCT 2100 ATAGGCATTA GCGTTCCTTT GGTCCAGTTG AAATCTAGGA TCGTTTCTAG CGATGGTGCT 2160 TATACCAATT CTATCACCCT CAATGAAGGG GGCAGTCATT TTAAAGTGTT TTTTAATTAC 2220 GGGTGGATTT TCTAA 2235 (2) INFORMATION FOR SEC ID NO: 80: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1590 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1590 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 80: ATGACTTATA TCAATTACAA CCAATTTTCT AGCGGTAACG GCAGTGGCTC TAAACCCCCA 60 TGCCCCCCAT ACGAAAACCA AGCAAATTGT GTGGCTAAAG TGCCGCCTTT CACCTCTCAA 120 GACGCTAAAA ATTTGACCAA TTTAATGCTG AACATGATGG CGGTGTTTGA TTCTAAATCT 180 TGGGAAGACG CCGTCTTAAA CGCTCCTTTC CAATTCAGCG ACAACAACCT GTCAGCGCCA 240 TGTTATTCTG ATTACCTTAC ATGCGTGAAT CCTTACAACG ATGGGCTTGT TGATCCTAAA 300 TTGATCGCCA AAAATAAAGG AGATGAATAC AATATAGAAA ACGGGCAAAC AGGCTCAGTG 360 ATATTAACGC CGCAAGATGT TATCTATAGC TATAGAGTCG CTAATAATAT TTATGTGAAT 420 CTCTTGCCCA CAAGAGGAGG GGATTTAGGG TTAGGGTCTC AATATGGTGG CCCGAATGGC 480 CCAGGCGATG ATGGCACCAA TTTTGGCGCT TTAGGGATAT TGTCCCCTTT CTTAGACCCT 540 GAAATATTGT TTGGCAAAGA ATTGAATAAA GTCGCCATCA TGCAATTAAG AGACATCATC 600 CATGAATACG GCCATACTTT AGGCTATACG CATAACGGGA ACATGACTTA CTAAAGAGTG 660 CGCATGTGCG AAGAAAACAA TGGGCCAGAA GAGCGCTGTC AGGGCGGAAG GATAGAGCAA 720 GTGGATGGGA AAGAAGTGCA AGTGTTTGAC AACGGGCATG AAGTGCGAGA CACCGATGGC 780ATGTGTGTTC TCGTTTTAAA GATAAGCCCT ATACAGCGGG CAGCTATCCT 840 AATTCCATCT ATACCGATTG CTCTCAAGTC CCCGCTGGGC TTATAGGCGT TACCAGCGCT 900 GTTTGGCAAC AACTCATTGA TCAAAACGCC CTACCGGTGG ATTTTACTAA TTTGAGCAGC 960 CAAACCAACT ATTTGAACGC CAGCTTGAAC ACGCAAGACT TTGCGACCAC CATGCTTAGC 1020 GCGATCAGTC AAAGCCTTTC ATCTTCTAAA TCTAGCGCCA CTACTTATCG CACTTCAAAA 1080 ACCTCACGGC CCTTTGGAGC CCCCCTATTA GGCGTTAATC TTAAAATGGG CTATCAAAAA 1140 TATTTTAATG ATTATCTAGG GTTGTCTTCT TATGGCATTA TCAAATACAA CTACGCTCAA 1200 GCCAACAACG AAAAAATCCA GCAATTAAGC TATGGCGTGG GAATGGATGT GCTGTTTGAT 1260 TTCATCACCA ATTACACTAA CGAAAAGAAC CCCAAAAGCA ATCTAACCAA GAAAGTTTTC 1320 TTGGGGTGACTTCCTCTCTT TGGGGGGTTA AGGGGCTTAT ACAACAGCTA TTATTTGTTG 1380 AACCAATACA AAGGGAGCGG TAATTTAAAT GTGACCGGTG GGTTGAATTA CCGCTACAAG 1440 CATTCCAAAT ATTCTATAGG CATTAGCGTT CCTTTGGTCC AGTTGAAATC TAGGATGCTT 1500 TCTAGCGATG GTGCTTATAC CAATTCTATC ACCCTCAATG AAGGGGGCAG TCATTTTAAA 1560 GTGTTTTTTA ATTACGGGTG GATTTTCTAA 1590 [2) INFORMATION FOR SEC ID NO: 81: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 564 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 564 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 81: TTGGGTTGCG TATCAATGAC TCTAGGTATT GATGAAGCGG GGAGGGGGTG TTTGGCCGGT 60 TCGCTTTTTG TGGCGGGGGT GGTGTGTAAT GAAAAAATAG CCTTAGAATT TCTAAAAATG 120 GGTCTTAAGG ATAGCAAGAA GCTCAGCCCC AAAAAGCGCT TTTTCTTAGA AGATAAAATC 180 AAAACGCATG GTGAGGTGGG GTTTTTCGTG GTTAAAAAAA GCGCGAATGA AATTGATCAT 240 TTGGGCTTAG GGGCGTGTTT GAAACTCGCT ATTGAAGAAA TTGTAGAAAA TGGTTGCTCT 300 TTAGCCAATG AAATAAAAAT AGATGGCAAC ACGGCGTTTG GCTTGAACAA ACGCTACCCC 360 AACATACAAA CCATCATCAA GGGCGATGAA ACAATCGCTC AAATCGCTAT GGCGTCTGTT 420 TTGGCGAAAG CTTCTAAGGA TAGGGAAATG TTAGAACTGC ACGCTTTGTT TAAGGAATAC 480 GGCTGGGATA AGAATTGCGG GTATGGGACT AAACAACATA TAGAAGCGAT CAATAAGCTA 540 GGGGCTACGC TTTCATCGGC ATAG_564_(2) INFORMATION FOR SEC ID NO: 82: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 615 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 82: ATGACTCTAG GTATTGATGA AGCGGGGAGG GGGTGTTTGG CCGGTTCGCT TTTTGTGGCG 60 GGGGTGGTGT GTAATGAAAA AATAGCCTTA GAATTTCTAA AAATGGGTCT TAAGGATAGC 120 AAGAAGCTCA GCCCCAAAAA GCGCTTTTTC TTAGAAGATA AAATCAAAAC GCATGGTGAG 180 GTGGGGTTTT TCGTGGTTAA AAAAAGCGCG AATGAAATTG ATCATTTGGG CTTAGGGGCG 240 TGTTTGAAAC TCGCTATTGA AGAAATGGTT GAAAATGGTT GCTCTTTAGC CAATGAAATA 300 AAAATAGATG GCAACACGGC GTTTGGCTTG AACAAACGCT ACCCCAACAT ACAAACCATC 360 ATCAAGGGCG ATGAAACAAT CGCTCAAATC GCTATGGCGT CTGTTTTGGC GAAAGCTTCT 420 AAGGATAGGG AAATGTTAGA ACTGCACGCT TTGTTTAAGG AATACGGCTG GGATAAGAAT 480 TGCGGGTATG GGACTAAACA ACATATAGAA GCGATCAATA AGCTAGGGGC TACGCCTTTT 540 CATCGGCATA GCTTCACGCT TAAAAACCGC ATCTTAAATC CCAAACTCTT AGAGGTGGAA 600 CAACGCCTTG TTTAA 615 (2) INFORMATION FOR SEC ID NO: 83: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 579 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 579 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 83: ATGAATGCAT TGAAAAAATT AAGTTTTTGC GCCTTGTTAT CCCTAGGCCT CTTCGCTCAA 60 ACAGTGCATG CTCAGCATTT AAAGGACACG ATTAACTATC CTGATTGGCT TAAAATCAAT 120 CTTTTTGATA AAAAGAACCC GCCCAATCAA TATGTCGGAT CGGCTTCAAT TTCTGGTAAA 180 AGGAACGATT TTTATTCCAA TTACATCCCC TATGATGACA AATTGCCCCC TGAAAAGAAC 240 GCTGAAGAAA TCGCTCTTTT AAGGGCCAGA ATGAACGCTT ACAGCACTTT AGAAAGCGCT 300 TTACTCACTA AAATGTGCAA TCGCATTGTT AAAGCGCTTC AAGTTAAAAA TAATGTTATC 360 AGCCATTTAT TCGGGTTTGT TGATTTTTTA ACGTCTAAAT CCATTTTGGC TAAAAGGTTC 420 GTGGATACCA CCAACCATCG TGTGTATGTC ATGGTGCAAT TCCCTTTCAT TCAGCCTGAA 480 GACTTAATCG CTTACTTTAA AGCCAAACGC ATCGACCTTT CTTTAGCGAG CGCTACCAAT 540 CTCAGCGCCA TTTTAAACAA GGCGTTGTTC CACCTCTAA 579 (2) INFORMATION FOR SEQ ID NO: 84 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 261 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 261 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 84: ATGAATGCAT TGAAAAAATT AAGTTTTTGC GCCTTGTTAT CCCTAGGCCT CTTCGCTCAA 60 ACAGTGCATG CTCAGCATTT AAAGGACACG ATTAACTATC CTGATTGGCT TAAAATCAAT 120 CTTTTTGATA AAAAGAACCC GCCCAATCAA TATGTCGGAT CGGCTTCAAT TTCTGGTAAA 180 AGGAACGATT TTTATTCCAA TTACATCCCC TATGATGACA AATTGCCCCC TGAAAGAACG 240 CTGAAGAAAT CGCTCTTTTA A 261 (2) INFORMATION FOR SEC ID NO: 85: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 228 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 228 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 85: TTGAAAATTT TAACCCTTTT TTTGATAGGT TTAAACGCAT TGTTCGCCCT AGATTTGAAC 60 GCGCTTAAAA CAGAAAT «AA AGAAACCTAT CTCAAAGAAT ACAAAGACTT AAAATTGGAA 120 ATTGAAACAA TTAATTTAGA AATCCCAGAG CGTTTTTCTC ACGCTTCCAT TTTAAGCTAT 180 GAATTGAACG CTTCTAACAA GCTTAAAAAA GATGGGTCGT GTTTTTAA 228 (2) INFORMATION FOR SEQ ID NO: 86: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 636 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 636 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 86: ATGTTTTCAA TAATTCTGGG GGGGGGGGGG GGTAATACCC CATGCGGCTT GACATGGCAA 60 CACTTCAAAT TAGGGGATTT GTTTGAAATT GAAAAAACCT TAAGCTTTAA TAAAGACGCT 120 TTAACGCAAG GACAAGATTA CGATTATATT ACAAGAACTT CGCAAAATCA AGGCGTTTTG 180 CAAACTACAG GATTTGTCAA TGCAGAAAAT TTAAACCCAC CATTTACTTG GAGTTTAGGG 240 CTTTTTGCAAA TGGATTTTTT CTATCGTAAA AAGTCATGGT ATGCGGGACA ATTCATGCGA 300 AAAATCACAC CAAAAAAAA AATTAAAAAT AAAATTAATT CACGCATAGC CCACTATTTC 360 ACAACGCTTT TAAACGCCTT AAAACGCCCT TTATTGAGTG TATTAGTTAG GGATATTGAT 420 AAAACTTTTA GGGAGCAAAA AATCCAACTA CCCCTAAAAC CCACCGCTAA AACTCAAAGC 480 CTTGATGGTA TTGATTTTGA TTTCATGCAC ACCCTAATCA ACGCCCTGAT GAAGCAAACC 540 ATTCAAGGCG TGGTTCAATA CTGCGACGCT AAAATACAGG CTACAAAAGA AGTTATCAGC 600 CAAGAAACGC CTATTCAAAA AGACTCGTTA TTTTGA 636 (2) INFORMATION FOR SEQ ID NO: 87 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1221 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 1221 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 87: GTGATTGGCC CCCTTAGCAG CCAACTCAAC GCTATTAAGT GGGGCGAGTT CAAATTAGGG 60 GATTTGTTTG AAGCGAGTAA CGGCGATTTT GACATTCAAA AACGCCACAT CAATCATAAG 120 GGCGAATTTG TCATCACCGC AGGGCTTAGC AATAATGGCG TTTTAGGGCA AAGCGATATA 180 AAAGCAAAAG TTTTTGAAAG CCATACCATT ACTATTGACA TGTTTGGTTG CGCGTTTTAT 240 CGCACTTTTG CTTATAAAAT GGTAACACAT GCTAGGGTAT TTTCTCTCAA CCTAAATTT 300 GAAATCAACC ATAAAATCGG CTTGTTTTTA TCCACGCTAT TTTTTGGTTA CCATAAAAAA 360 TTCGGCTATG AAAACATGTG TTCATGGGCA AAAATTAAAA ACGATAAAGT CATTCTACCC 420 CTAAAACCCA CCGCTAACAC TCAAACCCTT GAGGGTATTG ATTTTGATTT CATGGAAAAA 480 TTCATAGCCG AACTTGAGCA GTGTCGGCTC GCCGAACTTC AGGCTTATTT AAAAGCTACA 540 GGGCTAGAAA ACACCACCCT TTCTAACGAT GAAGAAAATG CCCTTAATGT TTTCAATAAT 600 TCTGGGGGGG GGGGGGGTAA TACCCCATGC GGCTTGACAT GGCAACACTT CAAATTAGGG 660 GATTTGTTTG AAATTGAAAA AACCTTAAGC TTTAATAAAG ACGCTTTAAC GCAAGGACAA 720 GATTACGATT ATATTACAAG AACTTCGCAA AATCAAGGCG TTTTGCAAAC TACAGGATTT 780 GTCAATGCAG AAAATTTAAA CCCACCATTT ACTTGGAGTT TAGGGCTTTT GCAAATGGAT 840 TTTTTCTATC GTAAAAAGTC ATGGTATGCG GGACAATTCA TGCGAAAAAT CACACCAAAA 900 ACTGAAATTA AAAATAAAAT TAATTCACGC ATAGCCCACT ATTTCACAAC GCTTTTAAAC 960 GCCTTAAAAC GCCCTTTATT GAGTGTATTA GTTAGGGATA TTGATAAAAC TTTTAGGGAG 1020 CAAAAAATCC AACTACCCCT AAAACCCACC GCTAAAACTC AAAGCCTTGA TGGTATTGAT 1080 TTTGATTTCA TGCACACCCT AATCAACGCC CTGATGAAGC AAACCATTCA AGGCGTGGTT 1140 CAATACTGCG ACGCTAAAAT ACAGGCTACA AAAGAAGTTA TCAGCCAAGA AACGCCTATT 1200 CAAAAAGACT CGTTATTTTG A 1221 (2) INFORMATION FOR SEQ ID NO: 88 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 828 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc__característica (B) LOCATION: 1 828 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 88: ATGAGTAAGA GTTTATACCA AACTTTAAAC GTGAGCGAAA ACGCCAGCCA AGATGAAATC 60 AAAAAATCCT ACCGCCGTTT AGCCAGGCAA TACCACCCGG ATTTGAATAA AACCAAAGAA 120 GCCGAAGAGA AATTCAAAGA AATCAACGCC GCTTATGAAA TTTTGAGCGA TGAAGAAAAA 180 CGCCGCCAAT ACGATCAATT TGGCGACAAC ATGTTTGGCG GGCAGAATTT CAGCGATTTT 240 GCCAGAAGCC GTGGTCCTAG TGAAGATTTA GATGATATTT TAAGCTCTAT TTTTGGGAAA 300 GGAGGCTTTT CGCAAAGATT TTCTCAAAAT TCGCAAGGCT TTTCTGGCTT TAATTTTTCC 360 AATTTCGCCC CTGAAAATTT AGATGTAACC GCTATTTTAA ATGTCTCTGT TTTAGACACC 420 CTTTTAGGCA ATAAAAAACA AGTGAGCGTC AATAATGAGA CTTTTAGCCT TAAAATCCCT 480 ATCGGCGTGG AAGAGGGCGA AAAGATTAGG GTTCGCAACA AAGGGAAAAT GGGGCGAACG 540 GGTAGGGGCG ATTTGCTCTT ACAGATCCAT ATTGAAGAAG ATGAAATGTA TAGGCGCGAA '600 AAAGACGATA TTATCCAAAT CTTTGATTTA CCCTTAAAAA CGGCTCTTTT TGGAGGGAAA 660 ATTGAAATCG CTACTTGGCA TAAAACCTTA ACCCTAACCA TTCCCCCTAA CACCAAAGGC 720 ATGCAAAAAT TCCGCATCAA AGACAAAGGG ATCAAAAGCA GAAAAACTTC GCATGTGGGG 780 GATTGTATTG CAAGCTCGTT TGATCTGCTA AAATTGAAAC GCTTCTAA 828 (2) INFORMATION FOR SEC ID NO: 89: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 837 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 837 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 89: ATGAGTAAGA GTTTATACCA AACTTTAAAC GTGAGCGAAA ACGCCAGCCA AGATGAAATC 60 AAAAAATCCT ACCGCCGTTT AGCCAGGCAA TACCACCCGG ATTTGAATAA AACCAAAGAA 120 GCCGAAGAGA AATTCAAAGA AATCAACGCC GCTTATGAAA TTTTGAGCGA TGAAGAAAAA 180 CGCCGCCAAT ACGATCAATT TGGCGACAAC ATGTTTGGCG GGCAGAATTT CAGCGATTTT 240 GCCAGAAGCC GTGGTCCTAG TGAAGATTTA GATGATATTT TAAGCTCTAT TTTTGGGAAA 300 GGAGGCTTTT CGCAAAGATT TTCTCAAAAT TCGCAAGGCT TTTCTGGCTT TAATTTTTCC 360 AATTTCGCCC CTGAAAATTT AGATGTAACC GCTATTTTAA ATGTCTCTGT TTTAGACACC 420 CTTTTAGGCA ATAAAAAACA AGTGAGCGTC AATAATGAGA CTTTTAGCCT TAAAATCCCT 480 ATCGGCGTGG AAGAGGGCGA AAAGATTAGG GTTCGCAACA AAGGGAAAAT GGGGCGAACG 540 GGTAGGGGCG ATTTGCTCTT ACAGATCCAT ATTGAAGAAG ATGAAATGTA TAGGCGCGAA 600 AAAGACGATA TTATCCAAAT CTTTGATTTA CCCTTAAAAA CGGCTCTTTT TGGAGGGAAA 660 ATTGAAATCG CTACTTGGCA TAAAACCTTA ACCCTAACCA TTCCCCCTAA CACCAAAGCC 720 ATGCAAAAAT TCCGCATCAA AGACAAAGGG ATCAAAAGCA GAAAAACTTC GCATGTGGGG 780 GATTGTATTG CAAGCTCGTT TGATCTGCCT AAAATTGAAA CGCTTCTAAT GAGTTGA 837 (2) INFORMATION FOR SEQ ID NO: 90:ERISTICS OF THE SEQUENCE: (A) LENGTH: 699 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 699 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 90: GTGGTTCAAA AATTTAATTT TTATAAGACA GGTGGCATGC GTTTAAAACA TTTTAAGACA 60 TTCCTTTTTA TCACAATGGC GGTGATTGTG ATAGGCACTG GTTGTGCGAA TAAAAAGAAA 120 AAAAAAGATG AATACAACAA ACCGGCGATG TTTTGGTATC AAGGGATTTT GAGAGAAATT 180 CTTTTTTGCTA ATTTAGAAAC AGCGGACAAT TACTATTCTT CCTTACAGAG CGAACACATC 240 AATTCCCCCC TTGTCCCAGA AGCTATGCTA GCTTTAGGGC AAGCGCACAT GAAAAAGAAA 300 GAGTATGTTT TAGCGTCTTT TTACTTTGAT GAATACATCA AGCGCTTTGG GACGAAGGAC 360 AATGTGGATT ATTTGACCTT TTTGAAACTG CAATCGCATT ATTACGCTTT CAAAAACCAT 420 TCTAAAGACC AGGAATTTAT CTCTAATTCT ATTGTGAGTT TAGGCGAATT TATAGAAAAA 480 TACCCTAACA GCCGTTACCG CCCCTATGTA GAATACATGC AAATCAAATT CATTTTAGGG 540 CAAAATGAGC TCAATCGCGC GATCGCGAAT GTCTATAAAA AACGCCACAA GCCCGAGGGC 600 GTGAAACGCT ATTTAGAAAG GATAGATGAG ACTTTAGAAA AAGAC3ACTAA ACCCAAACCA 660 TCGCACATGC CTTGGTATGT GTTAATTTTT GATTGGTAG_699_(2) INFORMATION FOR SEC ID NO: 91: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 345 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 91: ATGCGT.TTTT TGAATAACAA ACATAGAGAA AAGGGCTTAA AGGCTGAAGA AGAAGCTTGC 60 GGGTTTTTAA AAACGCTGGG TTTTGAAATG ATAGAGAGGA ACTTTTTTTTC ACAATTTGGT 120 GAAATTGATA TTATCGCTTT GAAAAAAGGG GTTTTGCATT TCATTGAAGT CAAAAGCGGG 180 GAAAATTTTG ATCCCATTTA TGCGATCACG CCGAGCAAAT TAAAAAAGAT GATTAAAACG 240 ATCCGCTGTT ATTTGTCTCA AAAAGATCCC AATAGCGATT TTTGCATTGA CGCTCTTATT 300 GTGAAAAATG GTAAATTTGA GCTTTTAGAA AATATCACTT TTTAG_345_(2) INFORMATION FOR SEQ ID NO: 92; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 306 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 306 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 92; ATGGGCAGCA TTGGGGCTAT GACTAAAGGG AGCTCTGATA GGTATTTTCA AGAGGGCGTG 60 GCGAGTGAAA AATTAGTCCC AGAAGGCATT CAGGGGCGTG TGCCTTATCG TGGTAAGGTT 120 TCGGATATGA TTTTCCAATT AGTAGGGGGC GTGCGTTCTT CTATGGGGTA TCAGGGGGCG 180 AAGAATATTT TGGAATTGTA TCAAAACGCT GAATTTGTAG AAATCACTAG CGCGGGGTTA 240 AAAAAAAGCC ATGTGCATGG CGTGGATATT ACTAAAGAAG CCCCTAATAT TATGGGTGAA 300 TTTTAA 306 (2) INFORMATION FOR SEC ID NO: 93: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 1446 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 1446 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 93: ATGAGAATTT CACAAAGGGC TTTGACTTTT GAAGACGTGT TGATGGTGCC TAGAAAATCC 60 AGCGTTTTAC CTAAAGATGT GAGCTTAAAG TCTCGCCTAA CCAAAAACAT TGGTTTGAAT 120 ATCCCTTTTA TTAGTGCGGC TATGGATACG GTTACAGAGC ATAAAACCGC TATCGCTATG 180 GCGCGCCTTG GGGGTATTGG CATCGTGCAT AAAAACATGG ATATTCAAAC GCAAGTCAAA 240 GAAATCACTA AAGTTAAAAA AAGCGAGAGC GGGGTGATTA AT «3ATCCTAT TTTTATCCAT 300 GCGCACAGGA CGCTAGCGGA CGCTAAAGTC ATAACGGATA ATTATAAGAT TTCAGGCGTG 360 CCTGTGGTAG ATGATAAGGG GTTGTTGATT GGGATTTTAA CCAACAGAGA CGTGCGTTTT 420 GAAACCGATT TGAGTAAAAA AGTGGGCGAT GTGATGACTA AAATGCCTTT AGTTACCGCT 480 CATGTGGGCA TTAGCTTAGA TGAAGCGAGC GATTTGATGC ACAAGCATAA GATTGAAAAA 540 TTGCCCATTG TGGATAAAGA TAATGTTTTA AAAGGCTTGA TCACGATCAA AGACATTCAA 600 AAACGCATTG AATACCCTGA GGCCAATAAA GATGATTTTG GGAGGTTGAG AGTGGGGGCG 660 GCTATTGGAG TGGGGCAGTT GGATAGGGCT GAAATGTTAG TTAAAGCGGG GGTGGATGCG 720 TTGGTGTTAG ACAGCGCGCA TGGGCATTCA GCCAATATTT TACACACTTT AGAAGAGATT 780 AAAAAAAGCT TGGTAGTGGA TGTGATTGTG GGGAATGTGG TTACTAAAGA AGCCACAAGC 840 GATTTGATTA GCGCGGGAGC GGACGCTGTT AAAGTGGGTA TTGGGCCAGG AAGCATTTGC 900 ACCACTAGGA TTGTGGCCGG GGTGGGAATG CCCCAAGTGA GCGCAATTGA TAATTGCGTG 960 GAAGTGGCGT CTAAATTTGA TATTCCTGTG ATTGCCGATG GAGGGATCCG CTATTCAGGC 1020 GATGTGGCTA AGGCTCTAGC TTTAGGAGCA TCAATCGTGA TGATAGGCTC TTTACTCGCT 1080 GGCACAGAAG AATCTCCAGG GGATTTTATG ATTTACCAAG GGAGGCAATA TAAAAGCTAT 1140 AGGGGCATGG GCAGCATTGG GGCTATGACT AAAGGGAGCT CTGATAGGTA TTTTCAAGAG 1200 GGCGTGGCGA GTGAAAAATT AGTCCCAGAA GGCATTGAGG GGCGTGTGCC TTATCGTGGT 1260 AAGGTTTCGG ATATGATTTT CCAATTAGTA GGGGGCGTGC GTTCTTCTAT GGGGTATCAG 1320 GGGGCGAAGA ATATTTTGGA ATTGTATCAA AACGCTGAAT TTGTAGAAAT CACTAGCGCG 1380 GGGTTAAAAG AAAGCCATGT GCATGGCGTG GATATTACTA AAGAAGCCCC TAATTATTAT 1440 GGGTGA 1446 (2) INFORMATION FOR SEQ ID NO: 94 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 615 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 615 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 94: ATGCAAGGGT TTCTTTTACA AACACAAAGC ATAAGAGATG AAGATTTGAT CGTGCACGTT 60 TTAACCAAAA ACCAGCTCAA AACCCTCTAT CGTTTCTATG GCAAACGCCA CAGCGTGCTG 120 AATGTGGGTC GTAAAATTGA TTTTGAAGAA GAAAACGATG ATAAATTTTT ACCCAAGTTA 180 AGGAATATTT TGCATTTAGG CTATATTTGG GAAAGAGAAA TGGAGCGCTT GTTTTTTTGG 240 CAACGCTTTT GCGCTCTTTT GTTCAAGCAT TTAGAGGGCG TGCATTCTTT AGATAGCATC 300 TATTTTGACA CTTTAGATGA TGGGGCTAGC AAACTCTCCA AACAGCACCC CTTAAGAGTG 360 ATTTTAGAAA TGTATGCAGT CCTTTTGAAT TTTGAAGGGC GCTTGCAAAG GTACAATTCT 420 TGTTTTTTTAT GCGATGCAAA ATTAGAGCGT TCTGTCGCTT TAGCGCAAGG GTTTATTTTA 480 GCGCACCCCT CTTGCTTGAA AGCTAAAAGC TTGGATTTAG AAAAAATCCA AGCTTTTTTC 540 CGCACTCAAA GCACGATTGA TCTAGAAACA GAAGAAGTGG AAGAATTATG GCGCACGCTG 600 AATTTAGGGT TTGA 615 (2) INFORMATION FOR SEQ ID NO: 95: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 249 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 249 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 95: ATGGGCGTCG GACGGGTCGG CAATATGGCA CTGTTGGCGT GTGGAGGTCC GATGGGCATC 60 GGCGCTATTG CTATCGCCAT TAACGGCGGC AGACAACGGT CGCGGATGTT GGTGGTCGAT 120 ATAGACGACA AACGTCTGGA GCAGGTACAG AAGATGCTGC CGGGGAATTG GCGGCCAGTA 180 ACGGCATTGA GCTGGTGTCT GTGCATACCA AAGCGAGGAG CGATCCGTGC CAGATGCTGC 240 GAGCGCTGA 249 (2) INFORMATION FOR SEC ID NO: 96: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 204 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: mise characteristic (B) LOCATION: 1 ... 204 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 96: TTGTCCGGTA CAGCCGTGAG TTGCCGGTGC ACATGCCGCA TACAGTTGGT ATTGGTGCGC 60 ACCAGCATCC CGGTTGTTAT CGGGTGCTCA TGCCCATTCC TTTCCAGTAT TGGGTTCACA 120 ACGGGAACCC ACCAATCACC CGTTAAACGC TGCGGGGTTA ACGCCGGAAA AACACCGTCA 180 AAAAAACATT TGCATTTAAA CTAA 204 (2) INFORMATION FOR SEQ ID NO: 97 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 345 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 97: GTGTGGCTGG CGGCGCTGGG CTTCCTGATC ACCGCGGTGG GGCTGCCGGT GATCACCGTG 60 ATCGCCCTGG CCAAGGTCGG CGGTTCGTCG ACGCCCTCAG CCATCCGATC GGCAGGTATG 120 CCGGCGGCCT GCTGGCGGCG GTCTGCTACC TGGCGGTCGG CCCGCTGTTC GCCATTCCGC 180 GCACCGCCAC GGTGTCCTTC GAAGGTCAGC GTGGTGCCGC TGCTCGGCGA AGAAGCGGCA 240 CGGCGCTGTT AGTCTACAGC CTGGCGTACT TCCTCCTCGC CCTGGCCATC TCCCTCTACC 300 CCGGTCGCCT GCTGGACACC GTCGGACGCT TCCTCGCCCC GCTGA 345 (2) INFORMATION FOR SEQ ID NO: 98 i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 228 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 228 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 98 Met Arg Phe Lys Gly Ser Arg Val Glu Ala Phe Leu Gly Ala Leu Glu 1 5 10 15 Phe Gln Glu Asn Glu Tyr Glu Glu Phe Lys Glu Leu Tyr Glu Ser Leu 20 25 30 Lys Thr Lys Gln Lys Pro His Thr Leu Phe lie Ser Cys Val Asp Ser 35 40 45 Arg Val Val Pro Asn Leu lie Thr Gly Thr Gln Pro Gly Glu Leu Tyr 50 55 60 Val lie Arg Asn Met Gly Asn Val He Pro Pro Lys Thr Ser Tyr Lys 65 70 75 80 Glu Ser Leu Ser Thr He Wing Ser Val Glu Tyr Wing He Wing His Val 85 90 95 Gly Val Gln Asn Leu He He Cys Gly His Ser Asp Cys Gly Ala Cys 100 105 110 Gly Ser He His Leu He His Asp Glu Thr Thr Lys Ala Lys Thr Pro 115 120 125 Tyr He Wing Asn Trp He Gln Phe Leu Glu Pro He Lys Glu Glu Leu 130 135 140 Lys Asn His Pro Gln Phe Ser Asn His Phe Wing Lys Arg Ser Trp Leu 145 150 155 160 Thr Glu Arg Leu Asn Wing Arg Leu Gln Leu Asn Asn Leu Leu Ser Tyr 165 170 175 Asp Phe He Gln Glu Arg Val He Asn Asn Glu Leu Lys He Phe Gly 180 185 190 Trp His Tyr He He Glu Thr Gly Arg He Tyr Asn Tyr Asn Phe Glu 195 200 205 Ser His Phe Phe Glu Pro He Glu Glu Thr He Lys Gln Arg He Ser 210 215 220 His Glu Asn Phe 225 INFORMATION FOR SEC ID NO: 99: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 221 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 221 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 99: Val Glu Ala Phe Leu Gly Ala Leu Glu Phe Gln Gln Asn Glu Tyr Glu 1 5 10 15 Glu Phe Lys Glu Leu Tyr Glu Ser Leu Lys Thr Lys Gln Lys Pro His 20 25 30 Thr Leu Phe He Ser Cys Val Asp Ser Arg Val Val Pro Asn Leu He 35 40 45 Thr Gly Thr Gln Pro Gly Glu Leu Tyr Val He Arg Asn Mer Gly Asn 50 55 60 Val He Pro Pro Lys Thr Ser Tyr Lys Glu Ser Leu Ser Thr He Ala 65 70 75 80 Ser Val Glu Tyr Wing He Wing His Val Gly Val Gln Asn Leu He He 85 90 95 Cys Gly His Ser Asp Cys Gly Ala Cys Gly Ser He His Leu He His 100 105 110 Asp Gly Thr Thr Lys Wing Lys Thr Pro tyr He Wing Asn Trp He Gln 115 120 125 Phe Leu Glu Pro He Lys Glu Glu Leu Lys Asn His Pro Gln Phe Ser 130 135 140 Asn His Phe Wing Lys Arg Ser Trp Leu Thr Glu Arg Leu Asn Wing Arg 145 150 155 160 Leu Gln Leu Asn Asn Leu Leu Ser Tyr Asp Phe He Gln Glu Arg Val 165 170 175 He Asn Asn Glu Leu Lys He Phe Gly Trp His Tyr He He Glu Thr 180 185 190 Gly Arg He Tyr Asn Tyr Asn Phe Glu Ser His Phe Phe Glu Pro He 195 200 205 Glu Glu Thr He Lys Gln Arg He Ser His Glu Asn Phe 210 215 220 INFORMATION FOR SEQ ID NO: 100: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 335 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 335 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 100: Met Leu Val Thr Arg Phe Lys Lys Wing Phe He Ser Tyr Ser Leu Gly 1 5 10 15 Val Leu Val Val Ser Leu Leu Leu Asn Val Cys Asn Ala Be Ala Gln 20 25 30 Glu Val Lys Val Lys Asp Tyr Phe Gly Glu Gln Thr He Lys Leu Pro 35 40 45 Val Ser Lys He Wing Tyr He Gly Ser Tyr Val Glu Val Pro Wing Met 50 55 60 Leu Asn Val Trp Asp Arg Val Val Gly Val Ser Asp Tyr Ala Phe Lys 65 70 75 80 Asp Asp He Val Lys Wing Thr Leu Lys Gly Glu Asp Leu Lys Arg Val 85 90 95 Lys His Met Ser Thr Asp His Thr Ala Ala Leu Asn Val Glu Leu Leu 100 105 110 Lys Lys Leu Ser Pro Asp Leu Val Val Thr Phe Val Gly Asn Pro Lys 115 120 125 Wing Val Glu His Wing Lys Lys Phe Gly He Ser Phe Leu Ser Phe Gln 130 135 140 Glu Thr Thr He Wing Glu Wing Met Gln Wing Met Gln Wing Gln Wing Thr 145 150 155 160 Val Leu Glu He Asp Wing Ser Lys Lys Phe Wing Lys Met Gln Glu Thr 165 170 175 Leu Asp Phe He Wing Glu Arg Leu Lys Gly Val Lys Lys Lys Lys Gly 180 185 190 Val Glu Leu Phe His Lys Wing Asn Lys He Ser Gly His Gln Wing He 195 200 205 Be Ser Asp He Leu Glu Lys Gly Gly He Asp Asn Phe Gly Leu Lys 210 215 220 Tyr Val Lys Phe Gly Arg Wing Asp He Ser Val glu Lys He Val Lys 225 230 235 240 Glu Asn Pro Glu He He Phe He Trp Trp Val Ser Pro Leu Thr Pro 245 250 255 Glu Asp Val Leu Asn Asn Pro Lys Phe Ser Thr He Lys Wing He Lys 260 265 270 Asn Lys Gln Val Tyr Lys Leu Pro Thr Met Asp He Gly Gly Pro Arg 275 280 285 Ala Pro Leu He Ser Leu Phe He Ala Leu Lys Ala His Pro Glu Ala 290 295 300 Phe Lys Gly Val Asp He Asn Wing He Val Lys Asp Tyr Tyr Lys Val 305 310 315 320 Val Phe Asp Leu Asn Asp Wing Glu He Glu Pro Phe Leu Trp His 325 330 335 INFORMATION FOR SEC ID NO: 101: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 274 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 274 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 101: Met Leu Val Thr Arg Phe Lys Lys Wing Phe He Ser Tyr Ser Leu Gly 1 5 10 15 Val Leu Val Val Ser Leu Leu Leu Asn Val Cys Asn Ala Be Ala Gln 20 25 30 Glu Val Lys Val Lys Asp Tyr Phe Gly Glu Gln Thr He Lys Leu Pro 35 40 45 Val Ser Lys He Wing Tyr He Gly Ser Tyr Val Glu Val Pro Wing Met 50 55 60 Leu Asn Val Trp Asp Arg Val Val Gly Val Ser Asp Tyr Ala Phe Lys 65 70 75 80 Asp Asp He Val Lys Wing Thr Leu Lys Gly Glu Asp Leu Lys Arg Val 85 90 95 Lys His Met Ser Thr Asp His Thr Ala Ala Leu Asn Val Glu Leu Leu 100 105 110 Lys Lys Leu Ser Pro Asp Leu Val Val Thr Phe Val Gly Asn Pro Lys 115 120 125 Wing Val Glu His Wing Lys Lys Phe Gly He Ser Phe Leu Ser Phe Gln 130 135 140 Glu Thr Thr He Wing Glu Wing Met Gln Wing Met Gln Wing Gln Wing Thr 145 150 155 160 Val Leu Glu He Asp Wing Ser Lys Lys Phe Wing Lys Met Gln Glu Thr 165 170 175 Leu Asp Phe He Wing Asp Arg Leu Lys Gly Val Lys Lys Lys Lys Gly 180 185 190 Val Glu Leu Phe His Lys Wing Asn Lys He Ser Gly His Gln Wing He 195 200 205 Asn Be Asp He Leu Gln Gln Gly He Asp Asn Phe Gly Leu Lys 210 215 220 Tyr Val Lys Phe Gly Arg Wing Asp He Ser Val Glu Lys He Val Lys 225 230 235 240 Glu Asn Pro Glu He He Phe He Arg Trp Val Thr Pro Leu Thr Pro 245 250 255 Asp Tyr Val Leu Asn Asn Pro Lys Phe Ser Thr He Asn Wing He Lys 260 265 270 Asn He (2) INFORMATION FOR SEC ID NO: 102: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 428 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: - (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 428 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 102: Met Lys Lys Lys Phe Leu Ser Leu Thr Leu Gly Ser Leu Leu Val Ser 1 5 10 15 Ala Leu Ser Ala Glu Asp Asn Gly Phe Phe Val Ser Ala Gly Tyr Gln 20 25 30 He Gly Glu Be Wing Gln Met Val Lys Asn Thr Lys Gly He Gln Asp 35 40 45 Leu Ser Asp Ser Tyr Glu Arg Leu Asn Asn Leu Leu Thr Asn Tyr Ser 50 55 60 Val Leu Asn Ala Leu He Arg Gln Ser Ala Asp Pro Asn Ala He Asn 65 70 75 80 Asn Ala Arg Gly Asn Leu Asn Ala Be Ala Lys Asn Leu He Asn Asp 85 90 95 Lys Lys Asn Ser Pro Wing Tyr Gln Wing Val Leu Leu Wing Leu Asn Wing 100 105 110 Ala Ala Gly Leu Trp Gln Val Met Ser Tyr Ala He Ser Pro Cys Gly 115 120 125 Pro Gly Lys Asp Thr Ser Lys Asn Gly Gly Val Gln Thr Phe His Asn 130 135 140 Thr Pro Ser Asn Gln Trp Gly Gly Thr Thr He Thr Cys Gly Thr Thr 145 150 155 160 Gly Tyr Glu Pro Gly Pro Tyr Ser He Leu Ser Thr Glu Asn Tyr Wing 165 170 175 Lys He Asn Lys Wing Tyr Gln He He Gln Lys Wing Phe Gly Ser Ser 180 185 190 Gly Lys Asp He Pro Wing Leu Being Asp Thr Asn Thr Glu Leu Lys Phe 195 200 205 Thr He Asn Lys Asn Asn Gly Asn Thr Asn Thr Asn Asn Asn Gly Glu 210 215 220 Glu He Val Thr Lys Asn Asn Wing Gln Val Leu Leu Glu Gln Wing Ser 225 230 235 240 Thr He He Thr Thr Leu Asn Ser Wing Cys Pro Trp He Asn Asn Gly 245 250 255 Gly Wing Gly Gly Wing Being Ser Gly Being Leu Trp Glu Gly He Tyr Leu 260 265 270 Lys Gly Asp Gly Be Wing Cys Gly He Phe Lys Asn Glu Be Ser Wing 275 280 285 He Gln Asp Met He Lys Asn Wing Wing He Wing Val Glu Gln Ser Lys 290 295 300 He Val Ala Ala Asn Ala Gln Asn Gln Arg Asn Leu Asp Thr Gly Lys 305 310 315 320 Thr Phe Asn Pro Tyr Lys Asp Wing Asn Phe Wing Gln Ser Met Phe Wing 325 330 335 Asn Ala Lys Ala Gln Ala Glu He Leu Asn Arg Ala Gln Ala Val Val 340 345 350 Lys Asp Phe Glu Arg He Pro Wing Glu Phe Val Lys Asp Ser Leu Gly 355 360 365 Val Cys His Glu Val Gln Asn Gly His Leu Arg Gly Thr Pro Ser Gly 370 375 380? Thr Val Thr Asp Asn Thr Trp Gly Wing Gly Cys Wing Tyr Val Gly Glu 385 390 395 400 Thr Val Thr Asn Leu Lys Asp Ser He Wing His Phe Gly Asp Gln Wing 405 410 415 Glu Arg He His Asn Wing Arg Asn Leu Wing Thr Leu 420 425 INFORMATION FOR SEC ID NO: 103: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 178 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 178 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 103: Met Asn Pro Leu Lue Gln Ast Tyr Ala Arg He Leu Leu Glu Trp Asn 1 5 10 15 Gln Thr His Asn Leu Ser Gly Ala Arg Asn Leu Ser Glu Leu Glu Pro 20 25 30 Gln He Thr Asp Ala Leu Lys Pro Leu Glu Phe Val Lys Asp Phe Lys 35 40 45 Be Cys Leu Asp He Gly Be Gly Wing Gly Leu Pro Wing He Pro Leu 50 55 60 Wing Leu Glu Lys Pro Glu Wing Gln Phe He Leu Leu Glu Pro Arg Val 65 70 75 80 Lys Arg Ala Ala Phe Leu Asn Tyr Leu Lys Ser Val Leu Pro Leu Asn 85 90 95 Asn He Glu He He Lys Lys Arg Leu Glu Asp Tyr Gln Asp Leu Leu 100 105 110 Gln Val Asp Leu He Thr Ser Arg Ala Val Wing Being Ser Phe Leu 115 120 125 He Glu Lys Ser Gln Arg Phe Leu Lys Asp Lys Gly Tyr Phe Leu Phe 130 135 140 Tyr Lys Gly Glu Gln Leu Lys Asn Glu He Wing Tyr Lys Thr Thr Glu 145 150 155 160 Cys Phe Met His Gln Lys Arg Val Tyr Phe Tyr Lys Ser Lys Glu Ser 165 170 175 Leu Cys (2) INFORMATION FOR SEQ ID NO: 104: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 240 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 240 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 104: Leu Gly Leu Lys Lys Arg Wing He Leu Trp Being Leu Met Gly Phe Cys 1 5 10 15 Ala Gly Leu Ser Ala Leu Asp Tyr Asp Thr Leu Asp Pro Lys Tyr Tyr 20 25 30 Lys Tyr He Lys Tyr Tyr Lys Wing Tyr glu Asp Lys Glu Val Glu Glu 35 40 45 Leu He Arg Asp Leu Lys Arg Wing Asn Wing Lys Ser Gly Leu He Leu 50 55 60 Gly He Asn Thr Gly Phe Phe Tyr Asn His Glu He Met Val Lys Thr 65 70 75 80 Asn Being Being He Thr Gly Asn He Leu Asn Tyr Leu Phe Wing Tyr 85 90 95 Gly Leu Arg Phe Gly Tyr Gln Thr Phe Arg Pro Ser Phe Phe Ala Arg 100 105 110 Leu Val Lys Pro Asn He He Gly Arg Arg He Tyr He Gln Tyr Tyr 115 120 125 Gly Gly Wing Pro Lys Lys Wing Gly Phe Gly Ser Val Gly Phe Gln Ser 130 135 140 Val Met Leu Asn Gly Asp Phe Leu Leu Asp Phe Pro Leu Pro Phe Val 145 150 155 160 Gly Lys Tyr Leu Tyr Met Gly Gly Tyr Met Gly Leu Gly Leu Gly Val 165 170 175 Val Ala His Gly Val Asn Tyr Thr Ala Glu Trp Gly Met Ser Phe Asn 180 185 190 Ala Gly Leu Ala Leu Thr Val Leu Gly Lys Asn Arg He Glu Phe Glu 195 200 205 Phe Lys He Leu Asn Asn Phe Pro Phe Leu Gln Ser Asn Ser Ser Lys 210 215 220 Glu Thr Trp Trp Gly Wing He Wing Being He Gly Tyr Gln Tyr Val Phe 225 230 235 240 (2) INFORMATION FOR SEC ID NO: 105: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 313 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 313 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 105: Leu Lys Leu Lys Tyr Trp Leu Val Tyr Leu Wing Phe He He Gly Leu 1 5 10 15 Gln Ala Thr Asp Tyr Asp Asn Leu Glu Glu Glu Asn Gln Gln Leu Asp 20 25 30 Glu Lys He Asn Asn Leu Lys Arg Gln Leu Thr Glu Lys Gly Val Ser 35 40 45 Pro Lys Glu Met Asp Lys Asp Lys Phe Glu Glu Glu Tyr Leu Glu Arg 50 55 60 Thr Tyr Pro Lys He Ser Ser Lys Lys Arg Lys Lys Leu Leu Lys Ser 65 70 75 80 Phe Ser He Wing Asp Asp Lys Ser Gly Val Phe Leu Gly Gly Gly Tyr 85 90 95 Wing Tyr Gly Glu Leu Asn Leu Ser Tyr Gln Gly Glu Met Leu Asp Arg 100 105 110 Tyr Gly Wing Asn Wing Pro Being Wing Phe Lys Asn Asn He Asn He Asn 115 120 125 Ala Pro Val Ser Met He Ser Val Lys Phe Gly Tyr Gln Lys Tyr Phe 130 135 140 Val Pro Tyr Phe Gly Thr Arg Phr Tyr Gly Asp Leu Leu Leu Gly Gly 145 150 155 160 Gly Ala Leu Lys Glu Asn Ala Leu Lys Gln Pro Val Gly Ser Phe Phe 165 170 175 Tyr Val Leu Gly Wing Met Asn Thr Asp Leu Leu Phe Asp Met Pro Leu 180 185 190 Asp Phe Lys Thr Lys Lys His Phe Leu Gly Val Tyr Wing Gly Phe Gly 195 200. 205 He Gly Lue Met Leu Tyr Gln Asp Lys Pro Asn Gln Asn Gly Arg Asn 210 215 220 Leu He Val Gly Gly Tyr Ser Ser Pro Asn Phe Leu Trp Lys Ser Leu 225 230 235 240 He Glu Val Asp Tyr Thr Phe Asn Val Gly Val Ser Leu Thr Leu Tyr 245 250 255 Arg Lys His Arg Leu Glu He Gly Thr Lys Leu Pro He Ser Tyr Leu 260 265 270 Arg Met Gly Val Glu Glu Gly Ala He Tyr His Asn Lys Glu Asn Asp 275 280 285 Glu Arg Leu Leu He Ser Wing Asn Asn Gln Phe Lys Arg Ser Ser Phe 290 295 300 Leu Leu Val Asn Tyr Ala Phe He Phe 305 310 INFORMATION FOR SEC ID NO: 106: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 393 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 393 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 106: Met Thr Ser Ala Ser Ser His Ser Phe Lys Glu Gln Asp Phe His He 1 5 10 15 Pro He Ala Phe Ala Phe Asp Lys Asn Tyr Leu He Pro Ala Gly Ala 20 25 30 Cys He Tyr Ser Leu Leu Glu Ser He Wing Lys Wing Asn Lys Lys He 35 40 45 Arg Tyr Thr Leu His Wing Leu Val Val Gly Leu Asn Glu Glu Asp Lys 50 55 60 Thr Lys Leu Asn Gln He Thr Glu Pro Phe Lys Glu Phe Wing Val Leu 65 70 75 80 Glu Val Lys Asp He Glu Pro Phe Leu Asp Thr He Pro Asn Pro Phe 85 90 95 Asp Glu Asp Phe Thr Lys Arg Phe Ser Lys Met Val Leu Val Lys Tyr 100 105 110 Phe Leu Wing Asp Leu Phe Pro Lys Tyr Ser Lys Met Val Trp Ser Asp 115 120 125 Val Asp Val He Phe Cys Asn Glu Phe Ser Wing Asp Phe Leu Asn He 130 135 140 Lys Glu Asp Asp Glu Asn Tyr Phe Tyr Gly Val Tyr Asp Lys He Tyr 145 150 155 160 Pro Tyr Glu Gly Phe Phe Tyr Cys Asn Leu Thr Tyr Gln Arg Lys Asn 165 170 175 Gln Phe Cys Lys Lys He Leu Glu He He Arg Ala Gln Lys He Asp 180 185 190 Lys Glu Pro Gln Leu Thr Glu Phe Cys Arg Ser Lys He Wing Pro Leu 195 200 205 Lys He Glu Tyr Cys He Phe Pro His Tyr Tyr Ser Leu Ser Glu Glu 210 215 220 His Leu Lys Gly Val Wing Asn Wing He Tyr His Asn Thr He Lys Gln 225 230 235 240 Ala Leu Arg Glu Pro He Val He Gln Tyr Asp Ser His Pro Tyr Phe 245 250 255 Gln He Lys Pro Trp Thr Tyr Pro Phe Gly Leu Lys Wing Asp Leu Trp 260 265 270 Leu Asn Ala Leu Ala Lys Thr Pro Phe Met Ser Asp Trp Ser Tyr Leu 275 280 285 He Thr Gly Gly Gly Gly He Gly Gly Glu Lys Trp His Tyr Tyr His 290 295 300 Gly He Ala Ala Tyr His Tyt Tyr Phe Pro Leu Trp Lys Ala Glu Glu 305 310 315 320 Gln He Ala His Asp Ala Leu Lys Thr Phe Leu Lys His Tyr Phe Leu 325 330 335 His He His Glu He Pro Gln Asn Wing Arg Arg Arg Leu Phe Lys Tyr 340 345 350 Cys He Ser He Pro Leu Lys Ser Phe He Ser Lys Thr Leu Lys Phe 355 360 365 Leu Lys Leu His Ala Leu Val Lys Lys He Leu He Gln Leu Lys Leu 370 375 380 Leu Lys Lys Asn Gln Ser Gln Asn Phe 385 390 (2) INFORMATION FOR SEQ ID NO: 107: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 435 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 435 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 107 Leu He Phe Leu Lys Lys Ser Leu Cys Ala Leu Leu He Ser Gly Phe 1 10 15 Phe He Pro Pro Leu Met Lys Wing Ala Ser Phe Val Tyr Asp Leu Lys 20 25 30 Phe Met Ser Phe Asn Phe Asn Leu Wing Ser Pro Pro Asn Asn Pro Tyr 35 40 45 Trp Asn Ser Leu Thr Lys Met Gln Gly Arg Leu Met Pro Gln He Gly 50 55 60 Val Gln Leu Asp Lys Arg Gln Wing Leu Met Phe Gly Wing Trp Phe He 65 70 75 80 Gln Asn Leu His Thr His Tyr Ser Tyr Phe Pro Tyr Ser Trp Gly Val 85 90 95 Thr Met Tyr Tyr Gln Tyr He Gly Lys Asn Leu Arg Phe Phe Leu Gly 100 105 110 He Val Pro Arg Ser Tyr Gln He Gly His Tyr Pro Leu Ser Ala Phe 115 120 125 Lys Lys Leu Phe Trp Phe He Asp Pro Thr Phe Arg Gly Gly Wing Phe 130 135 140 Gln Phe Lys Pro Wing Tyr Asp Pro Asn Arg Trp Trp Asn Gly Trp Phe 145 150 155 160 Glu Gly Val Val Asp Trp Tyr Gly Gly Arg Asn Trp Asn Asn Gln Pro 165 170 175 Lys Lys Lys Asn Tyr Asp Phe Asp Gln Phe Leu Tyr Phe Val Ser Ser 180 185 190 Glu Phe Gln Phe Leu Lys Gly Tyr Leu Gly Leu Gly Gly Gln Leu Val 195 200 205 He Phe His Asn Ala Asn Ser His Ser Met Gly Asp Asn Tyr Pro Tyr 210 215 220 Gly Gly Asn Ser Tyr Leu Lys Pro Gly Asp Wing Thr Pro Gln Trp Pro 225 230 235 240 Asn Gly Tyr Pro Tyr Phe Ser Gln Lys Asp Asn Pro Gln Gly Gly 245 250 255 He Gly Lys Tyr Ser Asn Pro Thr He Leu Asp Arg Val Tyr Tyr His 260 265 270 Wing Tyr Leu Lys Wing Asp Phe Lys Asn Leu Met Pro Tyr Met Asp Asn 275 280 285 He Phe Met Thr Phe Gly Thr Gln Ser Ser Gln Thr His Tyr Cys Val 290 295 300 Arg Tyr Wing Ser Glu Cys Lys Asn Wing Arg Phe Tyr Asn Ser Phe Gly 305 310 315 320 Gly Glu Phe Tyr Wing Gln Wing Gln Tyr Lys Gly Phe Gly He Phe Ans 325 330 335 Arg Tyr Tyr Phe Ser Asn Lys Pro Gln Met His Phe Tyr Wing Thr Tyr 340 345 350 Gly Gln Ser Leu Tyr Thr Gly Leu Pro Trp Tyr Arg Ala Pro Asn Phe 355 360 365.
Asp Met He Gly Leu Tyr Tyr Leu Tyr Lys Asn Lys Trp Leu Ser Val 370 375 380 Arg Ala Asp Ala Phe Phe Ser Phe Val Gly Gly Gly Asp Gly Tyr His 385 390 395 400 Leu Tyr Gly Lys Gly Gly Lys Trp Phe Val Met Tyr Gln Gln Phe Leu 405 410 415 Thr Leu Thr He Asp Thr Arg Glu Leu He Asp Phe Val Lys Ser Lys 420 425 430 He Pro Lys 435 (2) INFORMATION FOR SEQ ID NO: 108: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 220 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 220 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 108 Met Asn Lys Thr Thr He Lys He Leu Met Gly Met Wing Leu Leu Ser 1 5 10 15 Ser Leu Gln wing Wing Glu Wing Glu Leu Asp Glu Lys Ser Lys Lys Pro 25 30 Lys Phe Wing Asp Arg Asn Thr Phe Tyr Leu Gly Val Gly Tyr Gln Leu 35 40 45 Being Wing He Asn Thr Being Phe Being Thr Being Being He Asp Lys Being Tyr 50 55 60 Phe Met Thr Gly Asn Gly Phe Gly Val Val Leu Gly Gly Val Pys Val 65 70 75 80 Wing Lys Thr Gln Wing Val Glu His Val Gly Phe Arg Tyr Gly Leu Phe 85 90 95 Tyr Asp Gln Thr Phe Ser Ser His Lys Ser Tyr He Ser Thr Tyr Gly 100 105 110 Leu Glu Phe Ser Gly Leu Trp Asp Wing Phe Asn Ser Pro Lys Met Phe 115 120 125 Leu Gly Leu Glu Phe Gly Leu Gly He Wing Gly Wing Thr Tyr Met Pro 130 135 140 Gly Gly Met Wing His Gly He He Wing Gln Tyr Leu Gly Lys Glu Asn 145 150 155 160 Being Leu Phe Gln Leu Leu Val Lys Val Gly Phe Arg Phe Gly Phe Phe 165 170 175 His Asn Glu He Thr Phe Gly Leu Lys Phe Pro Val He Pro Asn Lys 180 185 190 Lys Thr Glu He Val Asp Gly Leu Ser Wing Thr Thr Leu Trp Gln Arg 195 200 205 Leu Pro Val Wing Tyr Phe Asn Tyr He Tyr Asn Phe 210 215 220 INFORMATION FOR SEC ID NO: 109; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 116 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 116 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 109: Leu Asn Leu His Phe Met Lys Gly Phe Val Met-Ser Gly Leu Arg Thr 1 5 10 15 Phe Ser Cys Val Val Val Leu Cys Gly Val Val Val Val Val Val Val Wing Gly Pro Lys He Glu Wing Arg Gly Glu Leu Gly Lys Phe Val Gly 35 40 45 Gly Ala Val Gly Asn Phe Val Gly Asp Lys Met Gly Gly Phe Val Gly 50 55 60 Gly Wing He Gly Gly Tyr He Gly Ser Glu Val Gly Asp Arg Val Glu 65 70 75 80 Asp Tyr He Arg Gly Val Asp Arg Glu Pro Gln Asn Lys Glu Pro Gln 85 90 95 Thr Pro Arg Glu Pro He Arg Asp Phe Tyr Asp Tyr Gly Tyr Ser Phe 100 105 110 Gly His Ala Trp 115 (2) INFORMATION FOR SEC ID NO: 110: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 436 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 436 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 110: Met Ser Arg Asp Phe Lys Phe Asp Ser Asn Tyr Leu Asn Val Asn Thr 1 5 10 15 Asn Pro Lys Leu Gly Pro Val Tyr Thr Asn Gln Asn Tyr Pro Gly Phe 25 30 Phe He Phe Asp His Leu Arg Arg Tyr Val Met Asn Wing Phe Glu Pro 35 40 45 Asn Leu Asn Leu Val Val Asn Thr Asn Lys Val Lys Gln Thr Phe Asn 50 55 60 Val Gly Met Arg Phe Met Thr Met Asp Met Phe He Arg Ser Asp Gln 65 70 75 80 Be Thr Cys Glu Lys Thr Asp He He Asn Gly Val Cys His Met Pro 85 90 95 Pro Tyr Val Leu Ser Lys Thr Pro Asn Asn Asn Gln Glu Met Phe Asn 100 105 110 Asn Tyr Thr Wing Val Trp Leu Ser Asp Lys He Glu Phe Phe Asp Ser 115 120 125 Lys Leu Val He Thr Pro Gly Leu Arg Tyr Thr Phe Leu Asn Tyr Asn 130 135 140 Asn Lys Glu Pro Glu Lys His Asp Phe Ser Val Trp Thr Ser Lys Lys 145 150 155 160 Gln Arg Gln Asn Glu Trp Ser Pro Ala Leu Asn He Gly Tyr Lys Pro 165 170 175 Met Glu Asn Trp He Trp Tyr Wing Asn Tyr Arg Arg Ser Phe He Pro 180 185 190 Pro Gln His Thr Met Val Gly He Thr Arg Thr Asn Tyr Asn Gln He 195 200 205 Phe Asn Glu He Glu Val Gly Gln Arg Tyr Ser Tyr Lys Asn Leu Leu 210 215 220 Ser Phe Asn Thr Asn Tyr Phe Val He Phe Wing Lys Arg Tyr Tyr Wing 225 230 235 240 Gly Gly Tyr Ser Pro Gln Pro Val Asp Ala Arg Ser Gln Gly Val Glu 245 250 255 Leu Glu Leu Tyr Tyr Ala Pro He Arg Gly Leu Gln Phe His Val Ala 260 265 270 Tyr Thr Tyr He Asp Wing Arg He Thr Ser Asn Wing Asp Asp He Wing 275 280 285 Tyr Tyr Phe Thr Gly He Val Asn Lys Pro Phe Asp He Lys Gly Lys 290 295 300 Arg Leu Pro Tyr Val Ser Pro Asn Gln Phe He Phe Asp Met Met Tyr 305 310 315 320 Thr Tyr Lys His Thr Thr Phe Gly He Ser Ser Tyr Phe Tyr Ser Arg 325 330 335 Wing Tyr Ser Being Met Leu A = n Gln Wing Lys Asp Gln Thr Val Cys Leu 340 345 350 Pro Leu Asn Pro Glu Tyr Thr Gly Gly Leu Lys Tyr Gly Cys Asn Ser 355 360 365 Val Gly Leu Leu Pro Leu Tyr Phe Val Leu Asn Val Gln Val Ser Ser 370 375 380 He Leu Trp Gln Ser Gly Arg His Lys He Thr Gly Ser Leu Gln He 385 390 395 400 Asn Asn Leu Phe Asn Met Lys Tyr Tyr Phe Arg Gly He Gly Thr Ser 405 410 415 Pro Trn Gly Arg Glu Pro Wing Pro Gly Arg Ser He Thr Wing Tyr Leu 420 425 430 Asn Tyr Glu Phe 435 INFORMATION FOR SEC ID NO: 111: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 767 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 767 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 111: Met Lys Arg He Leu Val Ser Leu Wing Val Leu Ser His Ser Wing His 1 5 10 15 Wing Val Lys Thr Hís Asn Leu Glu Arg Val Glu Wing Ser Gly Val Wing 20 25 30 Asn Asp Lys Glu Ala Pro Leu Ser Trp Arg Ser Lys Glu Val Arg Asn 35 40 45 Tyr Met Gly Ser Arg Thr Val He Ser Asn Lys Gln Leu Thr Lys Ser 50 55 60 Wing Asn Gln Ser He Glu Glu Wing Leu Gln Asn Val Pro Gly Val His 65 70 75 80 He Arg Asn Be Thr Gly He Gly Wing Val Pro Be He Be He Arg 85 90 95 Gly Phe Gly Wing Gly Gly Pro Gly His Ser Asn Thr Gly Met He Leu 100 105 110 Val Asn Gly He Pro He Tyr Val Wing Pro Tyr Val Glu He Gly Thr 115 120 125 Val He Phe Pro Val Thr Phe Gln Ser Val Asp Arg He Ser Val Thr 130 135 140 Lys Gly Gly Glu Ser Val Arg Tyr Gly Pro Asn Ala Phe Gly Gly Val 145 150 155 160 He Asn He He Thr Lys Gly He Pro Thr Asn Trp Glu Ser Gln Val 165 170 175 Ser Glu Arg Thr Thr Phe Trp Gly Lys Ser Glu Asn Gly Gly Phe Phe 180 185 190 Asn Gln Asn Ser Lys Asn He Asp Lys Ser Leu Val Asn Asn Met Leu 195 200 205 Phe Asn Thr Tyr Leu Arg Thr Gly Gly Met Met Asn Lys His Phe Gly 210 215 220 He Gln Ala Gln Val Asn Trp Leu Lys Gly Gln Gly Phe Arg Tyr Asn 225 230 235 240 Ser Pro Thr Asp He Gln Asn Tyr Met Leu Asp Ser Leu Tyr Gln He 245 250 255 Asn Asp Ser Asn Lys He Thr Wing Phe Phe Gln Tyr Tyr Ser Tyr Phe 260 265 270 Leu Thr Asp Pro Gly Ser Leu Gly He Wing Wing Tyr Asn Gln Asn Arg 275 280 285 Phe Gln Asn Asn Arg Pro Asn Asn Asp Lys Ser Gly Arg Ala Lys Arg 290 295 300 Trp Gly Wing Val Tyr Gln Asn Phe Phe Gly Asp Thr Asp Arg Val Gly 305 310 315 320 Gly Asp Phe Thr Phe Ser Tyr Tyr Gly His Asp Met Ser Arg Asp Phe 325 330 335 Lys Phe Asp Ser Asn Tyr Leu Asn Val Asn Thr Asn Pro Lys Leu Gly 340 345 350 Pro Val Tyr Thr Asn Gln Asn Tyr Pro Gly Phe Phe He Phe Asp His 355 360 365 Leu Arg Arg Tyr Val Met Asn Wing Phe Glu Pro Asn Leu Asn Leu Val 370 375 380 Val Asn Thr Asn Lys Val Lys Gln Thr Phe Asn Val Gly Met Arg Phe 385 390 395 400 Met Thr Met Asp Met Phe He Arg Ser Asp Gln Ser Thr Cys Glu Lys 405 410 415 Thr Asp He He Asn Gly Val Cys His Met Pro Pro Tyr Val Leu Ser 420 425 430 Lys Thr Pro Asn Asn Asn Gln Glu Met Phe Asn Asn Tyr Thr Wing Val 435 440 445 Trp Leu Ser Asp Lys He Glu Phe Phe Asp Ser Lys Leu Val He Thr 450 455 460 Pro Gly Leu Arg Tyr Thr Phe Leu Asn Tyr Asn Asn Lys Glu Pro Glu 465 470 475 480 Lys His Asp Phe Ser Val Trp Thr Ser Lys Lys Gln Arg Gln Asn Glu 485 490 495 Trp Ser Pro Ala Leu Asn He Gly Tyr Lys Pro Met Glu Asn Trp He 500 505 510 Trp Tyr Wing Asn Tyr Arg Arg Ser Phe He Pro Pro Gln His Thr Met 515 520 525 Val Gly He Thr Arg Thr Asn Tyr Asn Gln He Phe Asn Glu He Glu 530 535 540 Val Gly Gln Arg Tyr Ser Tyr Lys Asn Leu Leu Ser Phe Asn Thr Asn 545 550 555 560 Tyr Phe Val He Phe Wing Lys Arg Tyr Tyr Wing Gly Gly Tyr Ser Pro 565 570 575 Gln Pro Val Asp Ala Arg Ser Gln Gly Val Glu Leu Glu Leu Tyr Tyr 580 585 590 Ala Pro He Arg Gly Leu Gln Phe His Val Ala Tyr Thr Tyr He Asp 595 600 605 Wing Arg He Thr Ser Asn Wing Asp Asp He Wing Tyr Tyr Phe Thr Gly 610 615 620 lie Val Asn Lys Pro Phe Asp He Lys Gly Lys Arg Leu Pro Tyr Val 630 635 640 Ser Pro Asn Gln Phe He Phe Asp Met Met Tyr Thr Tyr Lys His Thr 645 650 655 Thr Phe Gly He Ser Ser Tyr Phe Tyr Ser Arg Ala Tyr Ser Ser Met 660 665 670 Leu Asn Gln Ala Lys Asp Gln Thr Val Cys Leu Pro Leu Asn Pro Glu 675 680 685 Tyr Thr Gly Gly Leu Lys Tyr Gly Cys Asn Ser Val Gly Leu Leu Pro 690 695 700 Leu Tyr Phe Val Leu Asn Val Gln Val Ser Ser He Leu Trp Gln Ser 705 710 715 720 Gly Arg His Lys He Thr Gly Ser Leu Gln He Asn Asn Leu Phe Asn 725 730 735 Met Lys Tyr Tyr Phe Arg Gly He Gly Thr Ser Pro Thr Gly Arg Glu 740 745 750 Pro Wing Pro Gly Arg Be He Thr Wing Tyr Leu Asn Tyr Glu Phe 755 760 765 INFORMATION FOR SEC ID NO: 112: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 115 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 115 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 112: Leu His Pro Leu Cys Wing His Gly Gln Cys Gly Ser Glu Wing He Wing 1 5 10 15 Cya Leu Glu Wing He Ser Val Gly He Val Pro Val He Wing Asn Ser 20 25 30 Pro Leu Ser Ala Thr Arg Gln Phe Ala Leu Asp Glu Arg Ser Leu Phe 35 40 45 Glu Pro Asn Asn Ala Lys Asp Leu Ser Ala Lys He Asp Trp Trp Leu 50 55 60 Glu Asn Lys Leu Glu Arg Glu Arg Met Gln Asn Glu Tyr Ala Lys Ser 65 70 75 80 Ala Leu Asn Tyr Thr Leu Glu Asn Ser Val He Gln He Glu Lys Val 85 90 95 Tyr Glu Glu Ala He Lys Asp Phe Lys Asn Asn Pro Asn Leu Phe Lys 100 105 110 Thr Leu Ser 115 (2) INFORMATION FOR SEQ ID NO: 113: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 389 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 389 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 113: Met Val He Val Leu Val Val Asp Ser Phe Lys Asp Thr Ser Asn Gly 1 5 10 15 Thr Ser Met Thr Wing Phe Arg Phe Phe Glu Wing Leu Lys Lys Arg Gly 20 25 30 His Wing Met Arg Val Val Wing Pro His Val Asp Asn Leu Gly Ser Glu 40 45 Glu Glu Gly Tyr Tyr Asn Leu Lys Glu Arg Tyr He Pro Leu Val Thr 50 55 60 Glu He Ser His Lys Gln His He Leu Phe Ala Lys Pro Asp Glu Lys 65 70 75 80 He Leu Arg Lys Wing Phe Lys Gly Wing Asp Met He His Thr Thyr Tyr Leu 85 90 95 Pro Phe Leu Leu Glu Lys Thr Wing Val Lys He Wing Arg Glu Met Arg 100 105 110 Val Pro Tyr He Gly Ser Phe His Leu Gln Pro Glu His He Ser Tyr 115 120 125 Asn Met Lys Leu Gly Gln Phe Ser Trp Leu Asn Thr Met Leu Phe Ser 130 135 140 Trp Phe Lys Ser Ser His Tyr Arg Tyr He His His He His Cys Pro 145 150 155 160 Ser Lys Phe He Val Glu Glu Leu Glu Lys Tyr Asn Tyr Gly Gly Lys 165 170 175 Lys Tyr Ala He Ser Asn Gly Phe Asp Pro Met Phe Lys Phe Glu His 180 185 190 Pro Gln Lys Ser Leu Phe Asp Thr Thr Pro Phe Lys He Wing Met Val 195 200 205 Gly Arg Tyr Ser Asn Glu Lys Asn Gln Ser Val Leu He Lys Ala Val 210 215 220 Ala Leu Ser Arg Tyr Lys Gln Asp He Val Leu Leu Leu Lys Gly Lys 225 230 235 240 Gly Pro Asp Glu Lys Lys He Lys Leu Leu Wing Gln Lys Leu Gly Val 245 250 255 Lys Thr Glu Phe Gly Phe Val Asn Ser His Glu Leu Leu Glu He Leu 260 265 270 Lys Thr Cys Thr Leu Tyr Wing His Thr Wing Asn Val Glu Ser Glu Wing 275 280 285 He Ala Cys Leu Glu Ala He Ser Val Gly He Val Pro Val He Ala 290 295 300 (2) INFORMATION FOR SEQ ID NO: 114 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 312 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (üi) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 312 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 114 Leu Ala Ser Tyr Gly Phe Phe Leu Gly Ala Leu Phe He Leu Wing Ser 1 5 10 15 Gly He Val Cys Leu Gln Thr Ala Gly Asn Pro Phe Val Thr Leu Leu 20 25 30 Ser Lys Gly Lys Glu Wing Arg Asn Leu Val Leu Val Gln Wing Phe Asn 35 40 45 Being Leu Gly Thr Thr Leu Gly Pro Th Phe Gly Being Leu Th Leu He Phe 50 55 60 Be Wing Thr Lys Thr Ser Asp Asn Leu Ser Leu He Asp Lys Leu Wing 65 70 75 80 Asp Ala Lys Ser Val Gln Met Pro Tyr Leu Gly Leu Ala Val Phe Ser 85 90 95 Leu Leu Leu Leu Val Val Met Tyr Leu Leu Leu Pro Asp Val Glu 100 105 110 Lys Glu Met Pro Lys Glu Thr Thr Gln Lys Ser Leu Phe Ser His Lys 115 120 125 His Phe Val Phe Gly Ala Leu Gly He Phe Phe Tyr Val Gly Gly Glu 130 135 140 Val Ala He Gly Ser Phe Leu Val Leu Ser Phe Glu Lys Leu Leu Asn 145 150 155 160 Leu Asp Ala Gln Ser Ser Ala His Tyr Leu Val Tyr Tyr Trp Gly Gly 165 170 175 Wing Met Val Gly Arg Phe Leu Gly Be Wing Leu Met Asn Lys He Wing 180 185 190 Pro Asn Lys Tyr Leu Wing Phe Asn Wing Leu Being Ser He He Leu He 195 200 205 Ala Leu Ala He Leu He Gly Gly Lys He Ala Leu Phe Ala Leu Thr 210 215 220 Phe Val Gly Phe Phe Asn Be He Mer Phe Pro Thr He Phe Ser Leu 225 230 235 240 Wing Thr Leu Asn Leu Gly His Leu Thr Ser Lys Wing Ser Gly Val He 245 250 255 Ser Met Wing He Val Gly Gly Wing Leu He Pro Pro He Gln Gly Val 260 265 270 Val Thr Asp Met Leu Thr Ala Thr Glu Ser Asn Leu Leu Tyr Ala Tyr 275 280 285 Ser Val Pro Leu Leu Cys Tyr Phe Tyr He Leu Phe Phe Ala Leu Lys 290 295 300 Gly Tyr Lys Gln Glu Glu Asn Ser 305 310 INFORMATION FOR SEC ID NO: 115: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 407 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 407 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 115: Met Gln Lys Thr Ser Asn Thr Leu Ala Leu Gly Ser Leu Thr Ala Leu 1 5 10 15 Phe Phe Leu Met Gly Phe He Thr Val Leu Asn asp He Leu He Pro 20 25 30 His Leu Lys Pro He Phe Asp Leu Thr Tyr Phe Glu Wing Ser Leu He 35 40 45 Gln Phe Cys Phe Phe Gly Wing Tyr Phe He Met Gly Gly Val Phe Gly 50 55 60 Asn Val He Ser Lys He Gly Tyr Pro Phe Gly Val Val Leu Gly Phe 65 70 75 80 Val He Thr Wing Ser Gly Cys Wing Leu Phe Tyr Pro Wing Wing His Phe 85 90 95 Gly Ser Tyr Gly Phe Phe Leu Gly Ala Leu Phe He Leu Wing Ser Gly 100 105 110 He Val Cys Leu Gln Thr Wing Gly Asn Pro Phe Val Thr Leu Leu Ser 115 120 125 Lys Gly Lys Glu Wing Arg Asn Leu Val Leu Val Gln Wing Phe Asn Ser 130 135 140 Leu Gly Thr Thr Leu Gly Pro He Phe Gly Ser Leu Leu He Phe Ser 145 150 155 160 Wing Thr Lys Thr Ser Asp Asn Leu Ser Leu He Asp Lys Leu Wing Asp 165 170 175 Wing Lys Ser Val Gln Met Pro Tyr Leu Gly Leu Wing Val Phe Ser Leu 180 185 190 Leu Leu Ala Leu Val Met Tyr Leu Leu Lys Leu Pro Asp Val Glu Lys 195 200 205 Glu Met Pro Lys Glu Thr Thr Gln Lys Ser Leu Phe Ser His Lys His 210 215 220 Phe Val Phe Gly Ala Leu Gly He Phe Phe Tyr Val Gly Gly Glu Val 225 230 235 240 Wing He Gly Ser Phe Leu Val Leu Ser Phe Glu Lys Leu Leu Asn Leu 245 250 255 Asp Ala Gln Ser Ser Ala His Tyr Leu Val Tyr Tyr Trp Gly Gly Ala 260 265 270 Met Val Gly Arg Phe Leu Gly Be Ala Leu Met Asn Lys He Ala Pro 275 280 285 Asn Lys Tyr Leu Wing Phe Asn Wing Leu Being Ser He He Leu He Wing 290 295 300 Leu Ala He Leu He Gly Gly Lys He Ala Leu Phe Ala Leu Thr Phe 305 310 315 320 Val Gly Phe Phe Asn Ser Met Met Phe Pro Thr He Phe Ser Leu Ala 325 330 335 Thr Leu Asn Leu Gly His Leu Thr Ser Lys Wing Ser Gly Val He Ser 340 345 350 Met Wing He Val Gly Gly Wing Leu He Pro Pro Hr Gln Gly Val Val 355 360 365 Thr Asp Met Leu Thr Ala Thr Glu Ser Asn Leu Leu Tyr Ala Tyr Ser 370 375 380 Val Pro Leu Leu Cys Tyr Phe Tyr He Leu Phe Phe Ala Leu Lys Gly 385 390 395 400 Tyr Lys Gln Glu Glu Asn Ser 405 (2) INFORMATION FOR SEC ID NO: 116: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 125 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 125 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 116: Met Asn Lys He Ala Pro Asn Lys Tyr Leu Ala Phe Gly Ala Leu Ser 1 5 10 15 Ser He He Leu He Wing Leu Wing He He Leu He Gly Gly Lys He Wing 25 30 Leu Phe Ala Leu Thr Phe Val Gly Phe Phe Asn Ser Met Met Phe Pro 35 40 45 Thr He Phe Ser Leu Wing Thr Leu Asn Leu Gly He Ser Leu Leu Met 50 55 60 Wing Ser Gly Val He Ser Mer Wing He Val Gly Gly Wing Leu He Pro 65 70 75 80 Pro He Gln gly Val Val Thr Asp Met Leu Thr Ala Thr Glu Ser Asn 85 90 95 Leu Leu Tyr Ala Tyr Ser Val Pro Leu Leu Cys Tyr Phe Tyr He Leu 100 105 110 Phe Phe Ala Leu Lys Gly Tyr Lys Gln Glu Glu Asn Ser 115 120 125 ) INFORMATION FOR SEQ ID NO: 117: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 330 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 330 [xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 117: Leu Lys Lys He Leu Pro Leu Leu Leu Met Gly Phe Val Gly Leu Asn 1 5 10 15 Wing Being Asp Arg Leu Leu Glu He Met Arg Leu Tyr Gln Lys Gln Gly 20 25 30 Leu Glu Val Val Gly Gln Lys Leu Asp Ser Tyr Leu Wing Asp Lys Ser 35 40 45 Phe Trp Wing Glu Glu Leu Gln Asn Lys Asp Thr Asp Phe Gly Tyr Tyr 50 55 60 Gln Asn Lys Gln Phe Leu Phe Val Wing Asp Lys Ser Lys Pro Ser Leu 65 70 75 80 Glu Phe Tyr Glu He Glu Asn Asn Met Leu Lys Lys He Asn Ser Ser 85 90 95 Lys Ala Leu Val Gly Ser Lys Lys Gly Asp Lys Thr Leu Glu Gly Asp 100 105 110 Leu Ala Thr Pro He Gly Val Tyr Arg He Thr Gln Lys Leu Glu Arg 115 120 125 Leu Asp Gln Tyr Tyr Gly Val Leu Wing Phe Val Thr Asn Tyr Pro Asn 130 135 140 Leu Tyr Asp Thr Leu Lys Lys Arg Thr Gly His Gly He Trp Val His 145 150 155 160 Gly Met Pro Leu Asn Gly Asp Arg Asñ Glu Leu Asn Thr Lys Gly Cys 165 170 175 He Ala He Glu Asn Pro He Leu Ser Ser Tyr Asp Lys Val Leu Lys 180 185 190 Gly Glu Lys Wing Phe Leu He Thr Tyr Glu Asp Lys Phe Ser Pro Ser 195 200 205 Thr Lys Glu Glu Leu be Met He Leu Ser Ser Leu Phe Gln Trp Lys 210 215 220 Glu Wing Trp Wing Arg Gly Asp Phe Glu Arg tyr Met Arg Phe Tyr Asn 225 230 235 240 Pro Asn Phe Thr Arg Tyr Asp Gly Met Ser Phe Asn Wing Phe Lys Glu 245 250 255 Tyr Lys Lys Arg Val Phe Wing Lys Asn Glu Lys Lys Asn He Wing Phe 260 265 270 Ser Ser He Asn Val He Pro Tyr Pro Asn Ser Gln Asn Lys Arg Leu 275 280 285 Phe Tyr Val Val Phe Asp Gln Asp Tyr Lys Ala Tyr Gln Gln Asn Lys 290 295 300 Leu Ser Tyr Ser Ser Asn Ser Gln Lys Glu Leu Tyr Val Glu He Glu 305 310 315 320 Asn Asn Gln Ala Ser He He Met Met Glu Lys 325 330 INFORMATION FOR SEC ID NO: 118: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 169 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 169 (xi) DESCRIPTION OF LGA SEQUENCE: SEQ ID NO: llf Leu Phe Glu Lys Trp He Gly Leu Thr Leu Leu Leu Ser Ser Leu Gly 1 5 10 15 Tyr Pro Cys Gln Lys Val Ser He Ser Phe Lys Gln Tyr Glu Asn Leu 25 30 He His He His Gln Lys Gly Cys Asn Asn Glu Val Val Cys Arg Thr 35 40 45 Leu He Ser Be Ala Leu Leu Glu Be Ser Leu Gly Leu Asn Asn Lys 50 55 60 Arg Glu Lys Ser Leu Lys Asp Thr Ser Tyr Ser Met Phe His He Thr 65 70 75 80 Leu Asn Thr Ala Lys Lys Phe Tyr Pro Thr Tyr Ser Lys Thr Leu Leu 85 90 95 Lys Thr Lys Leu Leu Asn Asp Val Gly Phe Ala He Gln Leu Ala Lys 100 105 110 Gln He Leu Lys Glu Asn Phe Asp Tyr Tyr His Gln Lys His Pro Asn 115 12Q 125 Lys Ser Val Tyr Gln Leu Val Gln Met Wing He Gly Wing Tyr Asn Gly 130 135 140 Gly Met Lys His Asn Pro Asn Gly Wing Tyr Met Lys Lys Phe Arg Cys 145 150 155 160 He Tyr Ser Gln Val Arg Tyr Asn Glu 165 INFORMATION FOR SEC ID NO: 119: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 215 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTIC:. (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 215 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 119: Met Lys Lys Pro Tyr Arg Lys He Ser Asp Tyr Wing He Val Gly Gly 1 5 10 15 Leu Ser Ala Leu Val Met Val Ser He Val Gly Cys Lys Ser Asn Ala 20 25 30 Asp Asp Lys Pro Lys Glu Gln Ser Ser Leu Ser Gln Ser Val Gln Lys 35 40 45 Gly Ala Phe Val He Leu Glu Glu Gln Lys Asp Lys Ser Tyr Lys Val 50 55 60 Val Glu Glu Tyr Pro Ser Ser Arg Thr His He Val Val Arg Asp Leu 65 70 75 80 Gln Gly Asn Glu Arg Val Leu Ser Asn Glu Glu He Gln Lys Leu He 85 90 95 Lys Glu Glu Glu Wing Lys He Asp Asn Gly Thr Ser Lys Leu Val Gln 100 105 110 Pro Asn Asn Gly Gly Ser Asn Glu Gly Ser Gly Phe Gly Leu Gly Ser 115 120 125 Wing He Leu Gly Wing Wing Wing Gly Wing He Leu Gly Ser Tyr He Gly 130 135 140 Asn Lys Leu Phe Asn Asn Pro Asn Tyr Gln Gln Asn Wing Gln Arg Thr 145 150 155 160 Tyr Lys Ser Pro Gln Wing Tyr Gln Arg Ser Gln Asn Ser Phe Ser Lys 165 170 175 Be Ala Pro Be Ala Be Ser Met Gly Thr Ala Be Lys Gly Gln Ser 180 185 190 Gly Phe Phe Gly Being Ser Arg Pro Thr Ser Ser Pro Pro Wing Being Ser 195 200 205 Gly Thr Arg Gly Phe Asn Wing 210 215 (2) INFORMATION FOR SEC ID NO: 120: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 253 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 253 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 120: Leu Lys Thr Leu Phe Ser Val Tyr Leu Phe Leu Ser Leu Asn Pro Leu 1 5 10 15 Phe Leu Glu Ala Lys Glu He Thr Trp Ser Gln Phe Leu Glu Asn Phe 20 25 30 Lys Asn Lys Asn Glu Asp Asp Lys Pro Lys Pro Leu Thr He Asp Lys 35 40 45 Asn Asn Glu Lys Gln Gln He Leu Asp Lys Asn Gln Gln He Leu Lys 50 55 60 Arg Ala Leu Glu Lys Ser Leu Lys Phe Phe Phe He Phe Gly Tyr Asn 65 70 75 80 Tyr Ser Gln Wing Wing Tyr Ser Thr Thr Asn Gln Asn Leu Thr Leu Thr 85 90 95 Wing Asn Ser He Gly Phe Asn Thr Wing Thr Gly Leu Glu His Phe Leu 100 105 110 Arg Asn His Pro Lys Val Gly Phe Arg He Phe Ser Val Tyr Asn Tyr 115 120 125 Phe His Ser Val Ser Leu Ser Gln Pro Gln He Leu Met Val Gln Asn 130 135 140 Tyr Gly Gly Ala Leu Asp Phe Ser Trp He Phe Val Asp Lys Lys Thr 145 150 155 160 Tyr Arg Phe Arg Ser Tyr Leu Gly He Wing Leu Glu Gln Gly Val Leu 165 170 175 Leu Val Asp Thr He Lys Thr Gly Ser Phe Thr Thr He He Pro Arg 180 185 190 Thr Lys Lys Thr Phe Phe Gln Wing Pro Leu Arg Phe Gly Phe He Val 195 200 205 Asp Phe He Gly Tyr Leu Ser Leu Gln Leu Gly He Glu Met Pro Leu 210 215 220 Val Arg Asn Val Phe Tyr Thr Tyr Asn Asn His Gln Glu Arg Phe Lys 225 230 235 240 Pro Arg Phe Asn Wing Asn Leu Ser Leu He Val Ser Phe 245 250 INFORMATION FOR SEC ID NO: 121: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 336 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 121; Leu Phe Phe Lys Phe He Leu Cys Leu Ser Leu Gly He Phe Wing Trp 1 5 10 15 Wing Lys Glu Val He Pro Thr Pro Ser Thr Pro Leu Thr Pro Ser Lys 20 25 30 Arg Tyr Ser He Asn Leu Met Thr Glu Asn Asp Gly Tyr He Asn Pro 35 40 45 Tyr He Asp Glu Tyr Tyr Thr Wing Gly Asn Gln He Gly Phe Ser Thr 50 55 60 Lys Glu Phe Asp Phe Ser Lys Asn Lys Wing Met Lys Trp Ser Ser Tyr 65 70 75 80 Leu Gly Phe Phe Asn Lys Ser Pro Arg Val Thr Arg Phe Gly He Ser 85 90 95 Leu Ala Gln Asp Met Tyr Thr Pro Ser Leu Ala Asn Arg Lys Leu Val 100 105 110 His Leu His Asp Asn His Pro Tyr Gly Gly Tyr Leu Arg Val Asn Leu 115 120 125 Asn Val Tyr Asn Arg His Gln Thr Phe Met Glu Leu Phe Thr He Ser 130 135 140 Leu Gly Thr Thr Gly Gln Asp Ser Leu Ala Wing Gln Thr Gln Arg Leu 145 150 155 160 He His Lys Trp Gly His Asp Pro Gln Phe Tyr Gly Trp Asn Thr Gln 165 170 175 Leu Lys Asn Glu Phe He Phe Glu Leu His Tyr Gln Leu Leu Lys Lys 180 185 190 Val Pro Leu Leu Lys Thr Arg Phe Phe Ser Met Glu Leu Met Pro Gly 195 200 205 Phe Asn Val Glu Leu Gly Asn Wing Arg Asp Tyr Phe Gln Leu Gly Ser 210 215 220 Leu Phe Arg Wing Gly Tyr Asn Leu Asp Wing Asp Tyr Gly Val Asn Lys 225 230 235 240 Val Asn Thr Wing Phe Asp Gly Gly Met Pro Tyr Ser Asp Lys Phe Ser 245 250 255 He Tyr Phe Phe Wing Gly Wing Phe Gly Arg Phe Gln Pro Leu Asn He 260 265 270 Phe He Gln Gly Asn Ser Pro Glu Thr Arg Gly He Wing Asn Leu Glu 275 280 285 Tyr Phe Val Tyr Wing Ser Glu He Gly Wing Wing Met Met Trp Arg Ser 290 295 300 Leu Arg Val Wing Phe Thr He Thr Asp He Ser Lys Thr Phe Gln Ser 305 310 315 320 Gln Pro Lys His His Gln He Gly Thr Leu Glu Leu Asn Phe Wing Phe 325 330 * 335 INFORMATION FOR SEC ID NO: 122 i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 108 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein dii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 108 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 122: Met Lys Pro He Phe Ser Leu Phe Phe Leu Leu He Val Leu Lys Ala 1 5 10 15 His Pro He Asn Pro Leu Leu Glu Pro Leu Tyr Phe Pro Ser Tyr Thr 20 25 30 Gln Phe Leu Asp Leu Glu Pro His Phe Val He Lys Lys Lys Arg Ala 35 40 45 Tyr Arg Pro Phe Gln Trp Gly Asn Thr He He He Lys Arg His Asp 50 55 60 Leu Glu Glu Arg Gln Ser Asn Gln Pro Be Asp He Phe Arg Gln Asn 65 70 75 80 Ala Glu He Asn Val Ser Ser Gln Thr Phe Leu Arg Gly He Ser Ser 85 90 95 Ala Ser Ser Arg He Val He Asp Ser Val Ala Gln 100 105 (2) INFORMATION FOR SEC ID NO :: 123 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 195 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 195 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 123: Met Being Asn Asn Pro Phe Lys Lys Val Gly Met Being Ser Gln Asn 1 5 10 15 Asn Asn Gly Ala Leu Asn Gly Leu Gly Val Gln Val Gly Tyr Lys Gln 20 25 30 Phe Phe Gly Glu Ser Lys Arg Trp Gly Leu Arg Tyr Tyr Gly Phe Phe 35 40 45 Asp Tyr Asn His Gly Tyr He Lys Ser Ser Phe Phe Asn Ser Ser Ser 50 55 60 Asp He Trp Thr Tyr Gly Gly Gly Ser Asp Leu Leu Val Asn Phe He 65 70 75 80 Asn Asp Ser He Thr Arg Lys Asn Asn Lys Leu Ser Val Gly Leu Phe 85 90 95 Gly Gly He Gln Leu Wing Gly Thr Thr Trp Leu Asn Ser Gln Tyr Met 100 105 110 Asn Leu Thr Ala Phe Asn Asn Pro Tyr Ser Ala Lys Val Asn Ala Ser 115 120 125 Asn Phe Gln Phe Leu Phe Asn Leu Gly Leu Arg Thr Asn Leu Wing Thr 130 135 140 Wing Lys Lys Lys Asp Ser Glu Arg Wing Wing Gln His Gly Wing Glu Leu 145 150 155 160 Gly He Lys He Pro Thr He Asn Thr Asn Tyr Tyr Ser Phe Leu Gly 165 170 175 Thr Lys Leu Glu Tyr Arg Arg Leu Tyr Ser Val Tyr Leu Asn Tyr Val 180 185 190 Phe Ala Tyr 195 (2) INFORMATION FOR SEQ ID NO: 124: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 227 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 227 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 124 Val Arg Phe Gly Lys He Asp Tyr Leu Asn Met Leu Pro Phe Asp Val 1 5 10 15 Phe He Lys Ser Tyr Pro Thr Pro Cys Tyr Phe Lys Gln Phe Leu Arg 20 25 30 Leu Lys Lys Thr Tyr Pro Ser Lys Leu Asn Glu Ser Phe Leu Phe Arg 35 40 45 Arg He Asp Wing Gly Phe He Be Ser Wing Wing Gly Tyr Pro Phe Wing 50 55 60 Leu Cys Ser Tyr Ser Leu Gly He Val Wing Tyr Lys Glu Val Leu Ser 65 70 75 80 Val Leu Val Val Asn Arg Glu Asn Ala Phe Asp Lys Glu Be Ala Be 85 90 95 Being Asn Ala Leu Being Lys Val Leu Gly Leu Lys Gly Glu Val Leu He 100 105 110 Gly Asn Lys Ala Leu Gln Phe Tyr Tyr Ser Asn Pro Lys Lys Asp Phe 115 120 125 He Asp Leu Ala Ala Leu Trp Tyr Glu Lys Lys Arg Leu Pro Phe Val 130 135 140 Phe Gly Arg Leu Cys Tyr Tyr Gln Asn Lys Asp Phe Tyr Lys Arg Leu 145 150 155 160 Ser Leu Ala Phe Lys His Gln Lys Thr Lys He Pro His Tyr He Leu 165 170 175 Lys Glu Ala Ala Leu Lys Thr Asn Leu Lys Arg Gln Asp He Leu Asn 180 185 190 Tyr Leu Gln Lys He Tyr Tyr Thr Leu Gly Lys Lys Glu Gln Ser Gly 195 200 205 Leu Lys Wing Phe Tyr Arg Glu Leu Leu Phe Lys Arg He Gln Lys Pro 210 215 220 Lys Arg Phe 225 (2) INFORMATION FOR SEC ID NO: 125: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 305 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 305 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 125: Met Gly Arg He Glu Ser Lys Lys Arg Leu Lys Ala Leu He Phe Leu 1 5 10 15 Ala Ser Leu Gly Val Leu Trp Gly Asn Ala Ala Glu Lys Thr Pro Phe 25 30 Phe Lys Thr Lys Asn His He Tyr Leu Gly Phe Arg Leu Gly Thr Gly 40 45 Wing Thr Thr Arg Thr Ser Met Trp Gln Gln Wing Tyr Lys Asp Asn Pro 50 55 60 Thr Cys Pro Ser Ser Val Cys Tyr Gly Glu Lys Leu Glu Wing Lys Tyr 65 70 75 80 Lys Gly Gly Lys Asn Leu Ser Tyr Thr Gly Gln He Gly Asp Glu He 85 90 95 Wing Phe Asp Lys Tyr His He Leu Gly Leu Arg Val Trp Gly Asp Val 100 105 110 Glu Tyr Ala Lys Ala Gln Leu Gly Gln Lys Val Gly Gly Asn Thr Leu 115 120 125 Leu Ser Gln Wing Asn Tyr Asn Pro Ser Wing He Lys Thr Tyr Asp Pro 130 135 140 Thr Ser Asn Wing Gln Gly Ser Leu Val Leu Gln Lys Thr Pro Ser Pro 145 150 155 160 Gln Asp Phe Leu Phe Asn Asn Gly His Phe Met Wing Phe Gly Leu Asn 165 170 175 Val Asn Met Phe Val Asn Leu Pro He Asp Thr Leu Leu Lys Leu Wing 180 185 190 Leu Lys Thr Glu Lys Met Leu Phe Phe Lys He Gly Val Phe Gly Gly 195 200 205 Gly Gly Val Glu Tyr Ala He Leu Trp Ser Pro Gln Tyr Lys Asn Gln 210 215 220 Asn Thr His Gln Asp Asp Lys Phe Phe Wing Wing Gly Gly Gly Phe Phe 225 230 235 240 Val Asn Phe Gly Gly Ser Leu Tyr He Gly Lys Arg Asn Arg Phe Asn 245 250 255 Val Gly Leu Lys He Pro Tyr Tyr Ser Leu Ser Wing Gln Ser Trp Lys 260 265 270 Asn Phe Gly Be Ser Asn Val Trp Gln Gln Gln Thr He Arg Gln Asn 275 280 285 Phe Ser Val Phe Arg Asn Lys Glu Val Phe Val Ser Tyr Ala Phe Leu 290 295 300 Phe 305 (2) INFORMATION FOR SEQ ID NO: 126: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 258 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc__característica (B) LOCATION: 1 ... 258 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 126: Met Phe Leu Arg Ser Tyr Pro Lys Leu Arg Tyr Ala Leu Cys Leu Pro 1 5 10 15 Leu Leu Thr Glu Thr Cys Tyr Ser Glu Glu Arg Thr Leu Asn Lys Val 20 25 30 Thr Thr Gln Wing Lys Arg He Phe Thr Tyr Asn Asn Glu Phe Lys Val 35 40 45 Thr Ser Lys Glu Leu Asp Gln Arg Gln Ser Asn Glu Val Lys Asp Leu 50 55 60 Phe Arg Thr Asn Pro Asp Val Asn Val Gly Gly Gly Ser Val Met Gly 65 70 75 80 Gln Lys He Tyr Val Arg Gly He Glu Asp Arg Leu Leu Arg Val Thr 85 90 95 Val Asp Gly Ala Ala Gln Asn Gly Asn He Tyr His His Gln Gly Asn 100 105 110 Thr Val He Asp Pro Gly Met Leu Lys Ser Val Glu Val Thr Lys Gly 115 120 125 Ala Ala Asn Ala Be Ala Gly Pro Gly Ala He Ala Gly Val He Lys 130 135 140 Met Glu Thr Lys Gly Wing Wing Asp Phe He Pro Arg Gly Lys Asn Tyr 145 150 155 160 Ala Ala Ser Gly Ala Val Ser Phe Tyr Thr Asn Phe Gly Asp Arg Glu 165 170 175 Thr Phe Arg Ser Ala Tyr Gln Ser Ala His Phe Asp He He Ala Tyr 180 185 190 Tyr Thr His Gln Asn He Phe Tyr Tyr Arg Ser Gly Wing Thr Val Met 195 200 205 Lys Asn Leu Phe Lys Pro Thr Gln Wing Asp Lys Glu Pro Gly Thr Pro 200 205 '210 Ser Glu Gln Asn Asn Ala Leu He Lys Met Asn Gly Tyr Leu Ser Asp 225 230 235 240 Arg Asp Thr Leu Thr Phe Ser Trp Asn Met Thr Arg Asp Asn Ala Thr 245 250 255 Arg Leu (2) INFORMATION FOR SEC ID NO: 127: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 192 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear di) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 192 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 127: Met Phe Leu Arg Ser Tyr Pro Lys Leu Arg Tyr Ala Leu Cys Leu Pro 1 5 10 15 Leu Leu Thr Glu Thr Cys Tyr Ser Glu Glu Arg Thr Leu Asn Lys Val 20 25 30 Thr Thr Gln Wing Lys Arg He Phe Thr Tyr Asn Asn Glu Phe Lys Val 35 40 45 Thr Ser Lys Glu Leu Asp Gln Arg Gln Ser Asn Glu Val Lys Asp Leu 50 55 60 Phe Arg Thr Asn Pro Asp Val Asn Val Gly Gly Ser Val Val Met Gly 65 70 75 80 Gln Lys He Tyr Val Arg Gly He Glu Asp Arg Leu Leu Arg Val Thr 85 90 95 Val Asp Gly Ala Ala Gln Asn Gly Asn He Tyr His His Gln Gly Asn 100 105 110 Thr Val He Asp Pro Gly Met Leu Lys Ser Val Glu Val Thr Lys Gly 115 120 125 Ala Ala Asn Ala Be Ala Gly Pro Gly Ala He Ala Gly Val He Lys 130 135 140 Met Glu Thr Lys Gly Wing Wing Asp Phe He Pro Arg Gly Lys Asn Tyr 145 150 155 160 Ala Ala Ser Gly Ala Val Ser Phe Tyr Thr Asn Phe Gly Asp Arg Glu 165 170 175 Thr Phe Arg Ser Wing Tyr Gln Ser Wing His Phe Asp He He Wing Tyr 180 185 190 (2) INFORMATION FOR SEC ID NO: 128: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 126 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 126 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 128: Val Pro Leu Ser Leu Gly Gly Asn Leu Leu Asn Pro Asn Asn Ser Ser 1 5 10 15 Val Leu Asn Leu Lys Asn Ser Gln Leu Val Phe Ser Asp Gln Gly Ser 20 25 30 Leu Asn He Ala Asn He Asp Leu Leu Ser Asp Leu Asn Gly Asn Lys 35 40 45 Asn Arg Val Tyr Asn He He Gln Wing Asp Met Asn Gly Asn Trp Tyr 50 55 60 Glu Arg He Asn Phe Phe Gly Met Arg He Asn Asp Gly He Tyr Asp 65 70 75 80 Wing Lys Asn Gln Thr Tyr Ser Phe Thr Asn Pro Leu Asn Asn Wing Val 85 90 95 Lys Phe Thr Glu Be Phe Phe He His Arg Leu Cys Gly Ser Leu Ser 100 105 110 Gln He Gln Lys Lys Lys Asn Thr He Val Ser Pro Arg Leu 115 120 125 INFORMATION FOR SEC ID NO: 129: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 565 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 565 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 129: Val Tyr Ser Tyr Ser Asp Asp Ala Gln Gly Val Phe Tyr Leu Thr Ser 1 5 10 15 Ser Val Lys Gly Tyr Tyr Asn Pro Asn Gln Ser Tyr Gln Wing Ser Gly 20 25 30 Ser Asn Asn Thr Thr Lys Asn Asn Asn Leu Thr Ser Glu Ser Ser Val 35 40 45 He Be Gln Thr Tyr Asn Wing Gln Gly Asn Pro He Wing Wing Leu His 50 55 '60 Val Tyr Asn Lys Gly Tyr Asn Phe Ser Asn He Lys Wing Leu Gly Gln 65 70 75 80 Met Ala Leu Lys Leu Tyr Pro Glu He Lys Lys He Leu Gly Asn Asp 85 90 95 Phe Ser Leu Ser Ser Leu Ser Asn Leu Lys Gly Asp Ala Leu Asn Gln 100 105 110 Leu Thr Lys Leu He Thr Pro Ser Asp Trp Lys Asn He Asn Glu Leu 115 120 125 He Asp Asn Wing Asn Asn Ser Val Val Gln Asn Phe Asn Asn Gly Thr 130 135 140 Leu He He Gly Wing Thr Lys He Gly Gln Thr Asp Thr Asn Ser Wing 145 '150 155 160 Val Val Phe Gly Gly Leu Gly Tyr Gln Lys Pro Cys Asp Tyr Thr Asp 165 170 175 He Val Cys Gln Lys Phe Arg Gly Thr Tyr Leu Gly Gln Leu Leu Glu 180 185 .190 Being Asn Being Wing Asp Leu Gly Tyr He Asp Thr Thr Phe Asn Wing Lys 195 200 '205 Glu He Tyr Leu Thr Gly Thr Leu Gly Ser Gly Asn Wing Trp Gly Thr 210 215 220 Gly Gly Ser Ala Ser Val Thr Phe Asn Ser Gln Thr Ser Leu He Leu 225 230 235 240 Asn Gln Ala Asn lie Val Ser Ser Gln Thr Asp Gly He Phe Ser Met 245 250 255 Leu Gly Gln Glu Gly He Asn Lys Val Phe Asn Gln Wing Gly Leu Wing 260 265 270 Asn He Leu Gly Glu Val Wing Met Gln Ser He Asn Lys Wing Gly Gly 275 280 285 Leu Gly Asn Leu He Val Asn Thr Leu Gly Ser Asp Ser Val He Gly 290 295 300 Gly Tyr Leu Thr Pro Glu Gln Lys Asn Gln Thr Leu Ser Gln Leu Leu 305 310 315 320 Gly Gln Asn Asn Phe Asp Asn Leu Met Asn Asp Ser Gly Leu Asn Thr 325 330 335 Ala He Lys Asp Leu He Arg Gln Lys Leu Gly Phe Trp Thr Gly Leu 340 345 350 Val Gly Gly Leu Wing Gly Leu Gly Gly He Asp Leu Gln Asn Pro Glu 355 360 365 Lys Leu He Gly Ser Met Ser He Asn Asp Leu Leu Ser Lys Lys Gly 370 375 380 Leu Phe Asn Gln He Thr Gly Phe He Ser Wing Asn Asp He Gly Gln 385 390 395 400 Val He Ser Val Met Leu Gln Asp He Val Lys Pro Ser Asp Ala Leu 405 410 415 Lys Asn Asp Val Ala Wing Leu Gly Lys Gln Met He Gly Glu Phe Leu 420 425 430 Gly Gln Asp Thr Leu Asn Ser Leu Glu Ser Leu Leu Gln Asn Gln Gln 435 440 445 He Lys Ser Val Leu Asp Lys Val Leu Ala Wing Lys Gly Leu Gly Ser 450 455 460 He Tyr Glu Gln Gly Leu Gly Asp Leu He Pro Asn Leu Gly Lys Lys 465 470 475 480 Gly He Phe Wing Pro Tyr Gly Leu Ser Gln Val Trp Gln Lys Gly Asp 485 490 495 Phe Ser Phe Asn Wing Gln Gly Asn Val Phe Val Gln Asn Ser Thr Phe 500 505 510 Being Asn Wing Asn Gly Gly Thr Leu Being Phe Asn Wing Gly Asn Being Leu 515 520 525 He Phe Wing Gly Asn Asn His He Wing Phe Thr Asn His Ser Gly Thr 530 535 540 Leu Asn Leu Leu Be Asn Gln Val Be Asn He Asn Val Thr Met Leu 545 550 555 560 Asn Ala Ala Thr Ala 565 INFORMATION FOR SEC ID NO: 130; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 172 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 172 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 130: Val Phe Gly Leu Ser Leu Wing Asp Met He Leu Glu Arg Phe Lys Asp 1 5 10 15 Phe Met Arg Glu Tyr Pro Glu Pro Tyr Lys Phe Leu Gln Val Phe Tyr 20 25 30 Wing Gln Glu Lys Glu Arg Phe Leu Asn His Lys Met Asn Asp Tyr He 35 40 45 Lys Gln Asn Lys Ser Lys Glu Glu Wing Ser He Leu Wing Arg Gln Gly 50 55 60 Phe Val Ser Val He Gly Arg Ala Leu Glu Lys He He Glu Leu Leu 65 70 75 80 Leu Lys Asp Phe Cys He Lys Asn Asn Val Lys Met Thr Asn Asp Lys 85 90 95 Thr Leu Arg Ala Lys Arg He Asn Gly Glu Leu Asp Lys Val Lys Arg 100 105 110 Ala Leu Leu Val His Phe Gly Gly Tyr Ser Val Leu Pro Asp He He 115 120 125 Leu Tyr Gln Thr Asn Lys Asp Asn He Lys He Leu Wing He Leu Ser 130 135 140 Val Lys Asn Ser Phe Arg Glu Arg Phe Thr Lys Asp Ala Leu Leu Glu 145 150 155 160 He Lys Thr Phe Wing He Wing Cys Asn Phe Ser His 165 170 INFORMATION FOR SEC ID NO: 131; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 331 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 331 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 131; Met Lys Arg Phe Val Leu Phe Leu Leu Phe He Cys Val Cys Val Cys 1 5 10 15 Val Gln Ala Tyr Ala Glu Gln Asp Tyr Phe Phe Arg Asp Phe Lys Ser 20 25 30 He Asp Leu Pro Gln Lys Leu His Leu Asp Lys Lys Leu Ser Gln Thr 35 40 45 He Gln Pro Cys Wing Gln Leu Asn Wing Ser Lys His Tyr Thr Wing Thr 50 55 60 Gly Val Arg Glu Pro Asp Wing Cys Thr Lys Ser Phe Lys Lys Ser Wing 65 70 75 80 Met Val Ser Tyr Asp Leu Ala Leu Gly Tyr Leu Val Ser Gln Asn Lys 85 90 95 Pro Tyr Gly Leu Lys Wing He Glu He Leu Asn Wing Trp Wing Asn Glu 100 105 110 Leu Gln Ser Val Asp Thr Tyr Gln Ser Glu Asp Asn He Asn Phe Tyr 115 120 125 Met Pro Tyr Met Asn Met Wing Tyr Trp Phe Val Lys Lys Glu Phe Pro 130 135 140 Ser Pro Glu Tyr Glu Asp Phe He Arg Arg Met Arg Gln Tyr Ser Gln 145 150 155 160 Be Wing Leu Asn Thr Asn His Gly Wing Trp Gly He Leu Phe Asp Val 165 170 175 Be Being Wing Leu Wing Leu Asp Asp His Wing Leu Leu Gln Being Wing Wing 180 185 190 Asn Arg Trp Gln Glu Trp Val Phe Lys Wing Asp Glu Asn Gly Val 195 200 205 He Wing Being Wing He Thr Arg Being Asp thr Being Asp Tyr His Gly Gly 210 215 220 Pro Thr Lys Gly He Lys Gly He Wing Tyr Thr Asn Phe Wing Leu Leu 225 230 235 240 Wing He Thr He Ser Gly Glu Leu Leu Phe Glu Asn Gly Tyr Asp Leu 245 250 255 Trp Tyr Ser Gly Wing Gly Gln Arg Leu Ser Val Wing Tyr Asn Lys Wing 260 265 270 Ala Thr Trp He Leu Asn Pro Glu Thr Phe Pro Tyr Phe Gln Pro Asn 275 280 285 Leu He Glu Val His Asn Asn Ala Tyr Phe He He Leu Ala Lys His 290 295 300 Tyr Ser Ser Pro Ser Wing Asp Glu Leu Leu Glu Gln Gly Asp Leu His 305 310 315 320 Glu Asp Gly Phe Arg Leu Lys Leu Arg Ser Pro 325 330 (2) INFORMATION FOR SEQ ID NO: 132; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 128 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 128 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 132 Met Arg Gln Tyr Ser Gln Ser Wing Leu Asn Thr Asn His Gly Wing Trp 1 5 10 15 Gly He Leu Phe Asp Val Being Ser Ala Leu Ala Leu Asp Asp His Wing 20 25 30 Leu Leu Gln Ser Being Wing Asn Arg Trp Gln Glu Trp Val Phe Lys Wing 35 40 45 He Asp Glu Asn Gly Val He Wing Be Wing He Thr Arg Ser Asp Thr 50 55 60 Being Asp Tyr His Gly Gly Pro Thr Lys Gly He Lys Gly He Wing Tyr 65 70 75 80 Thr Asn Phe Ala Leu Leu Ala He Thr He Ser Gly Glu Leu Leu Phe 85 90 95 Glu Asn Gly Tyr Asp Leu Trp Gly Ser Gly Wing Gly Gln Arg Leu Ser 100 105 110 Val Ala Tyr Asn Lys Ala Ala Thr Trp He Leu Asn Pro Glu Thr Phe 115 120 125 (2) INFORMATION FOR SEQ ID NO: 133: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 245 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 245 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 133; Leu Arg Thr Leu Leu Lys Met Leu Val Gly Val Ser Leu Leu Thr His 1 5 10 15 Ala Leu Met Ala Thr Glu Glu Be Ala Ala Pro Ser Trp Thr Lys Asn 20 25 30 Leu Tyr Met Gly Phe Asn Tyr Gln Thr Gly Ser He Asn Leu Met Thr 35 40 45 Asn He His Glu Val Arg Glu Val Thr Ser Tyr Gln Thr Gly Tyr Thr 50 55 60 Asn Val Met Thr Ser He Asn Ser Val Lys Lys Leu Thr Asn Met Gly 65 70 75 80 Being Asn Gly He Gly Leu Val Met Gly Tyr Asn His Phe Phe His Pro 85 90 95 Asp Lys Val Leu Gly Leu Arg Tyr Phe Wing Phe Leu Asp Trp Gln Gly 100 105 110 Tyr Gly Met Arg Tyr Pro Lys Gly Tyr Tyr Gly Gly Asn Asn Met He 115 120 125 Thr Tyr Gly Val Gly Val Asp Wing He Trp Asn Phe Phe Gln Gly Ser 130 135 140 Phe Tyr Gln Asp Asp He Gly Val Asp He Gly Val Phe Gly Gly He 145 150 155 160 Ala He Ala Gly Asn Ser Trp Tyr He Gly Asn Lys Gly Gln Glu Leu 165 170 175 Leu Gly He Thr Asn Ser Be Wing Val Asp Asn Thr Ser Phe Gln Phe 180 185 190 Leu Phe Asn Phe Gly Phe Lys Ala Leu Phe Val Asp Glu His Glu Phe 195 200 205 Glu He Gly Phe Lys Phe Pro Thr Leu Asn Asn Lys Tyr Tyr Thr Thr 210 215 220 Asp Ala Leu Lys Val Gln Met Arg Arg Val Phe Ala Phe Tyr Val Gly 225 230 235 240 Tyr Asn Tyr His Phe 245 (2) INFORMATION FOR SEQ ID NO: 134: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 290 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 290 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 134 Met Phe Glu Glu He Thr Leu Wing His His Asp Leu Phe Ser Arg Phe 1 5 10 15 Leu Gln Thr Gln Lys He Val Leu Ser Asp Val Ser Phe Thr Asn Cys 20 25 30 Phe Leu Trp Gln His Wing Arg Leu He Gln Val Wing Val He Arg Asp 35 40 45 Cys Leu Val He Gln Thr Thr Tyr Glu Asn Gln Lys Pro Phe Tyr Phe 50 55 60 Tyr Pro He Gly Lys Arg Pro His Glu Cys Val Lys Glu Leu Leu Glu 65 70 75 80 Leu Glu Lys Asn Leu Arg Phe His Ser Leu Thr Leu Glu Gln Lys Asp 85 90 95 Asp Leu Lys Asp Asn Phe Val Gly Val Phe Asp Phe Thr Tyr Asn Arg 100 105 110 Asp Arg Ser Asp Tyr Val Tyr Ser He Glu Glu Leu He Wing Leu Lys 115 120 125 Gly Lys Lys Tyr His Lys Lys Lys Asn His Leu Asn Gln Phe Leu Thr 130 135 140 Asn His Wing Asn Phe Val Tyr Glu Lys He Ser Pro Gln Asn Arg Lys 145 150 155 160 Glu Val Leu Glu Wing Ser Lys Wing Trp Phe Leu Glu Ser Gln Thr Asp 165 170 175 Asp He Gly Leu He Asn Glu Asn Lys Gly He Gln Ser Val Leu GLu 180 185 190 Asn Tyr Glu Being Leu Asp Leu Lys Gly Gly Leu He Arg Val Asn Gly 195 200 205 Glu He Val Being Phe Being Phe Gly Glu Val Leu Asn Glu Glu Being Wing 210 215 220 Leu He Lys He Glu Lys Wing Arg Thr Asp He Wing Wing Gly Wing Tyr Gln 225 230 235 240 He He Asn Gln Gln Leu Leu Leu Asn Glu Phe Ser His Leu Thr Tyr 245 250 255 Wing Asn Arg Glu Glu Asp Leu Gly Leu Glu Gly Leu Arg Arg Ser Lys 260 265 270 Met Ser Tyr Asn Pro Val Phe Leu As Asp Lys Tyr Glu Ala Val Wing 275 280 285 Arg Asn 290 (2) INFORMATION FOR SEQ ID NO: 135: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 110 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 135: Met Met Phe He Val Ala Val Leu Met Leu Ala Phe Leu He Phe Val 1 5 10 15 His Glu Leu Gly His Phe He He Wing Arg He Cys Gly Val Lys Val 20 25 30 Glu Val Phe Ser He Gly Phe Gly Lys Lys Leu Trp Phe Phe Lys Leu 35 40 45 Phe Gly Thr Gln Phe Ala Leu Ser Leu He Pro Leu Gly Gly Tyr Val 50 55 60 Lys Leu Lys Gly Met Asp Lys Glu Glu Asn Glu Glu Asn Lys He Asn 65 70 75 80 Gln Ala Asn Asp Ser Tyr Ala Lys Lys Ala Leu Ser Lys Ser Tyr Gly 85 90 95 Tyr Cys Leu Val Gly Arg Phe Leu He Phe Phe Leu Arg Phe 100 105 110 (2) INFORMATION FOR SEQ ID NO: 136: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 351 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 351 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 136: Met Met Phe He Val Ala Val Leu Met Leu Ala Phe Leu He Phe Val 1 5 10 15 His Glu Leu Gly His Phe He He Wing Arg He Cys Gly Val Lys Val 20 25 30 Glu Val Phe Ser He Gly Phe Gly Lys Lys Leu Trp Phe Phe Lys Leu 35 40 45 Phe Gly Thr Gln Phe Ala Leu Ser Leu He Pro Leu Gly Gly Tyr Val 50 55 60 Lys Leu Lys Gly Met Asp Lys Glu Glu Asn Glu Glu Asn Lys He Asn 65 70 75 80 Gln Ala Asn Asp Ser Tyr Wing Gln Lys Ser Pro Phe Gln Lys Leu Trp 85 90 95 He Leu Phe Gly Gly Wing Phe Phe Asn Phe Leu Phe Wing Val Leu Val 100 105 110 Tyr Phe Phe Leu Wing Leu Ser Gly Glu Lys Val Leu Leu Pro Val He 115 120 125 Gly Gly Leu Glu Lys Asn Wing Leu Glu Wing Gly Leu Leu Lys Gly Asp 130 135 140 Arg He Leu Being He Asn His Gln Lys He Wing Being Phe Arg Glu He 145 150 155 160 Arg Glu He Val Wing Arg Ser Gln Gly Glu Leu He Leu Glu He Glu 165 170 175 Arg Asn Asn Gln He Leu Glu Lys Arg Leu Thr Pro Lys He Val Wing 180 185 190 Val He Ser Glu Ser Asn Asp Pro Asn Glu He He Lys Tyr Lys He 195 200 205 He Gly He Lys Pro Asp Met Gln Lys Met Gly Val Val Ser Tyr Ser 210 215 220 Val Phe Gln Ala Phe Glu Lys Ala Leu Ser Arg Phe Lys Glu Gly Val 225 230 235 240 Val Leu He Val Asp Ser Leu Arg Arg Leu He Met Gly Ser Ala Ser 245 250 255 Val Lys Glu Leu Ser Gly Val He Gly He Val Gly Ala Leu Ser His 260 265 270 Wing Asn Ser Val Ser Met Leu Leu Leu Phe Gly Wing Phe Leu Ser He 275 280 285 Asn Leu Gly He Leu Asn Leu Leu Pro He Pro Ala Leu Asp Gly Ala 290 295 300 Gln Met Leu Gly Val Val Phe Lys Asn He Phe His He Wing Leu Pro 305 310 315 320 Thr Pro He Gln Asn Ala Leu Trp Leu Val Gly Val Gly Phe Leu Val 325 330 335 Phe Val Met Phe Leu Gly Leu Phe Asn Asp He Thr Arg Leu Leu 340 345 350 (2) INFORMATION FOR SEQ ID NO: 137: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 100 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 100 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 137 Met Gly Lys Asn Leu Asp Ser Leu Leu Glu Asn Leu Arg Ala Glu He 1 5 10 15 Asp Ala Leu Asp Asn Glu Leu Ser Asp Leu Leu Asp Lys Arg Leu Gly 20 25 30 He Ala Leu Lys He Ala Leu He Lys Gln Glu Ser Pro Gln Glu Asn 35 40 45 Pro He Tyr Cys Pro Lys Arg Glu Gln Glu He Leu Lys Arg Leu Ser 50 55 60 Gln Arg Gly Phe Lys His Leu Asn Gly Glu He Leu Wing Ser Phe Tyr 65 70 75 80 Wing Glu Val Phe Lys He Ser Arg Asn Phe Gln Glu Asn Ala Leu Lys 85 90 95 Glu Leu Lys Lys 100 (2) INFORMATION FOR SEQ ID NO: 138: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 174 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 174 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 138 Val Lys Met Arg Phe Phe Ser Gly Phe Gly Phe Val Asn Glu Ser Val 1 5 10 15 Leu Phe Glu Glu Trp Leu Leu Lys Gly Wing Tyr Asp Val Ser Gly Phe 20 25 30 Ser Met Gly Wing He Lys Wing He Glu Tyr Wing Tyr Asn Glu Val Leu 35 40 45 Gln Gln Arg Arg He His Ser Leu Leu Leu Phe Ser Pro Cys Met Leu 50 55 60 Ala His Lys Ser Leu Ala Phe Lys Arg Leu Gln Leu Phe Leu Phe Gln 65 70 75 80 Lys Asp Pro Gln Ser Tyr Met Asp Asn Phe Tyr Lys Glu Val Gly Leu 85 90 95 Asp Ala Gln Leu Glu Arg Phe Lys Lys Glu Gly Ser Leu Glu Glu Leu 100 105 110 Glu Phe Leu Leu Asp Tyr Lys Tyr Ser Asp Ser He He Arg Phe Leu 115 120 125 Leu Glu Lys Gly Val Lys He Glu Val Phe He Gly Leu Lys Asp Arg 130 135 140 He Thr Asp He Gln Wing Leu Leu Glu Phe Phe Met Pro Leu Val Gln 145 150 155 160 Val Trp Gln Phe Lys Asp Cys Asn His Leu Leu Gln Lys Ser 165 170 INFORMATION FOR SEC ID NO: 139: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 471 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 471 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 139: Met Lys Asn Thr Asn Thr Lys Glu He Lys Asn Thr Arg Met Lys Lys 1 5 10 15 Gly Tyr Ser Gln Tyr His Thr Leu ys Lys Gly Leu Leu Lys Thr Wing 20 25 30 Leu Leu Phe Ser Leu Pro Leu Ser Val Ala Leu Ala Glu Asp Asp Gly 35 40 45 Phe Tyr Met Gly Val Gly Tyr Gln He Gly Gly Ala Gln Gln Asn He 50 55 ~ 60 Asn Asn Lys Gly Ser Thr Leu Arg Asn Asn val As Asp Asp Phe Arg 65 70 75 80 Gln Val Gly Val Gly Met Wing Gly Gly Asn Gly Leu Leu Ala Leu Wing 85 90 95 Thr Asn Thr Thr Met Asp Wing Leu Leu Gly He Gly Asn Gln He Val 100 105 110 Asn Thr Asn Thr Thr Val Gly Asn Asn Asn Wing Glu Leu Thr Gln Phe 115 120 125 Lys Lys He Leu Pro Gln He Glu Gln Arg Phe Glu Thr Asn Lys Asn 130 135 140 Ala Tyr Ser Val Gln Ala Leu Gln Val Tyr Leu Ser Asn Val Leu Tyr 145 150 155 160 Asn Leu Val Asn Asn Ser Asn Asn Gly Ser Asn Asn Gly Val Val Pro 165 170 175 Glu Tyr Val Gly He He Lys Val Leu Tyr Gly Ser Gln Asn Glu Phe 180 185 190 Ser Leu Leu Ala Thr Glu Ser Val Ala Leu Leu Asn Ala Leu Thr Arg 195 200 205 Val Asn Leu Asp Ser Asn Ser Val Phe Leu Lys Gly Leu Leu Ala Gln 210 215 220 Met Gln Leu Phe Asn Asp Thr Ser Be Ala Lys Leu Gly Gln He Ala 225 230 235 240 Glu Asn Leu Lys Asn Gly Gly Wing Gly Wing Met Leu Gln Lys Asp Val 245 250 255 Lys Thr He Ser Asp Arg He Wing Thr Tyr Gln Glu Asn Leu Lys Gln 260 265 270 Leu Gly Gly Met Leu Lys A n Tyr Asp Glu Pro Tyr Leu Pro Gln Phe 275 280 285 Gly Pro Gly Thr Ser Ser Gln His Gly Val He Asn Gly Phe Gly He 290 295 300 Gln Val Gly Tyr Lys Gln Phe Phe Gly Ser Lys Lys Asn He Gly Leu 305 310 315 320 Arg Tyr Tyr Ala Phe Phe Asp Tyr Gly Phe Thr Gln Leu Gly Ser Leu 325 330 335 Asn Ser Wing Val Lys Wing Asn He Phe Thr Tyr Gly Wing Gly Thr Asp 340 345 350 Phe Leu Trp Asn He Phe Arg Arg Val Phe Ser Asp Gln Ser Leu Asn 355 360 365 Val Gly Val Phe Gly Gly He Gln He Wing Gly Asn Thr Trp Asp Ser 370 375 380 Ser Leu Arg Gly Gln He Glu Asn Ser Phe Lys Glu Tyr Pro Thr Pro 385 390 395 400 Thr Asn Phe Gln Phe Leu Phe Asn Leu Gly Leu Arg Wing His Phe Wing 405 410 415 Being Thr Met His Arg Arg Phe Leu Being Wing Being Gln Ser He Gln His 420 425 430 Gly Met Glu Phe Gly Val Lys He Pro Wing He Asn Gln Arg Tyr Leu 435 440 445 Lys Wing Asn Gly Wing Asp Val Asp Tyr Arg Arg Leu Tyr Wing Phe Tyr 450 455 460 He Asn Tyr Thr He Gly Phe 465 470 (2) INFORMATION FOR SEC ID NO: 140: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 129 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 129 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 140: Met Lys Ser He Arg Arg Gly Asp Gly Leu Asn Val Val Pro Phe He 1 5 10 15 Asp He Met Leu Val Leu Leu Wing He Val Leu Ser He Being Thr Phe 20 25 30 He Wing Gln Gly Lys He Lys Val Ser Leu Pro Asn Wing Lys Asn Wing 35 40 45 Glu Lys Ser Gln Pro Asn Asp Gln Lys Val Val Val He Ser Val Asp 50 55 60 Glu His Asp Asn He Phe Val Asp Asp Lys Pro Thr Asn Leu Glu Wing 65 70 75 80 Leu Ser Ala Val Val Lys Gln Thr Asp Pro Lys Thr Leu He Asp Leu 85 90 95 Lys Ser Asp Lys Ser Ser Arg Phe Glu Thr Phe He Ser Met Met Asp 100 105 110 He Leu Lys Glu His Asn His Glu Asn Phe Be He Be Thr Gln Ala 115 120 125 Gln (2) INFORMATION FOR SEQ ID NO: 141; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 75 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 75 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 141: Met Leu Val Leu Leu Ala He Val Leu Be He Ser Thr Phe He Ala 1 5 10 15 Gln Gly Lys He Lys Val Ser Leu Pro Asn Wing Lys Asn Wing Glu Lys 20 25 30 Ser Arg Pro Asn Asp Gln Lys Val Val Val He Ser Val Asp Glu His 35 40 45 Asp Asn He Phe Val Asp Asp Lys Pro Thr Asn Leu Glu Ala Leu Ser 50 55 60 Wing Val Val Lys Gln Thr Asp Pro Lys Thr Leu 65 70 75 INFORMATION FOR SEQ ID NO: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 223 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 223 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 142: Met Phe Ser Leu Ser Tyr Val Ser Lys Lys Phe Leu Ser Val Leu Leu 1 5 10 15 Leu He Ser Leu Phe Leu Be Ala Cys Lys Ser Asn Asn Lys Asp Lys 20 25 30 Leu Asp Glu Asn Leu Leu Be Ser Gly Thr Gln Ser Ser Lys Glu Leu 35 40 45 Asn Asp Lys Arg Asp Asn As As Lys Lys Ser Tyr Wing Gly Leu Glu 50 55 60 Asp Val Phe Leu Asp Asn Lys Ser Be Ser Pro Asn Asp Lys Tyr Met 65 70 75 80 Leu Leu Val Phe Gly Arg Asn Gly Cys Ser Tyr Cys Glu Arg Leu Lys 85 90 95 Lys Asp Leu Lys Asn Val Lys Glu Leu Arg Asn Tyr He Lys Glu His 100 105 110 Phe Ser Ala Tyr Tyr Val Asn He Ser Tyr Ser Lys Glu His Asn Phe 115 120 125 Lys Val Gly Asp Lys Asp Lys Asn Asp Glu Lys Glu He Lys Met Ser 130 135 140 Thr Glu Glu Leu Wing Gln He Tyr Wing Val Gln Ser Thr Pro Thr He 145 150 155 160 Val Leu Ser Asp Lys Thr Gly Lys Thr He Tyr Glu Leu Pro Gly Tyr 165 170 175 Met Pro Ser Val Gln Phe Leu Ala Val Leu Glu Phe He Gly Asp Gly 180 185 190 Lys Tyr Gln Asp Thr Lys Asn Asp Glu Asp Leu Thr Lys Lys Leu Lys 195 200 205 Ala Tyr He Lys Tyr Lys Thr Asn Leu Ser Lys Ser Lys Ser Ser 210 215 220 (2) INFORMATION FOR SEQ ID NO: 143: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 116 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 116 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 143: Leu Met Lys Ser Lys He thr His Phe He Val He Ser Phe Val Leu 1 5 10 15 Ser Val Leu Be Ala Cys Lys Asp Glu Pro Lys Lys Ser Ser Gln Ser 20 25 30 His Gln Asn Asn Thr Lys Thr Thr Gln Asn Asn Gln He Asn Gln Pro 35 40 45 Asn Lys Asp He Lys Lys He Glu His Glu Glu Glu Asp Glu Lys Val 50 55 60 Thr Lys Glu Val Asn Asp Leu He Asn Asn Glu Asn Lys He Asp Glu 65 70 75 80 He Asn Asn Glu Glu Asn Wing Asp Pro Being Gln Lys Arg Thr Asn Asn 85 90 95 Val Leu Gln Arg Ala Thr Asn His Gln Asp Asn Leu Ser Ser Pro Leu 100 105 110 Asn Arg Lys Tyr 115 ) INFORMATION FOR SEC ID NO: 144 i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 79 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 79 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 144; Met Phe Glu Lys He Arg Lys He Leu Wing Asp He Glu Asp Ser Gln 1 5 10 15 Asn Glu He Glu Met Leu Leu Lys Leu Wing Asn Leu Ser Leu Gly Asp 20 25 30 Phe He Glu He Lys Arg Gly Ser Met Asp Met Pro Lys Gly Val Asn 35 40 45 Glu Ala Phe Phe Thr Gln Leu Ser Glu Glu Val Glu Arg Leu Lys Glu 50 55 60 Leu He Asn Ala Leu Asn Lys He Lys Lys Gly Leu Leu Val Phe 65 70 75 INFORMATION FOR SEC ID NO: 145: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 51 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 51 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 145: Met Ser Met Phe He Ser Asn Leu Ala Phe Thr Ser Glu His Lys Asp 1 5 10 15 Wing Met Glu Val Wing Lys He Wing He Leu Leu Gly Ser Leu He Ser 20 25 30 Gly He He Gly Ala Leu Tyr Leu Phe Ala Leu Asp Lys Arg Ala Ala 35 40 45 Leu Lys Lys 50 (2) INFORMATION FOR SEQ ID NO: 146: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 449 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 449 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 146: Met Gly Leu Lys He Lys He Leu Arg Leu Ser Met Asn Leu Lys Lys 1 5 10 15 Thr Glu Asn Ala Leu Ser Leu Thr Leu Lys Asn Phe He Lys Ser Glu 20 25 30 Being Phe Gly He Phe Lehe Phe Leu Asn Ala Val Leu Ala Met Val 35 40 45 Val Wing Asn Ser Phe Leu Lys Glu Ser Tyr Phe Ala Leu Trp His Thr 50 55 60 Pro Phe Gly Phe Gln Val Gly Asp Phe Phe He Gly Phe Ser Leu His 65 70 75 80 Asn Trp He Asp asp Val Leu Met Ala Leu Phe Phe Leu Met He Gly 85 90 95 Leu Glu He Lys Arg Glu Leu Leu Phe Gly Glu Leu Ser Ser Phe Lys 100 105 110 Lys Ala Ser Phe Pro Val He Ala Ala Ala He Gly Gly Met He Ala Pro 115 120 125 Gly Leu He Tyr Phe Phe Leu Asn Wing Asn Thr Pro Ser Gln His Gly 130 135 140 Phe Gly He Pro Met Wing Thr Asp He Wing Phe Wing Leu Gly Val He 145 150 155 160 Met Leu Leu Gly Lys Arg Val Pro Thr Ala Leu Lys Val Phe Leu He 165 170 175 Thr Leu Ala Val Ala Asp Asp Leu Gly Ala He Val Val He Ala Leu 180 185 190 Phe Tyr Thr Thr Asn Leu Lys Phe Wing Trp Leu Leu Gly Wing Leu Gly 195 200 205 Val Val Leu Val Leu Ala He Leu Asn Arg Leu Asn He Arg Ser Leu 210 215 220 He Pro Tyr Leu Leu Leu Gly Val Leu Leu Trp Phe Cys Val His Gln 225 230 235 240 Ser Gly He His Wing Thr He Wing Wing Val Val Leu Wing Phe Met He 245 250 255 Pro Val Lys He Pro Lys Asp Ser Lys Asn Val Glu Leu Leu Glu Leu 260 265 270 Gly Lys Arg Tyr Ala Glu Thr Ser Ser Gly Val Leu Leu Thr Lys Glu 275 280 285 Gln Gln Glu He Leu His Ser He Glu Glu Lys Ala Ser Ala Leu Gln 290 295 300 Ser Pro Leu Glu Arg Leu Glu His Phe Leu Pro Pro Wing Ser Gly Tyr 305 310 315 320 Phe He Met Pro Leu Phe Wing Phe Wing Asn Wing Gly Val Ser Val Asp 325 330 335 Ser Ser He Asn Leu Glu Val Asp Lys Val Leu Leu Gly Val He Leu 340 345 350 Gly Leu Cys Leu Gly Lys Pro Leu Gly He Phe Leu He Thr Phe He 355 360 365 Ser Glu Lys Leu Lys He Thr Wing Arg Pro Lys Gly He Gly Trp Trp 370 375 380 His He Leu Gly Wing Gly Leu Leu Wing Gly He Gly Phe Thr Met Ser 385 390 395 400 Met Phe He Ser Asn Leu Ala Phe Thr Ser Glu His Lys Asp Ala Met 405 410 415 Glu Val Ala Lys He Ala He Leu Leu Gly Ser Leu He Ser Gly He 420 425 430 He Gly Ala Leu Tyr Leu Phe Ala Leu Asp Lys Arg Ala Ala Leu Lys 435 440 445 Lys (2) INFORMATION FOR SEQ ID NO: 147: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 815 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: fíelicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 815 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 147 Met Asn Asp Lys Arg Phe Arg Lys Tyr Cys Ser Phe Ser He Phe Leu 1 5 10 15 Be Leu Leu Gly Thr Phe Glu Leu Glu Wing Lys Glu Glu Glu Lys Glu 20 25 30 Glu Lys Lys Thr Glu Arg Asn Lys Asp Lys Glu Lys Asn Wing Gln His 35 40 45 Thr Leu Gly Lys Val Thr Thr Gln Ala Wing Lys He Phe Asn Tyr Asn 50 55 60 Asn Gln Thr Thr He Ser Ser Lys Glu Leu Glu Arg Arg Gln Wing Asn 65 70 75 80 Gln He Being Asp Met Phe Arg Arg Asn Pro Asn He Asn Val Gly Gly 85 90 95 Gly Ala Val He Ala Gln Lys He Tyr Val Arg Gly He Glu Asp Arg 100 105 110 Leu Ala Arg Val Thr Val Asp Gly Val Ala Gln Met Gly Ala Ser Tyr 115 120 125 Gly His Gln Gly Asn Thr He He Asp Pro Gly Met Leu Lys Ser Val 130 135 140 Val Val Thr Lys Gly Wing Gln Gln Wing Be Wing Gly Pro Met Wing Leu 145 150 155 160 He Gly Wing He Lys Met Glu Thr Arg Being Wing Being Asp Phe He Pro 165 170 175 Lys Gly Lys Asp Tyr Wing He Ser Gly Wing Wing Thr Phe Leu Thr Asn 180 185 190 Phe Gly Asp Arg Glu Thr He Met Gly Wing Tyr Arg Asn His His Phe 195 200 205 Asp Ala Leu Leu Tyr Tyr Thr His Gln Asn He Phe Tyr Tyr Arg Asp 210 215 220 Gly Asp Asn Wing Met Lys Asn Leu Phe Asp Pro Lys Wing Asp Asn His .225 230 235 240 Val Thr Ala Ser Pro Ser Glu Gln Asn Asn Val Met Wing Lys Met Asn 245 250 255 Gly Tyr Leu Ser Glu Arg Asp Thr Leu Thr Leu Ser Tyr Asn Met Thr 260 265 270 Arg Asp Asn Wing Asn Arg Pro Leu Arg Wing Asn Phe Thr Gly Thr Phe 275 280 285 Leu Pro Tyr Ser Cys Gly Asp Phe Asn Wing Phe Pro Asn Glu Lys Asn 290 295 300 Pro Ser Asp Cys Leu Phe Glu Asn Asp Wing Ser Leu Phe Lys Thr Tyr 305 310 315 320 Ser Val Asn Leu Val His Asn Val Ser Leu Asn Tyr Glu Arg Glu Gly 325 330 335 Gly Ser Arg Phe Gly Asp Pro Lys Leu Lys He Asn Gly Tyr Thr Ser 340 345 350 He Arg Asn Val Gln He Asp Pro Leu Phe Arg Pro Be Asp He Wing 355 360 365 Thr Thr He Pro Phe Thr Pro Asn Pro Gln Leu Ser Gln Gly Glu Glu 370 375 380 Asn Gln Cys Val Wing Gln Gly Gly íle Tyr Asp Ala Leu Lys Gln Thr 385 390 395 400 Cys Ser He Thr Phe Lys Ser Leu Gly Gly Gly Ser Val Val Wing Asn 405 410 415 Lys Asn Leu Phe He He Asn Ser Gly Phe Asn Wing Asn Val He His 420 425 430 Thr He Asp His Lys Asn Asp Asn Leu Leu Glu Tyr Gly Leu Asn Tyr 435 440 445 Gln Asn Leu Thr Thr Phe Asp Lys Wing Pro Pro Asp Ser Glu Leu Val 450 455 460 Lys Pro Gly Asp Wing Pro Asp Wing Cys Leu Arg Val Thr Gly Pro Asp 465 470 475 480 Asp Pro Asn Met Asn Gly Arg Cys Gln Arg Asn Gly Ala Thr Ala Asn 485 490 495 Val Val Gly Val Tyr Ala Gln Ala Asn Tyr Thr Leu His Pro Met Val 500 505 510 Thr Leu Gly Wing Gly Thr Arg Tyr Asp Val Tyr Thr Leu Val Asp Lys 515 520 525 Asp Trp Gln Leu His Val Thr Gln Gly Phe Ser Pro Ser Ala Leu Leu 530 535 540 Asn Val Ser Pro Leu Glu Asn Leu Asn Phe Arg Leu Ser Tyr Ala Tyr 545 550 555 560 Val Thr Arg Gly Pro Met Pro Gly Gly Leu Val Trp Met Arg Gln Asp 565 570 575 Asn Leu Arg Tyr Asn Arg Asn Leu Lys Pro Glu He Gly Gln Asn Wing 580 585 590 Glu Phe Asn Thr Glu Tyr Ser Ser Gln Tyr Phe Asp Phe Arg Ala Wing 595 600 605 Gly Phe Val Gln Leu He Ser Asn Tyr He Asn Gln Phe Ser Ser Thr 610 615 620 Leu Phe Val Thr Asn Leu Pro Wing Gln Asp He He Tyr Val Pro Gly 625 630 635 640 Tyr Glu Val Ser Gly Thr Ala Lys Tyr Lys Gly Phe Ser Leu Gly Leu 645 650 655 Ser Val Ala Arg Ser Trp Pro Ser Leu Lys Gly Arg Leu He Ala Asp 660 665 670 Val Tyr Glu Leu Wing Wing Thr Thr Gly Asn Val Phe He Leu Thr Wing 675 680 685 Ser Tyr Thr He Pro Arg Thr Gly Leu Ser He Thr Trp Leu Ser Arg 690 695 700 Phe Val Thr Asn Leu Ser Tyr Cys Ser Tyr Ser Pro Tyr Arg Asn Gly 705 710 715 720 Pro Thr Asp He Asp Arg Arg Pro Be Asn Cys Pro Lys Thr Pro Gly 725 730 735 He Phe His Val His Lys Pro Gly Tyr Gly Val Ser Ser Phe He 740 745 750 Thr Tyr Lys Pro Thr Tyr Lys Lys Leu Lys Gly Leu Ser Leu Asn Wing 755 760 765 Val Phe Asn Asn Val Phe Asn Gln Gln Tyr He Asp Gln Wing Ser Pro 770 775 780 Val Met Ser Pro Asp Glu Pro Asn Gln Asp Lys Tyr Wing Arg Gly Met 785 790 795 800 Wing Glu Pro Gly Phe Asn Wing Arg Phe Glu He Ser Tyr Lys Phe 805 810 815 (2) INFORMATION FOR SEC ID NO: 148: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 814 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES [vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 814 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 148 Met Thr Ser Val Leu Glu Lys Tyr Cys Ser Phe Ser He Phe Leu Ser 1 5 10 15 Leu Leu Gly Thr Phe Glu Leu Glu Wing Lys Glu Glu Glu Lys Glu Glu 20 25 30 Lys Lys Thr Glu Arg Asn Lys Asp Lys Glu Lys Asn Wing Gln His Thr 35 40 45 Leu Gly Lys Val Thr Thr Gln Ala Wing Lys He Phe Asn Tyr Asn Asn 50 55 60 Gln Thr Thr He Ser Ser Lys Glu Leu Glu Arg Arg Gln Wing Asn Gln 65 70 75 80 I Have Been Asp Met Phe Arg Arg Asn Pro Asn He Asn Val Gly Gly Gly 85 90 95 Wing Val He Wing Gln Lys He Tyr Val Arg Gly He Glu Asp Arg Leu 100 105 110 Wing Arg Val Thr Val Asp Gly Val Wing Gln Met Gly Wing Ser Tyr Gly 115 120 125 His Gln Gly Asn Thr He He Asp Pro Gly Met Leu Lys Ser Val Val 130 135 140 Val Thr Lys Gly Wing Wing Gln Wing Be Wing Gly Pro Met Wing Leu He 145 150 155 160 Gly Wing He Lys Met Glu Thr Arg Being Wing Being Asp Phe He Pro Lys 165 170 175 Gly Lys Asp Tyr Wing He Ser Gly Wing Wing Thr Phe Leu Thr Asn Phe 180 185 190 Gly Asp Arg Glu Thr He Met Gly Wing Tyr Arg Asn His His Phe Asp 195 200 205 Ala Leu Leu Tyr Tyr Thr His Gln Asn He Phe Tyr Tyr Arg Asp Gly 210 215 220 Asp Asn Wing Met Lys Asn Leu Phe Asp Pro Lys Wing Asp Asn Lys Val 225 230 235 240 Thr Ala Ser Pro Ser Glu Gln Asn Asn Val Met Wing Lys He Asn Gly 245 250 255 Tyr Leu Ser Glu Arg Asp Thr Leu Thr Leu Ser Tyr Asn Met Thr Arg 260 265 270 Asp Asn Wing Asn Arg Pro Leu Arg Wing Asn Phe Thr Gly Thr Phe Leu 275 280 285 Pro Tyr Ser Cys Gly Asp Phe Asn Wing Phe Pro Asn Glu Lys Asn Pro 290 295"300 Be Asp Cys Leu Phe Glu Asn Asp Wing Ser Leu Phe Lys Thr Tyr Ser 305 310 315 320 Val Asn Leu Val His Asn Val Ser Leu Asn Tyr Glu Arg Glu Gly Gly 325 330 335 Ser Arg Phe Gly Asp Pro Lys Leu Lys He Asn Gly Tyr Thr Ser He 340 345 350 Arg Asn Val Gln He Asp Pro Leu Phe Arg Pro Be Asp He Wing Thr 355 360 365 Thr He Pro Phe Thr Pro Asn Pro Gln Leu Ser Gln Gly Glu Glu Asn 370 375 380 Gln Cys Val Wing Gln Gly Gly He Tyr Asp Wing Leu Lys Gln Thr Cys 385 390 395 400 Ser He Thr Phe Lys Ser Leu Gly Gly Gly Ser Val Val Wing Asn Lys 405 410 415 Asn Leu Phe He He Asn Ser Gly Phe Asn Wing Asn Val He Lys Thr 420 425 430 He Asp His Lys Asn Asp Asn Leu Leu Glu Tyr Gly Leu Asn Tyr Gln 435 440 445 Asn Leu Thr Thr Phe Asp Lys Wing He Pro Asp Ser Glu Leu Val Lys 450 455 460 Pro Gly Asp Ala Pro Asp Ala Cys Leu Arg Val Thr Gly Pro Asp Asp 465 470 475 480 Pro Asn Met Asn Gly Arg Cys Gln Arg Asn Gly Ala Thr Ala Asn Val 485 490 495 Val Gly Val Tyr Ala Gln Ala Asn Tyr Thr Leu Lys Pro Met Val Thr 500 505 510 Leu Gly Wing Gly Thr Arg Tyr Asp Val Tyr Thr Leu Val Asp Lys Asp 515 520 525 Trp Gln Leu His Val Thr Gln Gly Phe Ser Pro Ser Ala Ala Leu Asn 530 535 540 Val Ser Pro Leu Glu Asn Leu Asn Phe Arg Leu Ser Tyr Wing Tyr Val 545 550 555 560 Thr Arg Gly Pro Met Pro Gly Gly Leu Val Trp Met Arg Gln Asp Asn 565 570 575 Leu Arg Tyr Asn Arg Asn Leu Lys Pro Glu He Gly Gln Asn Wing Glu 580 585 590 Phe Asn Thr Glu Tyr Ser Ser Gln Tyr Phe Asp Phe Arg Ala Wing Gly 595 600 605 Phe Val Gln Leu He Ser Asn Tyr He Asn Gln Phe Ser Ser Thr Leu 610 615 620 Phe Val Thr Asn Leu Pro Wing Gln Asp He He Tyr Val Pro Gly Tyr 625 630 635 640 Glu Val Ser Gly Thr Ala Lys Tyr Lys Gly Phe Ser Leu Gly Leu Ser 645 650 655 Val Ala Arg Ser Trp Pro Ser Leu Lys Gly Arg Leu He Ala Asp Val 660 665 670 Tyr Glu Leu Wing Wing Thr Thr Gly Asn Val Phe He Leu Thr Wing Ser 675 680 685 Tyr Thr He Pro Arg Thr Gly Leu Ser He Thr Trp Leu Ser Arg Phe 690 695 700 Val Thr Asn Leu Ser Tyr Cys Ser Tyr Ser Pro Tyr Arg Asn Gly Pro 705 710 715 720 Thr Asp He Asp Arg Arg Pro Be Asn Cys Pro Lys Thr Pro Gly He 725 730 735 Phe His Val His Lys Pro Gly Tyr Gly Val Ser Ser Phe Phe He Thr 740 745 750 Tyr Lys Pro Thr Tyr Lys Lys Leu Lys Gly Leu Ser Leu Asn Ala Val 755 760 765 Phe Asn Asn Val Phe Asn Gln Gln Tyr He Asp Gln Wing Ser Pro Val 770 775 780 Met Ser Pro Asp Glu Pro Asn Gln Asp Lys Tyr Wing Arg Gly Met Wing 785 790 795 800 Glu Pro Gly Phe Asn Wing Arg Phe Glu He Ser Tyr Lys Phe 805 810 (2) INFORMATION FOR SEQ ID NO: 149: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 527 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 527 [xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 149: Met Lys Gln Asn Leu Lys Pro Phe Lys Met He Lys Glu Asn Leu Met 1 5 10 15 Thr Gln Ser Gln Lys Val Arg Phe Leu Wing Pro Leu Ser Leu Wing Leu 20 25 30 Ser Leu Ser Phe Asn Pro Val Gly Wing Glu Glu Asp Gly Gly Phe Met 35 40 45 Thr Phe Gly Tyr Glu Leu Gly Gln Val Val Gln Gln Val Lys Asn Pro 50 '55 60 Gly Lys He Lys Wing Glu Glu Leu Wing Gly Leu Leu Asn Ser Thr Thr 65 70 75 80 Thr Asn Asn Thr Asn He Asn He Wing Gly Thr Gly Gly Asn Val Wing 85 90 95 Gly Thr Leu Gly Asn Leu Phe Met Asn Gln Leu Gly Asn Leu He Asp 100 105 110 Leu Tyr Pro Thr Leu Lys Thr Asn Asn Leu His Gln Cys Gly Ser Thr 115 120 125 Asn Ser Gly Asn Gly Ala Thr Ala Ala Ala Ala Thr Asn Asn Ser Pro 130 135 140 Cys Phe Gln Gly Asn Leu Ala Leu Tyr Asn Glu Met Val Asp Ser He 145 150 155 160 Lys Thr Leu Ser Gln Asn He Ser Lys Asn He Phe Gln Gly Asp Asn 165 170 175 Asn Thr Thr Ser Wing Asn Leu Ser Asn Gln Leu Ser Glu Leu Asn Thr 180 185 190 Wing Ser Val Tyr Leu Thr Tyr Met Asn Ser Phe Leu Asn Wing Asn Asn 195 200 205 Gln Ala Gly Gly He Phe Gln Asn Asn Thr Asn Gln Wing Tyr Glu Asn 210 215 220 Gly Val Thr Ala Gln Gln He Ala Tyr Val Leu Lys Gln Ala Ser He 225 230 235 240 Thr Met Gly Pro Ser Gly Asp Ser Gly Wing Wing Gly Wing Phe Leu Asp 245 250 255 Ala Ala Leu Ala Gln His Val Phe Asn Be Ala Asn Ala Gly Asn Asp 260 265 270 Leu Ser Ala Lys Glu Phe Thr Ser Leu Val Gln Asn He Val Asn Asn 275 280 285 Ser Gln Asn Ala Leu Thr Leu Ala Asn Asn Ala Asn He Ser Asn Ser 290 295 300 Thr Gly Tyr Gln Val Ser Tyr Gly Gly Asn He Asp Gln Wing Arg Ser 305 310 315 320 Thr Gln Leu Leu Asn Asn Thr Thr Asn Thr Leu Wing Lys Val Thr Wing 325 330 335 Leu Asn Asn Glu Leu Lys Wing Asn Pro Trp Leu Gly Asn Phe Wing Wing 340 345 350 Gly Asn Being Ser Gln Val Asn Ala Phe Asn Gly Phe He Thr Lys He 355 360 365 Gly Tyr Lys Gln Phe Phe Gly Glu Asn Lys Asn Val Gly Leu Arg Tyr 370 375 380 Tyr Gly Phe Phe Ser Tyr Asn Gly Wing Gly Val Gly Asn Gly Pro Thr 385 390 395 400 Tyr Asn Gln Val Asn Leu Leu Thr Tyr Gly Val Gly Thr Asp Val Leu 405 410 415 Tyr Asn Val Phe Ser Arg Ser Phe Gly Ser Arg Ser Leu Asn Wing Gly 420 425 430 Phe Phe Gly Gly He Gln Leu Gly Wing Asp Thr Tyr He Ser Thr Leu 435 440 445 Arg Asn Ser Pro Gln Leu Wing Ser Arg Pro Thr Wing Thr Lys Phe Gln 450 455 460 Phe Leu Phe Asp Val Gly Leu Arg Met Asn Phe Gly He Leu Lys Lys 465 470 475 480 Asp Leu Lys Ser His Asn Gln His Ser He Glu He Gly Val Gln He 485 490 495 Pro Thr He Tyr Asn Thr Tyr Tyr Lys Wing Gly Gly Wing Glu Val Lys 500 505 510 Tyr Phe Arg Pro Tyr Ser Val Tyr Trp Val Tyr Gly Tyr Wing Phe 515 520 525 (2) INFORMATION FOR SEQ ID NO: 150: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 459 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 459 [xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 150: Val Val Leu Leu Thr Met Thr Lys Arg Leu Phe Lys Gly Leu Leu Ala 1 5 10 15 He Ser Leu Ala Val Ser Leu His Gly Gly Glu Val Lys Glu Lys Lys 20 25 30 Pro Val Lys Pro Val Lys Glu Asp Pro Gln Glu Leu Ala Wing Lys Arg 35 40 45 Val Glu Ala Phe Ser Arg Phe Ser Asn Val Val Thr Glu He Glu Lys 50 55 60 Lys Tyr Val Asp Lys He Ser Be Glu He Met Met Thr Lys Ala He 65 70 75 80 Glu Gly Leu Leu Ser Asn Leu Asp Wing His Ser Wing Tyr Leu Asn Glu 85 90 95 Lys Lys Phe Lys Glu Phe Gln Wing Gln Thr Glu Gly Glu Phe Gly Gly 100 105 110 Leu Gly He Thr Val Gly Met Arg Asp Gly Val Leu Thr Val He Wing 115 120 125 Pro Leu Glu Gly Thr Pro Wing Tyr His Wing Gly Val Lys Ser Gly Asp 130 135 140 Ser He Leu Lys He Asn Asn Glu Be Thr Leu Ser Met Ser He Asp 145 150 155 160 Asp Ala Val Asn Leu Met Arg Gly Lys Pro Lys Thr Ser He Gln He 165 170 175 Thr Val Val Arg Lys Asn Glu Pro Lys Pro Leu Val Phe Asn He Val 180 185 190 Arg Asp He He Lys He Pro Ser Val Tyr Val Lys Lys He Lys Asp 195 200 205 Thr Pro Tyr Leu Tyr Val Arg Val Asn Ser Phe Asp Lys Asn Val Thr 210 215 220 Lys Ser Val Leu Asp Gly Leu Lys Wing Asn Pro Asn He Lys Gly Val 225 230 235 240 Val Leu Asp Leu Arg Gly Asn Pro Gly Gly Leu Leu Asn Gln Wing Val 245 250 255 Gly Leu Ser Asn Leu Phe He Lys Glu Gly Val Leu Val Ser Gln Arg 260 265 270 Gly Lys Asn Lys Glu Glu Asn Leu Glu Tyr Lys Wing Asn Gly Arg Wing 275 280 285 Pro Tyr Thr Asn Leu Pro Val Val Val Leu Val Asn Gly Gly Ser Ala 290 295 300 Be Ala Be Glu He Val Ala Gly Ala Leu Gln Asp His Lys Arg Ala 305 310 315 320 He He He He Gly Glu Lys Thr Phe Gly Lys Gly Ser Val Gln Val Leu 325 330 335 Leu Pro Val Asn Lys Asp Glu Wing He Lys He Thr Thr Wing Arg Tyr 340 345 350 Tyr Leu Pro Ser Gly. Arg Thr He Gln Wing Lys Gly He Thr Pro Asp 355 360 365 He Val He Tyr Pro Gly Lys Val Pro Glu Asn Glu Asn Lys Phe Ser 370 375 380 Leu Lys Glu Wing Asp Leu Lys His His Leu Glu Gln Glu Leu Lys Lys 385 390 395 400 Leu Asp Asp Lys Thr Pro He Ser Lys Glu Wing Asp Lys Asp Lys Lys 405 410 415 Ser Glu Glu Glu Lys Glu Val Thr Pro Lys Met He As Asp Asp He 420 425 430 Gln Leu Lys Thr Wing He Asp Ser Leu Lys Thr Trp Ser He Val Asp 435 440 445 Glu Lys Met Asp Glu Lys Val Pro Lys Lys Lys 450 455 INFORMATION FOR SEC ID NO: 151: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 104 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 104 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 151; Leu Leu Leu His Pro Leu His Wing His Wing Gln Val Leu Gly Phe Thr 1 5 10 15 Asn His Asp His Wing Pro Trp Leu Tyr Asp Phe He Lys Ser Phe Cys 20 25 30 Asn Leu Ser Gly Gln Pro Phe Leu Asp Leu Gln Wing Phe Wing He Asn 35 40 45 Phe Asn Glu Phe Ser Asp Arg Ala Asn Ala Tyr Asn Leu Phe Leu Arg 50 55 60 Asp He Ser His Wing Asn He Pro Lys Lys Arg Glu Gln Met Val Leu 65 70 75 80 Wing Ser Gly Val Lys Phe Asn Val Leu Ser His Tyr His Phe He Wing 85 90 95 Asn Ala Leu Lys He Arg Ala Phe 100 INFORMATION FOR SEC ID NO: 152: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 165 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 165 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 152: Met He Glu Leu He Leu His Asn Lys Ser He Gln He Asp Glu Thr 1 5 10 15 Leu Leu Asn Val Lys Glu His Leu Glu His Phe Tyr Ser Asn Lys Glu 20 25 30 Gln Glu Thr He Ala Lys Thr Leu Glu Ser Gln Thr Glu Leu Thr Cys 35 40 45 Ser Tyr Leu Leu Asp Lys Asp Phe Ser Leu Leu Glu Lys His Leu Glu 50 55 60 Asn Ser Leu Gly His Phe Thr Phe Glu Ser Glu Phe Ala Leu Leu Lys 65 70 75 80 Asp Lys Glu Pro Glu Asn Leu Wing Gln He Lys Gln He Gly Val Leu 85 90 95 Lys Val He Thr Tyr Glu Met Thr Gln Ala Leu Lys Asn Gln He He 100 105 110 His Leu Thr Gln He Val Asn Glu Glu Asn Leu Glu Phe Asp Glu Glu 115 120 125 Leu Val He Tyr His Leu Asn Phe Lys Leu Asn Gln Asn Thr Tyr Lys 130 135 140 Val Leu Ala Lys Phe Cys Val Leu Lys Lys Lys Gly Thr Leu His Glu 145 150 155 160 Lys Phe Lys Wing Phe 165 INFORMATION FOR SEC ID NO: 153: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 213 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc _characteristic (B) LOCATION: 1. . . 213 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 153: Met Asp Thr Glu Thr Gln Glu Lys Phe Leu Wing Tyr Leu Phe Glu Lys 1 5 10 15 Ala Leu Gln Lys Asn Leu Gln Ala Tyr Trp He Thr Thr Thr Glu Thr 20 25 30 Lys Asn Glu Leu Thr Arg Glu Glu Phe Ser Asn Leu He Arg Lys Thr 35 40 45 Met He Glu Leu He Leu His Asn His Ser He Gln He Asp Glu Thr 50 55 60 Leu Leu Asn Val Lys Glu His Leu Glu His Phe Tyr Ser Asn Lys Glu 65 70 75 80 Gln Glu Thr He Ala Lys Thr Leu Glu Ser Gln Thr Glu Leu Thr Cys 85 90 95 Ser Tyr Leu Leu Asp Lys Asp Phe Ser Leu Leu Glu Lys His Leu Glu 100 105 110 Asn Ser Leu Gly His Phe Thr Phe Glu Ser Glu Phe Ala Leu Leu Lys 115 120 125 Asp Lys Glu Pro Leu Asn Leu Wing Gln He Lys Gln He Gly Val Leu 130 135 140 Lys Val He Thr Tyr Glu Met Thr Gln Ala Leu Lys Asn Gln He He 145 150 155 160 His Leu Thr Gln He Val Asn Glu Glu Asn Leu Glu Phe Asp Glu Glu 165 170 175 Leu Val He Tyr His Leu Asn Phe Lys Leu Asn Gln Asn Thr Tyr Lys 180 185 190 Val Leu Ala Lys Phe Cys Val Leu Lys Lys Lys Gly Thr Leu His Glu 195 200 205 Lys Phe Lys Wing Phe 210 INFORMATION FOR SEC ID NO: 154: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 253 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 253 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 154 Met Ala He Ser He Lys Ser Pro Lys Glu He Lys Ala Leu Arg Lys 1 5 10 15 Wing Gly Glu Leu Thr Wing Gln Wing Leu Wing Leu Leu Glu Arg Glu Val 20 25 30 Arg Pro Gly Val Ser Leu Leu Glu Leu Asp Lys Met Wing Glu Asp Phe 35 40 45 He Lys Ser Ser His Wing Arg Pro Wing Phe Lys Gly Leu Tyr Gly Phe 50 55 60 Pro Asn Ser Val Cys Met Ser Leu Asn Glu Val Val He His Gly He 65 70 75 80 Pro Thr Asp Tyr Val Leu Gln Glu Gly Asp He He Gly Leu Asp Leu 85 90 95 Gly Val Glu Val Asp Gly Tyr Tyr Gly Asp Ser Ala Leu Thr Leu Pro 100 105 110 He Gly Ala He Ser Pro Gln Asp Glu Lys Leu Leu Ala Cys Ser Lys 115 120 125 Glu Being Leu Met His Wing Being Ser He Arg Val Gly Met His Phe 130 135 140 Lys Glu Leu Ser Gln He Leu Glu Gly Wing He Thr Glu Arg Gly Phe 145 150 155 160 Val Pro Leu Lys Gly Phe Cys Gly His Gly He Gly Lys Lys Pro His 165 170 175 Glu Glu Pro Glu He Pro Asn Tyr Leu Glu Lys Gly Val Lys Ala Asn 180 185 190 Ser Gly Pro Lys He Lys Glu Gly Met Val Phe Cys Leu Glu Pro Met 195 200 205 Val Cys Gln Lys Gln Gly Glu Pro Lys He Leu Wing Asp Lys Trp Ser 210 215 220 Val Val Ser Val Asp Gly Leu Asn Thr Ser His His Glu His Thr He 225 230 235 240 Ala He Val Gly Asn Lys Ala Val He Leu Thr Glu Arg 245 250 INFORMATION FOR SEC ID NO: 155: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 247 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 247 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 155: Lys Pro Lys Arg Asn Gln Ser Pro Lys Lys Ser Arg Glu Leu Thr Ala 1 5 10 15 Gln Ala Leu Ala Leu Leu Glu Arg Glu Val Arg Pro Gly Val Ser Leu 20 25 30 Leu Glu Leu Asp Lys Met Wing Glu Asp Phe He Lys Ser Ser His Wing 40 45 Arg Pro Wing Phe Lys Gly Leu Tyr Gly Phe Pro Asn Ser Val Cys Met 50 55 60 Ser Leu Asn Glu Val Val He His Gly He Pro Thr Asp Tyr Val Leu 65 70 75 80 Gln Glu Gly Asp He He Gly Leu Asp Leu Gly Val Glu Val Asp Gly 85 90 95 Tyr Tyr Gly Asp Be Wing Leu Thr Leu Pro He Gly Wing He Ser Pro 100 105 110 Gln Asp Glu Lys Leu Leu Wing Cys Ser Lys Glu Ser Leu Met His Wing 115 120 125 He Be Ser He Arg Val Gly Met His Phe Lys Glu Leu Ser Gln He 130 135 140 Leu Glu Gly Wing He Thr Glu Arg Gly Phe Val Pro Leu Lys Gly Phe 145 150 155 160 Cys Gly His Gly He Gly Lys Lys Pro His Glu Glu Pro Glu He Pro 165 170 175 Asn Tyr Leu Glu Lys Gly Val Lys Wing Asn Ser Gly Pro Lys He Lys 180 185 190 Glu Gly Met Val Phe Cys Leu Glu Pro Met Val Cys Gln Lys Gln Gly 195 200 205 Glu pro Lys He Leu Wing Asp Lys Trp Ser Val Val Ser Val Asp Gly 210 215 220 Leu Asn Thr Ser His His Glu His Thr He Wing He Val Gly Asn Lys 225 230 235 240 Wing Val He Leu Thr Glu Arg 245 INFORMATION FOR SEC ID NO: 156: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 340 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 340 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 156: Met Tyr Arg Lys Asp Leu Asp Asn Tyr Leu Lys Gln Arg Leu Pro Lys 1 5 10 15 Wing Val Phe Leu Tyr Gly Glu Phe Asp Phe Phe He His Tyr Tyr He 20 25 30 Gln Thr He Ser Ala Leu Phe Lys Gly Asn Asn Pro Asp Thr Glu Thr 35 40 45 Being Leu Phe Tyr Wing Being Asp Tyr Glu Lys Being Gln He Wing Thr Leu 50 55 60 Leu Glu Gln Asp Ser Leu Phe Gly Gly Ser Ser Leu Val He Leu Lys 65 70 75 80 Leu Asp Phe Ala Leu His Lys Lys Phe Lys Glu Asn Asp He Asn Pro 85 90 95 Phe Leu Lys Ala Leu Glu Arg Pro Ser His Asn Arg Leu He He Gly 100 105 110 Leu Tyr Asn Ala Lys Ser Asp Thr Thr Lys Tyr Lys Tyr Thr Ser Glu 115 120 125 He He Val Val Pys Phe Gln Lys Pro Pro Leu Lys Asp Glu Ala He 130 135 140 Cys Val Arg Phe Phe Thr Pro Lys Wing Trp Glu Ser Leu Lys Phe Leu 145 150 155 160 Gln Glu Arg Ala Asn Phe Leu His Leu Asp He Ser Gly His Leu Leu 165 170 175 Asn Ala Leu Phe Glu He Asn Asn Glu Asp Leu Ser Val Ser Phe Asn 180 185 190 Asp Leu Asp Lys Leu Wing Val Leu Asn Wing Pro He Thr Leu Glu Asp 195 200 205 He Gln Glu Leu Being Ser Asn Wing Gly Asp Met Asp Leu Gln Lys Leu 210 215 220 He Leu Gly Leu Phe Leu Lys Lys Ser Val Leu Asp He Tyr Asp Tyr 225 230 235 240 Leu Leu Lys Glu Gly Lys Lys Asp Wing Asp He Leu Arg Gly Leu Glu 245 250 255 Arg Tyr Phe Tyr Gln Leu Phe Leu Phe Phe Wing Lys He Lys Thr Thr 260 265 270 Gly Leu Met Asp Wing Lys Glu Val Leu Gly Tyr Wing Pro Pro Lys Glu 275 280 285 He Val Glu Asn Tyr Ala Lys Asn Ala Leu Arg Leu Lys Glu Ala Gly 290 295 300 Tyr Lys Arg Val Phe Glu He Phe Arg Leu Trp His Leu Gln Ser Met 305 310 315 320 Gln Gly Gln Lys Glu Leu Gly Phe Leu Tyr Leu Thr Pro He Gln Lys 325 330 335 He He Asn Pro 340 (2) INFORMATION FOR SEQ ID NO: 157 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 200 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 200 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 157: Val Phe Met Thr Ser Ala Le Leu Gly Leu Gln He Val Leu Ala Val 1 5 10 15 Leu He Val Val Val Leu Val Leu Gln Lys Ser Ser Be He Gly Leu 20 25 30 Gly Ala Tyr Ser Gly Ser Asn Asp Ser Leu Phe Gly Ala Lys Gly Pro 35 40 45 Wing Being Phe Met Wing Lys Leu Thr Met Phe Leu Gly Leu Leu Phe Val 50 55 60 He Asn Thr He Wing Leu Gly Tyr Phe Tyr Asn Lys Glu Tyr Gly Lys 65 70 75 80 Ser Val Leu Asp Glu Thr Lys Thr Asn Lys Glu Leu Ser Pro Leu Val 85 90 95 Pro Wing Thr Gly Thr Leu Asn Pro Thr Leu Asn Pro Thr Leu Asn Pro 100 105 110 Thr Leu Asn Pro Leu Glu Gln Ala Pro Thr Asn Pro Leu Met Pro Thr 115 120 125 Gln Thr Pro Lys Glu Leu Pro Lys Glu Pro Wing Lys Thr Pro Phe Val 130 135 140 Glu Ser Pro Lys Gln Asn Glu Lys Asn Glu Lys Asn Asp Ala Lys Glu 145 150 155 160 Asn Gly He Lys Gly Val Glu Lys Asn Lys Glu Asn Wing Lys Thr Pro 165 170 175 Pro Thr Thr His Gln Lys Pro Lys Thr His Wing Thr Thr Asn Wing His 180 185 190 Thr Asn Gln Lys Lys Asp Glu Lys 195 200 INFORMATION FOR SEC ID NO: 158: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 159 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 159 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 15Í Met Arg Ser Pro Asn Leu Glu Lys Glu Glu Thr Glu He He Glu Thr 1 5 10 15 Leu Leu Val Arg Glu Lys Met Arg Leu Cys Pro Leu Tyr Trp Arg He 20 25 30 Leu Ala Phe Leu He Asp Ser Leu Leu Val Ala Phe Leu Leu Ser Asp 35 40 45 Leu Leu Arg Ala Cys Ala Phe Leu His Ser leu Tyr Trp Leu Thr Asn 50 55 60 Pro lie Tyr Tyr Be Ala Phe Val Val Met Gly Phe He He Leu Tyr 65 70 75 80 Gly Val Tyr Glu He Phe Phe Val Cys Leu Cys Lys Met Ser Leu Ala 85 90 95 Lys Leu Val Phe Arg He Lys He He Asp He Tyr Leu Wing Asp Cys 100 105 110 Pro Ser Arg Ala He Leu Leu Lys Arg Lue Gly Leu Lys He Val Val 115 120 125 Phe Leu Cys Pro Phe Leu Trp Phe Val Val Phe Lys Asn Pro Tyr His 130 135 140 Arg Ala Trp His Glu Glu Lys Ser Lys Ser Leu Leu Val Leu Phe 145 150 155 (2) INFORMATION FOR SEQ ID NO: 159: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 234 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 234 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 159: Leu Asn Thr Asp Phe Ser His He Thr Asp He Glu Gly Met Arg Phe 1 5 10 15 Val Asn Glu Glu Asp Ala Leu Asn Lys Leu He Asn Glu He His Thr 20 25 30 Arg His He Asp Leu Lys Asp Ser He Let Leu Ala Leu Ser Phe Asn 35 40 45 Ala Leu Tyr Leu Ala Asn Ala Leu Ala Gln Lys Phe Gly Ala Thr Tyr 50 55 60 Asp He Leu Phe Leu Glu Pro He Leu Wing Pro Leu Asn Ser Lys Cys 65 70 75 80 Glu He Ala Leu Val Ser Glu Ser Met Asp He Val Met Asn Glu Ser 85 90 95 Leu He Asn Ser Phe Asp He Wing Leu Asp Tyr Val Tyr Gly Glu Wing 100 105 110 Lys Arg Ala Tyr Glu Glu Asp He Leu Ser His He Tyr Gln Tyr Arg 115 120 125 Lys Gly Asn Wing He Lys Ser Leu Lys Asp Lys Asn He Phe He Val 130 135 140 Asp Arg Gly He Glu Thr Gly Phe Arg Wing Gly Leu Gly Val Gln Thr 145 150 155 160 Cys Leu Lys Lys Glu Cys Gln Asp He Tyr He Leu Thr Pro He Leu 165 170 175 Wing Gln Asn Val Wing Gln Gly Leu Glu Being Leu Cys Asp Gly Val He 180 185 190 Ser Val Tyr Arp pro Glu Cys Phe Val Ser Val Glu His His Tyr Lys 195 200 205 Glu Leu Lys Arg Leu Ser Asn Glu Glu He Glu Lys Tyr Leu Gly Wing 210 215 220 Asn Asn Wing Pro Asn Leu Lys Lys Glu His 225 230 [2) INFORMATION FOR SEC ID NO: 160: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 287 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 287 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 160: Leu Lys Gln Ser Glu Met Wing Met Glu Phe Asn Asp Pro Arg Met Arg 1 5 10 15 Phe Phe He Gly Asp Val arg Asp Leu Glu Arg Leu Asn Tyr Ala Leu 20 25 30 Glu Gly Val Asp He Cys He His Ala Ala Ala Leu Lys His Val Pro 35 40 45 He Wings Glu Tyr Asn Pro Leu Glu Cys He Lys Thr Asn He Met Gly 50 55 60 Ala Ser Asn Val He Asn Ala Cys Leu Lys Asn Glu He Ser Gln Val 65 70 75 80 He Ala Ala Leu Ser Thr Asp Lys Ala Ala Asn Pro He Asn Leu Tyr Gly 85 90 95 Wing Thr Lys Leu Cys Ser Asp Lys Leu Phe Val Ser Wing Asn Asn Phe 100 105 110 Lys Gly Pro Ser Gln Thr Gln Phe Gly Val Val Arg Tyr Gly Asn Val 115 120 125 Val Gly Ser Arg Gly Ser Val Val Pro Phe Phe Lys Lys Leu Val Gln 130 135 140 Asn Lys Wing Ser Glu He Pro He Thr Asp He Arg Met Thr Arp Phe 145 150 155 160 Trp He Thr Leu Asp Glu Gly Val Ser Phe Val Leu Lys Ser Leu Lys 165 170 175 Arg Met His Gly Gly Glu He Phe Val Pro Lys He Pro Met Met Lys 180 185 190 Met He Asp Leu Ala Lys Ala Leu Ala Pro Asn He Pro Thr Lys He 195 200 205 He Gly He Arg Pro Gly Glu Lys Leu His Glu Val Met He Pro Lys 210 215 220 Asp Glu Ser His Leu Ala Leu Glu Phe Glu Asp Phe Phe He He Gln 225 230 235 240 Pro Thr lie Ser Phe Gln Thr Pro Lys Asp Tyr Thr Leu Thr Lys Leu 245 250 255 His Glu Lys Gly Gln Lys Val Wing Pro Asp Phe Glu Tyr Ser Ser His 260 265 270 Thr Asn Asn Gln Trp Leu Glu Pro Asp Asp Leu Leu Lys Leu Leu 275 280 285 (2) INFORMATION FOR SEQ ID NO: 161: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 201 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 201 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 161 Met Arg Leu His Thr Wing Phe Phe Gly He Asn Ser Leu Leu Val Wing 1 5 10 15 Thr Leu Leu He Ser Gly Cys Ser Leu Phe Lys Lys Arg Asn Thr Asn 20 25 30 Ala Gln Leu He Pro Pro Be Ala Asn Gly Leu Gln Ala Pro He Tyr 35 40 45 Pro Pro Thr Asn Phe Thr Pro Arg Lys Be He Gln Pro Leu Pro Ser 50 55 60 Pro Arg Leu Glu Asn Asn Asp Gln Pro He He Ser Ser Asn Pro thr 65 70 75 80 Asn Ala He pro Asn Thr Pro He Leu Thr Pro Asn Asn Val He Glu 85 90 95 Leu Asn Wing Val Gly Met Gly Val Wing Pro Glu Ser Thr He Ser Pro 100 105 110 Ser Gln Ala Leu Ala Leu Ala Lys Arg Ala Ala He Val Asp Gly Tyr 115 120 125 Arg Gln Leu Gly Glu Lys Met Tyr Gly He Arg Val Asn Wing Gln Asp 130 135 140 Thr Val Lys Asp Met Val Leu Gln Asn Ser Val He Lys Thr Arg Val 145 150 155 160 Asn Ala Leu He Arg Asn Ala Glu He Thr Glu Thr He Tyr Lys Asp 165 170 175 Gly Leu Cys Gln Val Ser Met Glu Leu Lys Leu Asp Gly Arg He Trp 180 185 190 Tyr Arg He Leu Ser Gly Ser Arg Gly 195 200 INFORMATION FOR SEC ID NO: 162; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 355 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 355 (xi) DESCRIPTION * OF THE SEQUENCE: SEQ ID NO: 162 Met Ser Tyr Thr He Asn Lys Arg Phe Ser Val Gly Val Gly Leu Arg 1 5 10 15 Gly Leu Tyr Ala Thr Gly Ser Phe Asn Asn Thr Val Tyr Val Pro Leu 20 25 30 Glu Gly Ala Ser Val Leu Ser Ala Glu Gln He Leu Asn Leu Pro Asn 35 40 45 Asn Val Phe Wing Asp Gln Val Pro Ser Asn Met Met Thr Leu Leu Gly 50 55 60 Asn He Gly tyr Gln Pro Wing Leu Asn Cys Gln Lys Wing Gly Gly Asp 65 70 75 80 Met Ser Asp Gln Ser Cys Gln Glu Phe Tyr Asn Gly Leu Lys Lys He 85 90 95 Met Gly Tyr Ser Gly Leu He Lys Wing Being Wing Asn Leu Tyr Gly Thr 100 105 110 Thr Gln Val Val Gln Lys Ser Asn Gly Gln Gly Val Ser Gly Gly Tyr 115 120 125 Arg Val Gly Ser Ser Leu Arg Val Phe Asp His Gly Met Phe Ser Val 130 135 140 Val Tyr Asn Being Ser Val Thr Phe Asn Met Lys Gly Gly Leu Val Wing 145 150 155 160 He Thr Glu Leu Gly Pro Ser Leu Gly Ser Val Leu Thr Lys Gly Ser 165 170 175 Leu Asn He Asn Val Ser Leu Pro Gln Thr Leu Ser Leu Ala Tyr Ala 180 185 190 His Gln Phe Phe Lys Asp Arg Leu Arg Val Glu Gly Val Phe Glu Arg 195 200 205 Thr Phe Trp Ser Gln Gly Asn Lys Phe Leu Val Thr Pro Asp Phe Wing 210 215 220 Asn Ala Thr Tyr Lys Gly Leu Ser Gly Thr Val Ala Ser Leu Asp Ser 225 230 235 240 Glu Thr Leu Lys Lys Met Val Gly Leu Wing Asn Phe Lys Ser Val Met 245 250 255 Asn Met Gly Wing Gly Trp Arg Asp Thr Asn Thr Phe Arg Leu Gly Val 260 265 270 Thr Tyr Met Gly Lys Ser Leu Arg Leu Met Gly Ala He Asp Tyr Asp 275 280 285 Gln Ala Pro Ser Pro Gln Asp Wing He Gly He Pro Asp Ser Asn Gly 290 295 300 Tyr Thr Val Wing Phe Gly Thr Lys Tyr Asn Phe Arg Gly Phe Asp Leu 305 310 315 320 Gly Val Ala Gly Ser Phe Thr Phe Lys Ser Asn Arg Ser Ser Leu tyr 325 330 335 Gln Ser Pro Thr He Gly Gln Leu Arg He Phe Ser Wing Ser Leu Gly 340 345 350 Tyr Arg Trp 355 (2) INFORMATION FOR SEQ ID NO: 163: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 587 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 587 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 163: Met Lys Asn Phe Ser Pro Leu Tyr Cys Leu Lys Lys Leu Lys Lys Arg 1 5 10 15 His Leu He Ala Leu Ser Leu Pro Leu Leu Ser Tyr Ala Asn Gly Phe 20 25 30 Lys He Gln Glu Gln Ser Leu Asn Gly Thr Ala Leu Gly Ser Ala Tyr 35 40 45 Val Ala Gly Ala Arg Gly Ala Asp Ala Ser Phe Tyr Asn Pro Ala Asn 50 55 60 Met Gly Phe Thr Asn Asp Trp Gly Glu Asn Arg Ser Glu Phe Glu Met 65 70 75 80 Thr Thr Thr Val He Asn He Pro Wing Phe Ser Phe Lys Val Pro Thr 85 90 95 Thr Asn Gln Gly Leu Tyr Ser Val Thr Ser Leu Glu He Asp Lys be 100 105 110 Gln Gln Asn He Leu Gly He He Asn Thr He Gly Leu Gly Asn He 115 120 125 Leu Lys Wing Leu Gly Asn Thr Wing Wing Thr Asn Gly Leu Ser Gln Wing 130 135 140 He Asn Arg Val Gln Gly Leu Met Asn Leu Thr Asn Gln Lys Val Val 145 150 155 160 Thr Leu Wing Ser Lys Pro Asp Thr Gln He Val Asn Gly Trp Thr Gly 165 170 175 Thr Thr Asn Phe Val Leu Pro Lys The The Tyr Lys Thr Arg Thr His 180 185 190 Asn Gly Phe Thr Phe Gly Gly Ser Phe Thr Pro Wing Ser Gly Leu Gly 195 200 205 Met Lys Trp Asn Gly Lys Gly Gly Glu Phe Leu His Asp Val Phe He 210 215 220 Met Met Val Glu Leu Ala Pro Ser Met Ser Tyr Thr He Asn Lys Arg 225 230 235 240 Phe Ser Val Gly Val Gly Leu Arg Gly Leu Tyr Ala Thr Gly Ser Phe 245 250 255 Asn Asn Thr Val Tyr Val Pro Leu Glu Gly Wing Ser Val Leu Ser Wing 260 265 270 Gln Gln He Leu Asn Leu Pro Asn Asn Val Phe Wing Asp Gln Val Pro 275 280 285 Being As Met Met Met Thr Leu Met Gly Asn He Met Gly Tyr Gln Pro Met Leu 290 295 300 Asn Cys Gln Lys Wing Gly Gly Asp Met Ser Asp Gln Ser Cys Gln Glu 305 310 315 320 Phe Tyr Asn Gly Leu Lys Lys He Met Gly Tyr Ser Gly Leu He Lys 325 330 335 Wing Being Wing Asn Leu Tyr Gly Thr Thr Gln Val Val Gln Lys Ser Asn 340 345 350 Gly Gln Gly Val Ser Gly Gly Tyr Arg Val Gly Ser Ser Leu Arg Val 355 360 365 Phe Asp His Gly Met Phe Ser Val Val Tyr Asn Ser Ser Val Thr Phe 370 375 380 Asn Met Lys Gly Gly Leu Val Wing He Thr Glu Leu Gly Pro Ser Leu 385 390 395 400 Gly Ser Val Leu Thr Lys Gly Ser Leu Asn He Asn Val Ser Leu Pro 405 410 415 Gln Thr Leu Ser Leu Ala Tyr Ala His Gln Phe Phe Lys Asp Arg Leu 420 425 430 Arg Val Glu Gly Val Phe Glu Arg Thr Phe Trp Ser Gln Gly Asn Lys 435 440 445 Phe Leu Val Thr Pro Asp Phe Wing Asn Wing Thr Tyr Lys Gly Leu Ser 450 455 460 Gly Thr Val Wing Ser Leu Asp Ser Glu Thr Leu Lys Lys Met Val Gly 465 470 475 480 Leu Wing Asn Phe Lys Ser Val Met Asn Met Gly Wing Gly Trp Arg Asp 485 490 495 Thr Asn Thr Phe Arg Leu Gly Val Thr Tyr Met Gly Lys Ser Leu Arg 500 505 510 Leu Met Gly Wing Asp Tyr Asp Gln Wing Pro Ser Pro Gln Asp Wing 515 520 525 He Gly He Pro Asp Ser Asn Gly Tyr Thr Val Wing Phe Gly Thr Lys 530 535 540 Tyr Asn Phe Arg Gly Phe Asp Leu Gly Val Wing Gly Ser Phe Thr Phe 545 550 555 560 Lys Ser Asn Arg Ser Ser Leu Tyr Gln Ser Pro Thr He Gly Gln Leu 565 570 575 Arg He Phe Ser Ala Be Leu Gly Tyr Arg Trp 580 585 INFORMATION OF SEQ ID NO: 164: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 205 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 205 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 164: Leu He Phe Arg Phe Phe Leu He Leu Ser Leu Leu Lys Gly Val Leu 1 5 10 15 Leu Ala Lys Lys Asp Trp Asn Phe Phe Lys Pro Leu Glu Pro Thr Lys 20 25 30 Lys Tyr Phe Gly Ser Phe Lys He Gly Tyr Leu Tyr Gln His Wing Glu 35 40 45 Thr Thr Lys Arg Phe Pro He Arg Pro Lys Asn Arg Pro Pro He Leu 50 55 60 Met Asp Lys He Tyr His Asp Wing Ser Leu Gly Phe Asp Wing Gly Tyr 65 70 75 80 Val Leu Lys Lys Lys Wing Leu Leu Gly Gly Tyr Leu Asp Wing Gly Met 85 90 95 Gly Asp Ser Tyr Phe Met Ser Wing Gly Leu Val Wing Gly Val Arg Leu 100 105 110 Phe Lys Gly Trp Val He Pro Lys He Wing Leu Gly Tyr Gln Leu Gln 115 120 125 He Leu Gly Wing Lys He Asp Lys Tyr Gln Phe Asn He Gln Ser Wing 130 135 140 Val Gly Ser Val Gly Leu Phe Phe Asn Wing Wing Lys Asn Phe Gly Leu 145 150 155 160 Ser He Glu Wing Arg Gly Gly He Pro Phe Tyr Phe He Gln Sser Arg 165 170 175 Phe Ser Lys Wing Phe Gly Thr Pro Arg Leu Asn He Tyr Ser Val Gly 180 185 190 He Thr Phe Thr Phe Tyr Asp Phe Thr Arg Phe Leu Gly 195 200 205 (2) INFORMATION FOR SEQ ID NO: 165: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 253 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 253 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 165: Leu Trp His Wing Wing Phe Ser Val Gly Glu Trp Gly Trp Asn Gly Asp 1 5 10 15 Glu He Pro Tyr Arg Asp Cys Asp Glu Trp Gly Leu Asp Asp Phe Tyr 20 25 30 Gly Val Lys Pro Thr Asp Cys Wing Gly Val Leu Ser Phe Wing Arg Ser 35 40 45 His Arg Arg Gln Asn Gln Wing Val Leu Ser Lys Pro Lys Ser Phe Arg 50 55 60 Met Lys Lys He Wing Phe He Leu Wing Leu Trp Val Gly Leu Leu Gly 65 70 75 80 Wing Phe Glu Pro Lys Lys Ser His He Tyr Phe Gly Wing Met Val Gly 85 90 95 Leu Ala Pro Val Lys He Thr Pro Lys Pro Wing Ser Asp Ser Ser Tyr 100 105 110 Thr Wing Phe Leu Trp Gly Wing Lys Gly Gly Tyr Gln Phe Wing Phe Phe 115 120 125 Lys Ala Leu Ala Leu Arg Gly Glu Phe Ser Tyr Leu Met Wing He Lys 130 135 140 Pro Thr Ala Leu His Thr He Asn Thr Ser Leu Leu Ser Leu Asn Met 145 150 155 160 Asp Val Leu Ser Asp Phe Tyr Thr Tyr Lys Lys Tyr Ser Phe Gly Val 165 170 175 Tyr Gly Gly Leu Gly He Gly Tyr Phe Tyr Gln Ser Asn His Leu Gly 180 185 190 Met His Asn Being Being Phe Met Gly Tyr Asn Gly Leu Phe Asn Val Gly 195 200 205 Leu Gly Ser Thr He Asp Arg His His Arg Val Glu Leu Gly Ala Lys 210 215 220 He Pro Phe Ser Lys Thr Arg Asn Ser Phe Lys Asn Ser Tyr Phe Leu 225 230 235 '240 Glu Ser Val Phe He His Wing Ala Tyr Ser Tyr Met Phe 245 250 (2) INFORMATION OF SEQ ID NO: 166: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 412 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 412 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 166: Met Glu Ser Val Lys Thr Val Lys Thr Asn Lys Val Gly Lys Asn Thr 1 5 10 15 Glu Thr Wing Asn Thr Glu Wing Ser Lys Glu Thr His Phe Lys Gln Wing 20 25 30 Be Wing He Thr Asn Thr Leu Arg Be He Gly Gly He Phe Thr Lys 35 40 45 He Ala Lys Lys Val Arg Glu Leu Val Lys Lys His Pro Lys Lys Ser 50 55 60 Ser Val Ala Leu Val Val Leu Thr His He Ala Cys Lys Arg Ala Lys 65 70 75 80 Glu Leu Asp Asp Lys Val Gln Asp Lys Ser Lys Gln Wing Glu Lys Glu 85 90 95 Asn Gln He Asn Trp Trp Lys Tyr Ser Gly Leu Thr He Wing Wing Ser 100 105 110 Leu Leu Leu Ala Wing Cys Ser Thr Gly Asp He Asp Lys Gln He Glu 115 120 125 Leu Glu Gln Glu Lys Lys Glu Wing Asn Lys Ser Gly He Lys Leu Glu 130 135 140 Gln Glu Arg Gln Lys Thr Glu Gln Glu Arg Gln Lys Thr Asn Lys Ser 145 150 155 160 Glu He Glu Leu Glu Gln Glu Arg Gln Lys Thr Asn Lys Ser Gly He 165 170 175 Glu Leu Wing Asn Being Gln He Lys Wing Glu Gln Glu Arg Gln Lys Thr 180 185 190 Glu Gln Glu Lys Gln Lys Wing Asn Lys Ser Glu He Glu Leu Glu Gln 195 200 205 Gln Lys Gln Lys Thr lie Asn Thr Gln Arg Asp Leu lie Lys Glu Gln 210 215 220 Lys Asp Phe He Lys Glu Thr Glu Gln Asn Cys Gln Glu Lys His Gly 225 230 235 240 Gln Leu Phe He Lys Lys Wing Arg He Lys Thr Gly He Thr Thr Gly 245 250 255 He Ala He Glu He Glu Ala Glu Cys Lys Thr Pro Lys Pro Ala Lys 260 265 270 Thr Asn Gln Thr Pro He Gln Pro Lys His Leu Pro Asn Ser Lys Gln 275 280 285 Pro Arg Ser Gln Arg Gly Ser Lys Wing Gln Glu Leu He Wing Tyr Leu 290 295 300 Gln Lys Glu Leu Glu Ser Leu Pro Tyr Ser Gln Lys Ala He Wing Lys 305 310 315 320 Gln Val Asp Phe Tyr Lys Pro Ser Ser He Wing Tyr Leu Glu Leu Asp 325 330 335 Pro Arg Asp Phe Lys Val Thr Glu Glu Trp Gln Lys Glu Asn Leu Lys 340 345 350 He Arg Be Lys Wing Gln Wing Lys Met Leu Glu Met Arg Asn Pro Gln 355 360 365 Ala His Leu Pro Thr Ser Gln Ser Leu Leu Phe Val Gln Lys He Phe 370 375 380 Wing Asp He Asn Lys Glu He Glu Wing Val Wing Asn Thr Glu Lys Lys 385 390 395 400 Thr Glu His Wing Gly Tyr Gly Tyr Ser Lys Arg Met 405 410 INFORMATION OF SEQ ID NO: 167: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 149 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 149 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 167 Leu Asn Trp Glu His Leu Met Lys Lys Leu Wing Phe Ser Leu Leu Phe 1 5 10 15 Thr Gly Thr Phe Leu Gly Leu Phe Leu Asn Wing Being Asp Phe Lys Ser 20 25 30 Met Asp Asn Lys Gln Leu Leu Glu Gln Wing Gly Lys Val Wing Pro Ser 35 40 45 Glu Val Pro Glu Phe Arg Thr Glu Val Asn Lys Arg Leu Glu Ala Met 50 55 60 Lys Glu Glu Glu Arg Gln Lys Tyr Lys Wing Asp Phe Lys Lys Wing Met 65 70 75 80 Asp Lys Asn Leu Wing Ser Leu Ser Gln Glu Asp Arg Asn Lys Arg Lys 85 90 95 Lys Glu He Leu Glu Val He Wing Asn Lys Lys Lys Thr Met Thr Met 100 105 110 Lys Glu Tyr Arg Glu Glu Gly Leu Asp Leu His Asp Cys Ala Cys Glu 115 120 125 Gly Pro Phe His Asp His Glu Lys Lys Gly Gln Lys Gly Lys Lys Pro 130 135 140 Ser His His Lys His 145 (2) INFORMATION OF SEC "ID NO: 168: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 204 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 204 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 168: Met Gln Ala Val He Leu Ala Asn Gly Glu Phe Pro Lys Ser Lys Lys 1 5 10 15 Cys Leu Asp He Leu Gln Asn Wing Pro Phe Leu He Wing Cys Asp Gly 20 25 30 Ala Val He Ser Leu His Ala Leu Gln Phe Lys Pro Ser Val Val He 40 45 Gly Asp Leu Asp Ser He Asp Ser His Leu Lys Ala Leu Tyr Asn Pro 50 55 60 He Arg Val Ser Glu Gln Asp Ser Asn Asp Leu Ser Lys Wing Phe Phe 65 70 75 80 Tyr Ala Leu Asn Arg Gly Cys Asp Asp Phe He Phe Leu Gly Leu Asn 85 90 95 Gly Lys Arg Glu Asp His Wing Leu Wing Asn Thr Phe Leu Leu Leu Glu 100 105 110 Tyr Phe Lys Phe Cys Lys Lys He Gln Ser Val Ser Asp Tyr Gly Leu 115 120 125 Phe Arg Val Leu Glu Thr Pro Phe Thr Leu Pro Ser Phe Lys Gly Glu 130 135 140 Gln He Ser Leu Phe Ser Leu Asp Leu Lys Ala Arg Phe Thr Ser Lys 145 150 155 160 Asn Leu Lys Tyr Pro Leu Lys Asp Leu Arg Leu Lys Thr Leu Phe Ser 165 170 175 Gly Ser Leu Asn Glu Wing Thr Asn His Cys Phe Ser Leu Ser Ser Glu 180 185 190 Pro Lys Ser Val Val Leu Val Tyr Gln Lys Phe Ser 195 200 (2) INFORMATION OF SEQ ID NO: 169: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 280 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein [iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 280 [xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 169; Val Phe Asp Ser Leu Gly Gly Phe Leu Gly Tyr Lys Thr Phe Lys Pro 1 5 10 15 He Val Asp Lys Val Lys Asn He Asn Wing Trp He Lys Asn Tyr Asp 20 25 30 Asn Lys Lys Wing Gln Glu He Met Gly Phe He Glu Asn Pro Thr Pro 35 40 45 Asp Phe Gln Asn Asn Lys Phe Leu Cys Val Leu Asn Arg Gln Gly Thr 50 55 60 Arg His Asn Asn Tyr Leu Gly Leu Thr Ser Thr Asn Leu Leu He Gly 65 70 75 80 Ala He Tyr Phe Ser He Arg His Cys He Lys Wing Thr Trp Gln Asn 85 90 95 Asp Arg Asp Gln Phe Tyr Wing Pro Tyr Asp Asp Wing Phe Gln Asp Asp 100 105 110 Ser Glu Phe Lys Asn Asn Cys Leu Wing Phe Met Leu Phe His Thr Gln 115 120 125 Asn Arg He Thr Wing Thr Gln Gly Thr Asn His Phe He Pro Phe Ser 130 135 140 Glu Asp Glu Val Asp Ser Lys Glu Arg Tyr Leu Ser His Wing Leu Leu 145 150 155 160 Asp Phe Leu Lys Gly Glu He Lys Glu Pro Lys Lys Ser Asp Ser Leu 165 170 175 Phe Leu Asn Ala Lys Lys Glu Asn Lys Pro Leu Lys Phe Ser Ser Ser 180 185 190 Wing Ser Lys Val Phe Asp Wing Gly Arg Glu He Tyr Arg Tyr Tyr His 195 200 205 Thr Gln Asp Phe He His Thr Pro Tyr Asn Wing Asn Wing Ser Leu Tyr 210 215 220 Asp He Lys Glu Phe Phe Gln Gly Arg Asn Lys Gln Gly Arg Leu Asn 225 230 235 240 Ser Pro Thr Lys Wing Lys Asp Glu Tyr Tyr Lys Gln Leu Tyr Wing Asn 245 250 255 Leu Gln Tyr Ala Leu Lys Asp Leu Ala Lys Glu He Gln Pro Lys Val 260 265 270 Tyr Glu Tyr Gly Phe Leu Arg Glu 275 280 INFORMATION OF SEQ ID NO: 170: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 309 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 309 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 170: Cys Asp Arg Ala He Pro His Trp Leu Phe Ser Leu Gly Tyr Arg Tyr 1 5 10 15 Pro Pro Pro Leu Lys Pro Thr Asn Wing Phe Asn Leu Glu Val Phe Asp 20 25 30 Being Leu Gly Gly Phe Leu Gly Tyr Lys Thr Phe Lys Pro He Val Asp 35 40 45 Lys Val Lys, Asn He Asn Wing Trp He Lys Asn Tyr Asp Asn Lys Lys 50 55 60 Wing Gln Glu He Met Gly Phe He Glu Asn Pro Thr Pro Asp Phe Gln 65 70 75 80 Asn Asn Lys Phe Leu Cys Val Leu Asn Arg Gln Gly Thr Arg His Asn 85 90 95 Asn Tyr Leu Gly Leu Thr Ser Thr Asn Leu Leu He Gly Wing He Tyr 100 105 110 Phe Ser He Arg His Cys He Lys Wing Thr Trp Gln Asn Asp Arg Asp 115 120 125 Gln Phe Tyr Ala Pro Tyr Asp Asp Ala Phe Gln Asp Asp Ser Glu Phe 130 135 140 Lys Asn Asn Cys Leu Wing Phe Met Leu Phe His Thr Gln Asn Arg He 145 150 155 160 Thr Ala Thr Gln Gly Thr Asn His Phe He Pro Phe Ser Glu Asp Glu 165 170 175 Val Asp Ser Lys Glu Arg Tyr Leu Ser His Wing Leu Leu Asp Phe Leu 180 185 190 Lys Gly Glu He Lys Glu Pro Lys Lys Ser Asp Ser Leu Phe Leu Asn 195 200 205 Wing Lys Lys Glu Asn Lys Pro Leu Lys Phe Ser Ser Ser Wing Ser Lys 210 215 220 Val Phe Asp Wing Gly Arg Glu He Tyr Arg Tyr Tyr His Thr Gln Asp 225 230 235 240 Phe He His Thr Pro Tyr Asn Wing Asn Wing Ser Leu Tyr Asp He Lys 245 250 255 Glu Phe Phe Gln Gly Arg Asn Lys Gln Gly Arg Leu Asn Ser Pro Thr 260 265 270 Lys Ala Lys Asp Glu Tyr Tyr Lys Gln Leu Tyr Ala Asn Leu Gln Tyr 275 280 285 Ala Leu Lys Asp Leu Ala Lys Glu He Gln Pro Lys Val Tyr Glu Tyr 290 295 300 Gly Phe Leu Arg Glu 305 (2) INFORMATION OF SEQ ID NO: 171: [i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 187 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear [ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 187 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 171 Leu Glu Thr Tyr He He Asp Wing Asp Asn He Asp Gly Asp Leu Phe 1 5 10 15 Phe Tyr Asn Leu Thr Arg Asn Ser Asn Asp Phe Ser Met Leu Pro Val 20 25 30 Phe Glu Leu Asp Arg He Wing Gln Lys He Arg Asn He Leu Lys Lys 35 40 45 His Gly Ser Arg Lys Asp He He Leu Lys His Asn Glu He Lys Glu 50 55 60 Wing Phe Phe Ser Pro Phe Lys Pro Gln Leu Lys Thr Val Gln Val Phe 65 70 75 '80 Leu Ser His Ser His Wing Asp Lys Asn Lys Wing Leu Gly Val Lys Asp 85 90 95 Tyr Leu Glu Ser Lys Thr Lys Arg Lys Val Phe He Asp Ser Leu Phe 100 105 110 Trp Asp Tyr Lys Asp Asp Val Leu Asn Lys Leu Wing Lys His Asp Asp 115 120 125 He Ser Lys He Glu Asp Ala Phe Thr Leu He Leu Arg Lys Ser Leu 130 135 140 Gln Asp Met He Glu Lys Cys Pro Tyr Phe Val Phe Leu Gln Ser Lys 145 150 155 160 Asn Ser Val Ser Asn Gln Gly Leu Ser Arg He Thr Tyr Ser Wing Trp 165 170 175 He Tyr Glu Glu Leu Lys He Wing Ser Phe Tyr 180 185 (2) INFORMATION OF SEQ ID NO: 172: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 198 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 198 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 172: Leu Glu Thr Tyr He He Asp Wing Asp Asn He Asp Gly Asp Leu Phe 1 5 10 15 Phe Tyr Asn Leu Thr Arg Asn Ser Asn Asp Phe Ser Met Leu Pro Val 20 25 30 Phe Glu Leu Asp Arg He Wing Gln Lys He Arg Asn He Leu Lys Lys 35 40 45 His Gly Ser Arg Lys Asp He He Leu Lys His Asn Glu He Lys Glu 50 55 60 Wing Phe Phe Ser Pro Phe Lys Pro Gln Leu Lys Thr Val Gln Val Phe 65 70 75 80 Leu Ser His Ser His Wing Asp Lys Asn Lys Wing Leu Gly Val Lys Asp 85 90 95 Tyr Leu Glu Ser Lys Thr Lys Arg Lys Val Phe He Asp Ser Leu Phe 100 105 110 Trp Asp Tyr Lys Asp Asp Val Leu Asn Lys Leu Wing Lys His Asp Asp 115 120 125 He Ser Lys He Glu Asp Ala Phe Thr Leu He Leu Arg Lys Ser Leu 130 135 140 Gln Asp Met He Glu Lys Cys Pro Tyr Phe Val Phe Leu Gln Ser Lys 145 150 155 160 Asn Ser Val Ser Asn Gln Gly Leu Ser Arg He Thr Tyr Ser Wing Trp 165 170 175 He Tyr Glu Glu Leu Lys He Wing Being Phe Leu Leu Wing Leu Leu Thr 180 185 190 Arg Val Ala Gln Phe Gln 195 (2) INFORMATION OF SEQ ID NO: 173: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 189 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 189 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 173: Met Met Thr Lys Asn Ala Tyr Ala Phe Val Val He Glu Lys Ser He 1 5 10 15 Met Val Phe Lys Cys Ala Lys Asp Lys Gly Leu He Pro He Thr Glu 20 25 30 Gly Phe Val Pro Leu Lys Glu Gly Phe Leu Arg Ser Phe Lys Glu Arg 35 40 45 Cys Asn Leu Asp Phe Leu Glu Asn Leu Asp Leu Leu Phe Leu Tyr Asp 50 55 60 Tyr Gln Phe Pro Ser Glu Val Phe Ser Leu Cys Lys Asp Leu Lys Asn 65 70 75 80 Ser He Trp Asp Arg Lys Leu Val Val Val Leu Val Glu Ala Leu Glu 85 90 95 Gly Phe Lys Gly Leu Asn Leu Ser Leu Lys He Glu Asp Arg His Ser 100 105 110 Asn Ser Leu Gly Asn Gly Val Gln Lys Leu Leu Thr Asn Wing Asp Leu 115 120 125 Gly Ser Asn His Lys Pro He Val He Asp Ser Met Lys Thr Tyr His 130 135 140 Gln Ser Gln Gln Glu Lys Tyr Lys Arg Glu Srg Gly Glu Thr Leu Glu 145 150 155 160 Val Arg Pro Thr Thr Pro Pro Ser Tyr Gly Gly Gly Ser He Arg He 165 170 175 Ser Gly Asp Lys Lys Pro Asp Ser Asn Glu Glu Asn Phe 180 185 (2) INFORMATION OF SEQ ID NO: 174: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 590 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 590 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 174: Met Lys Ala He Lys He Leu Leu He Met Met Thr Leu Ser Leu Asn Ala 1 5 10 15 He Ser Val Asn Arg Ala Leu Phe Asp Leu Lys Asp Ser Gln Leu Lys 20 25 30 Gly Glu Leu Thr Pro Lys He Val Asp Phe Gly Gly Tyr Lys Ser Asn 35 40 45 Thr Thr Glu Trp Gly Wing Thr Wing Leu Asn Tyr He Asn Wing Wing Asn 50 55 60 Gly Asp Ala Lys Lys Phe Ser Ala Leu Val Glu Lys Met Arg Phe Asn 65 70 75 80 Ser Gly He Leu Gly Asn Phe Arg Ala His Wing His Leu Arg Gln Wing 85 90 95 Leu Lys Leu Gln Lys Asn Leu Lys Tyr Cys Leu Lys He He Wing Arg 100 105 110 Asp Ser Phe Tyr Ser Tyr Arg Thr Gly He Tyr He Pro Leu Gly He 115 120 125 Be Leu Lys Asp Gln Lys Thr Wing Gln Lys Met Leu Wing Asp Leu Ser 130 135 140 Val Val Gly Ala Tyr Leu Lys Lys Gln Gln Lgu Asn Glu Lys Ala Gln 145 150 155 160 Ser Pro Tyr Tyr Arg Ser Asn Asn Tyr Tyr Asn Ser Tyr Tyr Ser Pro 165 170 175 Tyr Tyr Gly Met Tyr Gly Met Tyr Gly Met Gly Met Tyr Gly Met Tyr 180 185 190 Gly Met Gly Met Tyr Asp Phe Tyr Asp Phe Tyr Asp Gly Met Tyr Gly 195 200 205 Phe Tyr Pro Asn Met Phe Phe Met Met Gln Val Gln Asp Tyr Leu Met 210 215 220 Leu Glu Asn Tyr Met Tyr Ala Leu Asp Gln Glu Glu He Leu Asp His 225 230 235 240 Asp Ala Ser He Asn Gln Leu Asp Thr Pro Thr Asp Asp Asp Arg Asp 245 250 255 Asp Lys Asp Asp Lys Ser Ser Gln Pro Wing Asn Leu Met Ser Phe Tyr 260 265 270 Arg Asp Pro Lys Phe Ser Lys Asp He Gln Thr Asn Arg Leu Asn Ser 275 280 285 Ala Leu Val Asn Leu Asp Asn Ser His Met Leu Lys Asp Asn Ser Leu 290 295 300 Phe His Thr Lys Wing Met Pro Thr Lys Ser Val Asp Wing He Thr Ser 305 310 315 320 Gln Ala Lys Glu Leu Asn His Leu Val Gly Gln He Lys Glu Met Lys 325 330 335 Gln Asp Gly Ala Ser Pro Asn Lys He Asp Ser Val Val Asn Lys Wing 340 345 350 Met Glu Val Arg Asp Lys Leu Asp Asn Asn Leu Asn Gln Leu Asp Asn 355 360 365 Asp Leu Lys Asp Gln Lys Gly Leu Ser Glu Gln Gln Ala Gln Val 370 375 380 Asp Lys Ala Leu Asp Ser Val Gln Gln Leu Ser His Ser Ser Asp Val 385 390 395 400 Val Gly Asn Tyr Leu Asp Gly Ser Leu Lys He Asp Gly Asp Asp Arg 405 410 415 Asp Asp Leu Asn Asp Wing As Asn Asn Pro Met Gln Gln Pro Wing Gln 420 425 430 Gln Thr Pro He Asn Asn Met Asp Asn Thr His Wing Asn Asp Ser Lys 435 440 445 Asp Gln Gly Gly Asn Wing Leu He Asn Pro Asn Asn Wing Thr Asn Asp 450 455 460 Asp His Asn Asp Asp His Met Asp Thr Asn Thr Thr Asp Thr Ser Asn 465 470 475 480 Wing Asn Asp Thr Pro Thr Asp Asp Lys Asp Wing Ser Gly Asn Asn Thr 485 490 495 Gly Asp Met Asn Asn Thr Asp Thr Gly Asn Thr Asp Thr Gly Asn Thr 500 505 510 Asp Thr Gly Asn Thr Asp Asp Met Ser Asn Met Asn Asn Gly Asn Asp 515 520 525 Asp Thr Gly Asn Thr Asn Asp Asp Met Gly Asn Ser Asn Asp Met Gly 530 535 540 Asp Asp Met Asn Asn Wing Asn Asp Met Asn Asp Asp Met Gly Asn Ser 545 550 555 560 Asp Asp Asp Met Gly Asp Met Gly Asp Met As Asp Asp Met Gly Gly 565 570 575 Asp Met Gly Asp Met Gly Asp Met Gly Gly Asp Met Gly Asn 580 585 590 (2) INFORMATION OF SEQ ID NO: 175: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 195 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 195 (i) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 175: Leu Asn Leu Arg Leu Ala Gly Ala Ser Val Leu Thr Ala Cys Val Phe 1 5 10 15 Be Gly Cys Phe Phe Leu Lys Met Phe Asp Lys Lys Leu Ser Ser Asn 20 25 30 Asp Trp His He Gln Lys Val Glu Met Asn His Gln Val Tyr Asp He 35 40 45 Glu Thr Met Leu Ala Asp Ser Ala Phe Arg Glu His Glu Glu Glu Gln 50 55 60 Asp See Ser Leu Asn Thr Ala Leu Pro Glu Asp Lys Thr Ala He Glu 65 70 75 80 Ala Lys Glu Gln Glu Gln Lys Glu Lys Arg Lys His Trp Tyr Glu Leu 85 90 95 Phe Lys Lys Pro Lys Pro Lys Ser Ser Met Gly Glu Phe Val Phe 100 105 110 Asp Gln Lys Glu Asn Arg He Tyr Gly Lys Gly Tyr Cys Asn Arg Tyr 115 _ 120 125 Phe Ala Ser Tyr Thr Trp Gln Gly Asp Arg His He Wing He Glu Asp 130 135 140 Ser Gly He Ser Arg Lys Val Cys Arg Asp Glu His Leu Met Ala Phe 145 150 155 160 Glu Leu Glu Phe Met Glu Asn Phe Lys Gly Asn Phe Wing Val Thr Lys 165 170 175 Gly Lys Asp Thr Leu He Leu Asp Asn Gln Lys Met Lys He Tyr Leu 180 185 190 Lys Thr Pro 195 INFORMATION OF SEQ ID NO: 176: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 744 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 744 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 176: Met Leu Lys Leu Wing Ser Lys Thr He Cys Leu Ser Leu He Ser Ser 1 5 10 15 Phe Thr Wing Val Glu Wing Phe Gln Lys His Gln Lys Asp Gly Phe Phe 20 25 30 He Glu Wing Gly Phe Glu Thr Gly Leu Leu Gln Gly Thr Gln Thr Gln 35 40 45 Glu Gln Thr He Wing Thr Thr Gln Glu Lys Pro Lys Pro Lys Pro Lys 50 55 60 Pro Lys Pro He Thr Pro Gln Ser Thr Tyr Gly Lys Tyr Tyr He Ser 65 70 75 80 Gln Ser Thr He Leu Lys Asn Wing Thr Glu Leu Phe Wing Glu Asp Asn 85 90 95 He Thr Asn Leu Thr Phe Tyr Ser Gln Asn Pro Val Tyr Val Thr Ala 100 105 110 Tyr Asn Gln Glu Be Wing Glu Glu Wing Gly Tyr Gly Asn Asn Ser Leu 115 120 125 He Met He Gln Asn Phe Leu Pro Tyr Asn Leu Asn Asn He Glu Leu 130 135 140 Ser Tyr Thr Asp Asp Gln Gly Asn Val Val Ser Leu Gly Val He Glu 145 150 155 160 Thr He Pro Lys Gln Ser Gln He He Leu Pro Wing Ser Leu Phe Asn 165 170 175 Asp Pro Gln Leu Asn Wing Asp Gly Phe Gln Gln Leu Gln Thr Asn Thr 180 185 190 Thr Arg Phe Ser Asp Wing Ser Thr Gln Asn Leu Phe Asn Lys Leu Ser 195 200 205 Lys Val Thr Thr Asn Leu Gln Met Thr Tyr He Asn Tyr Asn Gln Phe 210 215 220 Be Ser Gly Asn Gly Be Gly Ser Lys Pro Pro Cys Pro Pro Tyr Glu 225 230 235 240 Asn Gln Wing Asn Cys Val Wing Lys Val Pro Pro Phe Thr Ser Gln Asp 245 250 255 Wing Lys Asn Leu Thr Asn Leu Met Leu Asn Met Met Wing Val Phe Asp 260 265 270 Ser Lys Ser Trp Glu Asp Wing Val Leu Asn Wing Pro Phe Gln Phe Ser 275 280 285 Asp Asn Asn Leu Be Wing Pro Cys Tyr Ser Asp Tyr Leu Thr Cys Val 290 295 300 Asn Pro Tyr Asn Asp Gly Leu Val Asp Pro Lys Leu He Wing Lys Asn 305 310 315 320 Lys Gly Asp Glu Tyr Asn He Glu Asn Gly Gln Thr Gly Ser Val He 325 330 335 Leu Thr Pro Gln Asp Val He Tyr Ser Tyr Arg Val Wing Asn Asn He 340 345 350 Tyr Val Asn Leu Leu Pro Thr Arg Gly Gly Asp Leu Gly Leu Gly Ser 355 360 365 Gln Tyr Gly Gly Pro Asn Gly Pro Gly Asp Asp Gly Thr Asn Phe Gly 370 375 380 Ala Leu Gly He Leu Ser Pro Phe Leu Asp Pro Glu He Leu Phe Gly 385 390 395 400 Lys Glu Leu Asn Lys Valí Wing He Met Gln Leu Arg Asp He He His 405 410 415 Glu Tyr Gly His Thr Leu Gly Tyr Thr His Asn Gly Asn Met Thr Tyr 420 425 430 Gln Arg Val Arg Met Cys Glu Glu Asn Asn Gly Pro Glu Glu Arg Cys 435 440 445 Gln Gly Gly Arg He Glu Gln Val Asp Gly Lys Glu Val Gln Val Phe 450 455 460 Asp Asn Gly His Glu Val Arg Asp Thr Asp Gly Ser Thr Tyr Asp Val 465 470 475 480 Cys Ser Arg Phe Lys Asp Lys Pro Tyr Thr Wing Gly Ser Tyr Pro Asn 485 490 495 Ser He Tyr Thr Asp Cys Ser Gln Val Pro Wing Gly Leu He Gly Val 500 505 510 Thr Ser Wing Val Trp Gln Gln Leu He Asp Gln Asn Wing Leu Pro Val 515 520 525 Asp Phe Thr Asn Leu Be Ser Gln Thr Asn Tyr Leu Asn Ala Ser Leu 530 535 540 Asn Thr Gln Asp Phe Wing Thr Thr Met Leu Ser Wing He Ser Gln Ser 545 550 555 560 Leu Being Being Lys Being Being Wing Thr Thr Tyr Arg Thr Being Lys Thr 565 570 575 Be Arg Pro Phe Gly Ala Pro Leu Leu Gly Val Asn Leu Lys Met Gly 580 585 590 Tyr Gln Lys Tyr Phe Asn Asp Tyr Leu Gly Leu Ser Ser Tyr Gly He 595 600 605 He Lys Tyr Asn Tyr Wing Gln Wing Asn Asn Glu Lys He Gln Gln Leu 610 615 620 Ser Tyr Gly Val Gly Met Asp Val Leu Phe Asp Phe He Thr Asn Tyr 625 630 635 640 Thr Asn Glu Lys Asn Pro Lys Ser Asn Leu Thr Lys Lys Val Phe Thr 645 650 655 Be Ser Leu Gly Val Phe Gly Gly Leu Arg Gly Leu Tyr Asn Ser Tyr 660 665 670 Tyr Leu Leu Asn Gln Tyr Lys Gly Ser Gly Asn Leu Asn Val Thr Gly 675 680 685 Gly Leu Asn Tyr Arg Tyr Lys His Ser Lys Tyr Ser He Gly He Ser 690 695 700 Val Pro Leu Val Gln Leu Lys Ser Arg He Val Ser Ser Asp Gly Ala 705 710 715 720 Tyr Thr Asn Ser He Thr Leu Asn Glu Gly Gly Ser His Phe Lys Val 725 730 735 Phe Phe Asn Tyr Gly Trp lie Phe 740 (2) INFORMATION OF SEQ ID NO: 177: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 529 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 529 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 177 Met Thr Tyr He Asn Tyr Asn Gln Phe Ser Ser Gly Asn Gly Ser Gly 1 5 10 15 Be Lys Pro Pro Cys Pro Pro Tyr Glu Asn Gln Wing Asn Cys Val Wing 20 25 30 Lys Val Pro Pro Phe Thr Ser Gln Asp Ala Lys Asn Leu Thr Asn Leu 35 40. Four. Five Met Leu Asn Met Met Ala Val Phe Asp Ser Lys Ser Trp Glu Asp Ala 50 55 60 Val Leu Asn Wing Pro Phe Gln Phe Ser Asp Asn Asn Leu Ser Wing Pro 65 70 75 80 Cys Tyr Ser Asp Tyr Leu Thr Cys Val Asn Pro Tyr Asn Asp Gly Leu 85 90 95 Val Asp Pro Lys Leu He Wing Lys Asn Lys Gly Asp Glu Tyr Asn He 100 105 110 Glu Asn Gly Gln Thr Gly Ser Val He Leu Thr Pro Gln Asp Val He 115 120 125 Tyr Ser Tyr Arg Val Wing Asn Asn He Tyr Val Asn Leu Leu Pro Thr 130 135 140 Arg Gly Gly Asp Leu Gly Leu Gly Ser Gln Tyr Gly Gly Pro Asn Gly 145 150 155 160 Pro Gly Asp Asp Gly Thr Asn Phe Gly Ala Leu Gly He Leu Ser Pro 165 170 175 Phe Leu Asp Pro Glu He Leu Phe Gly Lys Glu Leu Asn Lys Val Wing 180 185 190 He Met Gln Leu Arg Asp He He His Glu Tyr Gly His Thr Leu Gly 195 200 205 Tyr Thr His Asn Gly Asn Met Thr Tyr Gln Arg Val Arg Met Cys Glu 210 215 220 Glu Asn Asn Gly Pro Glu Glu Arg Cys Gln Gly Gly Arg He Glu Gln 225 230 235 240 Val Asp Gly Lys Glu Val Gln Val Phe Asp Asn Gly His Glu Val Arg 245 250 255 Asp Thr Asp Gly Ser Thr Tyr Asp Val Cys Ser Arg Phe Lys Asp Lys 260 265 270 Pro Tyr Thr Wing Gly Ser Tyr Pro Asn Ser He Tyr Thr Asp Cys Ser 275 280 285 Gln Val Pro Wing Gly Leu He Gly Val Thr Ser Wing Val Trp Gln Gln 290 295 300 Leu He Asp Gln Asn Ala Leu Pro Val Asp Phe Thr Asn Leu Ser Ser 305 310 315 320 Gln Thr Asn Tyr Leu Asn Wing Ser Leu Asn Thr Gln Asp Phe Wing Thr 325 330 335 Thr Met Leu Ser Ala Be Ser Gln Ser Leu Ser Ser Ser Lys Ser Ser 340 345 350 Wing Thr Thr Tyr Arg Thr Ser Lys Thr Ser Arg Pro Phe Gly Wing Pro 355 360 365 Leu Leu Gly Val Asn Leu Lys Met Gly Tyr Gln Lys Tyr Phe Asn Asp 370 375 380 Tyr Leu Gly Leu Be Ser Tyr Gly He He Lys Tyr Asn Tyr Ala Gln 385 390 395 400 Wing Asn Asn Glu Lys He Gln Gln Leu Ser Tyr Gly Val Gly Met Asp 405 410 415 Val Leu Phe Asp Phe He Thr Asn Tyr Thr Asn Glu Lys Asn Pro Lys 420 425 430 Be Asn Leu Thr Lys Lys Val Phe Thr Ser Ser Leu Gly Val Phe Gly 435 440 445 Gly Leu Arg Gly Leu Tyr Asn Ser Tyr Tyr Leu Leu Asn Gln Tyr Lys 450 455 460 Gly Ser Gly Asn Leu Asn Val Thr Gly Gly Leu Asn Tyr Arg Tyr Lys 465 470 475 480 His Ser Lys Tyr Ser He Gly He Ser Val Pro Leu Val Gln Leu Lys 485 490 495 Ser Arg He Val Ser Ser Asp Gly Ala Tyr Thr Asn Ser He Thr Leu 500 505 510 Asn Glu Gly Gly Ser His Phe His Val Phe Phe Asn Tyr Gly Trp He 515 520 525 Phe (2) INFORMATION OF SEQ ID NO: 178: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 187 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 187 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 178 Leu Gly Cys Val Ser Met Thr Leu Gly He Asp Glu Wing Gly Arg Gly 1 5 10 15 Cys Leu Wing Gly Ser Leu Phe Val Wing Gly Val Val Cys Asn Glu Lys 20 25 30 He Ala Leu Glu Phe Leu Lys Met Gly Leu Lys Asp Ser Lys Lys Leu 35 40 45 Ser Pro Lys Lys Arg Phe Phe Leu Glu Asp Lys He Lys Thr His Gly 50 55 60 Glu Val Gly Phe Phe Val Val Lys Lys Ser Wing Asn Glu He Asp His 65 70 75 80 Leu Gly Leu Gly Wing Cys Leu Lys Leu Wing He Glu Glu He Val Glu 85 90 95 Asn Gly Cys Ser Leu Wing Asn Glu He Lys He Asp Gly Asn Thr Wing 100 105 110 Phe Gly Leu Asn Lys Arg Tyr Pro Asn He Gln Thr He He Lys Gly 115 120 125 Asp Glu Thr He Wing Gln He Wing Met Wing Ser Val Leu Wing Lys Wing 130 135 140 Ser Lys Asp Arg Glu Met Leu Glu Leu His Wing Leu Phe Lys Glu Tyr 145 150 155 160 Gly Trp Asp Lys Asn Cys Gly Tyr Gly Thr Lys Gln His He Glu Wing 165 170 175 He Asn Lys Leu Gly Ala Thr Leu Ser Ser Ala 180 185 (2) INFORMATION OF SEQ ID NO: 179: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 204 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 204 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 179: Met Thr Leu Gly He Asp Glu Wing Gly Arg Gly Cys Leu Wing Gly Ser 1 5 10 15 Leu Phe Val Wing Gly Val Val Cys Asn Glu Lys He Wing Leu Glu Phe 20 25 30 Leu Lys Met Gly Leu Lys Asp Ser Lys Lys Leu Ser Pro Lys Lys Arg 35 40 45 Phe Phe Leu Glu Asp Lys He Lys Thr His Gly Glu Val Gly Phe Phe 50 55 60 Val Val Lys Lys Ser Wing Asn Glu He Asp His Leu Gly Leu Gly Wing 65 70 75 80 Cys Leu Lys Leu Wing He Glu Glu He Val Glu Asn Gly Cys Ser Leu 85 90 95 Wing Asn Glu He Lys He Asp Gly Asn Thr Wing Phe Gly Leu Asn Lys 100 105 110 Arg Tyr Pro Asn He Gln Thr He He Lys Gly Asp Glu Thr He Wing 115 120 125 Gln He Ala Met Ala Ser Val Leu Ala Lys Ala Ser Lys Asp Arg Glu 130 135 140 Met Leu Glu Leu His Ala Leu Phe Lys Glu Tyr Gly Trp Asp Lys Asn 145 150 155 160 Cys Gly Tyr Gly Thr Lys Gln His He Glu Wing He Asn Lys Leu Gly 165 170 175 Wing Thr Pro Phe His Arg His Ser Phe Thr Leu Lys Asn Arg He Leu 180 185 190 Asn Pro Lys Leu Leu Glu Val Glu Gln Arg Leu Val 195 200 (2) INFORMATION OF SEQ ID NO: 180: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 192 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 192 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 180: Met Asn Ala Leu Lys Lys Leu Ser Phe Cys Ala Leu Leu Ser Leu Gly 1 5 10 15 Leu Phe Wing Gln Thr Val His Wing Gln His Leu Lys Asn Thr He Asn 20 25 30 Tyr Pro Asp Trp Leu Lys He Asn Leu Phe Asp Lys Lys Asn Pro Pro 35 40 45 Asn Gln Tyr Val Gly Ser Wing Be He Be Gly Lys Arg Asn Asp Phe 50 55 60 Tyr Ser Asn Tyr He Pro Tyr Asp Asp Lys Leu Pro Pro Glu Lys Asn 65 70 75 80 Wing Glu Glu He Wing Leu Leu Arg Wing Arg Met Asn Wing Tyr Ser Thr 85 90 95 Leu Glu Be Ala Leu Leu Thr Lys Met Cys Asn Arg He Val Lys Ala 100 105 110 Leu Gln Val Lys Asn Asn Val He Ser His Leu Phe Gly Phe Val Asp 115 120 125 Phe Leu Thr Ser Lys Ser He Leu Wing Lys Arg Phe Val Asp Thr Thr 130 135 140 Asn His Arg Val Tyr Val Met Val Gln Phe Pro Phe He Gln Pro Glu 145 150 155 160 Asp Leu He Wing Tyr Phe Lys Wing Lys Arg He Asp Leu Ser Leu Wing 165 170 175 Ser Ala Thr Asn Leu Ser Ala He Leu Asn Lys Ala Leu Phe His Leu 180 185 190 (2) INFORMATION OF SEQ ID NO: 181: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 86 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 86 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 181: Met Asn Ala Leu Lys Lys Leu Ser Phe Cys Ala Leu Leu Ser Leu Gly 1 5 10 15 Leu Phe Wing Gln Thr Val His Wing Gln His Leu His Asp Thr He Asn 20 25 30 Tyr Pro Asp Trp Leu Lys He Asn Leu Phe Asp Lys Lys Asn Pro Pro 35 40 45 Asn Gln Tyr Val Gly Ser Wing Be He Be Gly Lys Arg Asn Asp Phe 50 55 60 Tyr Ser Asn Tyr He Pro Tyr Asp Asp Lys Leu Pro Pro Glu Arg Thr 65 70 75 80 Leu Lys Lys Ser Leu Phe 85 (2) INFORMATION OF SEQ ID NO: 182: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 75 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 75 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 182: Leu Lys He Leu Thr Leu Phe Leu He Gly Leu Asn Ala Leu Phe Wing 1 5 10 15 Leu Asp Leu Asn Ala Leu Lys Thr Glu He Lys Glu Thr Tyr Leu Lys 25 30 Glu Tyr Lys Asp Leu Lys Leu Glu He Glu Thr He Asn Leu Glu He 35 40 45 Pro Glu Arg Phe Ser His Wing Ser He Leu Ser Tyr Glu Leu Asn Wing 50 55 60 Ser Asn Lys Leu Lys Lys Asp Gly Ser Cys Phe 65 70 75 INFORMATION OF SEQ ID NO: 183: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 211 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 211 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 183: Met Phe Ser He He Leu Gly Gly Gly Gly Gn Asn Thr Pro Cys Gly 1 5 10 15 Leu Thr Trp Gln His Phe Lys Leu Gly Asp Leu Phe Glu He Glu Lys 20 25 30 Thr Leu Ser Phe Asn Lys Asp Wing Leu Thr Gln Gly Gln Asp Tyr Asp 35 40 45 Tyr He Thr Arg Thr Ser Gln Asn Gln Gly Val Leu Gln Thr Thr Gly 50 55 60 Phe Val Asn Ala Glu Asn Leu Asn Pro Pro Phe Thr Trp Ser Leu Gly 65 70 75 80 Leu Leu Gln Met Asp Phe Phe Tyr Arg Lys Lys Ser Trp Tyr Wing Gly 85 90 95 Gln Phe Met Arg Lys He Thr Pro Lys Thr Glu He Lys Asn Lys He 100 105 110 Asn Ser Arg He Wing His Tyr Phe Thr Thr Leu Leu Asn Wing Leu Lys 115 120 125 Arg Pro Leu Leu Ser Val Leu Val Arg Asp He Asp Lys Thr Phe Arg 130 135 140 Glu Gln Lys He Gln Leu Pro Leu Lys Pro Thr Ala Lys Thr Gln Ser 145 150 155 160 Leu Asp Lgy He Asp Phe Asp Phe Met His Thr Leu He Asn Ala Leu 165 170 175 Met Lys Gln Thr He Gln Gly Val Val Gln Tyr Cys Asp Ala Lys He 180 185 190 Gln Ala Thr Lys Glu Val He Ser Gln Glu Thr Pro He Gln Lys Asp 195 200 205 Ser Leu Phe 210 INFORMATION OF SEQ ID NO: 184: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 406 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 406 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 184 Val He Gly Pro Leu Ser Ser Gln Leu Asn Ala He Lys Trp Gly Glu 1 5 10 15 Phe Lys Leu Gly Asp Leu Phe Glu Wing Being Asn Gly Asp Phe Asp He 20 25 30 Gln Lys Arg His He Asn His Lys Gly Glu Phe Val He Thr Wing Gly 35 40 45 Leu Ser Asn Asn Gly Val Leu Gly Gln Ser Asp He Lys Ala Lys Val 50 55 60 Phe Glu Ser His Thr He Thr He Asp Met Phe Gly Cys Ala Phe Tyr 65 70 75 80 Arg Ser Phe Wing Tyr Lys Met Val Thr His Wing Arg Val Phe Ser Leu 85 90 95 Lys Pro Lys Phe Glu He Asn His Lys He Gly Leu Phe Leu Ser Thr 100 105 110 Leu Phe Phe Gly Tyr His Lys Lys Phe Gly Tyr Glu Asn Met Cys Ser 115 120 125 Trp Ala Lys He Lys Asn Asp Lys Val He Leu Pro Leu Lys Pro Thr 130 135 140 Wing Asn Thr Gln Thr Leu Glu Gly He Asp Phe Asp Phe Met Glu Lys 145 150 155 160 Phe He Wing Glu Leu Glu Gln Cys Arg Leu Wing Glu Leu Gln Wing Tyr 165 170 175 * Leu Lys Wing Thr Gly Leu Glu Asn Thr Thr Leu Ser Asn Asp Glu Glu 180 185 190 Asn Ala Leu Asn Val Phe Asn Asn Ser Gly Gly Gly Gly Gly Asn Thr 195 200 205 Pro Cys Gly Leu Thr Trp Gln His Phe Lys Leu Gly Asp Leu Phe Glu 210 215 220 He Glu Lys Thr Leu Ser Phe Asn Lys Asp Ala Leu Thr Gln Gly Gln 225 230 235 240 Asp Tyr Asp Tyr He Thr Arg Thr Ser Gln Asn Gln Gly Val Leu Gln 245 250 255 Thr Thr Gly Phe Val Asn Wing Glu Asn Leu Asn Pro Pro Phe Thr Trp 260 265 270 Being Leu Gly Leu Leu Gln Met Asp Phe Phe Tyr Arg Lys Lys Ser Trp 275 280 285 Tyr Wing Gly Gln Phe Met Arg Lys He Thr Pro Lys Thr Glu He Lys 290 295 300 Asn Lys He Asn Ser Arg He Wing His Tyr Phe Thr Thu Leu Leu Asn 305 310 315 320 Ala Leu Lys Arg Pro Leu Leu Ser Val Leu Val Arg Asp He Asp Lys 325 330 335 Thr Phe Arg Glu Gln Lys He Gln Leu Pro Leu Lys Pro Thr Ala Lys 340 345 350 Thr Gln Ser Leu Asp Gly He Asp Phe Asp Phe Met His Thr Leu He 355 360 365 Asn Ala Leu Met Lys Gln Thr He Gln Gly Val Val Gln Tyr Cys Asp 370 375 380 Wing Lys He Gln Wing Thr Lys Glu Val He Ser Gln Glu Thr Pro He 385 390 395 400 Gln Lys Asp Ser Leu Phe 405 (2) INFORMATION OF SEQ ID NO: 185: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 275 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 275 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 185: Met Ser Lys Ser Leu Tyr Gln Thr Leu Asn Val Ser Glu Asn Wing Ser 1 5 10 15 Gln Asp Glu He Lys Lys Ser Tyr Arg Arg Leu Wing Arg Gln Tyr His 20 25 30 Pro Asp Leu Asn Lys Thr Lys Glu Wing Glu Glu Lys Phe Lys Glu He 35 40 45 Asn Ala Ala Tyr Glu He Leu Ser Asp Glu Glu Lys Arg Arg Gln Tyr 50 55 60 Asp Gln Phe Gly Asp Asn Met Phe Gly Gly Gln Asn Phe Ser Asp Phe 65 70 75 80 Wing Arg Ser Arg Gly Pro Ser Glu Asp Leu Asp Asp He Leu Ser Be 85 90 95 He Phe Ser Gly Phe Asn Phe Ser A = n Phe Wing Pro Glu Asn Leu Asp 100 105 110 Gly Phe Ser Gly Phe Asn Phe Ser Asn Phe Wing Pro Glu Asn Leu Asp 115 120 125 Val Thr Ala He Leu Asn Val Ser Val Leu Asp Thr Leu Leu Gly Asn 130 135 140 Lys Lys Gln Val Ser Val Asn Asn Glu Thr Phe Ser Leu Lys He Pro 145 150 155 160 He Gly Val Glu Glu Gly Glu Lys He Arg Val Arg Asn Lys Gly Lys 165 170 175 Met Gly Arg Thr Gly Arg Gly Asp Leu Leu Leu Gln He His He Glu 180 185 190 Glu Asp Glu Met Tyr Arg Arg Glu Lys Asp Asp He He Gln He Phe 195 200 205 Asp Leu Pro Leu Lys Thr Ala Leu Phe Gly Gly Lys He Glu He Ala 210 215 220 Thr Trp His Lys Thr Leu Thr Leu Thr He Pro Pro Asn Thr Lys Wing 225 230 235 240 Met Gln Lys Phe Arg He Lys Asp Lys Gly He Lys Ser Arg Lys Thr 245 250 255 Ser His Val Gly Asp Cys He Wing Being Ser Phe Asp Leu Leu Lys Leu 260 265 270 Lys Arg Phe 275 (2) INFORMATION OF SEQ ID NO: 186: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 278 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 278 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 186: Met Ser Lys Ser Leu Tyr Gln Thr Leu Asn Val Ser Glu Asn Wing 1 5 10 15 Gln Asp Glu He Lys Lys Ser Tyr Arg Arg Leu Wing Arg Gln Tyr His 20 25 30 Pro Asp Leu Asn Lys Thr Lys Glu Wing Glu Glu Lys Phe Lys Glu He 35 40 45 Asn Ala Ala Tyr Glu He Leu Ser Asp Glu Glu Lys Arg Arg Gln Tyr 50 55 60 Asp Gln Phe Gly Asp Asn Met Phe Gly Gly Gln Asn Phe Ser Asp Phe 65 70 75 80 Wing Arg Ser Arg Gly Pro Ser Glu Asp Leu Asp Asp He Leu Ser Ser 85 90 95 He Phe Gly Lys Gly Gly Phe Ser Gln Arg Phe Ser Gln Asn Ser Gln 100 105 110 Gly Phe Ser Gly Phe Asn Phe Ser Asn Phe Wing Pro Glu Asn Leu Asp 115 120 125 Val Thr Ala He Leu Asn Val Ser Val Leu Asp Thr Leu Leu Gly Asn 130 135 140 Lys Lys Gln Val Ser Val Asn Asn Glu Thr Phe Ser Leu Lys He Pro 145 150 155 160 He Gly Val Glu Glu Gly Glu Lys He Arg Val Arg Asn Lys Gly Lys 165 170 175 Met Gly Arg Thr Gly Arg Gly Asp Leu Leu Leu Gln He His He Glu 180 185 190 Glu Asp Glu Met Tyr Arg Arg Glu Lys Asp Asp He He Gln He Phe 195 200 205 Asp Leu Pro Leu Lys Thr Wing Leu Phe Gly Gly Lys He Glu He Wing 210 215 220 Thr Trp His Lys Thr Leu Thr Leu Thr He Pro Pro Asn Thr Lys Wing 225 230 235 240 Met Gln Lys Phe Arg He Lys Asp Lys Gly He Lys Ser Arg Lys Thr 245 250 255 Ser His Val Gly Asp Cys He Wing Being Ser Phe Asp Leu Pro Lys He 260 265 270 Glu Thr Leu Leu Met Ser 275 (2) INFORMATION OF SEQ ID NO: 187: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 232 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: mise characteristic (B) LOCATION 1. . . 232 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 187: Val Val Gln Lys Phe Asn Phe Tyr Lys Thr Gly Gly Met Arg Leu Lys 1 5 10 15 His Phe Lys Thr Phe Leu Phe He Thr Met Wing Val He Val He Gly 20 25 30 Thr Gly Cys Wing Asn Lys Lys Lys Lys Lys Asp Glu Tyr Asn Lys Pro 35 40 45 Wing He Phe Trp Tyr Gln Gly He Leu Arg Glu He Leu Phe Wing Asn 50 55 60 Leu Glu Thr Wing Asp Asn Tyr Tyr Ser Ser Leu Gln Ser Glu His He 65 70 75 80 Asn Ser Pro Leu Val Pro Glu Ala Met Leu Ala Leu Gly Gln Ala His 85 90 95 Met Lys Lys Lys Glu Tyr Val Leu Wing Ser Phe Tyr Phe Asp Glu Tyr 100 105 110 He Lys Arg Phe Gly Thr Lys Asp Asn Val Asp Tyr Leu Thr Phe Leu 115 120 125 Lys Leu Gln Ser His Tyr Tyr Ala Phe Lys Asn His Ser Lys Asp Gln 130 135 140 Glu Phe He Ser Asn Ser He Val Ser Leu Gly Glu Phe He Glu Lys 145 150 155 160 Tyr Pro Asn Ser Arg Tyr Arg Pro Tyr Val Glu Tyr Met Gln He Lys 165 170 175 Phe He Leu Gly Gln Asn Glu Leu Asn Arg Wing He Wing Asn Val Tyr 180 185 190 Lys Lys Arg His Lys Pro Glu Gly Val Lys Arg Tyr Leu Glu Arg He 195 200 205 Asp Glu Thr Leu Glu Lys Glu Thr Lys Pro Lys Pro Ser His Met Pro 210 215 220 Trp Tyr Val Leu He Phe Asp Trp 225 230 (2) INFORMATION OF SEQ ID NO: 188: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 114 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 114 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 18 Met Arg Phe Leu Asn Asn Lys His Arg Glu Lys Gly Leu Lys Ala Glu 1 5 10 15 Glu Glu Wing Cys Gly Phe Leu Lys Thr Leu Gly Phe Glu Met He Glu 20 25 30 Arg Asn Phe Phe Ser Gln Phe Gly Glu He Asp He He Wing Leu Lys 40 45 Lys Gly Val Leu His Phe He Glu Val Lys Ser Gly Glu Asn Phe Asp 50 55 60 Pro He Tyr Ala He Thr Pro Ser Lys Leu Lys Lys Met He Lys Thr 65 70 75 80 He Arg Cys Tyr Leu Ser Gln Lys Asp Pro Asn Ser Asp Phe Cys He 85 90 95 Asp Ala Leu He Val Lys Asn Gly Lys Phe Glu Leu Leu Glu Asn He 100 105 110 Thr Phe (2) INFORMATION OF SEQ ID NO: 189: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 101 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 101 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 189: Met Gly Ser He Gly Wing Met Thr Lys Gly Seer Ser Asp Arg Tyr Phe 1 5 10 15 Gln Glu Gly Val Wing Ser Glu Lys Leu Val Pro Glu Gly He Glu Gly 20 25 30 Arg Val Pro Tyr Arg Gly Lys Val Ser Asp Met He Phe Gln Leu Val 35 40 45 Gly Gly Val Arg Ser Ser Met Gly Tyr Gln Gly Ala Lys Asn He Leu 50 55 60 Glu Leu Tyr Gln Asn Wing Glu Phe Val Glu He Thr Ser Wing Gly Leu 65 70 75 80 Lys Lys Ser His Val His Gly Val Asp He Thr Lys Glu Ala Pro Asn 85 90 95 He Met Gly Glu Phe 100 INFORMATION OF SEQ ID NO: 190: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 481 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: mise characteristic (B) LOCATION 1 ... 481 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 190: Met Arg He Leu Gln Arg Ala Leu Thr Phe Glu Asp Val Leu Met Val 1 5 10 15 Pro Arg Lys Be Ser Val Leu Pro Lys Asp Val Ser Leu Lys Ser Arg 20 25 30 Leu Thr Lys Asn He Gly Leu Asn He Pro Phe He Ser Wing Wing Met 35 40 45 Asp Thr Val Thr Glu His Lys Thr Wing He Wing Met Wing Arg Leu Gly 50 55 60 Gly He Gly He Val His Lys Asn Met Asp He Gln Thr Gln Val Lys 65 70 75 80 Glu He Thr Lys Val Lys Lys Ser Glu Ser Gly Val He Asn Asp Pro 85 90 95 He Phe He His Wing His Arg Thr Leu Wing Asp Wing Lys Val He Thr 100 105 110 Asp Asn Tyr Lys He Be Gly Val Pro Val Val Asp Asp Lys Gly Leu 115 120 125 Leu He Gly He Leu Thr Asn Arg Asp Val Arg Phe Glu Thr Asp Leu 130 135 140 Be Lys Lys Val Gly Asp Val Met Thr Lys Met Pro Leu Val Thr Ala 145 150 155 160 His Val Gly He Ser Leu Asp Glu Ala Ser Asp Leu Met His Lys His 165 170 175 Lys He Glu Lys Leu Pro He Val Asp Lys Asp Asn Val Leu Lys Gly 180 185 190 Leu He Thr He Lys Asp He Gln Lys Arg He Glu Tyr Pro Glu Ala 195 200 205 Asn Lys Asp Asp Phe Gly Arg Leu Arg Val Gly Ala Wing He Gly Val 210 215 220 Gly Gln Leu Asp Arg Ala Glu Met Leu Val Lys Ala Gly Val Asp Ala 225 230 235 240 Leu Val Leu Asp Ser Ala His Gly His Ser Ala Asn He Leu His Thr 245 250 255 Leu Glu Glu He Lys Lys Ser Leu Val Val Asp Val He Val Gly Asn 260 265 270 Val Val Thr Lys Glu Wing Thr Ser Asp Leu He Ser Wing Gly Wing Asp 275 280 285 Wing Val Lys Val Gly He Gly Pro Gly Ser He Cys Thr Thr Arg He 290 295 300 Val Wing Gly Val Gly Met Pro Gln Val Ser Wing He Asp Asn Cys Val 305 310 315 320 Glu Val Ala Ser Lys Phe Asp He Pro Val He Wing Asp Gly Gly He 325 330 335 Arg Tyr Ser Gly Asp Val Wing Lys Wing Leu Wing Leu Gly Wing Being Ser 340 345 350 Val Met He Gly Ser Leu Leu Wing Gly Thr Glu Glu Ser Pro Gly Asp 355 360 365 Phe Met He Tyr Gln Gly Arg Gln Tyr Lys Ser Tyr Arg Gly Met Gly 370 375 380 Be He Gly Wing Met Thr Lys Gly Be Ser Asp Arg Tyr Phe Gln Glu 385 390 395 400 Gly Val Ala Ser Glu Lys Leu Val Pro Glu Gly He Glu Gly Arg Val 405 410 415 Pro Tyr Arg Gly Lys Val Ser Asp Met He Phe Gln Leu Val Gly Gly 420 425 430 Val Arg Being Ser Met Gly Tyr Gln Gly Ala Lys Asn He Leu Glu Leu 435 440 445 Tyr Gln Asn Wing Glu Phe Val Glu He Thr Ser Wing Gly Leu Lys Glu 450 455 460 Ser His Val His Gly Val Asp He Thr Lys Glu Ala Pro Asn Tyr Tyr 465 470 475 480 Gly (2) INFORMATION OF SEQ ID NO: 191: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 204 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION 1 ... 204 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 191: Met Gln Gly Phe Leu Leu Gln Thr Gln Ser He Arg Asp Glu Asp Leu 1 5 10 15 He Val His Val Leu Thr Lys Asn Gln Leu Lys Thr Leu Tyr Arg Phe 20 25 30 Tyr Gly Lys Arg His Ser Val Leu Asn Val Gly Arg Lys He Asp Phe 40 45 Glu Glu Glu Asn Asp Asp Lys Phe Leu Pro Lys Leu Arg Asn He Leu 50 55 60 His Leu Gly Tyr He Trp Glu Arg Glu Met Glu Arg Leu Phe Phe Trp 65 70 75 80 Gln Arg Phe Cys Ala Leu Leu Phe Lys His Leu Glu Gly Val His Ser 85 90 95 Leu Asp Ser He Tyr Phe Asp Thr Leu Asp Asp Gly Wing Ser Lys Leu 100 105 110 Ser Lys Gln His Pro Leu Arg Val He Leu Glu Met Tyr Ala Val Leu 115 120 125 Leu Asn Phe Glu Gly Arg Leu Gln Ser Tyr Asn Ser Cys Phe Leu Cys 130 135 140 Asp Ala Lys Leu Glu Arg Ser Val Ala Leu Ala Gln Gly Phe He Leu 145 150 155 160 Ala His Pro Ser Cys Leu Lys Ala Lys Ser Leu Asp Leu Glu Lys He 165 170 175 Gln Ala Phe Phe Arg Thr Gln Ser Thr He Asp Leu Glu Thr Glu Glu 180 185 190 Val Glu Glu Leu Trp Arg Thr Leu Asn Leu Gly Phe 195 200 (2) INFORMATION OF SEQ ID NO: 192: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 82 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 82 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 192: Met Gly Val Gly Arg Val Gly Asn Met Ala Leu Leu Ala Cys Ala Gly 1 5 10 15 Pro Met Gly He Gly Wing He Wing He Wing He Asn Gly Gly Arg Gln 20 25 30 Arg Ser Arg Met Leu Val Val Asp He Asp Asp Lys Arg Leu Glu Gln 35 40 45 Val Gln Lys Met Leu Pro Gly Asn Trp Arg Pro Val Thr Ala Leu Ser 50 55 60 Trp Cys Leu Cys He Pro Lys Arg Gly Wing He Arg Wing Arg Cys Cys 65 70 75 80 Glu Arg (2) INFORMATION OF SEQ ID NO: 193: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 67 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 67 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 193: Leu Ser Gly Thr Wing Val Ser Cys Arg Cys Thr Cys Arg He Gln Leu 1 5 10 15 Val Leu Val Arg Thr Ser He Pro Val Val He Gly Cys Ser Cys Pro 20 25 30 Phe Leu Ser Be He Gly Phe Thr Thr Gly Thr His Gln Ser Pro Val 35 40 45 Lys Arg Cys Gly Val Asn Allah Gly Lys Thr Pro Ser Lys Lys His Leu 50 55 60 His Leu Asn 65 [2) INFORMATION OF SEQ ID NO: 194: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 114 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) TYPE OF MOLECULE: protein (iii) HYPOTHETICAL: YES (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION 1 ... 114 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 194 Val Trp Leu Ala Ala Leu Gly Phe Leu He Thr Ala Val Gly Leu Pro 1 5 10 15 Val He Thr Val He Wing Leu Wing Lys Val Gly Gly Ser Ser Thr Pro 20 25 30 Be Ala He Arg Be Ala Gly Met Pro Ala Ala Cys Trp Arg Arg Ser 35 40 45 Wing Thr Trp Arg Ser Wing Arg Cys Ser Pro Phe Arg Wing Pro Pro Arg 50 55 60 Cys Pro Ser Lys Val Ser Val Val Pro Leu Leu Gly Glu Glu Ala Ala 65 70 75 80 Arg Arg Cys Ser Ser Thr Wing Trp Arg Thr Ser Ser Ser Pro Trp Pro 85 90 95 Ser Pro Pro Thr Pro Val Wing Cys Trp Thr Pro Ser Asp Wing Ser Ser 100 105 110 Pro Arg (2) INFORMATION FOR SEC ID NO: 195: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc__característica (B) LOCATION: 1 ... 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 195: TATACCATGG TGGGCGCTAA 20 (2) INFORMATION FOR SEQ ID NO: 196: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv ') ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 196: ATGAATTCGA GTAAGGATTT TTG 23 (2) INFORMATION FOR SEQ ID NO: 197: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 197: TTAACCATGG TGAAAAAGCGA TA 22 (2) INFORMATION FOR SEQ ID NO: 198: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 198: TAGAATTCGC ATAACGATCA ATC 23 (2) INFORMATION FOR SEQ ID NO: 199: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 199: ATATCCATGG TGAGTTTGTA GA 22 (2) INFORMATION FOR SEC ID NO: 200: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 200: ATGAATTCAA TTTTTTATTT TGCCA 25 (2) INFORMATION FOR SEQ ID NO: 201: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 201: AATTCCATGG TGGGGGCTAT G 21 (2) INFORMATION FOR SEC ID NO: 202: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 202: ATGAATTCTC GATAGCCAAAA ATC 23 (2) INFORMATION FOR SEC ID NO: 203: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 203: AATTCCATGG TGCATAACTT CCATT 25 (2) INFORMATION FOR SEQ ID NO: 204: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 204 AAGAATTCTC TAGCATCCAA ATGGA 25 (2) INFORMATION FOR SEQ ID NO: 205: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 205: ATTTCCATGG TCATGTCTCA TATT 24 (2) INFORMATION FOR SEQ ID NO: 206: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 206: ATGAATTCCA TCTTTTATTC CAC 23 (2) INFORMATION FOR SEQ ID NO: 207: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 27 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 207: AACCATGGTG ATTTTAAGCA TTGAAAG 27 (2) INFORMATION FOR SEC ID NO: 208: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 28 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 208 AAGAATTCCA CTCAAAATTT TTTAACAG (2) INFORMATION FOR SEQ ID NO: 209: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 209: GATCATCCAT ATGTTACTT CTAAT 25 s (2) INFORMATION FOR SEC ID NO: 210: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 210: TGAATTCAAC CATTTTAACC CTG 23 (2) INFORMATION FOR SEQ ID NO: 211: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 27 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 211: TATACCATGG TGAAATTTTT TCTTTTA 27 (2) INFORMATION FOR SEC ID NO: 212: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRITION OF THE SEQUENCE: SEQ ID NO: 212: AGAATTCAAT TGCGTCTTGT AAAAG 25 (2) INFORMATION FOR SEQ ID NO: 213: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 213: TATACCATGG TGATGGACAA ACTC 24 (2) INFORMATION FOR SEQ ID NO: 214: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter, pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 214: ATGAATTCCC ACTTGGGGCG ATA 23 (2) INFORMATION FOR SEC ID NO: 215: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 215: TTATGGATCC AAACCAATTA AAACT 25 (2) INFORMATION FOR SEQ ID NO: 216: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NOAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 216: TATCTCGAGT TATAGAGAAG GGC 23 (2) INFORMATION FOR SEQ ID NO: 217: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 217: TTAACCATGG TGAAAAGCGA TA 22 (2) INFORMATION FOR SEQ ID NO: 218: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 218: TAGAATTCGC CTCTAAAACT TTAG_24_(2) INFORMATION FOR SEQ ID NO: 219: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 219: TTAACCATGG TGAAAAGCGA TA 22 (2) INFORMATION FOR SEC ID NO: 220: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 220: TAGAATTCGC ATAACGAATCA ATC 23 (2) INFORMATION FOR SEQ ID NO: 221: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc__characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 221 ATATCCATGG TGAGTTTGAT GA 22 (2) INFORMATION FOR SEQ ID NO: 222: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF SEQUENCE: SEQ ID NO: 222: ATGAATTCAA TTTTTTATTT TGCCA 25 (2) INFORMATION FOR SEQ ID NO: 223: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 223: AATTCCATGG CTATCCAAAT CCG 23 (2) INFORMATION FOR SEQ ID NO: 224: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 224: ATGAATTCGC CAAAATCGTA GTATT 25 (2) INFORMATION FOR SEQ ID NO: 225: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 225: GATACCATGG AATTTATGAA AAAG 24 (2) INFORMATION FOR SEQ ID NO: 226: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 226: TGAATTCGAA AAAGTGTAGT TATAC 25 (2) INFORMATION FOR SEQ ID NO: 227: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 227: CCCTTCATTT TAGAAATCG 19 (2) INFORMATION FOR SEQ ID NO: 228: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 228: ATTTCAACCA ATTCAATGCG 20 (2) INFORMATION FOR SEQ ID NO: 229: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 229: GCCCCTTTTG ATTTGAAGCT 20 (2) INFORMATION FOR SEC ID NO: 230: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 230: TCGCTCCAAG ATACCAAGAA GT 22 (2) INFORMATION FOR SEQ ID NO: 231: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 231: CTTGAATTAG GGGCAAAGAT CG 22 (2) INFORMATION FOR SEC ID NO: 232: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 232: ATGCGTTTTT ACCCAAAGAA GT 22 (2) INFORMATION FOR SEQ ID NO: 233: [i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 233: ATAACGCCAC TTCCTTATTG GT 22 (2) INFORMATION FOR SEQ ID NO: 234: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 234: CTTTGGGTAA AAACGCATC 19 (2) INFORMATION FOR SEQ ID NO: 235: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 20 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 235: CGATCTTTGA TCCTAATTCA 20 (2) INFORMATION FOR SEQ ID NO: 236: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 236: ATCAAGTTGC CTATGCTGA 19 (2) INFORMATION FOR SEQ ID NO: 237 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 237: TTGAACACTT TTGATTATGC GG 22 (2) INFORMATION FOR SEQ ID NO: 238: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 238: GGATTATGCG ATTGTTTTAC AAG 23 (2) INFORMATION FOR SEQ ID NO: 239: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 239: GTCTTTAGCA AAAATGGCGT C 21 (2) INFORMATION FOR SEC ID NO: 240: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 240: AATGAGCGTA AGAGAGCCTT C 21 (2) INFORMATION FOR SEC ID NO: 241: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 18 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 241: CTTATGGGGG TATTGTCA 18 (2) INFORMATION FOR SEQ ID NO: 242: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1. . . 18 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 242: AGCATGTGGG TATCCAGC 18 (2) INFORMATION FOR SEQ ID NO: 243: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 243: AGGTTGTTGC CTAAAGACT 19 (2) INFORMATION FOR SEQ ID NO: 244: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 18 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 244: CTGCCTCCAC CTTTGATC 18 (2) INFORMATION FOR SEQ ID NO: 245: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 245; ACCAATATCA ATTGGCACT 19 (2) INFORMATION FOR SEC ID NO: 246: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 18 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 246: ACTTGGAAAA GCTCTGCA 18 (2) INFORMATION FOR SEQ ID NO: 247 (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 19 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 247 CTTGCTTGTC ATATCTAGC 19 (2) INFORMATION FOR SEQ ID NO: 248; (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 18 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 248 GTTGAAGTGT TGGTGCTA 18 (2) INFORMATION FOR SEQ ID NO: 249: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 249: CAAGCAAGTG GTTTGGTTTT AG 22 (2) INFORMATION FOR SEC ID NO: 250: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 22 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 250: TGGAAAGAGC AAATCATTGA AG 22 (2) INFORMATION FOR SEQ ID NO: 251: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 251: GCCCATAATC AAAAAGCCCA T 21 (2) INFORMATION FOR SEQ ID NO: 252: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 252: CTAAAACCAA ACCACTTGCT TGTC 24 (2) INFORMATION FOR SEQ ID NO: 253: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 16 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 253: GTAAAACGAC GGCCAG 16 (2) INFORMATION FOR SEQ ID NO: 254: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 17 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 254 CAGGAAACAG CTATGAC 17 (2) INFORMATION FOR SEC ID NO: 255: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 255; ATCTTACCTA TCACCTCAAA T 21 (2) INFORMATION FOR SEQ ID NO: 256: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc__característica (B) LOCATION: 1 ... 21 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 256: AGACAGCAAC ATCTTTGTGA A 21 (2) INFORMATION FOR SEQ ID NO: 257: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 50 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característiea (B) LOCATION: 1 ... 50 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 257: CGCGGATCCA TATGGCTGAA AAAACGCCTT TTTTTAAAAC TAAAAACCAC 50 (2) INFORMATION FOR SEQ ID NO: 258: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 34 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 258: CCGGAATTCA TCAGTATTCA ATGGGAATAA AGCC 34 (2) INFORMATION FOR SEQ ID NO: 259: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 50 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 50 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 259: CGCGGATCCA TATGAAAGAA GAAGAAAAAG AAGAAAAAAA GACAGAAAGG 50 (2) INFORMATION FOR SEQ ID NO: 260: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 37 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 260: CCGGAATTCG CTTAAAAGAA AATAGTCCCC CAAACGC 37 (2) INFORMATION FOR SEQ ID NO: 261: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid - (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 43 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 261: CGCGGATCCA TATGAAAGAG GTCATTCCCA CCCCTTCAAC CCC 43 (2) INFORMATION FOR SEQ ID NO: 262: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 36 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 262: CCGGAATTCA TATAAATATC ATATAGGCAG AAAAAC 36 (2) INFORMATION FOR SEQ ID NO: 263: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 37 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 263: CGCGGATCCA TATGGAGGCA GAGCTTCATG AAAAATC 37 (2) INFORMATION FOR SEQ ID NO: 264: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 36 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 264 CCGGAATTCG ATTGATTTTG TCAAATCTAA AATCCC 36 (2) INFORMATION FOR SEQ ID NO: 265: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 265: TATTATACAT ATGGAAGAAG ATGGG 25 (2) INFORMATION FOR SEQ ID NO: 266: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 23 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 266: TAATCTCGAG TTTAGAAGGC GTA 23 (2) INFORMATION FOR SEQ ID NO: 267: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 25 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 267: TTATATTCAT ATGGAAGACG ATGGC 25 (2) INFORMATION FOR SEQ ID NO: 268 (i) CHARACTERISTICS OF THE SEQUENCE: '(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 24 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 268: AATTCTCGAG CCTCTTTATA AGCC 24 (2) INFORMATION FOR SEQ ID NO: 269: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 46 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 269: CGCGGATCCA TATGGTAGAA GCCTTTCAAA AACACCAAAA AGACGG 46 (2) INFORMATION FOR SEC ID NO: 270: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) CHARACTERISTICS: (A) NAME / KEY: misc_característica (B) LOCATION: 1.. . 32 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 270: CCGGAATTCG GAGCCAATAG GGAGCTAAAG CC 32 (2) INFORMATION FOR SEQ ID NO: 271: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 31 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 271; CGGGATCCGA AGGTGATGGT GTTTATATAG G 31 (2) INFORMATION FOR SEQ ID NO: 272: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_characteristic (B) LOCATION: 1 ... 32 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 272: CGCATATGGA AGGTGATGGT GTTTATATAG GG 32 (2) INFORMATION FOR SEQ ID NO: 273: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 37 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 273: GCGAATTCTC ACTCTTTCCA ATAGTTTGCT GCAGAGC 37 (2) INFORMATION FOR SEQ ID NO: 274: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 37 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 274: CCGGAATTCT TAATCCCGTT TCAAATGGTA ATAAAGG 37 (2) INFORMATION FOR SEQ ID NO: 275: (i) CHARACTERISTICS OF THE SEQUENCE: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) HEBRA: double (D) TOPOLOGY: circular (ii) TYPE OF MOLECULE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vi) ORIGINAL SOURCE: (A) ORGANISM: Helicobacter pylori (ix) FEATURE: (A) NAME / KEY: misc_característica (B) LOCATION: 1 ... 36 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 275: GCGAATTCCC TTTTATTTAA AAAGTGTAGT TATACC 36

Claims (36)

  1. CLAIMS 1. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a polypeptide of f. pyl ori at least 60% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 102, 108, 111, 121, 123, 133, 148, 149, 176 and 177.
  2. 2. The nucleic acid of claim 1, characterized in that it comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 5, 11, 14, 26, 28, 36, 42, 51, 52 and 79 or a complement thereof .
  3. 3. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence that encodes a polypeptide of. pyl ori at least 60% homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194.
  4. 4. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding an H. pyl ori polypeptide selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194.
  5. 5. An isolated nucleic acid encoding an H. pyl ori polypeptide, characterized in that it comprises a nucleotide sequence at least 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97, or a complement to it.
  6. 6. The nucleic acid of claim 3, characterized in that it comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97, or a complement thereof.
  7. 7. A nucleic acid molecule encoding a H. pyl ori polypeptide, characterized in that it comprises a nucleotide sequence that hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence selected from the group consisting of SEQ ID NO. : l-SEQ ID NO: 97, or a complement thereof.
  8. 8. An isolated nucleic acid comprising a nucleotide sequence of at least 8 nucleotides in length, characterized in that the sequence hybridizes under stringent hybridization conditions with a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1- SEQ ID NO: 97, or a complement thereof.
  9. 9. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a H. pyl ori cell envelope polypeptide or a fragment thereof, the nucleic acid is selected from the group consisting of SEQ ID NO: 63, SEQ ID NO. : SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28 , SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEC ID NO: 94, SEQ ID NO: 5, SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO : 29, SEQ ID NO: 30, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 , SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 34, SEC ID NO: 35, SEQ ID NO: 60, SEQ ID NO: 69, and SEQ ID NO: 83, or a complement thereto.
  10. 10. The nucleic acid isolated from the claim 9, characterized in that the cellular envelope polypeptide of f. pyl ori or a fragment thereof is a flagellum-associated polypeptide. pyl ori or a fragment thereof comprising a nucleotide sequence of SEQ ID NO: 63, or a complement thereof.
  11. 11. The isolated nucleic acid of claim 9, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an internal polypeptide of the ff membrane. pyl ori or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, and SEQ ID NO: 39, or a complement thereto.
  12. 12. The isolated nucleic acid of claim 11, characterized in that the internal membrane polypeptide of ff. pyl ori or a fragment thereof is a polypeptide of ff. pyl ori or a fragment thereof involved in transport encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 44, or a complement thereto.
  13. 13. The isolated nucleic acid of claim 9, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an outer polypeptide of the H. pyl ori membrane or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO. : 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 50, SEQ ID NO: 51 , SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 5, SEC ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO-.29, SEQ ID NO: 30, SEQ ID NO: 65, and SEQ ID NO: 66.
  14. 14. The isolated nucleic acid of claim 13, characterized in that the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a polypeptide of. pyl ori having a terminal phenylalanine residue or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: ll, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, and SEQ ID NO: 94, or a complement thereto.
  15. 15. The isolated nucleic acid of claim 14, characterized in that the outer polypeptide of the ff. pyl ori or a fragment thereof is a H. pyl ori polypeptide having a terminal phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 11 , SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, and SEQ ID NO: 52, or a complement thereto.
  16. 16. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence that encodes a cellular envelope polypeptide of. pyl ori or a fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 160, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 103, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 157, SEQ ID NO: 166, and SEQ ID NO. : 180 17. The isolated nucleic acid of claim 16, characterized in that the cellular envelope polypeptide of ff. pyl ori or a fragment thereof is a flagellum-associated polypeptide. pyl ori or a fragment thereof having an amino acid sequence of SEQ ID NO: 160. 18. The isolated nucleic acid of claim 16, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an internal polypeptide of the ff membrane. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEC ID NO: 141, SEQ ID NO: 135 and SEQ ID NO: 136. 19. The isolated nucleic acid of claim 18, characterized in that the internal polypeptide of the H. pyl ori membrane or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in transport selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, and SEQ ID NO: 141. 20. The isolated nucleic acid of claim 16, characterized in that the cellular envelope polypeptide of ff. pyl ori or a fragment thereof is an outer polypeptide of the membrane. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEC ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO. : 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126 , SEQ ID NO: 127, SEQ ID NO: 162, and SEQ ID NO: 163. 21. The isolated nucleic acid of claim 20, characterized in that the outer polypeptide of the membrane of. pyl ori or a fragment thereof is a polypeptide of ff. pyl ori having a terminal phenylalanine residue or a fragment thereof selected from the group consisting of SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEC ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125 SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181 SEQ ID NO: 182, SEQ ID NO: 188, and SEQ ID NO: 191 22. The isolated nucleic acid of claim 21, characterized in that the outer polypeptide of the H. pyl ori membrane or a fragment thereof is a polypeptide of. pyl ori having a terminal phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139 , and SEQ ID NO: 149. 23. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a cytoplasmic polypeptide of H. pyl ori or a fragment thereof, the nucleic acid is selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 92, and SEQ ID NO: 93, or a complement thereto. 24. The isolated nucleic acid of claim 23, characterized in that the cytoplasmic polypeptide of ff. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the translation of the mRNA, the nucleic acid is selected from the group consisting of SEQ ID NO: 57, and SEQ ID NO: 58, or a complement of it. 25. The isolated nucleic acid of claim 23, characterized in that the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of ff. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome, the nucleic acid is selected from the group consisting of SEQ ID NO: 86, SEQ ID NO: 87, or a complement thereof. 26. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence that encodes a cytoplasmic polypeptide of. pyl ori or a fragment thereof, the polypeptide is selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO. : 186, SEQ ID NO: 189, and SEQ ID NO: 190. 27. The isolated nucleic acid of claim 26, characterized in that the cytoplasmic polypeptide of ff. pyl ori or a fragment thereof is a polypeptide of f. pyl ori or a fragment thereof involved in the translation of mRNA selected from the group consisting of SEQ ID NO: 154, and SEQ ID NO: 155. 28. The nucleic acid isolated from the claim 26, characterized in that the cytoplasmic polypeptide of H. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome selected from the group consisting of SEQ. NO: 183, and SEQ ID NO: 184. 29. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a ff secreted polypeptide. pylori or a fragment thereof, the nucleic acid is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 20, SEQ ID NO : 25, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 45, SEQ ID NO: 46, SEC ID NO: 53, SEQ ID NO: 64, SEQ ID NO: 67, SEQ ID NO: 70, SEC ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEC ID NO: 90, SEQ ID NO: 95, and SEQ ID NO: 97, or a complement thereto. 30. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a secreted polypeptide of f. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 117, SEQ ID NO: 122, SEC ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 150, SEQ ID NO: 161, SEQ ID NO: 164, SEQ ID NO: 167, SEQ ID NO. : 174, SEQ ID NO: 175, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 187, SEQ ID NO: 192, and SEQ ID NO: 194. 31. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a cellular polypeptide of ff. pyl ori or a fragment thereof, the nucleic acid is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, and SEQ ID NO: 96, or a complement thereto. 32. An isolated nucleic acid, characterized in that it comprises a nucleotide sequence encoding a cellular polypeptide of ff. pyl ori or a fragment thereof, wherein the polypeptide is selected from the group consisting of SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 118, SEQ ID NO: 130, SEQ ID NO: 134, SEC ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 156, SEQ ID NO: 159, SEQ ID NO. : 165, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, and SEQ ID NO: 193. 33. A probe, characterized in that it comprises a nucleotide sequence consisting of at least 8 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97, or a complement thereof. 34. A recombinant expression vector, characterized in that the nucleic acid of any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 16, 23, 26, 29, 30, 31 or 32 is operably linked to a regulatory element of transcription. 35. A cell, characterized in that it comprises a recombinant expression vector of claim 34. 36. A method for producing an H. pyl ori polypeptide, characterized in that it comprises culturing a cell of claim 35 under conditions that allow expression of the polypeptide. 37. The method of claim 36, characterized in that it further comprises purifying the polypeptide from the cell. 38. A method for detecting the presence of a Helicobacter nucleic acid in a sample, characterized in that it comprises: (a) contacting a sample with a nucleic acid of any of claims 8 or 33 so that a hybrid can be formed between the probe and a Helicobacter nucleic acid in the sample; and (b) detecting the hybrid formed in step (a), wherein the detection of a hybrid indicates the presence of a Helicobacter nucleic acid in the sample. 39. A polypeptide isolated from H. pyl ori, characterized in that it comprises an amino acid sequence at least 60% homologous to a polypeptide of ff. pyl ori selected from the group consisting of SEQ ID NO: 102, 108, 111, 121, 123, 133, 148, 149, 176 and 177. 40. A polypeptide isolated from ff. pyl ori which is encoded by a nucleic acid, characterized in that it comprises a nucleotide sequence at least 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 5, 11, 14, 26, 28, 36, 42 , 51, 52 and 79. 41. A polypeptide isolated from ff. pyl ori, characterized in that it comprises at least 60% amino acid sequence homologous to an H. pyl ori polypeptide selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194. 42. A polypeptide isolated from ff. pyl ori which is encoded by a nucleic acid, characterized in that it comprises a nucleotide sequence at least 60% homologous to a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97. 43. The polypeptide isolated from. pyl ori of claim 42, characterized in that the polypeptide is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97. 44. A polypeptide isolated from id. pyl ori which is encoded by a nucleic acid, characterized in that it hybridizes under stringent hybridization conditions to a nucleic acid selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 97, or a complement thereof. 45. A polypeptide isolated from id. pyl ori, characterized in that it comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194. 46. A polypeptide isolated from the cellular envelope of ff. pyl ori or a fragment thereof, characterized in that the polypeptide is selected from the group consisting of SEQ ID NO: 160, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEC ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEQ ID NO: 14'l, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 103, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 157, SEQ ID NO: 166, and SEQ ID NO: 180. 47. The isolated polypeptide of claim 46, characterized in that the cellular envelope polypeptide of f. pyl ori or a fragment thereof is a flagellum-associated polypeptide of H. pyl ori or a fragment thereof having an amino acid sequence of SEQ ID NO: 160. 48. The isolated polypeptide of claim 47, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an internal polypeptide of the membrane. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, SEC ID N0: 141, SEQ ID NO: 135 and SEQ ID NO: 136. 49. The isolated polypeptide of claim 48, characterized in that the internal polypeptide of the membrane of. pyl ori or a fragment thereof is a polypeptide of H. pyl ori or a fragment thereof involved in the transport selected from the group consisting of SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 140, and SEQ ID NO: 141. 50. The isolated nucleic acid of claim 47, characterized in that the polypeptide of the cellular envelope of. pyl ori or a fragment thereof is an outer polypeptide of the membrane. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO.-104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 110, SEQ ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 188, SEQ ID NO: 191, SEQ ID NO: 102, SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 149, SEQ ID NO: 119, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 162, and SEQ ID NO: 163. 51. The isolated polypeptide of claim 50, characterized in that the outer polypeptide of the membrane of. pyl ori or a fragment thereof is a polypeptide of ff. pyl ori having a terminal phenylalanine residue or a fragment thereof selected from the group consisting of SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEC ID NO: lll, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125 SEQ ID NO: 133, SEQ ID NO: 139, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 158, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 181 SEQ ID NO: 182, SEQ ID NO: 188, and SEQ ID NO: 191 52. The isolated nucleic acid of claim 51, characterized in that the outer polypeptide of the membrane of. pyl ori or a fragment thereof is a polypeptide of f. pyl ori having a terminal phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof selected from the group consisting of SEQ ID NO: 108, SEQ ID NO: 123, SEQ ID NO: 133, SEQ ID NO: 139 , and SEQ ID NO: 149. 53. A polypeptide isolated from the H. pyl ori cell envelope or a fragment thereof, the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 63, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEC ID NO: 28, SEQ ID NO: 50, SEQ ID NO: -51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 60, SEQ ID NO: 69, and SEQ ID NO: 83. 54. The isolated polypeptide of claim 53, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is a flagellum-associated polypeptide. pyl ori or a fragment thereof comprising a nucleotide sequence of SEQ ID NO: 63. 55. The isolated polypeptide of claim 53, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an internal polypeptide of the membrane. pyl ori or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 38, and SEQ ID NO: 39. 56. The isolated polypeptide of claim 55, characterized in that the internal polypeptide of the membrane of. pyl ori or a fragment thereof is a polypeptide of f. pyl ori or a fragment thereof involved in transport encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 43, and SEQ ID NO: 44. 57. The isolated polypeptide acid of claim 53, characterized in that the cellular envelope polypeptide of. pyl ori or a fragment thereof is an outer polypeptide of the membrane. pyl ori or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, SEQ ID NO: 94, SEQ ID NO: 5, SEQ ID NO: ll, SEQ ID NO: 26, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 52, SEQ ID NO: 22, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 65, and SEQ ID NO: 66. 58. The isolated polypeptide of claim 57, characterized in that the outer polypeptide of the H. pyl ori membrane or a fragment thereof is an H. pyl ori polypeptide having a terminal phenylalanine residue or a fragment thereof encoded by a nucleic acid. selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: ll, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 36, SEQ ID NO: 42, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 61, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 91, and SEQ ID NO: 94. 59. The isolated polypeptide of claim 58, characterized in that the outer polypeptide of the ff. pyl ori or a fragment thereof is a polypeptide of f. pyl ori having a terminal phenylalanine residue and a C-terminal tyrosine cluster or a fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 36 SEC ID NO: 42, and SEQ ID NO: 52. 60. A cytoplasmic polypeptide of. pyl ori or a fragment thereof, characterized in that the polypeptide is selected from the group consisting of SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEC ID NO: 186, SEQ ID NO: 189, and SEQ ID NO: 190. 61. The isolated polypeptide of claim 60, characterized in that the cytoplasmic polypeptide of. pyl ori or a fragment thereof is a polypeptide of f. pyl ori or a fragment thereof involved in the translation of mRNA selected from the group consisting of SEQ ID NO: 154 and SEQ ID NO: 155. 62. The isolated polypeptide of claim 60, characterized in that the cytoplasmic polypeptide of. pyl ori or a fragment thereof is a polypeptide of f. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome selected from the group consisting of SEQ ID NO.:183 and SEQ ID NO: 184. 63. A cytoplasmic polypeptide of H. pylori or a fragment thereof, characterized in that polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 86, SEQ ID NO. : 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 92, and SEQ ID NO: 93. 64. The isolated polypeptide of claim 63, characterized in that the cytoplasmic polypeptide of. pyl ori or a fragment thereof is a polypeptide of ff. pyl ori or a fragment thereof involved in the translation of the mRNA, the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 57, and SEQ ID NO: 58. 65. The isolated polypeptide of claim 63, characterized in that the cytoplasmic polypeptide of ff. pyl ori or a fragment thereof is a polypeptide of f. pyl ori or a fragment thereof involved in the replication, transcription, recombination and repair of the genome, the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 86 and SEQ ID NO: 87. 66. A cellular polypeptide of íf. pyl ori isolated or a fragment thereof, characterized in that the polypeptide is selected from the group consisting of SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 118, SEQ ID NO: 130, SEQ ID NO: 134, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 144, SEQ ID NO: 151, SEQ ID NO: 152, SEQ ID NO: 153, SEQ ID NO: 156, SEQ ID NO: 159, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 169, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, and SEQ ID NO: 193. 67. An isolated H. pyl ori cell polypeptide or a fragment thereof, characterized in that the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEC ID NO: 59, SEQ ID NO: 62, SEQ ID NO: 68, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO : 76, and SEQ ID NO: 96. 68. A polypeptide secreted from. pyl ori isolated or a fragment thereof, characterized in that the polypeptide is selected from the group consisting of SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 117, SEQ ID NO: 122, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 150, SEQ ID NO: 161, SEQ ID NO: 164, SEQ ID NO: 167, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 178, SEQ ID NO: 179, SEQ ID NO: 187, SEQ ID NO: 192, and SEQ ID NO: 194. 69. A polypeptide secreted from ff. pyl ori isolated or a fragment thereof, characterized in that the polypeptide is encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 10, SEQ ID NO: 12, SEC ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 53, SEQ ID NO: 64, SEQ ID NO : 67, SEQ ID NO: 70, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 90, SEQ ID NO: 95, and SEQ ID NO: 97 70. A fusion protein, characterized in that it comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194 operably linked to a polypeptide that is not of ff. pyl ori 71. A vaccine formulation for prophylactic or therapeutic treatment of a ff infection. pyl ori, characterized in that it comprises an effective amount of at least one nucleic acid isolated from any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 16, 23, 26, 29, 30, 31 or 32. 72. A vaccine formulation for prophylactic or therapeutic treatment of a yeast infection. pyl ori, characterized in that it comprises an effective amount of at least one polypeptide of. pyl ori or a fragment thereof of any of claims 39, 40, 41, 42, 44, 45, 46, 53, 60, 63, 66, 67, 68 or 69. 73. A vaccine formulation of claim 71, characterized in that it further comprises a pharmaceutically acceptable carrier. 74. A vaccine formulation of the claim 72, characterized in that it also comprises a pharmaceutically acceptable carrier. 75. A vaccine formulation of the claim 73, characterized in that the pharmaceutically acceptable carrier contains an adjuvant. 76. A vaccine formulation of claim 74, characterized in that the pharmaceutically acceptable carrier contains an adjuvant. 77. A vaccine formulation of the claim 73, characterized in that the pharmaceutically acceptable carrier contains a delivery system. 78. A vaccine formulation of the claim 74, characterized in that the pharmaceutically acceptable carrier contains a delivery system. 79. A vaccine formulation of claim 77, characterized in that the delivery system contains a living vector. 80. A vaccine formulation of claim 78, characterized in that the delivery system contains a live vector. 81. A vaccine formulation of claim 79, characterized in that the live vector is a bacterium or a virus. 82. A vaccine formulation of claim 80, characterized in that the living vector is a bacterium or a virus. 83. A vaccine formulation of claim 77, characterized in that the pharmaceutically acceptable carrier further contains an adjuvant. 84. A vaccine formulation of claim 78, characterized in that the pharmaceutically acceptable carrier further contains an adjuvant. 85. A vaccine formulation for prophylactic or therapeutic treatment of an H. pylori infection, characterized in that it comprises an effective amount of at least one isolated nucleic acid encoding an outer polypeptide of the membrane. pyl ori or a fragment thereof, the nucleic acid is selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 50, SEQ ID NO: 24, SEQ ID NO: 11, SEQ ID NO: 52, SEQ ID NO: 42 and SEQ ID NO: 79. 86. The vaccine formulation of claim 85, characterized in that the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 52. 87. A vaccine formulation for prophylactic or therapeutic treatment of an H. pylori infection, characterized in that it comprises an effective amount of at least one external polypeptide of the membrane. pyl ori or a fragment thereof, the polypeptide is selected from the group consisting of SEQ ID NO: 125, SEQ ID NO: 147, SEQ ID NO: 121, SEQ ID NO: 108, SEQ ID NO: 149, SEQ ID NO. : 139 and SEQ ID NO: 176. 88. The vaccine formulation of claim 85, characterized in that the nucleic acid comprises a nucleotide sequence of SEQ ID NO: 149. 89. A vaccine formulation of claims 85 or 87, characterized in that it further comprises a pharmaceutically acceptable carrier. 90. A vaccine formulation of claim 89, characterized in that the pharmaceutically acceptable carrier contains an adjuvant. 91. A vaccine formulation of claim 89, characterized in that the pharmaceutically acceptable carrier contains a delivery system. 92. A vaccine formulation of the claim 91, characterized in that the delivery system contains a living vector. 93. A vaccine formulation of the claim 92, characterized in that the living vector is a bacterium or a virus. 94. A vaccine formulation of claim 90, characterized in that the pharmaceutically acceptable carrier further contains an adjuvant. 95. A method to treat or reduce a risk of ich infection. pyl ori in a subject, characterized in that it comprises administering to a subject a vaccine formulation of claim 72, in such a way that the treatment or reduction of risk of infection is presented. pyl ori 97. A method to treat or reduce a risk of ich infection. pyl ori in a subject, characterized in that it comprises administering to a subject a vaccine formulation of claim 85, in such a way that the treatment or reduction of risk of infection is presented. pyl ori 98. A method to treat or reduce a risk of HIV infection. pylori in a subject, characterized in that it comprises administering to a subject a vaccine formulation of claim 87, in such a way that the treatment or reduction of risk of infection is presented. pyl ori 99. A method for producing a vaccine formulation, characterized in that it comprises: combining at least one polypeptide isolated from H. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194 with a pharmaceutically vehicle acceptable to form a vaccine formulation. 100. A method for producing a vaccine formulation, characterized in that it comprises: (a) providing at least one polypeptide isolated from ff. pyl ori or a fragment thereof selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194; and (b) combining at least one polypeptide isolated from f. pyl ori or a fragment thereof with a pharmaceutically acceptable carrier to thereby form a vaccine formulation. 101. A method for producing a vaccine formulation, characterized in that it comprises: (a) culturing a cell under condition that allows the expression of a H. pyl ori polypeptide or a fragment thereof selected from the group consisting of SEQ ID NO: 98- SEQ ID NO: 194; (b) isolating the ff polypeptide. pyl ori or a fragment thereof from the cell; and (c) combining at least one polypeptide isolated from ff. pyl ori or a fragment thereof with a pharmaceutically acceptable carrier to thereby form a vaccine formulation. 102. A chimeric H. pyl ori polypeptide, characterized in that it comprises at least two polypeptides of ff. pyl ori or fragments thereof, wherein the polypeptides are encoded by nucleic acid sequences selected from the group consisting of SEQ ID NO: l-SEQ ID NO: 97. 103. A chimeric polypeptide of. pyl ori, characterized in that it comprises at least two polypeptides of. pyl ori or fragments thereof, wherein the polypeptides are encoded by nucleic acid sequences selected from the group consisting of SEQ ID NO: 98-SEQ ID NO: 194. SUMMARY OF THE INVENTION Substantially pure preparations of ff are described. pyl ori The nucleic acids encoding the polypeptides are also described. The polypeptides of ff. pyl ori are useful for diagnostic and vaccine compositions, wherein the figure represents an amino acid sequence alignment of five H. pyl ori proteins. 1/2 08 -. 08 -fít, nr - VAYFNYIYNF 23 SVYLNYVFAY 33 AFYVGYNYHF 39 AFYINY IGF 49 SVYWVYGYAF 2/2
MXPA/A/1999/004890A 1996-12-05 1999-05-26 Nucleic acid and amino acid sequences relating to helicobacter pylori MXPA99004890A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US759625 1996-12-05
US823745 1997-03-25
US891928 1997-07-14

Publications (1)

Publication Number Publication Date
MXPA99004890A true MXPA99004890A (en) 2000-02-02

Family

ID=

Similar Documents

Publication Publication Date Title
KR101916290B1 (en) Capsular gram-positive bacteria bioconjugate vaccines
WO1996040893A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
AU756010B2 (en) Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US20040033236A1 (en) Recombinant constructs of borrelia burgdorferi
WO1998058943A1 (en) Borrelia burgdorferi polynucleotides and sequences
AU739641B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
AU734052B2 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
KR20160065198A (en) Haemophilus parasuis vaccine serovar type four
CZ297698A3 (en) Nucleic acid and amino acid sequences relating to heliobacter pylori and vaccination composition thereof
WO1997019098A9 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
AU750792B2 (en) 76 kDa, 32 kDa, and 50 kDa helicobacter polypeptides and corresponding polynucleotide molecules
AU735391B2 (en) Helicobacter polypeptides and corresponding polynucleotide molecules
WO1997019098A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
MXPA99004890A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori
US20030124141A1 (en) Helicobacter polypeptides and corresponding polynucleotide molecules
CZ198899A3 (en) Sequence of nucleic acids and amino acids connected with Helicobacter pylori and vaccine compositions prepared therefrom
US20030023066A1 (en) Helicobacter polypeptides and corresponding polynucleotide molecules
AU710880C (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
CA2223395A1 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for diagnostics and therapeutics
CZ148399A3 (en) Sequence of nucleic acids and amino acids connected with Helicobacter pylori and vaccine preparations
CA2546836A1 (en) Immunization against chlamydia infection
AU3795699A (en) Nucleic acid and amino acid sequences relating to helicobacter pylori for therapeutics